(12) STANDARD PATENT (11) Application No. **AU 2017217542 B2**
(19) AUSTRALIAN PATENT OFFICE

(54) Title
Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators

(51) International Patent Classification(s)
C07D 401/12 (2006.01)
A61K 31/4192 (2006.01)
A61P 9/10 (2006.01)
A61P 25/02 (2006.01)
A61P 25/04 (2006.01)
A61P 25/06 (2006.01)
A61P 25/16 (2006.01)
A61P 25/24 (2006.01)
A61P 25/28 (2006.01)
A61P 25/30 (2006.01)
C07D 401/14 (2006.01)
C07D 403/12 (2006.01)
C07D 403/14 (2006.01)
C07D 405/14 (2006.01)
C07D 409/14 (2006.01)

(21) Application No: **2017217542** (22) Date of Filing: **2017.02.09**

(87) WIPO No: **WO17/139428**

(30) Priority Data

(31) Number	(32) Date	(33) Country
62/293,680	**2016.02.10**	**US**

(43) Publication Date: **2017.08.17**
(44) Accepted Journal Date: **2021.06.03**

(71) Applicant(s)
Janssen Pharmaceutica NV

(72) Inventor(s)
Chen, Gang;Chrovian, Christa C.;Coate, Heather R.;Dvorak, Curt A.;Gelin, Christine F.;Hiscox, Afton;Letavic, Michael A.;Rech, Jason C.;Soyode-Johnson, Akinola;Stenne, Brice;Wall, Jessica L.;Zhang, Wei

(74) Agent / Attorney
Shelston IP Pty Ltd., L 9 60 Margaret St, Sydney, NSW, 2000, AU

(56) Related Art
STN CAS Online, Chemical Abstracts Registry #1394745-67-5, Entered STN: 18th September 2012
WO 2009/118187 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 August 2017 (17.08.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/139428 A1

(51) International Patent Classification:
C07D 401/12 (2006.01) *A61P 25/24* (2006.01)
C07D 401/14 (2006.01) *A61P 25/28* (2006.01)
C07D 403/12 (2006.01) *A61P 25/06* (2006.01)
C07D 403/14 (2006.01) *A61P 25/02* (2006.01)
C07D 405/14 (2006.01) *A61P 25/04* (2006.01)
C07D 409/14 (2006.01) *A61P 25/30* (2006.01)
A61K 31/4192 (2006.01) *A61P 9/10* (2006.01)
A61P 25/16 (2006.01)

(21) International Application Number:
PCT/US2017/017093

(22) International Filing Date:
9 February 2017 (09.02.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/293,680 10 February 2016 (10.02.2016) US

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 BEERSE (BE).

(72) Inventors: **CHEN, Gang**; 3210 Merryfield Row, San Diego, California 92121 (US). **CHROVIAN, Christa C.**; 3210 Merryfield Row, San Diego, California 92121 (US). **COATE, Heather R.**; 3210 Merryfield Row, San Diego, California 92121 (US). **DVORAK, Curt A.**; 3210 Merryfield Row, San Diego, California 92121 (US). **GELIN, Christine F.**; 3210 Merryfield Row, San Diego, California 92121 (US). **HISCOX, Afton**; 3210 Merryfield Row, San Diego, California 92121 (US). **LETAVIC, Michael A.**; 3210 Merryfield Row, San Diego, California 92121 (US). **RECH, Jason C.**; 3210 Merryfield Row, San Diego, California 92121 (US). **SOYODE-JOHNSON, Akinola**; 3210 Merryfield Row, San Diego, California 92121 (US). **STENNE, Brice**; 3210 Merryfield Row, San Diego, California 92121 (US). **WALL, Jessica L.**; 3210 Merryfield Row, San Diego, California 92121 (US). **ZHANG, Wei**; 3210 Merryfield Row, San Diego, California 92121 (US).

(74) Agents: **ATKINS, Michael J.** et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2017/139428 A1

(54) Title: SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS

(57) Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

02 Mar 2021 2017217542

SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS

Field of the Invention

The present invention is related to compounds having NR2B modulating properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with NR2B receptor activity in animals, in particular humans.

Background of the Invention

Glutamate is one of the major excitatory neurotransmitters that is widely spread in the brain. First indication of its role as an excitatory messenger was in the 1950's when it was observed that intravenous administration of glutamate induces convulsions. However, the detection of the whole glutamatergic neurotransmitter system with its various receptors did not take place before the 1970's and 1980's when numerous antagonists were developed or, as in the case of PCP and ketamine, were identified as antagonists. Finally, in the 1990's molecular biology provided the tools for the classification of the glutamatergic receptors.

N-methyl-D-aspartate (NMDA) receptors are a subtype of ionotropic glutamate receptors that mediate excitatory synaptic transmission in the brain. NMDA receptors are ubiquitously distributed thoroughout the brain and play a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. NMDA receptors are distinct from other major subtypes of ionotropic glutamate receptors (AMPA and kainate receptors) in that they are blocked by Mg^{2+} at resting membrane potentials, are highly Ca^{2+} permeable, and require co-activation by two distinct neurotransmitters: glutamate and glycine (or D-serine) (Traynelis SF et al., *Pharmacol Rev.* **2010**; 62(3):405-96). The influx of Ca^{2+} through NMDA receptors triggers signaling cascades and regulates gene expression that is critical for different forms of synaptic plasticity including both long-term potentiation of synapse efficacy (LTP) (Berberich S et al., *Neuropharmacology* **2007**; 52(1):77-86) and long-term depression (LTD) (Massey, PV et al., *J Neurosci.* **2004** Sep 8;24(36):7821-8).

The vast majority of the mammalian NMDA receptors form a heterotetramer made of two obligatory GluN1 units and two variable GluN2 receptor subunits encoded by the GRIN1 gene and one of four GRIN2 genes, respectively. One or both GluN2 subunits can be potentially replaced by a GluN3A or a GluN3B subunit. The GRIN1 gene product has 8 splice variants while there are 4 different GRIN2 genes (GRIN2A-D) encoding four distinct GluN2 subunits. The glycine binding site is present on the GluN1 subunit and the glutamate binding site is present on the GluN2 subunit.

The GluNR2 subunits play a dominant role in determining the functional and pharmacological properties of the NMDA receptor assembly and exhibit distinct distribution in different areas of the brain. For instance, GluN2B subunits are expressed primarily in the forebrain in the adult mammalian brain (Paoletti P et al., *Nat Rev Neurosci*. **2013**; 14(6):383-400; Watanabe M et al., *J Comp Neurol.* **1993**; 338(3):377-90) and are implicated in learning, memory processing, mood, attention, emotion and pain perception (Cull-Candy S et al., *Curr Opin Neurobiol*. **2001**; 11(3):327-35).

Compounds that modulate GluN2B-containing NMDA receptor function can be useful in treatment of many neurological and psychiatric disorders including but not limited to bipolar disorder (Martucci L et al., *Schizophrenia Res*, **2006**; 84(2-3):214-21),, major depressive disorder (Miller OH et al., *eLife.* **2014**; 3:e03581; Li N et al., *Biol Psychiatry.* **2011**; 69(8):754-61), treatment-resistant depression (Preskorn SH et al. *J Clin Psychopharmacol.* **2008**; 28(6):631-7) and ther mood disorders (including schizophrenia (Grimwood S et al., *Neuroreport.* **1999**;10(3):461-5; Weickert CS et al. *Molecular Psychiatry* (**2013**) 18, 1185–1192), ante- and postpartum depression, seasonal affective disorder and the like), Alzheimer's disease (Hanson JE et al., *Neurobiol Dis*. **2015**; 74:254-62*;* Li S et al., *J Neurosci*. **2011**; 31(18):6627-38) and other dementias (Orgogozo JM et al. Stroke 2002, 33: 1834–1839), Parkinson's disease (Duty S, *CNS Drugs.* **2012**; 26(12):1017-32; Steece-Collier K et al., *Exp Neurol. 2000*; 163(1):239-43; Leaver KR et al. *Clin Exp Pharmacol Physiol.* **2008**; 35(11):1388-94), Huntington's chorea (Tang TS et al., *Proc Natl Acad Sci USA.* **2005**; 102(7):2602-7; Li L et al., *J Neurophysiol.* **2004**; 92(5):2738-46), multiple sclerosis (Grasselli G et al., *Br J Pharmacol.* **2013**; 168(2):502-17; Farjam M et

2017217542 02 Mar 2021

al., *Iran J Pharm Res*. **2014**; 13(2):695-705), cognitive impairment (Wang D et al. **2014**, *Expert Opin Ther Targets Expert Opin Ther Targets.* **2014***;18(10):1121-30*), head injury (Bullock MR et al., *Ann N Y Acad Sci.* **1999**; 890:51-8), spinal cord injury, stroke (Yang Y et al., *J Neurosurg.* **2003**; 98(2):397-403), epilepsy (Naspolini AP et al., *Epilepsy Res.* **2012** Jun;100(1-2):12-9), movement disorders (e.g. dyskinesias) (Morissette M et al., *Mov Disord.* **2006**; 21(1):9-17), various neurodegenerative diseases (e.g. amyotrophic lateral sclerosis (Fuller PI et al., *Neurosci Lett.* **2006**; 399(1-2):157-61) or neurodegeneration associated with bacterial or chronic infections), glaucoma (Naskar R et al. *Semin Ophthalmol.* **1999** Sep;14(3):152-8), pain (e.g. chronic, cancer, post-operative and neuropathic pain (Wu LJ and Zhuo M, *Neurotherapeutics.* **2009**; 6(4):693-702), diabetic neuropathy, migraine (Peeters M et al., *J Pharmacol Exp Ther.* **2007**; 321(2):564-72), cerebral ischemia (Yuan H et al., *Neuron*. **2015**; 85(6):1305-18), encephalitis (Dalmau J. et al*., Lancet Neurol.* **2008**; 7(12):1091-8.), autism and autism spectrum disorders (Won H. et al., *Nature.* **2012**; 486(7402):261-5), memory and learning disorders (Tang, Y. P. et al., *Nature.* **1999**; 401(6748):63-9), obsessive compulsive disorder (Arnold PD et al., *Psychiatry Res*. **2009**;172(2):136-9.), attention deficit hyperactivity disorder (ADHD) (Dorval KM et al., *Genes Brain Behav.* **2007**; 6(5):444-52), PTSD (Haller J et al. *Behav Pharmacol.* 2011;22(2):113-21; Leaderbrand K et al. *Neurobiol Learn Mem.* 2014; 113:35-40), tinnitus (Guitton MJ, and Dudai Y, *Neural Plast.* 2007; 80904; Hu SS et al. **2016**; 273(2): 325-332), sleep disorders (like narcolepsy or excessive daytime sleepiness, patent WO 2009058261 A1), vertigo and nystagmus (Straube A. et al., *Curr Opin Neurol.* 2005;18(1):11-4; Starck M et al. *J Neurol.* **1997** Jan;244(1):9-16), anxiety autoimmunological disorders like neuropsychiatric systemic lupus erythematosus (Kowal C et al. *Proc. Natl. Acad. Sci. U.S.A.* **2006**; 103, 19854–19859) and addictive illnesses (e.g. alcohol addiction, drug addiction) (Nagy J, **2004**, *Curr Drug Targets CNS Neurol Disord.* **2004**; 3(3):169-79.; Shen H et al., *Proc Natl Acad Sci USA*. 2011;108(48):19407-12).

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

art

In view of the clinical importance of NR2B, the identification of compounds that modulate NR2B receptor function represents an attractive avenue into the development of new therapeutic agents. Such compounds are provided herein.

It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.

Summary of the Invention

The invention is directed to the general and preferred embodiments defined, respectively, by the independent and dependent claims appended hereto, which are incorporated by reference herein. Disclosed herein are compounds of Formula (I):



(I) ,

wherein:

Ar^1 is selected from the group consisting of:

(a) phenyl substituted with one substituent selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}perhaloalkyl, and OC_{1-6}perhaloalkyl; phenyl substituted with two or three substituents each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, C_{3-6}cycloalkyl, and azetidinyl;

(b) pyridinyl; pyridinyl substituted with one or two members each independently selected from the group consisting of: halo, CH_3, CF_3, and CF_2H; and

(c) thienyl substituted with CF_3; 1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl; or 2,3-dihydro-1H-inden-5-yl;

R^1 is H, halo, or CH_3;

R^2 is H or CH_3; and

Ar^3 is selected from the group consisting of:

(a) pyridinyl; pyridinyl substituted with one or two substituents each independently selected from the group consisting of: Cl, F, CH_3, OCH_3, CF_3, $C(CH_3)_2OH$; azetidin-1-yl; 3-fluoroazetidin-1-yl; and 3,3-difluoroazetidin-1-yl;

(b) pyridazinyl; pyridazinyl substituted with one or two substituents each independently selected from the group consisting of: CH_3, OCH_3, and CF_3;


(c) pyrimidin-4-yl; pyrimidin-4-yl substituted with one or two substituents each independently selected from the group consisting of: Cl, CH_3, CF_3, and OCH_3; pyrimidin-2-yl; pyrimidin-2-yl substituted one or two members each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}alkyl substituted with OH or OCH_3, $C(OH)(CH_3)(CF_3)$, CH_2OCHF_2, CH_2OCF_3, $CH_2OCH_2CH_3$, $CH(NH_2)CH_3$, $CH_2NH(CH_3)$, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, $C(=N\text{-}OH)(CH_3)$, NH_2, $NH(CH_3)$, $N(CH_3)_2$; $NH(CH_2CH_3)$, $NH(CH_2CHF_2)$, NH(cyclopropyl), NH(difluorocyclobutyl), NH-oxetanyl, CN, $C(=O)CH_3$, $C(=O)NH(CH_3)$, $C(=O)N(CH_3)_2$, SO_2CH_3, CO_2CH_3, $C(CH_3)(=N\text{-}OH)$, cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholinyl, 1H-pyrrol-2-yl, 2-furyl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-pyrazol-1-yl, 2-methyl-1H-imidazol-1-yl, 1-methylpyrazol-3-yl, and phenyl;

(d) 5-fluoro-pyrazin-2-yl; 5-methylpyrazin-2-yl; 6-methylpyrazin-2-yl; pyrazin-4-yl; 5-(thien-2-yl)pyrazin-2-yl, and 2,3-dimethylpyrazin-5-yl; and

(e) 5-methyl-1H-imidazol-2-yl; 5-methylthiazol-2-yl;

and pharmaceutically acceptable salts Formula (I).

One aspect of this invention concerns compounds of Formula (II):



(II)

wherein:

$Ar^{1'}$ is phenyl substituted with C_{1-3}perhaloalkyl; or phenyl substituted with two substituents each independently selected from the group consisting of: halo, C_{1-3}alkyl, C_{1-3}perhaloalkyl, and OC_{1-3}perhaloalkyl;

$R^{2'}$ is H or CH_3; and

Ar^2 is selected from the group consisting of:

(a) pyridin-2-yl; pyridazin-3-yl; pyrimidin-4-yl; pyrimidin-2-yl; pyrimidin-2-yl substituted with one or two substituents each independently selected from the group consisting of halo, C_{1-3}alkyl, $C(CH_3)_2OH$, C_{1-3}perhaloalkyl, OCH_3, and cyclopropyl; and

(b) 1-methyl-imidazol-2-yl; oxazol-2-yl; 1-methyl-pyrazol-4-yl; 1-methyl-pyrazol-3-yl; and 1-methyl-1H-pyrazol-5-yl;

and pharmaceutically acceptable salts Formula (II).

Further embodiments are provided by pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II), pharmaceutically acceptable prodrugs of compounds of Formula (I) or Formula (II), and pharmaceutically active metabolites of compounds of Formula (I) or Formula (II).

In certain embodiments, the compounds of Formula (I) are compounds selected from those species described or exemplified in the detailed description below.

In certain embodiments, the compounds of Formula (II) are compounds selected from those species described or exemplified in the detailed description below.

In a further aspect, the invention relates to enantiomers and diastereomers of the compounds of Formula (I) or Formula (II), as well as the pharmaceutically acceptable salts.

In a further aspect, the invention relates to pharmaceutical compositions for treating a disease, disorder, or medical condition mediated by NR2B receptor activity, comprising an effective amount of at least one compound selected from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of Formula (I).

In a further aspect, the invention relates to pharmaceutical compositions for treating a disease, disorder, or medical condition mediated by NR2B receptor activity, comprising an effective amount of at least one compound selected from compounds of Formula (II), pharmaceutically acceptable salts of compounds of Formula (II), pharmaceutically acceptable prodrugs of compounds of Formula (II), and pharmaceutically active metabolites of Formula (II).

Pharmaceutical compositions according to the invention may further comprise one or more pharmaceutically acceptable excipients.

In another aspect, the chemical embodiments of the present invention are useful as NR2B receptor modulators. Thus, the invention is directed to a method for modulating NR2B receptor activity, including when such receptor is in a subject, comprising exposing NR2B receptor to an effective amount of at least one compound selected from compounds of Formula (I) or Formula (II), pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II), pharmaceutically acceptable prodrugs of compounds of Formula (I) or Formula (II), and pharmaceutically active metabolites of compounds of Formula (I) or Formula (II).

In another aspect, the invention is directed to a method of treating a subject suffering from, or diagnosed with a disease, disorder, or medical condition mediated by NR2B receptor activity, comprising administering to the subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I) or Formula (II),

pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II), pharmaceutically acceptable prodrugs of compounds of Formula (I) or Formula (II), and pharmaceutically active metabolites of compounds of Formula (I) or Formula (II). Additional embodiments of methods of treatment are set forth in the detailed description.

In another aspect, the method of studying isotopically labeled compounds in metabolic studies (preferably with ^{14}C), reaction kinetic studies (with, for example ^{2}H or ^{3}H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients. For example, an ^{18}F or ^{11}C labeled compound may be particularly preferred for PET or SPECT studies.

Additional embodiments of this invention include methods of making compounds of Formula (I) or Formula (II), pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II), pharmaceutically acceptable prodrugs of compounds of Formula (I) or Formula (II), and pharmaceutically active metabolites of Formula (I) or Formula (II).

An object of the present invention is to overcome or ameliorate at least one of the disadvantages of the conventional methodologies and/or prior art, or to provide a useful alternative thereto.

Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.

Detailed Description of Invention

In one aspect, provided herein is a compound having the structure of Formula (I):,



(I) ,

or a pharmaceutically acceptable salt thereof,

wherein:

Ar^1 is selected from the group consisting of:

(a) phenyl substituted with one substituent selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}perhaloalkyl, and OC_{1-6}perhaloalkyl; phenyl substituted with two or three substituents each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, C_{3-6}cycloalkyl, and azetidinyl;

(b) pyridinyl; pyridinyl substituted with one or two members each independently selected from the group consisting of: halo, CH_3, CF_3, and CF_2H; and

(c) thienyl substituted with CF_3; 2,2-difluorobenzo[d][1,3]dioxol-5-yl; or 2,3-dihydro-1H-inden-5-yl;

R^1 is H, halo, or CH_3;

R^2 is H or CH_3; and

Ar^3 is selected from the group consisting of:

(a) pyridinyl; pyridinyl substituted with one or two substituents each independently selected from the group consisting of: Cl, F, CH_3, OCH_3, CF_3, and $C(CH_3)_2OH$; azetidin-1-yl; 3-fluoroazetidin-1-yl; and 3,3-difluoroazetidin-1-yl;

(b) pyridazinyl; pyridazinyl substituted with one or two substituents each independently selected from the group consisting of: CH_3, OCH_3, and CF_3;

(c) pyrimidin-4-yl; pyrimidin-4-yl substituted with one or two substituents each independently selected from the group consisting of: Cl, CH_3, CF_3, and OCH_3; pyrimidin-2-yl; pyrimidin-2-yl substituted with one or two members each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}alkyl substituted with OH or OCH_3, $C(OH)(CH_3)(CF_3)$, CH_2OCHF_2, CH_2OCF_3, $CH_2OCH_2CH_3$, $CH(NH_2)CH_3$, $CH_2NH(CH_3)$, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, $C(=N\text{-}OH)(CH_3)$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, $NH(CH_2CH_3)$, $NH(CH_2CHF_2)$, NH(cyclopropyl), NH(difluorocyclobutyl), NH-oxetanyl, CN, $C(=O)CH_3$, $C(=O)NH(CH_3)$, $C(=O)N(CH_3)_2$, SO_2CH_3, CO_2CH_3, cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholinyl, 1H-pyrrol-2-yl, 2-

furyl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-pyrazol-1-yl, 2-methyl-1H-imidazol-1-yl, 1-methylpyrazol-3-yl, and phenyl;

(d) 5-fluoro-pyrazin-2-yl; 5-methylpyrazin-2-yl; 6-methylpyrazin-2-yl; pyrazin-2-yl; 5-(thien-2-yl)pyrazin-2-yl; and 2,3-dimethylpyrazin-5-yl; and

(e) 5-methyl-1H-imidazol-2-yl; and 5-methylthiazol-2-yl;

with the proviso that the compound is other than 5-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyridine.

An additional embodiment of the invention is a compound of Formula (I) wherein R^1 is H, F, I or CH_3.

An additional embodiment of the invention is a compound of Formula (I) wherein R^1 is H.

An additional embodiment of the invention is a compound of Formula (I) wherein R^2 is H.

An additional embodiment of the invention is a compound of Formula (I) wherein Ar^1 is phenyl substituted with one substituent selected from the group consisting of: Br, Cl, F, CH_3, CF_3, CHF_2, CF_2CH_3, $CH(CH_3)_2$, $OCHF_2$, and OCF_3.

An additional embodiment of the invention is a compound of Formula (I) wherein Ar^1 is 3-bromophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-isopropylphenyl, 3-(trifluoromethyl)phenyl, 3-(difluoromethyl)phenyl, 3-(1,1-difluoroethyl)phenyl, 3-(trifluoromethoxy)phenyl, 4-(trifluoromethoxy)phenyl, 3-(difluoromethoxy)phenyl, or 4-(difluoromethoxy)phenyl.

An additional embodiment of the invention is a compound of Formula (I) wherein Ar^1 is phenyl substituted with two substituents each independently selected from the group consisting of: Br, Cl, F, CH_3, CH_2CH_3, $CH(CH_3)_2$, CF_3, CF_2H, CF_2CH_3, $CH_2CH_2CH_2Cl$, $CH_2CH_2CH_2F$, OCH_3, OCF_2H, OCH_2CH_2F, cyclopropyl, and azetidin-1-yl.

An additional embodiment of the invention is a compound of Formula (I) wherein Ar^1 is 2,4-difluoro-5-methyl-phenyl, 3-(difluoromethyl)-2,4-difluoro-phenyl, or 2,4-difluoro-3-methyl-phenyl.

An additional embodiment of the invention is a compound of Formula (I) wherein Ar^1 is 6-methyl-pyridin-2-yl, 2-methyl-pyridin-4-yl, 5-methyl-pyridin-3-yl, 4-methyl-pyridin-2-yl, 2-bromo-pyridin-4-yl, 2-(trifluoromethyl)-pyridin-4-yl, 5-chloro-6-(trifluoromethyl)pyridin-2-yl, 2-(difluoromethyl)pyridin-4-yl, 5-(trifluoromethyl)pyridin-2-yl, 5-bromo-6-fluoropyridin-3-yl, or pyridin-4-yl.

An additional embodiment of the invention is a compound of Formula (I) wherein Ar^1 is 6-methyl-pyridin-2-yl, 2-methyl-pyridin-4-yl, 5-methyl-pyridin-3-yl, 4-methyl-pyridin-2-yl, 2-bromo-pyridin-4-yl, 2-(trifluoromethyl)-pyridin-4-yl; 1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl; 5-(trifluoromethyl)thiophen-2-yl or 2,3-dihydro-1H-inden-5-yl.

An additional embodiment of the invention is a compound of Formula (I) wherein Ar^1 is 4-chloro-3-(difluoromethoxy)phenyl, 3-(difluoromethyl)-4-fluoro-phenyl, 4-chloro-3-(1,1-difluoroethyl)phenyl, 3-(1,1-difluoroethyl)-4-fluoro-phenyl, 3-(difluoromethoxy)-4-fluoro-phenyl, 4-chloro-3-(difluoromethyl)phenyl, 4-chloro-3-(2-fluoroethoxy)phenyl, 3-(3-chloropropyl)-4-fluoro-phenyl, or 5-(trifluoromethyl)thiophen-2-yl.


An additional embodiment of the invention is a compound of Formula (I) wherein Ar^3 is pyridin-2-yl, 3-fluoro-pyridin-2-yl, 6-fluoro-pyridin-2-yl, 3-chloro-pyridin-2-yl, 5-chloro-pyridin-2-yl, 4-methyl-pyridin-2-yl, 5-methyl-pyridin-2-yl, 6-methyl-pyridin-2-yl, 5-(trifluoromethyl)pyridine-2-yl, 6-(trifluoromethyl)pyridine-2-yl,pyridine-3-yl, 3-methoxy-pyridin-2-yl, 2-methoxy-pyridin-3-yl, 2-methyl-pyridin-5-yl, 2,3-dimethyl-pyridin-2-yl, 5-chloro-3-methoxy-pyridin-2-yl, or 2-chloro-5-methyl-pyridin-4-yl.

An additional embodiment of the invention is a compound of Formula (I) wherein Ar^3 is pyrimidin-2-yl; pyrimidin-2-yl substituted one or two members each independently selected from the group consisting of: halo, $C_{1\text{-}3}$alkyl, $C_{1\text{-}3}$alkyl substituted with OH or OCH_3, $C(OH)(CH_3)(CF_3)$, $CH(NH_2)CH_3$, $CH_2NH(CH_3)$, $C_{1\text{-}3}$perhaloalkyl, $OC_{1\text{-}3}$alkyl, $OC_{1\text{-}3}$perhaloalkyl, NH_2; $NH(CH_3)$,

$N(CH_3)_2$, $NH(CH_2CH_3)$, $NH(CH_2CHF_2)$, CN, $C(=O)CH_3$, $C(=O)NH(CH_3)$, $C(=O)N(CH_3)_2$, SO_2CH_3, CO_2CH_3, cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholinyl, 2-furyl, 1H-pyrazol-4-yl, and 1-methylpyrazol-3-yl.

An additional embodiment of the invention is a compound of Formula (I) wherein Ar^3 is pyrimidin-2-yl substituted one or two members each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}alkyl substituted with OH or CH_3, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, and azetidine-1-yl.

An additional embodiment of the invention is a compound of Formula (I) having the Formula (IA):



(IA)


wherein

Ar^1 is phenyl substituted with two substituents each independently selected from the group consisting of: halo, C_{1-3}perhaloalkyl, and OC_{1-3}perhaloalkyl; and

Ar^3 is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, 3-chloro-pyridin-2-yl, 5-chloro-pyridin-2-yl, 3-fluoro-pyridin-2-yl, 6-fluoro-pyridin-2-yl, 4-methyl-pyridin-2-yl, 2-methyl-pyridin-5-yl, 5-methyl-pyridin-2-yl, 6-methyl-pyridin-2-yl, 2,3-dimethyl-pyridin-6-yl, 2-chloro-5-methylpyridin-4-yl, 3-methoxy-pyridin-2-yl, 2-methoxy-pyridin-3-yl, 2-(pyridin-3-yl)propan-2-ol, 5-chloro-3-methoxy-pyridin-2-yl, 5-(trifluoromethyl)pyridin-2-yl, 6-(trifluoromethyl)pyridin-2-yl, pyridazin-3-yl, pyrazin-2-yl, 5-methylpyrazin-2-yl, 5-fluoro-pyrazin-2-yl, and 5-(thien-2-yl)pyrazin-2-yl;

and pharmaceutically acceptable salts of compounds of Formula (IA).

An additional embodiment of the invention is a compound of Formula (I) having the Formula (IB):



(IB)

wherein

Ar^1 is phenyl substituted with two substituents each independently selected from the group consisting of: halo, C_{1-3}alkyl, C_{1-3}perhaloalkyl, OCH_3, and OC_{1-3}perhaloalkyl;

R^1 is selected from the group consisting of: H, F, I, and CH_3;

R^2 is H or CH_3;

n is 0,1,or 2; and

each R^4 is independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}alkyl substituted with OH or OCH_3, $C(OH)(CH_3)(CF_3)$, $CH(NH_2)CH_3$, $CH_2NH(CH_3)$, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, NH_2, $NH(CH_3)$, $N(CH_3)_2$, $NH(CH_2CH_3)$, $NH(CH_2CHF_2)$, CN, $C(=O)CH_3$, $C(=O)NH(CH_3)$, $C(=O)N(CH_3)_2$, SO_2CH_3, CO_2CH_3, cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholine, 2-furyl, 1H-pyrazol-4-yl, and 1-methylpyrazol-3-yl;

and pharmaceutically acceptable salts of compounds of Formula (IB).

An additional embodiment of the invention is a compound of Formula (I) having the Formula (IB) wherein:

Ar^1 is selected from the group consisting of: 4-chloro-3-(difluoromethoxy)phenyl, 3-(difluoromethoxy)-4-fluoro-phenyl, 3-(difluoromethoxy)-4-methyl-phenyl, 4-chloro-3-(1,1-difluoroethyl)phenyl, 3-(1,1-difluoroethyl)-4-fluoro-phenyl, 4-chloro-3-(2-fluoroethoxy)phenyl,

3-(3-chloropropyl)-4-fluoro-phenyl, 4-fluoro-3-(3-fluoropropyl)phenyl, 3-bromo-4-fluoro-phenyl, 2-fluoro-3-(trifluoromethyl)phenyl, 3-(difluoromethyl)-4-fluoro-phenyl, 4-chloro-3-(difluoromethyl)phenyl, 4-chloro-3-methoxy-phenyl), 4-fluoro-3-isopropyl-phenyl, 3-chloro-4-fluoro-phenyl, 3-ethyl-4-fluoro-phenyl, 3,4-difluorophenyl, 4-fluoro-3-methyl-phenyl, and 3,5-dimethylphenyl;


R^1 is H;

R^2 is H;

n is 1 or 2; and

each R^4 is independently selected from the group consisting of: Cl, F, C_{1-3}alkyl, C_{1-3}perhaloalkyl, CH_2OH, CH_2OCH_3, $C(CH_3)_2(OH)$, OCH_3, OC_{1-3}perhaloalkyl, $C(=O)CH_3$, and azetidine-1-yl.

An additional embodiment of the invention is a compound of Formula (I) having the Formula (IC):



(IC)

wherein


Ar^1 is selected from the group consisting of: 2-bromo-pyridin-4-yl, 6-methyl-pyridin-2-yl, 4-methyl-pyridin-2-yl, 2-methyl-pyridin-4-yl, 5-methyl-pyridin-3-yl, 2-(trifluoromethyl)-pyridin-4-yl, 5-(trifluoromethyl)pyridin-2-yl, 5-chloro-6-(trifluoromethyl)pyridin-2-yl, 5-bromo-6-methyl-pyridin-2-yl, 5-bromo-6-fluoropyridin-3-yl, and 5-(trifluoromethyl)-2-thienyl;

R^6 is selected from the group consisting of: Cl, F, CH_3, CH_2CH_3, CF_3, and OCH_3; and

R^7 is H or CH_3;

and pharmaceutically acceptable salts of compounds of Formula (IC).

An additional embodiment of the invention is a compound of Formula (I) having the Formula (ID):



(ID)

wherein


Ar^1 is phenyl substituted with one substituent selected from the group consisting of: Br, Cl, F, C_{1-3}alkyl, C_{1-3}perhaloalkyl, and OC_{1-3}perhaloalkyl;

n is 0, 1, or 2; and

each R^4 is independently selected from the group consisting of: Br, Cl, F, C_{1-3}alkyl, C_{1-3}perhaloalkyl, OCH_3, $OCHF_2$, CH_2OH, CH_2OCH_3, $CH(CH_3)(OH)$, $C(OH)(CH_3)_2$, $C(OCH_3)(CH_3)_2$, $C(OH)(CH_3)(CF_3)$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, $C(=O)CH_3$, cyclopropyl, azetidine-1-yl, 3-fluoroazetidin-1-yl, pyrrolidin-1-yl, and piperidin-1-yl;

and pharmaceutically acceptable salts of compounds of Formula (ID).

In another aspect the invention provides a compound having the structure of Formula (II):



(II)

or a pharmaceutically acceptabel salt thereof, wherein:

$Ar^{1'}$ is phenyl substituted with C_{1-3}perhaloalkyl; or phenyl substituted with two substituents each independently selected from the group consisting of: halo, C_{1-3}alkyl, C_{1-3}perhaloalkyl, and OC_{1-3}perhaloalkyl;

$R^{2'}$ is H or CH_3; and


Ar^2 is selected from the group consisting of:

(a) pyridin-2-yl; pyridazin-3-yl; pyrimidin-4-yl; pyrimidin-2-yl; pyrimidin-2-yl substituted with one or two substituents each independently selected from the group consisting of halo, C_{1-3}alkyl, $C(CH_3)_2OH$, C_{1-3}perhaloalkyl, OCH_3, and cyclopropyl; and

(b) 1-methyl-imidazol-2-yl; oxazol-2-yl; 1-methyl-pyrazol-4-yl; 1-methyl-pyrazol-3-yl; and 1-methyl-1H-pyrazol-5-yl;

or a pharmaceutically acceptable salt of compounds of Formula (II).

An additional embodiment of the invention is a compound of Formula (II) having the Formula (IIA):



(IIA)


wherein:

$Ar^{1'}$ is selected from the group consisting of: 4-chloro-3-(difluoromethoxy)phenyl, 3-(difluoromethoxy)-4-fluoro-phenyl, 4-fluoro-3-(trifluoromethyl)phenyl, 3-(difluoromethyl)-4-fluoro-phenyl, and 4-chloro-3-(difluoromethyl)phenyl; and

Ar^2 is selected from the group consisting of:oxazol-2-yl, pyrimidin-4-yl, 1-methyl-pyrazol-3-yl, 1-methyl-imidazol-2-yl, and 1-methyl-pyrazol-4-yl;

and pharmaceutically acceptable salts of compounds of Formula (IIA).

An additional embodiment of the invention is a compound of Formula (II) having the Formula (IIB):



(IIB)

wherein:

2017217542 02 Mar 2021

$Ar^{1'}$ is selected from the group consisting of: 3-(difluoromethyl)phenyl, 4-fluoro-3-methyl-phenyl, 4-chloro-3-(difluoromethoxy)phenyl, 3-(difluoromethoxy)-4-fluoro-phenyl, 4-fluoro-3-(trifluoromethyl)phenyl, 3-(difluoromethyl)-4-fluoro-phenyl, 4-chloro-3-(difluoromethyl)phenyl, and 3-(1,1-difluoroethyl)-4-fluoro-phenyl;

n is 1 or 2; and

each R^4 is independently selected from the group consisting of halo, C_{1-3}alkyl, $C(CH_3)_2OH$, C_{1-3}perhaloalkyl, OCH_3, and cyclopropyl;

and pharmaceutically acceptable salts of compounds of Formula (IIB).

Another aspect of the current invention is a compound as shown below in Table 1.

Ex #.	Compound Name
1	2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
4	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;
5	3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine;
8	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine;
9	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine;
10	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
11	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine;
12	4-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
13	4-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
14	3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridazine;
15	2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]pyrimidine;
16	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;

17	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
18	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4,6-dimethyl-pyrimidine;
19	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
20	2-[[1-(4-Fluoro-3-methoxy-phenyl)triazol-4-yl]methoxy]pyrimidine;
21	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
22	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
23	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrazine;
25	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
26	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
27	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
28	5-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
29	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;
30	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
31	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
32	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
33	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
34	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrazine;
35	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;
37	5-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
38	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
39	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
40	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;

41	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
42	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-chloro-pyrimidine;
43	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;
44	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
45	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
46	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
47	5-Chloro-2-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
48	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;
49	5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
50	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
51	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
52	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
53	(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
54	(R*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
55	(S*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
56	(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;
57	(R*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;
58	(S*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;
59	(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-4-methyl-pyrimidine;
60	(R/S)-5-Chloro-2-[1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
61	5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
62	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;

63	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
64	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
65	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine;
66	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
67	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
68	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
69	5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
70	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;
71	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
72	5-Ethyl-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
73	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
74	5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
75	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;
76	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
77	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
78	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
79	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
80	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
81	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
82	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
83	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
84	5-Fuoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;

85	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
86	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
87	2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
88	2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
89	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
90	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
91	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
92	5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
93	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
94	2-[[1-(5-Bromo-6-methyl-2-pyridyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
95	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
96	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine;
103	3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-2-methoxy-pyridine;
104	5-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-2-methyl-pyridine;
105	3-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine;
106	5-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-methoxy-pyridine;
107	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-fluoro-pyridine;
108	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-methoxy-pyridine;
111	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;
112	5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;
113	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine;
114	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine;

115	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine;
116	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine;
117	5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;
118	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine;
119	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine;
120	5-Methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
121	5-Methyl-2-((1-(4-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
122	2-((1-(3-(Difluoromethyl)-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
123	2-((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
124	2-((1-(4-Chloro-3-(oxetan-3-yl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
125	2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-fluoro-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
126	2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
127	2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
128	2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylthiazole;
129	1-(4-Chloro-3-(difluoromethyl)phenyl)-4-(((5-methyl-1H-imidazol-2-yl)oxy)methyl)-1H-1,2,3-triazole;
130	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyridine;
131	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methylpyridine;
132	6-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,3-dimethylpyridine;
133	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methylpyrazine;
134	5-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,3-dimethylpyrazine;
135	5-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyrimidine;
136	6-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,4-dimethylpyridazine;

137	3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(trifluoromethyl)pyridazine;
138	3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methoxypyridazine;
139	4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyrimidine;
140	4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-(trifluoromethyl)pyrimidine;
141	4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methoxypyrimidine;
142	2-((1-(5-Chloro-6-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
143	2-((1-(2-(Difluoromethyl)pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
146	3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxypyridine;
147	4-Chloro-3-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
148	4-((1-(3-(Difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine;
149	2-((1-(3-(Difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
150	5-Methyl-2-((1-(5-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
151	2-((1-(5-Bromo-6-fluoropyridin-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
152	5-Methyl-2-((1-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
155	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
156	1-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
157	(R/S)-1-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;
158	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine;
159	[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
160	[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;
161	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
162	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-4-carboxamide;

163	(R/S) 1-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]ethanamine;
164	5-Chloro-2-[[1-(4-fluorophenyl)triazol-4-yl]methoxy]pyrimidine;
165	5-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
166	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine;
167	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine;
168	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;
169	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine;
170	4-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]morpholine;
171	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
172	2-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
173	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methyl-pyrimidine;
174	5-Methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;
175	5-Methyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]pyrimidine;
176	5-Methyl-2-[[1-(5-methyl-3-pyridyl)triazol-4-yl]methoxy]pyrimidine;
177	2-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
178	2-[2-[[1-(3-Cyclobutyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
179	2-[2-[[1-(4-Fluoro-3-isopropyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
180	2-[2-[[1-(3-Cyclopropyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
181	2-[2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
182	2-[2-[[1-(3-Ethyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
183	5-Bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
184	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1-methylpyrazol-3-yl)pyrimidine;

185	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1H-pyrazol-4-yl)pyrimidine;
186	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1H-pyrazol-4-yl)pyrimidine;
187	4-(2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine;
188	2-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
189	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrazine;
190	4-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
191	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-fluoro-pyrimidine;
192	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine;
193	2-[[1-[4-Chloro-3-(2-fluoroethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
194	2-[[1-[4-Fluoro-3-(3-fluoropropyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
195	2-[[1-[3-(3-Chloropropyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
196	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine;
225	5-Chloro-2-[[1-(4-chlorophenyl)triazol-4-yl]methoxy]pyrimidine;
226	2-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
227	2-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;
228	2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]pyrimidine;
229	5-Fluoro-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine;
230	2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
231	5-Chloro-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine;
232	2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
233	5-Ethyl-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine;
234	2-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;

235	2-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
236	2-[[1-(o-Tolyl)triazol-4-yl]methoxy]pyrimidine;
237	5-Fluoro-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;
238	5-Methoxy-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;
239	5-Chloro-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;
240	5-Methyl-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;
241	5-Ethyl-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;
242	2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidine;
243	5-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
244	4-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
245	5-Ethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
246	5-Chloro-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
247	5-Fluoro-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
248	5-Methoxy-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
249	2-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
250	4-(Methoxymethyl)-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
251	4,5-Dimethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
252	5-Fluoro-4-methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
253	5-Chloro-4-methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
254	5-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidin-4-amine;
255	1-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
256	2-[[1-(p-Tolyl)triazol-4-yl]methoxy]pyrimidine;

257	5-Fluoro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;
258	5-Methoxy-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;
259	5-Chloro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;
260	5-Methyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;
261	5-Ethyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;
262	2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]pyrimidine;
263	5-Fluoro-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine;
264	2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
265	5-Chloro-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine;
266	2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
267	5-Ethyl-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine;
268	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
269	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
270	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine;
271	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
272	2-[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
273	5-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
274	4-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
275	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
276	5-(Difluoromethoxy)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
277	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
278	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;

279	5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
280	2-Chloro-4-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
281	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine;
282	5-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
283	4-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
284	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;
285	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine;
286	5-Methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
287	5-Ethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
288	5-Isopropyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
289	5-(Difluoromethyl)-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
290	4,5-Dimethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
291	5-Chloro-4-methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
292	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
293	5-Bromo-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
294	5-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
295	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
296	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
297	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
298	[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;
299	[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
300	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;

301	2-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
302	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine;
303	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine;
304	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine;
305	(R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol;
306	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
307	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;
308	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;
309	1-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
310	(R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;
311	(R/S)-2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(1-methoxyethyl)pyrimidine;
312	5-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
313	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
314	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
315	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;
316	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
317	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
318	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
319	5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
320	5-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
321	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine;
322	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;

323	2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
324	2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
325	2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
326	5-Chloro-2-[[1-[3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
327	2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
328	2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
329	2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
330	2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
331	2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
332	5-Chloro-2-[[1-[4-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
333	2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
334	2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
335	2-[[1-[4-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
336	5-Fluoro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
337	5-Methoxy-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
338	5-Chloro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
339	5-Methyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
340	5-Ethyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
341	2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
342	5-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
343	5-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
344	1-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;

345	2-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
346	4-(Methoxymethyl)-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
347	4-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
348	5-Fluoro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
349	5-Methoxy-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
350	5-Chloro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
351	5-Ethyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
352	N-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
353	2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
354	2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
355	2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]pyrimidine;
356	5-Chloro-2-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]pyrimidine;
357	2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
358	2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
359	2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
360	2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]pyrimidine;
361	2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
362	2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
363	5-Chloro-2-[[1-(3,5-dimethylphenyl)triazol-4-yl]methoxy]pyrimidine;
364	2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
365	2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
366	2-[(1-Indan-5-yltriazol-4-yl)methoxy]-5-methyl-pyrimidine;

367	5-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]pyrimidine;
368	2-[(1-Indan-5-yltriazol-4-yl)methoxy]-4-(methoxymethyl)pyrimidine;
369	2-[2-[(1-Indan-5-yltriazol-4-yl)methoxy]pyrimidin-5-yl]propan-2-ol;
370	4-(Difluoromethyl)-2-[(1-indan-5-yltriazol-4-yl)methoxy]pyrimidine;
371	5-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]-4-methyl-pyrimidine;
372	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
373	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;
374	2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
375	5-Chloro-2-[(1R)-1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
376	2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;
377	2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methoxy-pyrimidine;
378	2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
379	5-Chloro-2-[(1S)-1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
380	2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;
381	2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methoxy-pyrimidine;
382	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
383	[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
384	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
385	2-[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
386	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-isopropoxypyrimidine;
387	Methyl 2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine-4-carboxylate;
388	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-N-(2,2-difluoroethyl)-5-fluoro-pyrimidin-4-amine;

389	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;
390	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine;
391	5-(Azetidin-1-yl)-2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
392	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine;
393	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3,3-difluoroazetidin-1-yl)pyrimidine;
394	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-6-fluoro-pyridine;
395	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-(trifluoromethyl)pyridine;
396	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrazine;
397	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(2-thienyl)pyrazine;
398	5-Bromo-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
399	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
400	[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
401	2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
402	4-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
403	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine;
404	(R/S)-2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol;
405	5-(Difluoromethoxy)-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
406	5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
407	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
408	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
409	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-5-carboxamide;
410	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidine-4-carboxamide;

411	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methoxy-5-methyl-pyrimidine;
412	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
413	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
414	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;
415	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
416	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine;
417	5-(Azetidin-1-yl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
418	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1-yl)pyrimidine;
419	5-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
420	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoro-3-methylazetidin-1-yl)pyrimidine;
421	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-(difluoromethyl)azetidin-1-yl)pyrimidine;
422	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3,3-difluoropyrrolidin-1-yl)pyrimidine;
423	5-Cyclopropyl-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
424	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(2-furyl)pyrimidine;
425	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]-5-iodo-triazol-4-yl]methoxy]-5-methyl-pyrimidine;
426	[3H]-2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl-5-t)methoxy)-5-methylpyrimidine;
427	3-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine;
428	5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine;
429	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine;
430	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine;
431	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine;
432	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine;

433	2-[6-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-3-pyridyl]propan-2-ol;
434	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrazine;
435	2-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
436	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine;
437	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(methoxymethyl)pyrimidine;
438	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
439	5-(Difluoromethyl)-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
440	4-(Difluoromethyl)-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
441	(R/S)-1,1,1-Trifluoro-2-[2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
442	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;
443	5-Ethoxy-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
444	5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
445	5-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
446	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
447	1-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
448	(R/S)-1-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;
449	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
450	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
451	5-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
452	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-5-carboxamide;
453	5-Cyclopropyl-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
454	5-Bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;

455	2-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine;
456	4-(2-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine;
457	5-(Azetidin-1-yl)-2-((1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methylpyrimidine;
458	2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethyl-4-methylpyrimidin-5-amine;
459	2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethylpyrimidin-5-amine;
460	2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1-yl)pyrimidine;
461	5-Chloro-2-[[1-[2-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
462	4-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-6-methyl-pyrimidine;
463	5-Chloro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
464	2-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
465	5-Fluoro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
466	2-[2-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
467	2-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
468	5-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
469	2-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
470	5-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
471	5-(Difluoromethoxy)-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
472	2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-4-amine;
473	2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
474	5-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
475	2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
476	5-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;

477	2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
478	5-Ethyl-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
479	2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
480	2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
481	5-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
482	5-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
483	5-(2-Fluoroethoxy)-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
484	2-[[1-(2-Fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
485	5-Chloro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
486	5-Fluoro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
487	5-Fluoro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
488	2-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
489	5-Chloro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
490	2-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
491	5-Ethyl-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
492	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
493	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
494	5-Bromo-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
495	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-ethyl-pyrimidine;
496	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine;
497	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;
498	[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;

499	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
500	2-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
501	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
502	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-amine;
503	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
504	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethylpyrimidin-4-amine;
505	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
506	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-phenyl-pyrimidine;
507	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine;
508	5-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
509	4-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
510	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3-fluoroazetidin-1-yl)pyrimidine;
511	4-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
512	(R)-2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-[(3R)-3-fluoropyrrolidin-1-yl]pyrimidine;
513	5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
514	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
515	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine;
516	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine;
517	N-(2,2-Difluoroethyl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidin-4-amine;
518	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;
519	N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine;
520	1-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)-N-methylmethanamine;

521	2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
522	1-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
523	2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
524	2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
525	5-Bromo-2-[[1-[3-(difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidine;
526	2-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
527	2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
528	2-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
529	5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine;
530	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
531	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
532	2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
533	[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;
534	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
535	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine;
536	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine;
537	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
538	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine;
539	(R/S)-2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol;
540	[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
541	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;
542	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;

543	5-Chloro-2-[[1-[4-chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
544	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
545	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
546	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4,6-dimethyl-pyrimidine;
547	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
548	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
549	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;
550	1-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
551	(R/S)-1-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;
552	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-cyclopropyl-pyrimidine;
553	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;
554	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;
555	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-3-fluoro-pyridine;
556	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine;
557	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine;
558	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine;
559	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine;
560	6-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-2,3-dimethyl-pyridine;
561	3-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-2-methoxy-pyridine;
562	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine;
563	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine;
564	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine;

565	(R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol;
566	2-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
567	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine;
568	[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
569	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(methoxymethyl)pyrimidine;
570	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
571	[2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;
572	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;
573	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
574	5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
575	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
576	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
577	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine;
578	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;
579	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine;
580	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
581	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
582	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
583	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine-5-carbonitrile;
584	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methylsulfonyl-pyrimidine;
585	1-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
586	(R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;

587	5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
588	5-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
589	2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine;
590	2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N,N-dimethylpyrimidin-5-amine;
591	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;
592	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine;
593	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
594	5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine;
595	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
596	5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-4-methyl-pyrimidine;
597	2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]pyrimidine;
598	2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
599	2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
600	5-Chloro-2-[[1-(3,4-difluorophenyl)triazol-4-yl]methoxy]pyrimidine;
601	2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
602	2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
603	2-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
604	2-[2-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
605	5-Chloro-2-[[1-(2,3-difluorophenyl)triazol-4-yl]methoxy]pyrimidine;
606	2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
607	2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]pyrimidine;
608	2-[2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;

609	2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
610	2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
611	2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine;
612	5-Chloro-2-[[1-(3-chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine;
613	2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
614	2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
615	2-[2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
616	[2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;
617	[2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
618	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine;
619	2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine;
620	2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
621	2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
622	2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
623	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine;
624	[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;
625	[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
626	2-[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
627	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
628	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine;
629	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
630	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-cyclopropyl-pyrimidine;

631	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-cyclopropyl-pyrimidine;
632	2-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
633	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine;
634	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;
635	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine;
636	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine;
637	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine;
638	2-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
639	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;
640	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-isopropyl-pyrimidine;
641	5-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
642	4-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
643	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
644	2-[2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
645	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
646	5-(Difluoromethoxy)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
647	5-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
648	4-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
649	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
650	5-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
651	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
652	2-[[1-[3-(Difluoromethyl)-2,4-difluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;

653	5-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
654	2-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
655	2-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
656	5-(Difluoromethyl)-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
657	5-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
658	5-Cyclopropyl-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
659	5-Chloro-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;
660	5-Ethyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;
661	5-Chloro-4-methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;
662	5-Methyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;
663	5-Ethyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;
664	5-Ethyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]pyrimidine;
665	2-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
666	5-Methyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-yl]methoxy]pyrimidine;
667	5-Ethyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-yl]methoxy]pyrimidine;
668	5-Fluoro-4-methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
669	5-Methoxy-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
670	5-(Trifluoromethyl)-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
671	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-(oxetan-3-yl)pyrimidin-4-amine;
672	5-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
673	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyridine;
674	5-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;

675	2-(Azetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
676	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(3-fluoroazetidin-1-yl)pyridine;
677	2-(3,3-Difluoroazetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
678	4-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
679	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(3-fluoroazetidin-1-yl)pyridine;
680	4-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
681	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrrol-2-yl)pyrimidine;
682	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine;
683	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrrol-2-yl)pyrimidine;
684	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine;
685	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethyl-5-fluoropyrimidin-4-amine;
686	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoro-N-(oxetan-3-yl)pyrimidin-4-amine;
687	N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine;
688	N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine;
689	N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine;
690	N-Cyclopropyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine;
691	N-Ethyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine;
692	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(2-methyl-1H-imidazol-1-yl)pyrimidine;
693	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(2-methyl-1H-imidazol-1-yl)pyrimidine;
694	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine;
695	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine;
696	4-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;

697	4-((Difluoromethoxy)methyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
698	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-1-yl)pyrimidine;
699	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-1-yl)pyrimidine;
700	(E)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one oxime;
701	5-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
702	(Z)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-one oxime;
703	(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-yl)methanol;
704	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)-5-fluoropyrimidine;
705	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)pyrimidine;
706	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoro-4-((trifluoromethoxy)methyl)pyrimidine;
707	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((trifluoromethoxy)methyl)pyrimidine;
708	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(methoxymethyl-d2)pyrimidine;
709	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((methoxy-d3)methyl-d2)pyrimidine;
710	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((methoxy-d3)methyl)pyrimidine;
711	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(ethoxymethyl)pyrimidine;
712	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1-methoxyethyl)pyrimidine;
713	1-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-ol;
714	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(2-methoxypropan-2-yl)pyrimidine;
715	2-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)propan-2-ol;
716	4-((2,2-Difluoroethoxy)methyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;

or a pharmaceutically acceptable salt thereof.

Another aspect of the current invention is a compound as shown below in Table 2.

2017217542 02 Mar 2021

Ex #	Compound Name
2	N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]pyridin-2-amine;
3	N-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
6	N-((1-(3-(Difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)pyrimidin-2-amine;
7	N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-imidazol-2-amine;
24	N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
36	N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
97	N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]oxazol-2-amine;
98	N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
99	N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-4-amine;
100	N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-3-amine;
101	N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-3-amine;
102	N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-4-amine;
109	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
110	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-4-amine;
144	N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidin-2-amine;

145	N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine;
153	5-Chloro-N-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
154	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine;
197	N-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methyl]-5-fluoro-pyrimidin-2-amine;
198	N-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine;
199	5-Chloro-N-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-4-methyl-pyrimidin-2-amine;
200	5-Chloro-N-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
201	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-4-methyl-pyrimidin-2-amine;
202	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-ethyl-pyrimidin-2-amine;
203	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-methoxy-pyrimidin-2-amine;
204	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-(difluoromethyl)pyrimidin-2-amine;
205	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine;
206	N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine;
207	N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-ethyl-pyrimidin-2-amine;
208	N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-isopropyl-pyrimidin-2-amine;
209	5-Cyclopropyl-N-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;

210	N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-4,5-dimethyl-pyrimidin-2-amine;
211	N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine;
212	5-Chloro-N-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
213	N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine;
214	2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methylamino]pyrimidin-5-yl]propan-2-ol;
215	N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine;
216	N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-ethylpyrimidin-2-amine;
217	N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine;
218	5-Chloro-N-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methylpyrimidin-2-amine;
219	N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine;
220	N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-imidazol-2-amine;
221	N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine;
222	N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidin-2-amine;
223	N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine; and
224	N-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethyl]-5-methyl-pyrimidin-2-amine;

or a pharmaceutically acceptable salt thereof.

A further aspect of the current invention is a compound as shown below in Table 3.

Compound Name
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine;
2-[[1-[4-Chloro-3-(2-fluoroethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-[3-(3-Chloropropyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine;
[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
5-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; and
5-Fluoro-4-methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;

or a pharmaceutically acceptable salt thereof.

An additional embodiment of the invention is a pharmaceutical composition comprising:

(A) an effective amount of at least one compound selected from compounds of Formula (I):



(I) ,

wherein:

Ar^1 is selected from the group consisting of:

(a) phenyl substituted with one substituent selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}perhaloalkyl, and OC_{1-6}perhaloalkyl; phenyl substituted with two or three substituents each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, C_{3-6}cycloalkyl, and azetidinyl;

(b) pyridinyl; pyridinyl substituted with one or two members each independently selected from the group consisting of: halo, CH_3, CF_3, and CF_2H; and

(c) thienyl substituted with CF_3; 1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl; or 2,3-dihydro-1H-inden-5-yl;

R^1 is H, halo, or CH_3;

R^2 is H or CH_3; and

Ar^3 is selected from the group consisting of:

(a) pyridinyl; pyridinyl substituted with one or two substituents each independently selected from the group consisting of: Cl, F, CH_3, OCH_3, CF_3, $C(CH_3)_2OH$; azetidin-1-yl; 3-fluoroazetidin-1-yl; and 3,3-difluoroazetidin-1-yl;

(b) pyridazinyl; pyridazinyl substituted with one or two substituents each independently selected from the group consisting of: CH_3, OCH_3, and CF_3;

(c) pyrimidin-4-yl; pyrimidin-4-yl substituted with one or two substituents each independently selected from the group consisting of: Cl, CH_3, CF_3, and OCH_3; pyrimidin-2-yl; pyrimidin-2-yl substituted one or two members each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}alkyl substituted with OH or OCH_3,

$C(OH)(CH_3)(CF_3)$, CH_2OCHF_2, CH_2OCF_3, $CH_2OCH_2CH_3$, $CH(NH_2)CH_3$, $CH_2NH(CH_3)$, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, $C(=N\text{-}OH)(CH_3)$, NH_2, $NH(CH_3)$, $N(CH_3)_2$; $NH(CH_2CH_3)$, $NH(CH_2CHF_2)$, NH(cyclopropyl), NH(difluorocyclobutyl), NH-oxetanyl, CN, $C(=O)CH_3$, $C(=O)NH(CH_3)$, $C(=O)N(CH_3)_2$, SO_2CH_3, CO_2CH_3, $C(CH_3)(=N\text{-}OH)$, cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholinyl, 1H-pyrrol-2-yl, 2-furyl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-pyrazol-1-yl, 2-methyl-1H-imidazol-1-yl, 1-methylpyrazol-3-yl, and phenyl;

(d) 5-fluoro-pyrazin-2-yl; 5-methylpyrazin-2-yl; 6-methylpyrazin-2-yl; pyrazin-4-yl; 5-(thien-2-yl)pyrazin-2-yl, and 2,3-dimethylpyrazin-5-yl; and


(e) 5-methyl-1H-imidazol-2-yl; 5-methylthiazol-2-yl;

and pharmaceutically acceptable salts of compounds of Formula (I);

and (B) at least one pharmaceutically acceptable excipient.

An additional embodiment of the invention is a pharmaceutical composition comprising:

(A) an effective amount of at least one compound selected from compounds of Formula (II):



(II)

wherein:

$Ar^{1'}$ is phenyl substituted with C_{1-3}perhaloalkyl; or phenyl substituted with two substituents each independently selected from the group consisting of: halo, C_{1-3}alkyl, C_{1-3}perhaloalkyl, and OC_{1-3}perhaloalkyl;

$R^{2'}$ is H or CH_3; and

2017217542 02 Mar 2021

Ar^2 is selected from the group consisting of:

(a) pyridin-2-yl; pyridazin-3-yl; pyrimidin-4-yl; pyrimidin-2-yl; or pyrimidin-2-yl substituted with one or two substituents each independently selected from the group consisting of halo, C_{1-3}alkyl, $C(CH_3)_2OH$, C_{1-3}perhaloalkyl, OCH_3, and cyclopropyl; and

(b) 1-methyl-imidazol-2-yl; oxazol-2-yl; 1-methyl-pyrazol-4-yl; 1-methyl-pyrazol-3-yl; or 1-methyl-1H-pyrazol-5-yl;

and pharmaceutically acceptable salts of compounds of Formula (II);

and (B) at least one pharmaceutically acceptable excipient.

An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound of Formula (IA) (as well as Formulas (IB), (IC), and (ID)), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IA) (as well as Formulas (IB), (IC), and (ID)), pharmaceutically acceptable prodrugs of compounds of Formula (IA) (as well as Formulas (IB), (IC), and (ID)), and pharmaceutically active metabolites of Formula (IA) (as well as Formulas (IB), (IC), and (ID)); and at least one pharmaceutically acceptable excipient.

An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound of Formula (IIA) (as well as Formula (IIB)), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIA) (as well as Formula (IIB)), pharmaceutically acceptable prodrugs of compounds of Formula (IIA) (as well as Formula (IIB)), and pharmaceutically active metabolites of Formula (IIA) (as well as Formula (IIB)); and at least one pharmaceutically acceptable excipient.

An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound in Table 1 (as well Table 2 and Table 3), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Table 1 (as well Table 2 and Table 3), pharmaceutically acceptable prodrugs of compounds of Table 1 (as well Table 2 and Table 3), and pharmaceutically active metabolites of Table 1

2017217542 02 Mar 2021

(as well Table 2 and Table 3); and at least one pharmaceutically acceptable excipient.

Also within the scope of the invention are enantiomers and diastereomers of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)). Also within the scope of the invention are the pharmaceutically acceptable salts, N-oxides or solvates of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)). Also within the scope of the invention are the pharmaceutically acceptable prodrugs of compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)), and pharmaceutically active metabolites of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)).

Also within the scope of the invention are enantiomers and diastereomers of the compounds of Formula (II) (as well as Formulas (IIA) and (IB)). Also within the scope of the invention are the pharmaceutically acceptable salts, N-oxides or solvates of the compounds of Formula (II) (as well as Formulas (IIA) and (IB)). Also within the scope of the invention are the pharmaceutically acceptable prodrugs of compounds of Formula (II) (as well as Formulas (IIA) and (IB)), and pharmaceutically active metabolites of the compounds of Formula (II) (as well as Formulas (IIA) and (IB)).

Also within the scope of the invention are isotopic variations of compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)), such as, e.g., deuterated compounds of Formula (I). Also within the scope of the invention are the pharmaceutically acceptable salts, N-oxides or solvates of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)). Also within the scope of the invention are the pharmaceutically acceptable prodrugs of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)), and pharmaceutically active metabolites of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)).

Also within the scope of the invention are isotopic variations of compounds of Formula (II) (as well as Formulas (IIA) and (IB)), such as, e.g., deuterated compounds of Formula (II). Also within the scope of the invention are the pharmaceutically acceptable salts, N-oxides or solvates of the isotopic

variations of the compounds of Formula (II) (as well as Formulas (IIA) and (IB)). Also within the scope of the invention are the pharmaceutically acceptable prodrugs of the isotopic variations of the compounds of Formula (II) (as well as Formulas (IIA) and (IB)), and pharmaceutically active metabolites of the isotopic variations of the compounds of Formula (II) (as well as Formulas (IIA) and (IB)).

An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by NR2B receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I):



(I)

,

wherein:

Ar^1 is selected from the group consisting of:

(a) phenyl substituted with one substituent selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}perhaloalkyl, and OC_{1-6}perhaloalkyl; phenyl substituted with two or three substituents each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, C_{3-6}cycloalkyl, and azetidinyl;

(b) pyridinyl; pyridinyl substituted with one or two members each independently selected from the group consisting of: halo, CH_3, CF_3, and CF_2H; and

(c) thienyl substituted with CF_3; 1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl; or 2,3-dihydro-1H-inden-5-yl;

R^1 is H, halo, or CH_3;

R^2 is H or CH_3; and

Ar^3 is selected from the group consisting of:

2017217542 02 Mar 2021

(a) pyridinyl; pyridinyl substituted with one or two substituents each independently selected from the group consisting of: Cl, F, CH_3, OCH_3, CF_3, $C(CH_3)_2OH$; azetidin-1-yl; 3-fluoroazetidin-1-yl; and 3,3-difluoroazetidin-1-yl;

(b) pyridazinyl; pyridazinyl substituted with one or two substituents each independently selected from the group consisting of: CH_3, OCH_3, and CF_3;

(c) pyrimidin-4-yl; pyrimidin-4-yl substituted with one or two substituents each independently selected from the group consisting of: Cl, CH_3, CF_3, and OCH_3; pyrimidin-2-yl; pyrimidin-2-yl substituted one or two members each independently selected from the group consisting of: halo, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkyl substituted with OH or OCH_3, $C(OH)(CH_3)(CF_3)$, CH_2OCHF_2, CH_2OCF_3, $CH_2OCH_2CH_3$, $CH(NH_2)CH_3$, $CH_2NH(CH_3)$, $C_{1\text{-}6}$perhaloalkyl, $OC_{1\text{-}6}$alkyl, $OC_{1\text{-}6}$perhaloalkyl, $C(=N\text{-}OH)(CH_3)$, NH_2, $NH(CH_3)$, $N(CH_3)_2$; $NH(CH_2CH_3)$, $NH(CH_2CHF_2)$, NH(cyclopropyl), NH(difluorocyclobutyl), NH-oxetanyl, CN, $C(=O)CH_3$, $C(=O)NH(CH_3)$, $C(=O)N(CH_3)_2$, SO_2CH_3, CO_2CH_3, $C(CH_3)(=N\text{-}OH)$, cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholinyl, 1H-pyrrol-2-yl, 2-furyl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-pyrazol-1-yl, 2-methyl-1H-imidazol-1-yl, 1-methylpyrazol-3-yl, and phenyl;


(d) 5-fluoro-pyrazin-2-yl; 5-methylpyrazin-2-yl; 6-methylpyrazin-2-yl; pyrazin-4-yl; 5-(thien-2-yl)pyrazin-2-yl, and 2,3-dimethylpyrazin-5-yl; and

(e) 5-methyl-1H-imidazol-2-yl; 5-methylthiazol-2-yl;

or a pharmaceutically acceptable salts thereof, to a subject in need thereof.

An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by NR2B receptor activity, comprising administering to a

subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (II):



(II)

wherein:

$Ar^{1'}$ is phenyl substituted with C_{1-3}perhaloalkyl; or phenyl substituted with two substituents each independently selected from the group consisting of: halo, C_{1-3}alkyl, C_{1-3}perhaloalkyl, and OC_{1-3}perhaloalkyl;

$R^{2'}$ is H or CH_3; and

Ar^2 is selected from the group consisting of:

(a) pyridin-2-yl; pyridazin-3-yl; pyrimidin-4-yl; pyrimidin-2-yl; or pyrimidin-2-yl substituted with one or two substituents each independently selected from the group consisting of halo, C_{1-3}alkyl, $C(CH_3)_2OH$, C_{1-3}perhaloalkyl, OCH_3, and cyclopropyl; and

(b) 1-methyl-imidazol-2-yl; oxazol-2-yl; 1-methyl-pyrazol-4-yl; 1-methyl-pyrazol-3-yl; or 1-methyl-1H-pyrazol-5-yl;

and pharmaceutically acceptable salts thereof, to a subject in need thereof.

An additional aspect of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by NR2B receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I) (as well as (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)), or a pharmaceutically acceptable salt of any of the foregoing.

In another aspect the invention provides the use of at least one compound selected from compounds of Formula (I) (as well as (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)), or a pharmaceutically acceptable salt of any of the foregoing in the manufacture of a medicament for treating a subject suffering

2017217542 02 Mar 2021

from or diagnosed with a disease, disorder, or medical condition mediated by NR2B receptor activity.

In preferred embodiments of the inventive method, the disease, disorder, or medical condition is selected from: neurologic and psychiatric disorders including, but not limited to: (1) mood disorders and mood affective disorders; (2) neurotic, stress-related and somatoform disorders including anxiety disorders; (3) disorders of psychological development; (4) behavioral syndromes associated with physiological disturbances and physical factors; (5) extrapyramidal and movement disorders; (6) episodic and paroxysmal disorders, epilepsy; (7) pain; (8) forms of neurodegeneration; (9) cerebrovascular diseases, acute and chronic; and any sequelae of cerebrovascular diseases.

Examples of mood disorders and mood affective disorders that can be treated according to the present invention include, but are not limited to, bipolar disorder I depressed, hypomanic, manic and mixed form; bipolar disorder II; depressive disorders, such as single depressive episode or recurrent major depressive disorder, minor depressive disorder, treatment-resistant depression, depressive disorder with postpartum onset, depressive disorders with psychotic symptoms; persistent mood disorders, such as cyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder.

Examples of disorders belonging to the neurotic, stress-related and somatoform disorders that can be treated according to the present invention include, but are not limited to, anxiety disorders, general anxiety disorder, panic disorder with or without agoraphobia, specific phobia, social anxiety disorder, chronic anxiety disorders; obsessive compulsive disorder; reaction to sever stress and adjustment disorders, such as post-traumatic stress disorder (PTSD); other neurotic disorders such as depersonalisation-derealisation syndrome.

Examples of disorders of psychological development that can be treated according to the present invention include, but are not limited to pervasive developmental disorders, including but not limited to Asperger's syndrome and Rett's syndrome, autistic disorders, childhood autism and

overactive disorder associated with mental retardation and stereotyped movements, specific developmental disorder of motor function, specific developmental disorders of scholastic skills.

Examples of behavioral syndromes associated with physiological disturbances and physical factors according to the present invention include, but are not limited to mental and behavioural disorders associated with childbirth, including but not limited to postnatal (postpartum) and prenatal depression; eating disorders, including but not limited to anorexia nervosa, bulimia nervosa, pica and binge eating disporder.

Examples of extrapyramidal and movement disorders that can be treated according to the present invention include, but are not limited to Parkinson's disease; second Parkinsonism, such as postencephalitic Parkinsonism; Parkinsonism comprised in other disorders; Lewis body disease; degenerative diseases of the basal ganglia; other extrapyramidal and movement disorders including but not limited to tremor, essential tremor and drug-induced tremor, myoclonus, chorea and drug-induced chorea, drug-induced tics and tics of organic origin, drug-induced acute dystonia, drug-induced tardive dyskinesia, L-dopa-induced dyskinesia; neuroleptic-induced movement disorders including but not limited to neuroleptic malignant syndrome (NMS), neuroleptic induced parkinsonism, neuroleptic-induced early onset or acute dyskinesia, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia, neuroleptic-induced tremor; restless leg syndrome, Stiff-man syndrome.

Further examples of movement disorders with malfunction and/or degeneration of basal ganglia that can be treated according to the present invention include, but are not limited to dystonia including but not limited to focal dystonia, multiple-focal or segmental dystonia, torsion dystonia, hemispheric, generalised and tardive dystonia (induced by psychopharmacological drugs). Focal dystonia include cervical dystonia (torticolli), blepharospasm (cramp of the eyelid), appendicular dystonia (cramp in the extremities, like the writer's cramp), oromandibular dystonia and spasmodic dysphonia (cramp of the vocal cord);

2017217542 02 Mar 2021

Examples for episodic and paroxysmal disorders that can be treated according to the present invention include, but are not limited to epilepsy, including localization-related (focal)(partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, generalized idiopathic epilepsy and epileptic syndromes including but not limited to myoclonic epilepsy in infancy, neonatal convulsions (familial), childhood absence epilepsy (pyknolepsy), epilepsy with grand mal seizures on awakening, absence epilepsy, myoclonic epilepsy (impulsive petit mal) and nonspecific atonic, clonic, myoclonic, tonic, tonic-clonic epileptic seizures.

Further examples of epilepsy that can be treated according to the present invention include, but are not limited to epilepsy with myoclonic absences, myoclonic-astatic seizures, infantile spasms, Lennox-Gastaut syndrome, Salaam attacks, symptomatic early myoclonic encephalopathy, West's syndrome, petit and grand mal seizures; status epilepticus.

Examples of pain include, but are not limited to pain disorders related to psychological factors, such as persistent somatoform disorders; acute, chronic and chronic intractable pain, headache; acute and chronic pain related to physiological processes and physical disorders including but not limited to back pain, tooth pain, abdominal pain, low back pain, pain in joints; acute and chronic pain that is related to diseases of the musculoskeletal system and connective tissue including, but not limited to rheumatism, myalgia, neuralgia and fibromyalgia; acute and chronic pain that is related to nerve, nerve root and plexus disorders, such as trigeminal pain, postzoster neuralgia, phantom limb syndrome with pain, carpal tunnel syndrome, lesion of sciatic nerve, diabetic mononeuropathy; acute and chronic pain that is related to polyneuropathies and other disorders of the peripheral nervous system, such as hereditary and idiopathic neuropathy, inflammatory polyneuropathy, polyneuropathy induced by drugs, alcohol or toxic agents, polyneuropathy in neoplastic disease, diabetic polyneuropathy.

2017217542 02 Mar 2021

Examples of diseases that include forms of neurodegeneration include, but are not limited to, acute neurodegeneration, such as intracranial brain injuries, such as stroke, diffuse and local brain injuries, epidural, subdural and subarachnoid haemorrhage, and chronic neurodegeneration, such as Alzheimer's disease, Huntington's disease, multiple sclerosis and ALS.

Examples of cerebrovascular diseases include, but are not limited to, subarachnoid haemorrhage, intracerebral haemorrhage and other nontraumatic intracranial haemorrhage, cerebral infarction, stroke, occlusion and stenosis or precerebral and cerebral arteries, not resulting in cerebral infarction, dissection of cerebral arteries, cerebral aneurysm, cerebral atherosclerosis, progressive vascular leukoencephalopathy, hypertensive encephalopathy, nonpyogenic thrombosis of intracranial venous system, cerebral arteritis, cerebral amyloid angiopathy and sequelae of cerebrovascular diseases.

In some embodiments, administration of a compound of the invention, or pharmaceutically acceptable salt thereof, is effective in preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.

Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.

The invention may be more fully appreciated by reference to the following description, including the following glossary of terms and the concluding examples. For the sake of brevity, the disclosures of the publications, including patents, cited in this specification are herein incorporated by reference.

As used herein, the terms "including", "containing" and "comprising" are used herein in their open, non-limiting sense.

The term "alkyl" refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain. Examples of alkyl groups include methyl (Me, which also may be structurally depicted by the symbol,


"/"), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples. The term C_{1-3}alkyl as used here refers to a straight- or branched-chain alkyl group having from 1 to 3 carbon atoms in the chain. The term C_{1-6}alkyl as used here refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain.

The term "halo" represents chloro, fluoro, bromo or iodo.


The term "perhaloalkyl" or "haloalkyl" refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain optionally substituting hydrogens with halogens. The term "C_{1-3}perhaloalkyl" as used here refers to a straight- or branched-chain alkyl group having from 1 to 3 carbon atoms in the chain, optionally substituting hydrogens with halogens. The term "C_{1-6}perhaloalkyl" as used here refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain, optionally substituting hydrogens with halogens. Examples of "perhaloalkyl", "haloalkyl" groups include trifluoromethyl (CF_3), difluoromethyl (CF_2H), monofluoromethyl (CH_2F), pentafluoroethyl (CF_2CF_3), tetrafluoroethyl ($CHFCF_3$),monofluoroethyl (CH_2CH_2F), trifluoroethyl (CH_2CF_3), tetrafluorotrifluoromethylethyl ($CF(CF_3)_2$), chloropropyl ($CH_2CH_2CH_2Cl$), and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.

The term "cyano" refers to the group CN.

The term "cycloalkyl" refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle. Illustrative examples of cycloalkyl groups include the following entities, in the form of properly bonded moieties:



The term "phenyl" represents the following moiety:




. The phenyl moiety can be attached through any one of the 1-, 2-, 3-, 4-, 5-, or 6-position carbon atoms.

The term "thienyl" represents the following moiety:




.

The term "pyridinyl" or "pyridyl" represents the following moiety:




The pyridinyl or pyridyl moiety can be attached through any one of the 2-, 3-, 4-, 5-, or 6-position carbon atoms.

The term "pyrimidinyl" represents the following moiety:




The pyrimidinyl moiety can be attached through any one of the 2-, 4-, 5-, or 6-position carbon atoms.

The term "pyrazinyl" represents the following moiety:




The pyrazinyl moiety can be attached through any one of the 2-, 3-, 5-, or 6-position carbon atoms.

The term "pyridazinyl" represents the following moiety:




The pyridazinyl moiety can be attached through any one of the 3-, 4-, 5-, or 6-position carbon atoms.

The term "pyrazolyl" represents the following moiety:




The pyrazolyl moiety can be attached through any one of the 1-, 2-, 3-, 4-, or 5-position carbon atoms.

The term “piperidinyl” represents the following moiety:



When the piperidinyl moiety is a substituent, it can be attached through any one of the 1-, 2-, 3-, 4-, 5-, or 6-position atoms, as permitted.


The term “pyrrolidinyl” represents the following moiety:



When the piperidinyl moiety is a substituent, it can be attached through any one of the 1-, 2-, 3-, 4-, or 5- position atoms, as permitted.

The term “azetidinyl” represents a 4-membered heterocycloalkyl moiety having one ring nitrogen. When the azetidinyl moiety is a substituent, it can be attached through any carbon atom or through the nitrogen atom, as permitted.

The term “morpholinyl” represents the following moiety:




When the morpholinyl moiety is a substituent, it can be attached through any one of the 2-, 3-, 4-, 5-, or 6-position atoms, as permitted.

The term “substituted” means that the specified group or moiety bears one or more substituents. The term "unsubstituted" means that the specified group bears no substituents. The term “optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents. Where the term “substituted” is used to describe a structural system, the

substitution is meant to occur at any valency-allowed position on the system. In cases where a specified moiety or group is not expressly noted as being optionally substituted or substituted with any specified substituent, it is understood that such a moiety or group is intended to be unsubstituted.

The terms "para", "meta", and "ortho" have the meanings as understood in the art. Thus, for example, a fully substituted phenyl group has substituents at both "ortho"(*o*) positions adjacent to the point of attachment of the phenyl ring, both "meta" (*m*) positions, and the one "para" (*p*) position across from the point of attachment. To further clarify the position of substituents on the phenyl ring, the 2 different ortho positions will be designated as ortho and ortho' and the 2 different meta positions as meta and meta' as illustrated below.



To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term "about". It is understood that, whether the term "about" is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations due to the experimental and/or measurement conditions for such given value. Whenever a yield is given as a percentage, such yield refers to a mass of the entity for which the yield is given with respect to the maximum amount of the same entity that could be obtained under the particular stoichiometric conditions. Concentrations that are given as percentages refer to mass ratios, unless indicated differently.

The terms "buffered" solution or "buffer" solution are used herein interchangeably according to their standard meaning. Buffered solutions are used to control the pH of a medium, and their choice, use, and function is known to those of ordinary skill in the art. See, for example, G.D. Considine, ed., Van Nostrand's Encyclopedia of Chemistry, p. 261, 5th ed. (2005),

2017217542 02 Mar 2021

describing, inter alia, buffer solutions and how the concentrations of the buffer constituents relate to the pH of the buffer. For example, a buffered solution is obtained by adding $MgSO_4$ and $NaHCO_3$ to a solution in a 10:1 w/w ratio to maintain the pH of the solution at about 7.5.

Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula. Thus, any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof. Furthermore, certain structures may exist as geometric isomers (i.e., *cis* and *trans* isomers), as tautomers, or as atropisomers.

It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers."

Stereoisomers that are not mirror images of one another are termed "diastereomers" and those that are non-superimposable mirror images of each other are termed "enantiomers." When a compound has an asymmetric center, for example, it is bonded to four different groups, and a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R-and *S*-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (*i.e.*, as (+)- or (-)-isomers respectively). A chiral compound can exist as either an individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture."

"Tautomers" refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of π electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment

with either acid or base. Another example of tautomerism is the aci-and nitro-forms of phenyl nitromethane, that are likewise formed by treatment with acid or base.

Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.

The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (*R*)- or (*S*)-stereoisomers or as mixtures thereof.

Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.

Certain examples contain chemical structures that are depicted as an absolute enantiomer but are intended to indicate enatiopure material that is of unknown configuration. In these cases (R*) or (S*) is used in the name to indicate that the absolute stereochemistry of the corresponding stereocenter is unknown. Thus, a compound designated as (R*) refers to an enantiopure compound with an absolute configuration of either (R) or (S). In cases where the absolute stereochemistry has been confirmed, the structures are named using (R) and (S).

The symbols  and are used as meaning the same spatial arrangement in chemical structures shown herein. Analogously, the symbols  and  are used as meaning the same spatial arrangement in chemical structures shown herein.

Additionally, any formula given herein is intended to refer also to hydrates, solvates, and polymorphs of such compounds, and mixtures thereof, even if such forms are not listed explicitly. Certain compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)), or pharmaceutically acceptable salts of compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) may be obtained as solvates. Solvates include those formed from the interaction or complexation of compounds of the invention with one or more solvents, either in solution or

as a solid or crystalline form. In some embodiments, the solvent is water andthe solvates are hydrates.

In addition, certain crystalline forms of compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) or pharmaceutically acceptable salts of compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) may be obtained as co-crystals.

In other embodiments, pharmaceutically acceptable salts of compounds of Formula (I) may be obtained in a crystalline form. In still other embodiments, compounds of Formula (I) may be obtained in one of several polymorphic forms, as a mixture of crystalline forms, as a polymorphic form, or as an amorphous form. In other embodiments, compounds of Formula (I) may convert in solution between one or more crystalline forms and/or polymorphic forms.

Reference to a compound herein stands for a reference to any one of: (a) the actually recited form of such compound, and (b) any of the forms of such compound in the medium in which the compound is being considered when named. For example, reference herein to a compound such as R-COOH, encompasses reference to any one of, for example, R-$COOH_{(s)}$, R-$COOH_{(sol)}$, and R-$COO^{-}{}_{(sol)}$. In this example, R-$COOH_{(s)}$ refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation; R-$COOH_{(sol)}$ refers to the undissociated form of the compound in a solvent; and R-$COO^{-}{}_{(sol)}$ refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from R-COOH, from a salt thereof, or from any other entity that yields R-COO^{-} upon dissociation in the medium being considered. In another example, an expression such as “exposing an entity to compound of formula R-COOH” refers to the exposure of such entity to the form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such exposure takes place. In still another example, an expression such as “reacting an entity with a compound of formula R-COOH” refers to the reacting of (a) such entity in the chemically relevant form, or forms, of such entity that exists, or exist, in the medium in which such reacting takes place,

2017217542 02 Mar 2021

with (b) the chemically relevant form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such reacting takes place. In this regard, if such entity is for example in an aqueous environment, it is understood that the compound R-COOH is in such same medium, and therefore the entity is being exposed to species such as $R\text{-}COOH_{(aq)}$ and/or $R\text{-}COO^{-}_{(aq)}$, where the subscript "(aq)" stands for "aqueous" according to its conventional meaning in chemistry and biochemistry. A carboxylic acid functional group has been chosen in these nomenclature examples; this choice is not intended, however, as a limitation but it is merely an illustration. It is understood that analogous examples can be provided in terms of other functional groups, including but not limited to hydroxyl, basic nitrogen members, such as those in amines, and any other group that interacts or transforms according to known manners in the medium that contains the compound. Such interactions and transformations include, but are not limited to, dissociation, association, tautomerism, solvolysis, including hydrolysis, solvation, including hydration, protonation, and deprotonation. No further examples in this regard are provided herein because these interactions and transformations in a given medium are known by any one of ordinary skill in the art.

In another example, a zwitterionic compound is encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its zwitterionic form. Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard IUPAC-endorsed names that are well known and part of standard sets of defined scientific names. In this regard, the name zwitterion is assigned the name identification CHEBI:27369 by the Chemical Entities of Biological Interest (ChEBI) dictionary of molecular entities. As generally well known, a zwitterion or zwitterionic compound is a neutral compound that has formal unit charges of opposite sign. Sometimes these compounds are referred to by the term "inner salts". Other sources refer to these compounds as "dipolar ions", although the latter term is regarded by still other sources as a misnomer. As a specific example, aminoethanoic acid (the amino acid glycine) has the formula H_2NCH_2COOH, and it exists in some media (in this case in neutral media) in

the form of the zwitterion $^{+}H_3NCH_2COO^{-}$. Zwitterions, zwitterionic compounds, inner salts and dipolar ions in the known and well established meanings of these terms are within the scope of this invention, as would in any case be so appreciated by those of ordinary skill in the art. Because there is no need to name each and every embodiment that would be recognized by those of ordinary skill in the art, no structures of the zwitterionic compounds that are associated with the compounds of this invention are given explicitly herein. They are, however, part of the embodiments of this invention. No further examples in this regard are provided herein because the interactions and transformations in a given medium that lead to the various forms of a given compound are known by any one of ordinary skill in the art.

Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine such as ^{2}H, ^{3}H, ^{11}C, ^{13}C, ^{14}C, ^{15}N, ^{18}O, ^{17}O, ^{31}P, ^{32}P, ^{35}S, ^{18}F, ^{36}Cl, ^{125}I, respectively. Such isotopically labeled compounds are useful in metabolic studies (preferably with ^{14}C), reaction kinetic studies (with, for example deuterium (i.e., D or ^{2}H); or tritium (i.e., T or ^{3}H)), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an ^{18}F or ^{11}C labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., ^{2}H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting

a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the same choice of the species for the variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula, unless stated otherwise.

According to the foregoing interpretive considerations on assignments and nomenclature, it is understood that explicit reference herein to a set implies, where chemically meaningful and unless indicated otherwise, independent reference to embodiments of such set, and reference to each and every one of the possible embodiments of subsets of the set referred to explicitly.

By way of a first example on substituent terminology, if substituent $S^1_{example}$ is one of S_1 and S_2, and substituent $S^2_{example}$ is one of S_3 and S_4, then these assignments refer to embodiments of this invention given according to the choices $S^1_{example}$ is S_1 and $S^2_{example}$ is S_3; $S^1_{example}$ is S_1 and $S^2_{example}$ is S_4; $S^1_{example}$ is S_2 and $S^2_{example}$ is S_3; $S^1_{example}$ is S_2 and $S^2_{example}$ is S_4; and equivalents of each one of such choices. The shorter terminology "$S^1_{example}$ is one of S_1 and S_2, and $S^2_{example}$ is one of S_3 and S_4" is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing first example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein. The foregoing convention given herein for substituents extends, when applicable, to members such as R^1, $R^{1'}$, R^2, $R^{2'}$, R^4, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^f, R^g, R^h, HAL, PG, LG, *n*, Ar^1, $Ar^{1'}$, Ar^2, Ar^3, and any other generic substituent symbol used herein.

Furthermore, when more than one assignment is given for any member or substituent, embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof. By way of a second example on substituent terminology, if it is herein described that substituent $S_{example}$ is one of S_1, S_2, and S_3, this

2017217542 02 Mar 2021

listing refers to embodiments of this invention for which $S_{example}$ is S_1; $S_{example}$ is S_2; $S_{example}$ is S_3; $S_{example}$ is one of S_1 and S_2; $S_{example}$ is one of S_1 and S_3; $S_{example}$ is one of S_2 and S_3; $S_{example}$ is one of S_1, S_2 and S_3; and $S_{example}$ is any equivalent of each one of these choices. The shorter terminology "$S_{example}$ is one of S_1, S_2, and S_3" is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing second example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein. The foregoing convention given herein for substituents extends, when applicable, to members such as R^1, $R^{1'}$, R^2, $R^{2'}$, R^4, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^f, R^g, R^h, HAL, PG, LG, *n,* Ar^1, $Ar^{1'}$, Ar^2, Ar^3 and any other generic substituent symbol used herein.

The nomenclature "C_{i-j}" with j > i, when applied herein to a class of substituents, is meant to refer to embodiments of this invention for which each and every one of the number of carbon members, from i to j including i and j, is independently realized. By way of example, the term C_{1-4} refers independently to embodiments that have one carbon member (C_1), embodiments that have two carbon members (C_2), embodiments that have three carbon members (C_3), and embodiments that have four carbon members (C_4).

The term C_{n-m}alkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies $n \le N \le m$, with $m > n$. Any disubstituent referred to herein is meant to encompass the various attachment possibilities when more than one of such possibilities are allowed. For example, reference to disubstituent –A-B-, where $A \neq B$, refers herein to such disubstituent with A attached to a first substituted member and B attached to a second substituted member, and it also refers to such disubstituent with A attached to the second substituted member and B attached to the first substituted member.

The invention includes also pharmaceutically acceptable salts of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)), preferably of those described above and of the specific compounds exemplified herein, and methods of treatment using such salts.

2017217542 02 Mar 2021

The term “pharmaceutically acceptable” means approved or approvable by a regulatory agency of Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U. S. Pharmcopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.

A "pharmaceutically acceptable salt” is intended to mean a salt of a free acid or base of compounds represented by Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) that are non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. It should possess the desired pharmacological activity of the parent compound. See, generally, G.S. Paulekuhn, et al., “Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database”, *J. Med. Chem.*, **2007**, 50:6665–72, S.M. Berge, et al., “Pharmaceutical Salts”, *J Pharm Sci.*, **1977**, 66:1-19, and *Handbook of Pharmaceutical Salts, Properties, Selection, and Use,* Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, **2002**. Examples of pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. A compound of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.

Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates,

2017217542 02 Mar 2021

methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.

When the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) contain a basic nitrogen, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art. For example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspartic acid, glutaric acid or glutamic acid, an aromatic acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid, a sulfonic acid, such as laurylsulfonic acid, *p*-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, any compatible mixture of acids such as those given as examples herein, and any other acid and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.

When the compound of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) is an acid, such as a carboxylic acid or sulfonic acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology. Illustrative examples of suitable salts include organic salts derived from amino acids, such as *N*-methyl-D-glucamine, lysine, choline, glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic

2017217542 02 Mar 2021

amines, such as tromethamine, benzylamines, pyrrolidines, piperidine, morpholine, and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.

The invention also relates to pharmaceutically acceptable prodrugs of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)), and treatment methods employing such pharmaceutically acceptable prodrugs. The term "prodrug" means a precursor of a designated compound that, following administration to a subject, yields the compound *in vivo* via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula (I). A "pharmaceutically acceptable prodrug" is a prodrug that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "*Design of Prodrugs*", ed. H. Bundgaard, Elsevier, **1985**.

Exemplary prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, covalently joined through an amide or ester bond to a free amino, hydroxyl, or carboxylic acid group of a compound of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)). Examples of amino acid residues include the twenty naturally occurring amino acids, commonly designated by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.

Additional types of prodrugs may be produced, for instance, by derivatizing free carboxyl groups of structures of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) as amides or alkyl esters. Examples of amides include those derived from ammonia, primary C_{1-6}alkyl amines and secondary di(C_{1-6}alkyl) amines. Secondary amines include 5- or 6-membered heterocycloalkyl or heteroaryl ring moieties. Examples of amides

2017217542 02 Mar 2021

include those that are derived from ammonia, C_{1-3}alkyl primary amines, and di(C_{1-2}alkyl)amines. Examples of esters of the invention include C_{1-7}alkyl, C_{5-7}cycloalkyl, phenyl, and phenyl(C_{1-6}alkyl) esters. Preferred esters include methyl esters. Prodrugs may also be prepared by derivatizing free hydroxy groups using groups including hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, following procedures such as those outlined in Fleisher et al., *Adv. Drug Delivery Rev.* **1996**, *19*, 115-130. Carbamate derivatives of hydroxy and amino groups may also yield prodrugs. Carbonate derivatives, sulfonate esters, and sulfate esters of hydroxy groups may also provide prodrugs. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester, optionally substituted with one or more ether, amine, or carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also useful to yield prodrugs. Prodrugs of this type may be prepared as described in Robinson et al., *J Med Chem.* **1996**, *39* (1), 10-18. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including ether, amine, and carboxylic acid functionalities.

The present invention also relates to pharmaceutically active metabolites of the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)), which may also be used in the methods of the invention. A "pharmaceutically active metabolite" means a pharmacologically active product of metabolism in the body of a compound of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) as applicable) or salt thereof. Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini, et al., *J Med Chem*. **1997**, *40*, 2011-2016; Shan, et al., *J Pharm Sci*. **1997**, *86 (7)*, 765-767; Bagshawe, *Drug Dev Res*. **1995**, *34*, 220-230; Bodor, *Adv Drug Res*. **1984**, *13*, 224-331; Bundgaard, *Design of Prodrugs* (Elsevier Press, **1985**); and Larsen, *Design and Application of Prodrugs, Drug Design and Development* (Krogsgaard-Larsen, et al., eds., Harwood Academic Publishers, **1991**).

2017217542 02 Mar 2021

The compounds of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of the present invention are useful as modulators of the NR2B receptor in the methods of the invention. As such modulators, the compounds may act as antagonists, agonists, or inverse agonists. The term “modulators” include both inhibitors and activators, where "inhibitors” refer to compounds that decrease, prevent, inactivate, desensitize, or down-regulate the NR2B receptor expression or activity, and “activators” are compounds that increase, activate, facilitate, sensitize, or up-regulate NR2B receptor expression or activity.

The term "treat", “treatment” or "treating", as used herein, is intended to refer to administration of an active agent or composition of the invention to a subject for the purpose of affecting a therapeutic or prophylactic benefit through modulation of NR2B receptor activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition mediated through modulation of NR2B receptor activity. The term "subject" refers to a mammalian patient in need of such treatment, such as a human.

Accordingly, the invention relates to methods of using the compounds described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated by NR2B receptor activity, such as: bipolar disorder I depressed, hypomanic, manic and mixed form; bipolar disorder II; depressive disorders, such as single depressive episode or recurrent major depressive disorder, minor depressive disorder, treatment-resistant depression, depressive disorder with postpartum onset, disruptive mood dysregulation disorder, depressive disorders with psychotic symptoms; persistent mood disorders, such as cyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder; anxiety disorders, general anxiety disorder, panic disorder with or without agoraphobia, specific phobia, social anxiety disorder, chronic anxiety disorders; obsessive compulsive disorder; reaction to sever stress and adjustment disorders, such as post traumatic stress

2017217542 02 Mar 2021

disorder (PTSD); other neurotic disorders such as depersonalisation-derealisation syndrome; pervasive developmental disorders, including but not limited to Asperger's syndrome and Rett's syndrome, autistic disorders, childhood autism and overactive disorder associated with mental retardation and stereotyped movements, specific developmental disorder of motor function, specific developmental disorders of scholastic skills; postnatal (postpartum) and prenatal depression; eating disorders, including but not limited to anorexia nervosa, bulimia nervosa, pica and binge eating disorder; Parkinson's disease; second Parkinsonism, such as postencephalitic Parkinsonism; Parkinsonism comprised in other disorders; Lewis body disease; degenerative diseases of the basal ganglia; other extrapyramidal and movement disorders including but not limited to tremor, essential tremor and drug-induced tremor, myoclonus, chorea and drug-induced chorea, drug-induced tics and tics of organic origin, drug-induced acute dystonia, drug-induced tardive dyskinesia, L-dopa-induced dyskinesia; neuroleptic-induced movement disorders including but not limited to neuroleptic malignant syndrome (NMS), neuroleptic induced parkinsonism, neuroleptic-induced early onset or acute dyskinesia, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia, neuroleptic-induced tremor; restless leg syndrome, Stiff-man syndrome; dystonia including but not limited to focal dystonia, multiple-focal or segmental dystonia, torsion dystonia, hemispheric, generalised and tardive dystonia (induced by psychopharmacological drugs). Focal dystonia include cervical dystonia (torticolli), blepharospasm (cramp of the eyelid), appendicular dystonia (cramp in the extremities, like the writer's cramp), oromandibular dystonia and spasmodic dysphonia (cramp of the vocal cord); epilepsy, including localization-related (focal)(partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, generalized idiopathic epilepsy and epileptic syndromes including but not limited to myoclonic epilepsy in infancy, neonatal convulsions (familial), childhood absence epilepsy (pyknolepsy),

2017217542 02 Mar 2021

epilepsy with grand mal seizures on awakening, absence epilepsy, myoclonic epilepsy (impulsive petit mal) and nonspecific atonic, clonic, myoclonic, tonic, tonic-clonic epileptic seizures; epilepsy with myoclonic absences, myoclonic-astatic seizures, infantile spasms, Lennox-Gastaut syndrome, Salaam attacks, symptomatic early myoclonic encephalopathy, West's syndrome, petit and grand mal seizures; status epilepticus; persistent somatoform disorders; acute, chronic and chronic intractable pain, headache; acute and chronic pain related to physiological processes and physical disorders including but not limited to back pain, tooth pain, abdominal pain, low back pain, pain in joints; acute and chronic pain that is related to diseases of the musculoskeletal system and connective tissue including, but not limited to rheumatism, myalgia, neuralgia and fibromyalgia; acute and chronic pain that is related to nerve, nerve root and plexus disorders, such as trigeminal pain, postzoster neuralgia, phantom limb syndrome with pain, carpal tunnel syndrome, lesion of sciatic nerve, diabetic mononeuropathy; acute and chronic pain that is related to polyneuropathies and other disorders of the peripheral nervous system, such as hereditary and idiopathic neuropathy, inflammatory polyneuropathy, polyneuropathy induced by drugs, alcohol or toxic agents, polyneuropathy in neoplastic disease, diabetic polyneuropathy; and acute neurodegeneration, such as intracranial brain injuries, such as stroke, diffuse and local brain injuries, epidural, subdural and subarachnoid haemorrhage, and chronic neurodegeneration, such as Alzheimer's disease, Huntington's disease, multiple sclerosis, and ALS; subarachnoid haemorrhage, intracerebral haemorrhage and other nontraumatic intracranial haemorrhage, cerebral infarction, stroke, occlusion and stenosis or precerebral and cerebral arteries, not resulting in cerebral infarction, dissection of cerebral arteries, cerebral aneurysm, cerebral atherosclerosis, progressive vascular leukoencephalopathy, hypertensive encephalopathy, nonpyogenic thrombosis of intracranial venous system, cerebral arteritis, cerebral amyloid angiopathy and sequelae of cerebrovascular diseases; glaucoma and other neuopathies; dementias, vascular demensia, Lewy body dementia, frontotemporal dementia, and HIV-dementia; vertigo and nystagmus; tinnitus; neuropsychiatric systemic lupus erythematosus; disruptive mood

dysregulation disorder; schizophrenia spectrum disorder; and sleep/wake disorders.

In treatment methods according to the invention, an effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition. An "effective amount" means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the compounds of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. An example of a dose is in the range of from about 0.001 to about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.

Once improvement of the patient's disease, disorder, or condition has occurred, the dose may be adjusted for preventative or maintenance treatment. For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.

In addition, the active agents of the invention may be used in combination with additional active ingredients in the treatment of the above conditions. The additional active ingredients may be co-administered separately with an active agent of compounds of Table 1 or included with such an agent in a pharmaceutical composition according to the invention. In

an exemplary embodiment, additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by NR2B activity, such as another NR2B modulator or a compound active against another target associated with the particular condition, disorder, or disease. The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an active agent according to the invention), decrease one or more side effects, or decrease the required dose of the active agent according to the invention.

The active agents of the invention are used, alone or in combination with one or more additional active ingredients, to formulate pharmaceutical compositions of the invention. A pharmaceutical composition of the invention comprises: (a) an effective amount of at least one active agent in accordance with the invention; and (b) a pharmaceutically acceptable excipient.

A "pharmaceutically acceptable excipient" refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

Delivery forms of the pharmaceutical compositions containing one or more dosage units of the active agents may be prepared using suitable pharmaceutical excipients and compounding techniques known or that become available to those skilled in the art. The compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.

The preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories. Preferably, the compositions are formulated for intravenous infusion, topical administration, or oral administration.

For oral administration, the compounds of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. To prepare the oral compositions, the compounds may be formulated to yield a dosage of, e.g., from about 0.05 to about 100 mg/kg daily, or from about 0.05 to about 35 mg/kg daily, or from about 0.1 to about 10 mg/kg daily. For example, a total daily dosage of about 5 mg to 5 g daily may be accomplished by dosing once, twice, three, or four times per day.

Oral tablets may include a compound according to the invention mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like. Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.

Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, compounds of the invention may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the compound of the invention with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.

Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose,

2017217542 02 Mar 2021

aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.

The active agents of this invention may also be administered by non-oral routes. For example, the compositions may be formulated for rectal administration as a suppository. For parenteral use, including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the compounds of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms will be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses may range from about 1 to 1000 µg/kg/minute of compound, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.

For topical administration, the compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle. Another mode of administering the compounds of the invention may utilize a patch formulation to affect transdermal delivery.

Compounds of the invention may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.

Exemplary compounds useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to

2017217542 02 Mar 2021

employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. Unless otherwise specified, the variables are as defined above in reference to Formula (I). Reactions may be performed between the melting point and the reflux temperature of the solvent, and preferably between 0 °C and the reflux temperature of the solvent. Reactions may be heated employing conventional heating or microwave heating. Reactions may also be conducted in sealed pressure vessels above the normal reflux temperature of the solvent.

Abbreviations and acronyms used herein include the following:

Table 4:

Term	**Acronym**
Acetonitrile	ACN
Aqueous	aq
Atmosphere	atm
tert-Butylcarbamoyl	Boc, or BOCa
Broad	br
Diatomaceous Earth	Celite®
Diethylaminosulfur trifluoride	DAST
Di-*tert*-butyl azodicarboxylate	DBAD
1,8-Diazabicyclo[5.4.0]undec-7-ene	DBU
Dichloromethane	DCM
Bis(2-methoxyethyl)aminosulfur trifluoride	Deoxo-Fluor®
Diisopropylethylamine	DIPEA, DIEA, or Hunig's base
4-Dimethylaminopyridine	DMAP
1,2-Dimethoxyethane	DME
N,N-Dimethylformamide	DMF
Dimethylsulfoxide	DMSO
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide	EDCI, EDAC, or EDC
Diethyl ether	Ether, Et_2O

2017217542 02 Mar 2021

Term	Acronym
Ethyl Acetate	EtOAc, or EA
Ethanol	EtOH
Electrospray ionization	ESI
Normal-phase silica gel chromatography	FCC
Grams	g
Hours	h
Hydroxybenzotriazole	HOBt
High-pressure liquid chromatography	HPLC
Hertz	Hz
Isopropyl alcohol	*i*PrOH, IPA
Lithium aluminum hydride	LAH
Liquid chromatography and mass spectrometry	LCMS
Lithium bis(trimethylsilyl)amide	LHMDS
Molar	M
Mass to charge ratio	m/z
meta-Chloroperoxybenzoic acid	*m*CPBA
Methyl Iodide	MeI
Methanol	MeOH
Milligrams	mg
Minute	min
Milliliter	mL
Microliter	µL
Millimoles	mmol
Mass spectrometry	MS
Normal	N
Sodium *tert*-butoxide	NaO*t*-Bu
Nuclear magnetic resonance	NMR
CF_3SO_3- or triflate	OTf
Palladium (II) acetate	$Pd(OAc)_2$
Palladium(II)bis(triphenylphosphine) dichloride	$Pd(PPh_3)_2Cl_2$


2017217542 02 Mar 2021

Term	Acronym
Tetrakis(triphenylphosphine)palladium(0)	$Pd(PPh_3)_4$
[1,1′-Bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II)	$PdCl_2$(dtbpf) or $Pd(dtbpf)_2Cl_2$
[1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium (II)	$PdCl_2$(dppf) or $Pd(dppf)_2Cl_2$
Parts per million	ppm
Precipitate	ppt
Polytetrafluoroethylene	PTFE
Retention time	R_t
Room temperature	rt
Saturated	sat
1-Chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)	Selectfluor®
[2-(Trimethylsilyl)ethoxy]methyl acetal	SEM
Supercritical Fluid Chromatography	SFC
Temperature	T
Tert-Butyl alcohol	*t*BuOH, t-BuOH
Tetra-n-butylammonium fluoride	TBAF
Triethylamine	TEA
Trifluoroacetic acid	TFA
Tetrahydrofuran	THF
Thin layer chromatography	TLC
Volume in milliliters of solvent per gram of substrate	V, or volumes
(Diethylamino)difluorosulfonium tetrafluoroborate	XtalFluor®

PREPARATIVE EXAMPLES

Exemplary compounds useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation below and the specific examples to follow.

SCHEME A




According to SCHEME A, a compound of formula (V) where HAL is Cl, and R^{10} is F, is oxidized under conditions known to one skilled in the art, to afford a compound of formula (VI). For example, reaction of a compound of formula (V), where HAL is Cl, and R^{10} is F, is oxidized with an oxidizing agent such as *m*CPBA, and the like, in a suitable solvent such as DCM, and the like, at temperatures ranging from 0 °C to rt, to provide a compound of formula (VI), where LG is SO_2CH_3.

Commercially available or synthetically accessible pyrimidines of formula (V), where HAL is Br, and R^{10} is H, are reacted in a metal mediated cross coupling with an amine of formula (VII), to provide a compound of formula (VIII). For example, a pyrimidine of formula (V), where HAL is Br, and R^{10} is H, is reacted with a palladium catalyst such as $Pd(OAc)_2$, a ligand such as Xantphos, and the like, a base such as NaOtBu, and the like, an amine such as azetidine, 3-fluoroazetidine, 3,3-difluoroazetidine, and the like, in a suitable solvent such as toluene, a temperatures ranging from 90- 120 °C, for a period of 2-5 h, to provide a compound of formula (VIII). A compound of formula (VIII), is oxidized, employing conditions previously described, to provide a compound of formula (IX).

Commercially available or synthetically accessible pyrimidines of formula (VI), where LG is Cl, R^{10} is H, and HAL is Cl, are reacted with a suitable nucleophile such as an amine of formula (VII) (wherein the amine is an alkylamine or heterocycloalkyl amine which is optionally substituted with one or more halogen members), with or without a suitable base such as TEA,

in a suitable solvent such as DMF, THF, DCM, and the like, for a period of 1-6 h, to provide a compound of formula (IX), where $NR^{11}R^{12}$ is ($N(C_{1-6}alkyl)_2$) or heterocycloalkylamine and R^{10} is H. In a preferred embodiment, the amine is azetidine, 3-fluoroazetidine, 3,3-difluoroazetidine, pyrrolidine, 3,3-difluoropyrrolidine piperidine, or morpholine, and the base is TEA.

SCHEME B



According to SCHEME B, a compound of formula (Xa), where LG is Cl, R^{19} is OH, or CH_2OH, is reacted with a silyl chloride reagent such as tert-butyl(chloro)dimethylsilane, and the like, a base such as imidazole, in a solvent such as DCM and the like, to provide silyl ether compound of formula (XI). Alternately a compound of formula (Xa) is alkylated with a suitable alkylating agent, such as 1-fluoro-2-iodoethane, employing a base such as NaH, K_2CO_3, Na_2CO_3, TEA, Cs_2CO_3, and the like, in a suitable solvent such as DMF, ACN, DCM, at temperatures ranging from 0 °C to 85 °C, to afford a compound of formula (XI), where R^4 is $O\text{-}C_{1-6}alkyl$, $CH_2O\text{-}C_{1-6}alkyl$, $O\text{-}C_{1-6}perhaloalkyl$, or $CH_2O\text{-}C_{1-6}perhaloalkyl$, and LG is Cl.

A compound of formula (XI), where LG is SO_2CH_3 and R^4 is $CH_2O\text{-}C_{1-6}alkyl$, $CH_2O\text{-}C_{1-6}perhaloalkyl$, and $CH_2O\text{-}CD_3$, may be prepared in two steps from a compound of formula (Xb) where R^{19} is CH_2OH. In a first step a compound of formula (Xb) may be alkylated employing conditions previously described, with a suitable base such as NaH, K_2CO_3, and the like, and an alkylating agent such as Et-I, CD_3-I, 2-chloro-2,2-difluoro-1-phenylethan-1-one, and the like. In a second step, oxidation of the thiomethyl employing


previously described conditions, may provide a compound of formula (XI), where R^4 is CH_2O-C_{1-6}alkyl, CH_2O-C_{1-6}perhaloalkyl, or CH_2O-CD_3, and LG is SO_2CH_3.

A compound of formula (XI), where R^4 is CH_2O-C_{1-6}alkyl and LG is SO_2CH_3 may also be prepared in three steps from a compound of formula (Xb) where R^{19} is $C(=O)CH_3$ or CO_2CH_3. In a first step, reduction of the kenone employing conditions known to one skilled in the art, for example with a reducing agent such as $LiBH_4$, $LiBD_4$, and the like, may provide a compound of formula (Xb), where R^{19} is CH_2OH. Subsequent alkylation and oxidation may provide a compound of formula (XI), where R^4 is CH_2O-C_{1-6}alkyl and LG is SO_2CH_3. A compound of formula (Xb) may additionally be substituted with a halogen such as F.

A compound of formula (XI), where R^4 is CH_2O-C_{1-6}alkyl and LG is SO_2CH_3 may also be prepared in three steps from a compound of formula (Xb) where R^{19} is $C(=O)CH_3$. Reaction of the ketone with a reagent such as MeMgBr, employing conditions known to one skilled in the art, may provide a compound of formula (Xb), where R^{19} is $C(CH_3)_2OH$. Subsequent alkylation and oxidation may provide a compound of formula (XI), where R^4 is CH_2O-C_{1-6}alkyl and LG is SO_2CH_3.


A compound of formula (Xb), where R^{19} is $C(CH_3)_2OH$ or CH_2OH may also be reacted with a silyl chloride reagent such as tert-butyl(chloro)dimethylsilane, under conditions previously described.

SCHEME C



According to SCHEME C, a compound of formula (XII), where LG is Cl, R^{14} is H, F, or CH_3, R^{15} is C_{1-6}alkyl or C_{1-6}perhaloalkyl, is protected with a suitable nitrogen protecting group (PG) such as BOC (tert-butyloxycarbonyl), SEM (2-(trimethylsilyl)ethoxymethyl), and the like, under conditions known to one skilled in the art, to provide a compound of formula (XIII).

SCHEME D




According to SCHEME D, a compound of formula (XIV), where LG is Cl, and R^{14} is H, is reduced and subsequently protected in a one pot reaction to provide a compound of formula (XV), where PG is BOC, and R^{17} is H. For example, 2-chloropyrimidine-4-carbonitrile, is reacted with di-tert-butyl dicarbonate, Pd/C, under an atmosphere of H_2, in a suitable solvent such as EtOH, and the like, to provide tert-butyl ((2-chloropyrimidin-4-yl)methyl)carbamate.

A compound of formula (XV) is also prepared from a compound of formula (XVII) in three steps. In a first step, a compound of formula (XVII), where R^{14} is H, is reacted in a reductive amination reaction with a suiable amine such as methyl amine, a reducing agent such as $NaBH(OAc)_3$, $NaBH_4$, and the like, in a solvent such as THF, DCM and the like, for a period of 12-20 h. In a second step, the alkyl amine is protected with a suitable nitrogen protecting group such as BOC, employing conditions previously described. In a third step, the methylthioether is oxidized employing conditions previously described to provide a compound of formula (XV), where LG is SO_2CH_3, R^{17} is CH_3, and PG is BOC.


A compound of formula (XV), where LG is Cl, PG is BOC, and R^{17} is H, is alkylated employing conditions known to one skilled in the art. For example, alkylation with an alkyl halide agent such as MeI, and the like, a base such as NaH, in a solvent such as THF, DMF, and the like, provides a compound of formula (XVI), where R^{18} is CH_3.

SCHEME E



According to SCHEME E, 5-bromo-2-methoxypyrimidine is reacted in a metal mediated cross coupling with an alkyne such as prop-2-yn-1-ol, a palladium catalyst such as $PdCl_2(PPh_3)_2$, and the like, a base such trimethylamine, CuI, in a solvent such as DMF, and the like, to provide 3-(2-methoxypyrimidin-5-yl)prop-2-yn-1-ol. The alkyne is reduced, employing conditions previously described, to afford 3-(2-methoxypyrimidin-5-yl)propan-1-ol. The alcohol is protected with a suitable alkyl alcohol protecting group such as an alkyl tosylate. For example, 3-(2-methoxypyrimidin-5-yl)propan-1-ol is reacted with sulfonyl chloride, a base such as TEA, trimethylamine, and the like, in a solvent such DCM, for a period of 12 – 24 h, provides a compound of formula (XVIII). Fluorination of a compound of formula (XVIII), employing TBAF, in a solvent such as THF, provides 5-(3-fluoropropyl)-2-methoxypyrimidine. A compound of formula (XIX) is prepared in two steps from 5-(3-fluoropropyl)-2-methoxypyrimidine. In a first step, demethylation of the methyl ether is achieved with HCl/Dioxane, at a temperature of 100 °C, for a period of 4-6 h. Chlorination of 5-(3-fluoropropyl)pyrimidin-2(1H)-one is achieved under chlorination conditions, for example, reaction with $POCl_3$, and the like, at temperatures ranging from 70-90 °C, to afford a compound of formula (XIX), where LG is Cl.

SCHEME F




According to SCHEME F, a compound of formula (XXII), where Ar^1 is a substituted phenyl ring, is commercially available or synthetically accessible from a compound of formula (XX), where R^f and R^g are selected from: H, OH, halo, $C(O)C_{1-3}$alkyl, CHO, C_{1-3}alkyl, OC_{1-3}alkyl, C_{1-6}perhaloalkyl, and OC_{1-}

$_{6}$perhaloalkyl. A compound of formula (XX), where R^f is defined as above and R^g is OH, is alkylated with a reagent such as chlorodifluoroacetate, MeI, and the like, in the presence of a base, such as K_2CO_3, Cs_2CO_3, NaH, and the like, in a suitable solvent such as DMF, water, or a mixture thereof, at temperatures ranging from room temperature to 120 °C, or conventional heating, for a period of 2 to 5 h, to provide a compound of formula (XXI), where R^f is defined as above and R^g is OC_{1-6}alkyl or OC_{1-6}perhaloalkyl. In a preferred method, a compound of formula (XX), where R^f is Cl and R^g is OH, is alkylated with chlorodifluoroacetate, in the presence of a base, such as K_2CO_3, in a suitable solvent such as DMF, water, or a mixture thereof, at 100 °C, for 2.5 h, to afford compound of formula (XXI), where R^f is Cl, and R^h is OCF_2H. A compound of formula (XX), where R^f is defined as above and R^g is CHO, is fluorinated with a fluorinating agent such as, DAST, XtalFluor®, Deoxo-Fluor®, and the like, in a suitable solvent such as DCM, and the like, at temperatures ranging from -78 °C to 50 °C, for a period of 2-24 h. In a preferred method, a compound of formula (XX), where R^f is Cl and R^g is CHO, is reacted with the a fluorinating agent such as DAST, in a solvent suitable solvent such as DCM, at room temperature, for 20 h, provides a compound of formula (XXI), where R^f is Cl and R^h is CF_2H.

A nitro compound of formula (XXI) is reduced, employing conditions known to one skilled in the art, to provide a compound of formula (XXII), where Ar^1 is a substituted phenyl ring as defined in Formula (I). A nitro compound of formula (XX), where R^f and R^g are selected from H, halo, $C(O)C_{1-4}$alkyl, C_{1-4}alkyl, OC_{1-4}alkyl, C_{1-6}perhaloalkyl, or OC_{1-6}perhaloalkyl, is reduced with a reducing agent, such as but not limited to: Pd/C under an atmosphere of H_2 (balloon); Fe powder in a solution of HCl; Zn powder in a solution of aqueous NH_4Cl; in a suitable solvent such as MeOH, EtOH, THF, acetone, and the like, at temperatures ranging from room temperature (23 °C) to about 50 °C, for a period of 30 minutes to 16 h, to afford a compound of formula (XXII). In a preferred method, a nitro compound of formula (XXI), where R^f is Cl and R^h is OCF_2H, is reduced with Fe powder, concentrated HCl, in a solvent such as MeOH, at room temperature, for a period of about 2 h. In a preferred method, a nitro compound of formula (XXI), where R^f is Cl and R^h

is CF_2H, is reduced with Zn powder, NH_4Cl, in a suitable solvent such as acetone/water, at temperatures ranging from 0 °C to rt, for a period of 16 h.

SCHEME G




According to SCHEME G, an azide compound of formula (XXIII) is prepared from a compound of formula (XXII) employing azidation conditions known to one skilled in the art. In a preferred method, a compound of formula (XXII), where Ar^1 is a suitably substituted phenyl or pyridyl, in a suitable solvent such as *i*PrOH, THF, and the like, is treated with 6 N HCl in *i*PrOH, and reacted in flow, or conventional methods known to one skilled in the art, with sodium nitrite in a suitable solvent such as water, and sodium azide in a suitable solvent such as water, respectively, under acidic conditions (such as H_2SO_4, HCl, TFA, etc.) to afford an azide compound of formula (XXIII). Alternatively, aryl azides of formula (XXIII) may be prepared employing conditions known to one skilled in the art, for example, copper(II)-catalyzed conversion of organoboron compounds; arenediazonium tosylates and sodium azide in water at room temperature; S_NAr reactions using sodium azide and a halogenated aryl. A compound of formula (XXIII), were Ar^1 is a suitably substituted thiophene may be made according to the methods recited above.

A compound of formula (XXV), where R^1 is H, R^2 is H or CH_3, and Ar^1 is a suitably substituted phenyl or pyridyl, is obtained thru a metal-catalyzed azide-alkyne 1,3-dipolar cycloaddition reaction of a compound of formula (XXIII) and an alkyne of formula (XXIV), in the presence of metal catalyst such as copper sulfate, $(CuOTf)_2{\cdot}C_6H_6$, $RuCp^*Cl(PPh_3)_2$, and the like, with or without a reducing agent such as L-sodium ascorbate and the like, in a solvent such as H_2O, *t*BuOH, isopropanol, dioxane, toluene, or a mixture thereof, at temperatures ranging from rt to 100 °C, for a period of 30 min to 24 h. In a preferred method, the alkyne of formula (XXIV) where R^1 is H, R^2 is H

or CH_3, is reacted with an azide compound of formula (XXIII), copper sulfate, L-sodium ascorbate, in *t*BuOH /H_2O, at room temperature overnight. In an alternate method, the alkyne is *N*-propargyl phthalimide.

A compound of formula (XXV), where Ar_1 is a suitably substituted phenyl or pyridyl, can be prepared as described in B. Chattopadhyay *et al. Org. Lett.* **2010**, *12*, 2166-2169. One skilled in the art will recognize that the azide-alkyne cycloaddition can also be accomplished by methods described in H. Kolb *et al. Angew. Chem. Int. Ed.* **2001**, *40*, 2004-2021.


SCHEME H



According to SCHEME H, a compound of formula (XXVI), where R^1 is CH_3, CF_2H, or CF_3, is reacted with an Ar^1-boronic acid, where Ar^1 is a suitably substituted phenyl ring, NaN_3, a transition metal catalyst such as $Cu(OAc)_2$, Cu_2O, CuBr, or Cu powder, a base such as piperidine, trimethylamine, K_2CO_3 and the like, in a solvent such as DMSO, THF, DMF, and water, at temperatures ranging from room temperature to 80 °C, for a period of 2 to 24h, to provide a compound of formula (XXVII). Alternately, the addition of NaI in the previously described transformation of a compound of formula (XXVI) to a compound of formula (XXVII) provides a compound of formula (XXV) where R^1 is I.

A compound of formula (XXVI), where R^1 is CH_3, CF_2H, or CF_3, is reacted with an Ar^1-N_3 of formula (XXIII), where Ar^1 is a suitably substituted phenyl ring, an amine catalyst such as diethylamine, piperidine, proline, triethylamine, and the like, in a solvent such as DMSO, to provide a compound of formula (XXVII). Reduction of a compound of formula (XXVII), with a reducing agent, such as $LiAlH_4$, $LiBH_4$, and the like, in a solvent such as THF, and the like, affords a compound of formula (XXV), where R^1 is H or CH_3 and R^2 is H.

SCHEME I



Referring to SCHEME I, a compound of Formula (I), where Ar^3 is pyrimidine, pyridine, or pyridazine substituted with one or two substituents, R^1 is H, and R^2 is H or CH_3, is obtained from a compound of formula (XXV), by a S_NAr, S_N2, or Mitsunobu reaction. For example, a compound of Formula (I) is obtained from a compound of formula (XXV), by S_NAr reaction with LG-Ar^3, where Ar^3 is a commercially available or synthetically accessible heteroaromatic five or six membered ring, and LG is a suitable leaving group such as F, Cl, Br, I, SO_2Me, or OTf, in the presence of a base, such as NaH, K_2CO_3, Cs_2CO_3, and the like, in a solvent such as DMF, THF, ACN, and the like, at temperatures ranging from room temperature (about 23 °C) to about 140 °C, employing conventional or microwave heating. In a preferred method the base is NaH, the solvent is DMF and the reaction is performed at room temperature.

A compound of Formula (I), where Ar^3 is pyrimidine, pyridine, or pyridazine substituted with one or two substituents, R^1 is H, and R^2 is H or CH_3, is also obtained from a compound of formula (XXV), by a Mitsunobu reaction with a compound of Ar^3-OH, where Ar^3-OH is a commercially available or synthetically accessible heteroaromatic five or six membered ring selected from is pyrimidine, pyridine, or pyridazine substituted with one or two substituents. For example, a compound of formula (XXV), where R^1 is H, and R^2 is H or CH_3, is reacted with Ar^3-OH, where Ar^3 is a commercially available or synthetically accessible heteroaromatic five or six membered ring, PPh_3, and the like, a base such as DEAD, DCAD, DIAD, DBAD, and the like, in a suitable solvent such as THF, DMF, and the like, at temperatures ranging from room temperature (about 23 °C) to about 50 °C, to provide a compound

of Formula (I). In a preferred method, a compound of formula (XXV) is reacted with Ar^3-OH, PPh_3, DBAD, in THF at room temperature to provide a compound of Formula (I).

A compound of Formula (I), where Ar^3 is pyrimidine, pyridine, or pyridazine substituted with one or two substituents, R^1 is H, and R^2 is H or CH_3, is also obtained in two steps from a compound of formula (XXV), by S_N2 reaction. In the first step, a chloro compound of formula (XXVIII) is prepared from a compound of formula (XXV) employing chlorination conditions known to one skilled in the art, such as thionyl chloride, in a suitable solvent such as DCM, $CHCl_3$, and the like, at temperatures ranging from room temperature to about 50 °C, for a period of 30 min to 6 h. In the second step, a compound of Formula (I) is prepared by reacting a chloro compound of formula (XXVIII) with a nucleophile such as Ar^3-OH in a S_N2 reaction. For example, a chloro compound of formula (XXVIII) is reacted with a nucleophile of formula Ar^3-OH, where a Ar^3-OH is a suitable commercially available or synthetically accessible hydroxy-substituted heteroaryl compound, in the presence of a base, such as NaH, K_2CO_3 and the like, in a solvent such as DMF at temperatures ranging from room temperature (about 23 °C) to about 50 °C to provide a compound of Formula (I). In a preferred method, the base is K_2CO_3, the solvent is DMF and the reaction is performed at room temperature.

A compound of Formula (I) where Ar^3 is substituted with Br, is reacted in a metal mediated cross coupling reaction to provide a compound of Formula (I) where Ar^3 is xx. For example, a compound of Formula (I), where Ar^3 is substituted with Br or Cl, is reacted with a suitably substituted commercially available or synthetically accessible aryl or heteroaryl boronic acid, boronate ester, trimethylboroxine, and the like, in the presence of a palladium catalyst such as XPhos Palladacycle Gen. 3, $PdCl_2$(dtbpf), $Pd(PPh_3)_4$, $PdCl_2$(dppf), $Pd(PPh_3)_2Cl_2$, and the like, a base such as K_3PO_4, aq. Na_2CO_3, Na_2CO_3, Cs_2CO_3, and the like, in a suitable solvent such as 1,2-dimethoxyethane, 1,4-dioxane, THF, DMF, water, or a mixture thereof, at a temperature ranging from 60 to 180 °C, employing microwave or conventional

2017217542 02 Mar 2021

heating, for a period of about 30 min to 16 h, to provide a compound of Formula (I), where 1-methylpyrazol-3-yl, 1H-pyrazol-4-yl, and the like.

In a similar fashion, a compound of Formula (I), where Ar^1 is substituted with a suitable halogen such as Br, is reacted in a metal mediated cross coupling reaction with an alkylzinc halide, cyclallkylzinc halide such as cyclobutylzinc bromide, 2-propylzinc bromide, and the like, a palladium catalyst such as $Pd(t\text{-}Bu_3P)_2$, and the like, in a suitable solvent such as THF, at a temperature of about 50 °C, for a period of 12-24 h, to provide a compound of Formula (I), where Ar^1 is substituted with $C_{1\text{-}6}$alkyl or $C_{3\text{-}6}$cycloalkyl.

In a similar fashion, a compound of Formula (I), where Ar^1 is substituted with a suitable halogen such as Br, is reacted in a metal mediated cross coupling reaction with a suitably substituted commercially available or synthetically accessible boronic acid, potassium trifluoroborate, trimethylboroxine, and the like in the presence of a palladium catalyst such as RuPhos-Pd-G3, and the like, in a suitable solvent such as 1,4-dioxane, with a suitable base such as K_2CO_3, potassium phosphate tribasic, and the like at a temperature of about 100 °C, for a period of 12-24 h, to provide a compound of Formula (I), where Ar^1 is substituted with $C_{1\text{-}6}$alkyl or $C_{3\text{-}6}$cycloalkyl.


A compound of Formula (I), where Ar^1 is substituted with a suitable halogen leaving group such as F, is reacted with a 4-6 membered heterocycloalkyl such as azetidine, pyrrolidine, piperidine or morpholine, a base such as DIPEA, and the like, in a suitable solvent such as ACN, and the like, at temperatures ranging from 50-100 °C, for a period of 12-24 h, to provide a compound of Formula (I), where Ar^1 is substituted with 4-6 membered heterocycloalkyl.

A compound of Formula (I) where Ar^1 is substituted with an ester is saponified to a carboxylic acid using a base such as Cs_2CO_3, and the like, in a suitable solvent such as ACN, and the like, at a temperature of around 140 °C in a microwave reactor for 2 h, then the carboxylic acid is converted to an amide under conditions known to one skilled in the art, to privde and compound of Formula (I).

Conversion of a compound of Formula (I), where Ar^3 is a pyrazine substituted with Cl, to a compound of Formula (I), where Ar^3 is substituted with F, is achieved with CsF, in a solvent such as DMSO and the like, a temperatures ranging from 90 - 110 °C, for a period of 2- 4 h.

Conversion of a compounds of Formula (I), where Ar^3 is a pyrimidine substituted with Cl, to a compound of Formula (I), where Ar^3 is substituted with.NH_2, is achieved with a solution of ammonia in MeOH, in a solvent such as THF, at a temperature around 100 °C under microwave irradiation for 8 h.

SCHEME J



Referring to SCHEME J, a compound of Formula (II), where Ar^2 is pyrazole, oxazole, imidazole, pyrimidine, pyridine, or pyridazine substituted with one or two substituents, and R^1 and R^2 are H, is obtained from a compound of formula (XXVIII) by an S_NAr, S_N2, or metal mediated cross-coupling reaction.


A compound of Formula (II), where Ar^2 pyrimidine , pyridine, or pyridazine substituted with one or two substituents, and R^1 and R^2 are H, is obtained from a compound of formula (XXVIII) in two steps. In the first step, nucleophilic displacement of the chlorine in a compound of formula (XXVIII) with an amine, such as a solution of ammonia in methanol, provides the corresponding primary amine compound of formula (XXIX). Alternatively, nucleophilic displacement of the chlorine in a compound of formula (XXVIII) with phthalimide followed by deprotection using hydrazine hydrate provides the corresponding primary amine compound of formula (XXIX). In the second step, reaction of a compound of formula (XXIX) in a S_NAr reaction with Ar^2-LG, where Ar^2 is a commercially available or synthetically accessible heteroaromatic five or six membered ring, and LG is a suitable leaving group such as F, Cl, Br, I, or OTf, in the presence of a base, such as NaH, Et_3N, K_2CO_3 and the like, in a solvent such as EtOH and the like, at temperatures

ranging from room temperature (about 23 °C) to about 200 °C, employing conventional or microwave heating. In a preferred method the base is Et_3N, the solvent is EtOH and the reaction was heated in a microwave reactor at 120 °C for 2 h and then at 150 °C for 10 min.

A compound of Formula (II), where Ar^2 is imidazole , pyrazole, pyrimidine, pyridine, or pyridazine substituted with one or two substituents, and R^1 and R^2 are H, is also obtained from a compound of formula (XXIX), by a metal mediated cross-coupling reaction with Ar^2-LG, where Ar^2 is a commercially available or synthetically accessible heteroaromatic five or six membered ring, and LG is a suitable leaving group such as F, Cl, Br, I, or OTf, in the presence of a palladium catalyst such as $Pd_2(dba)_3$, $Pd(OAc)_2$, and the like, a phosphine ligand such as XPhos, *t*BuBrettPhos, and the like, a base such as KO*t*Bu, LHMDS, and the like, in a suitable solvent such as toluene, DME, *t*BuOH, and DMF, at temperatures ranging from room temperature (about 23 °C) to about 110 °C. In a preferred method the palladium catalyst is $Pd_2(dba)_3$, the ligand is *t*BuXPhos, the base is KO*t*Bu, and the solvent is *t*BuOH.

A compound of Formula (II), where Ar^2 is pyrazole , pyrimidine , pyridine, or pyridazine substituted with one or two substituents, and R^1 and R^2 are H, is obtained from a compound of formula (XXVIII), in a S_N2 reaction with a compound of formula Ar^2-NH_2. For example, a chloro compound of formula (XXVIII) is reacted with a compound of formula Ar^2-NH_2, where a Ar^2-NH_2 is a suitable commercially available or synthetically accessible amino-substituted heteroaryl compound, in the presence of a base, such as NaH, K_2CO_3,TEA, and the like, in a solvent such as DMF, EtOH, ACN and the like, at temperatures ranging from room temperature (about 23 °C) to about 100 °C, for a period of about 3 h to 16 h, to provide a compound of Formula (II). In a preferred method the base is K_2CO_3, the solvent is DMF and the reaction is heated to 80 °C.

SCHEME K



(XXV) (XXX) (II)

Referring to SCHEME K, a compound of Formula (II), where Ar^2 pyridine, oxazole, pyrazole, and R^1 and R^2 are H, is obtained from a compound of formula (XXV) in two steps. In the first step, a compound of formula (XXV) is oxidized to an aldehyde of formula (XXX) employing oxidation conditions known to one skilled in the art, for example, DMP (Dess-Martin periodinane), SO_3-pyridine, Swern conditions [$(COCl)_2$, DMSO, Et_3N], PCC, and the like, in a solvent such as EtOAc, DMSO, DCM, and the like, at temperatures ranging from about -78 °C to room temperature (about 23 °C). In a preferred method, a compound of formula (XXV) is oxidized to a compound of formula (XXX) with Dess-Martin periodinane, in DCM, at 20 °C for 4 hours. In the second step, a carbonyl compound of formula (XXX) is reacted with a compound of formula Ar^2-NH_2, where a Ar^2-NH_2 is a suitable commercially available or synthetically accessible amino-substituted heteroaryl compound, in a reductive amination reaction, a suitable reducing agent such as $NaBH_4$, $NaHB(OAc)_3$, $NaBH_3CN$ and the like in a solvent such as MeOH, DCM and the like, at temperatures ranging from room temperature (about 23 °C) to about 50 °C, for a period of 8-24 h to provide a compound of Formula (II). In a preferred method, the reducing agent is $NaHB(OAc)_3$ and the solvent is DCM.

Compounds of Formula (I) (as well as Formula (II)) may be converted to their corresponding salts using methods known to one of ordinary skill in the art. For example, an amine of Formula (I) (as well as Formula (II)) is treated with trifluoroacetic acid, HCl, or citric acid in a solvent such as Et_2O, CH_2Cl_2, THF, CH_3OH, chloroform, or isopropanol to provide the corresponding salt form. Alternately, trifluoroacetic acid or formic acid salts are obtained as a result of reverse phase HPLC purification conditions. Cyrstalline forms of pharmaceutically acceptable salts of compounds of Formula (I) (as well as Formula (II)) may be obtained in crystalline form by recrystallization from polar solvents (including mixtures of polar solvents and

2017217542 02 Mar 2021

aqueous mixtures of polar solvents) or from non-polar solvents (including mixtures of non-polar solvents).

Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

Compounds prepared according to the schemes described above may be obtained as single forms, such as single enantiomers, by form-specific synthesis, or by resolution. Compounds prepared according to the schemes above may alternately be obtained as mixtures of various forms, such as racemic (1:1) or non-racemic (not 1:1) mixtures. Where racemic and non-racemic mixtures of enantiomers are obtained, single enantiomers may be isolated using conventional separation methods known to one of ordinary skill in the art, such as chiral chromatography, recrystallization, diastereomeric salt formation, derivatization into diastereomeric adducts, biotransformation, or enzymatic transformation. Where regioisomeric or diastereomeric mixtures are obtained, as applicable, single isomers may be separated using conventional methods such as chromatography or crystallization.

The following specific examples are provided to further illustrate the invention and various preferred embodiments.

EXAMPLES

In obtaining the compounds described in the examples below and the corresponding analytical data, the following experimental and analytical protocols were followed unless otherwise indicated.

Unless otherwise stated, reaction mixtures were magnetically stirred at room temperature (rt) under a nitrogen atmosphere. Where solutions were "dried," they were generally dried over a drying agent such as Na_2SO_4 or $MgSO_4$. Where mixtures, solutions, and extracts were "concentrated", they were typically concentrated on a rotary evaporator under reduced pressure. Reactions under microwave irradiation conditions were carried out in a Biotage Initiator or CEM (Microwave Reactor) Discover instrument.

2017217542 02 Mar 2021

For the reactions conducted under continuous flow conditions, "flowed through a LTF-VS mixer" refers to the use of a Chemyx Fusion 100 Touch Syringe Pump that is in line via 1/16" PTFE tubing to a LTF-VS mixer (Little Things Factory GmbH (http://www.ltf-gmbh.com), unless otherwise indicated.

Normal-phase silica gel chromatography (FCC) was performed on silica gel (SiO_2) using prepacked cartridges.

Preparative reverse-phase high performance liquid chromatography (RP HPLC) was performed on either:

METHOD A. An Agilent HPLC with an Xterra Prep RP18 column (5 μM, 30 x 100 or 50 x 150mm) or an XBridge C18 OBD column (5 μM, 30 x 100 or 50 x 150mm), and a mobile phase of 5% ACN in 20mM NH_4OH was held for 2 min, then a gradient of 5-99% ACN over 15 min, then held at 99% ACN for 5 min, with a flow rate of 40 or 80 mL/min.

or

METHOD B. A Shimadzu LC-8A Series HPLC with an Inertsil ODS-3 column (3 μm, 30 x 100mm, T = 45 °C), mobile phase of 5% ACN in H_2O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 6 min, then held at 99% ACN for 3 min, with a flow rate of 80 mL/min.

or

METHOD C. A Shimadzu LC-8A Series HPLC with an XBridge C18 OBD column (5 μm, 50 x 100mm), mobile phase of 5% ACN in H_2O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 14 min, then held at 99% ACN for 10 min, with a flow rate of 80 mL/min.

or

METHOD D. A Gilson HPLC with an XBridge C18 column (5μm, 100 x 50mm), mobile phase of 5-99% ACN in 20 mM NH_4OH over 10 min and then hold at 99 ACN for 2 min, at a flow rate of 80 mL/min.

or

METHOD E. A Shimadzu LC-8A Series HPLC with a Sunfire C18 OBD column 15 (5 μm, 50 x 100mm), mobile phase of 5% ACN in H2O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 14 min, then held at 99% ACN for 10 min, with a flow rate of 80 mL/min.

2017217542 02 Mar 2021

Preparative supercritical fluid high performance liquid chromatography (SFC) was performed either on a Jasco preparative SFC system, an APS 1010 system from Berger instruments, or a SFC-PICLAB-PREP 200 (PIC SOLUTION, Avignon, France). The separations were conducted at 100 to 150 bar with a flow rate ranging from 40 to 60 mL/min. The column was heated to 35 to 40 °C.


Mass spectra (MS) were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass corresponds to the exact mass.

Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers. Definitions for multiplicity are as follows: s = singlet, d = doublet, t= triplet, q = quartet, m = multiplet, br = broad. It will be understood that for compounds comprising an exchangeable proton, said proton may or may not be visible on an NMR spectrum depending on the choice of solvent used for running the NMR spectrum and the concentration of the compound in the solution.

Chemical names were generated using ChemDraw Ultra 12.0, ChemDraw Ultra 14.0 (CambridgeSoft Corp., Cambridge, MA) or ACD/Name Version 10.01 (Advanced Chemistry).

Compounds designated as R* or S* are enantiopure compounds where the absolute configuration was not determined.

Intermediate 1. (1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol



Step A. 1-Chloro-2-(difluoromethoxy)-4-nitrobenzene. A mixture of 2-chloro-5-nitrophenol (10 g, 58 mmol), K_2CO_3 (9.4 g, 68 mmol), and sodium chlorodifluoroacetate (18 g, 115 mmol) in DMF (192 mL) and H_2O (25 mL) was degassed with nitrogen for 5 minutes, and then the reaction mixture was heated to 100 °C for 2.5 h. The mixture was cooled to rt and 12 N HCl (17 mL)

2017217542 02 Mar 2021

and H_2O (25 mL) was added. The mixture was stirred at room temperature for 1 h. The resulting mixture was then cooled to 0 °C, and an aqueous solution of 1 N NaOH (213 mL) was added portion wise. The reaction mixture was diluted with H_2O and extracted with Et_2O (2X). The organic layer was further washed with H_2O (1X), dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-50% DCM in hexanes) afforded the title compound (12 g, 55 mmol, 95% yield). ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.15 - 8.12 (m, 1H), 8.08 (dd, *J* = 8.8, 2.5 Hz, 1H), 7.65 (d, *J* = 8.8 Hz, 1H), 6.65 (t, *J* = 71.9 Hz, 1H).


Step B. 4-Chloro-3-(difluoromethoxy)aniline. To a solution of 1-chloro-2-(difluoromethoxy)-4-nitrobenzene (5 g, 22 mmol) in methanol (72 mL) was added Fe powder (5 g, 89 mmol) followed by the drop-wise addition of concentrated HCl (37% in H_2O, 19 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction was quenched with ice water and basified with solid $NaHCO_3$. Celite® was added to the crude reaction mixture and stirred for 10 minutes. The heterogeneous mixture was filtered over a pad of Celite® and the filtrate was concentrated under reduced pressure to remove MeOH. The resultant aqueous layer was extracted with DCM (3X). The combined organics were concentrated under reduced pressure to yield the title compound (3.3 g) as a light orange oil, which was used without further purification. MS (ESI) mass calcd. for $C_7H_6ClF_2NO$, 193.0; m/z found 194.1 $[M+H]^+$. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.16 (d, *J* = 8.6 Hz, 1H), 6.68 - 6.28 (m, 3H), 3.77 (s, 2H).

Step C. (1-(4-Chloro-3-(difluoromethoxy)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol. Two solutions, 4-chloro-3-(difluoromethoxy)aniline (2.5 g, 13 mmol) in 6 N HCl (6N HCl in *i*PrOH, 8 mL) and *i*PrOH (19 mL), and sodium nitrite (1 g, 15 mmol) in H_2O (12 mL) were flowed through a LTF-MS mixer (0.2 mL) at 1 mL/min and 0.4 mL/min, respectively. The outcome was mixed with sodium azide (1 g, 15 mmol) in H_2O (12 mL) at 0.4 mL/min in a T-piece and flowed through a LTF-VS mixer (1 mL). The mixture was collected over K_2CO_3 (8.9 g, 65 mmol) in *i*PrOH (32 mL). The reaction mixture was stirred for 10 minutes after completion, and then propargyl alcohol (0.9 mL, 15 mmol),

2017217542 02 Mar 2021

$CuSO_4 \cdot 5H_2O$ (322 mg, 1.29 mmol), and L-sodium ascorbate (256 mg, 1.29 mmol) were added to the crude reaction. The heterogeneous reaction mixture was stirred at rt overnight. The reaction was diluted with EtOAc, H_2O, and a saturated aqueous solution of NH_4Cl. The biphasic mixture was stirred for 5 min, and then the layers were separated and the aqueous layer further extracted with EtOAc (3X). The combined organics were dried (Na_2SO_4), filtered, and concentrated under reduced pressure to afford a dark orange solid. Purification (FCC, SiO_2, 40-100% EtOAc in hexanes) gave the title compound (2.9 g, 10 mmol, 80% yield). MS (ESI) mass calcd. for $C_{10}H_8ClF_2N_3O_2$, 275.0; m/z found 276.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.04 - 7.94 (m, 1H), 7.74 - 7.67 (m, 1H), 7.64 - 7.60 (m, 1H), 7.59 - 7.54 (m, 1H), 6.64 (t, *J* = 72.5 Hz, 1H), 4.91 (s, 2H).

Intermediate 2. R/S-1-(1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-o1.




Step A. 4-Azido-1-chloro-2-(difluoromethoxy)benzene. Two solutions, 4-chloro-3-(difluoromethoxy)aniline (Intermediate 1, product from Step B, 0.8 g, 4.1 mmol) in 6 N HCl (6N HCl in *i*PrOH, 2.6 mL) and *i*PrOH (6.4 mL), and sodium nitrite (342 mg, 4.96 mmol) in H_2O (12 mL) were flowed through a LTF-MS mixer (0.2 mL) at 1 mL/min and 0.4 mL/min, respectively. The outcome was mixed with sodium azide (322 mg, 4.96 mmol) in H_2O (4 mL) at 0.4 mL/min in a T-piece and flowed through a LTF-VS mixer (1 mL). The mixture was collected over K_2CO_3 (2.9 g, 21 mmol) in H_2O (10 mL). The reaction mixture was stirred for 10 minutes after completion. The crude reaction mixture was extracted with Et_2O (3X). The combined organics were dried (Na_2SO_4), filtered, and concentrated to a dark orange oil. The title compound was used crude in the next step without further purification.

Step B. R/S-1-(1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol. To a solution of the crude 4-azido-1-chloro-2-

2017217542 02 Mar 2021

(difluoromethoxy)benzene (from Step A) 1:1 mixture of *t*BuOH/H_2O (14 mL) and 3-butyn-2-ol (0.37 mL, 4.96 mmol) was added $CuSO_4 \cdot 5H_2O$ (103 mg, 0.413 mmol), and L-sodium ascorbate (82 mg, 0.413 mmol). The reaction mixture stirred at room temperature over the weekend. The reaction was diluted with EtOAc, H_2O, and a saturated aqueous solution of NH_4Cl. The biphasic mixture was stirred for 5 min, and then the layers were separated and the aqueous layer further extracted with EtOAc (3X). The combined organics were dried (Na_2SO_4), filtered, and concentrated to a dark orange solid. Purification (FCC, SiO_2, 30-100% EtOAc in hexanes) afforded the title compound (785 mg, 2.71 mmol, 66% yield). MS (ESI) mass calcd. for $C_{11}H_{10}ClF_2N_3O_2$, 289.0; m/z found 290.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 7.97 - 7.88 (m, 1H), 7.73 - 7.66 (m, 1H), 7.63 - 7.58 (m, 1H), 7.58 - 7.54 (m, 1H), 6.64 (t, *J* = 72.6 Hz, 1H), 5.17 (q, *J* = 6.5 Hz, 1H), 2.65 (s, 1H), 1.66 (d, *J* = 6.5 Hz, 3H).

Intermediate 3. 4-Chloro-3-(difluoromethyl)aniline.




Step A. 1-Chloro-2-(difluoromethyl)-4-nitrobenzene. To 2-chloro-5-nitrobenzaldehyde (3.08 g, 16.61 mmol) stirring in DCM (50 mL) at rt was slowly added DAST (2.83 mL, 21.59 mmol), and the resulting solution was stirred at rt for 20 h. The completed reaction was poured over ice (100 g) and allowed to stir until all the ice was melted. The layers were separated and the aqueous layer was extracted with DCM (3 x 20 mL). The combined organics were washed once with brine (20 mL), dried (Na_2SO_4), and then concentrated under reduced pressure. The resulting orange residue (3.4 g, 98 %) was carried forward without purification. ^1H NMR (500 MHz, $CDCl_3$) δ 8.55 (d, *J* = 2.5 Hz, 1H), 8.33 – 8.27 (m, 1H), 7.67 – 7.62 (m, 1H), 6.98 (t, *J* = 54.3 Hz, 1H).

Step B. 4-Chloro-3-(difluoromethyl)aniline. To a stirred mixture of 1-chloro-2-(difluoromethyl)-4-nitrobenzene (3.31 g, 15.95 mmol) and ammonium chloride (4.27 g, 79.73 mmol) in 5:1 acetone:water (90 mL) at 0 °C was added zinc

2017217542 02 Mar 2021

powder (10.43 g, 159.46 mmol). The reaction was allowed to warm to rt and stirred for 16 h. Upon completion, the reaction was filtered through Celite®, concentrated under reduced pressure, and then taken in up in EtOAc (50 mL) and H_2O (50 mL). The layers were separated and the organic layer was washed with 1 M NaOH (3 x 15 mL), and then filtered again through Celite®. The resulting solution was dried (Na_2SO_4), and concentrated under reduced pressure to afford an orange oil that solidified upon standing (2.29 g, 78%). The material was carried forward crude without further purification. MS (ESI): mass calcd. for $C_7H_6ClF_2N$, 177.0; m/z found, 177.9 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 7.19 – 7.13 (m, 1H), 6.94 (d, J = 2.9 Hz, 1H), 6.87 (t, J = 55.1 Hz, 1H), 6.73 – 6.67 (m, 1H).


Intermediate 4. 1-(4-Chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole.



To a solution of (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1, 243 mg, 0.882 mmol) in DCM (2 mL) was added thionyl chloride (2 mL). The reaction mixture was stirred at room temperature for 3 h. Upon completion the reaction mixture was poured over a solution of ice water and K_2CO_3. The biphasic mixture was stirred until all of the ice melted and the layers separated. The aqueous layer was further extracted with DCM (3X). The combined organics were dried (Na_2SO_4), filtered, and concentrated under reduced pressure to give the title compound as a yellow solid (231 mg), which was used without further purification. MS (ESI) mass calcd. for $C_{10}H_7Cl_2F_2N_3O$, 293.0; m/z found 294.1 $[M+H]^+$.

02 Mar 2021 2017217542

Intermediate 5. (1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol.




Step A. 4-Azido-1-fluoro-2-(trifluoromethyl)benzene. 4-Fluoro-3-(trifluoromethyl)aniline (1 mL, 7.77 mmol) was added via syringe to a cooled solution of TFA (6 mL)/H_2SO_4 (1.2 mL) at 0 °C. A white ppt forms and the flask was removed from the ice bath and stirred until homogeneous (~15 min). The resulting solution was placed back in the ice bath and a solution of $NaNO_2$ (664 mg, 9.6 mmol) in water (5 mL) was added dropwise. After stirring for 30 min at 0 °C a solution of NaN_3 (880 mg, 13.5 mmol) in water (5 mL) was then added slowly. Caution: gas evolution observed. After the addition was complete the reaction mixture was warmed to rt. and stirred for an additional 30 min. Ether was added (75 mL) and the layers were separated. The organic layer was placed over aqueous $NaHCO_3$ (sat) and the acidic aqueous layer was extracted (1x) with ether and the organic layers combined, washed with aqueous $NaHCO_3$ (sat), brine, dried ($MgSO_4$), filtered, and concentrated under reduced pressure to afford the title compound which was used crude in the next step.

Step B. (1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol. To a solution of 4-azido-1-fluoro-2-(trifluoromethyl)benzene in t-BuOH/water (20 mL; 1:1) was added prop-2-yn-1-ol (0.6 mL, 10.3 mmol); copper sulfate (195 mg, 0.78 mmol) and sodium ascorbate (152 mg, 0.77 mmol). The resulting mixture was stirred at rt overnight. The reaction was poured into water (200 mL) and extracted with EtOAc (3 x 50 mL). The combined organics were concentrated under reduced pressure. The residue was loaded directly onto SiO_2 (DCM /w trace MeOH). Purification (FCC, SiO_2, DCM/EtOAc (10% MeOH) 0 - 70%) afforded the title compound as an off white solid (87%). ^1H NMR (500 MHz, $CDCl_3$) δ 8.02 - 7.98 (m, 2H), 7.98 - 7.93 (m, 1H), 7.43 - 7.36 (m, 1H), 4.97 - 4.87 (m, 2H), 2.24 (t, J = 6.0 Hz, 1H).

2017217542 02 Mar 2021

Intermediate 6. (1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol.



Method A.

The title compound was prepared in a manner analogous to Intermediate 1. MS (ESI): mass calcd. for $C_{10}H_8F_3N_3O_2$, 259.1; m/z found, 260.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 2.44 (s, 1H), 4.91 (s, 2H), 6.65 (t, *J* = 72.6 Hz, 1H), 7.35 (t, *J* = 9.2 Hz, 1H), 7.53 - 7.64 (m, 1H), 7.70 (dd, *J* = 6.6, 2.7 Hz, 1H), 7.97 (s, 1H).

Method B.

Step A. 3-(Difluoromethoxy)-4-fluoroaniline. To a suspension of 2-(difluoromethoxy)-1-fluoro-4-nitrobenzene (1.4 g, 6.8 mmol) and Zn powder (4.0 g, 60.8 mmol) in acetone (31 mL) and water (3.1 mL) was added ammonium chloride (3.3 g, 60.8 mmol) at 0°C. Upon completion, the reaction mixture was filtered through a pad of Celite® and rinsed with MeOH. The filtrate was concentrated under vacuum. Purification (FCC, SiO_2, 0-10% EtOAc in hexanes) afforded (1.2 g, 6.6 mmol, 97%). MS (ESI): mass calcd. for $C_7H_6F_3NO$, 177.0; m/z found, 178.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 7.10 (t, *J* = 73.7 Hz, 1H), 6.99 (dd, *J* = 10.8, 8.8 Hz, 1H), 6.49 – 6.45 (m, 1H), 6.39 (ddd, *J* = 8.8, 3.8, 2.7 Hz, 1H), 5.20 (s, 2H).

Step B. 4-Azido-2-(difluoromethoxy)-1-fluorobenzene. Sodium nitrite (1.3 M in H_2O, 6.4 mL, 8.3 mmol) was added dropwise to a solution of 3-(difluoromethoxy)-4-fluoroaniline (1.2 g, 6.6 mmol) in TFA (5.1 mL, 66.1 mmol) and H_2SO_4 (1.1 mL, 19.8 mmol) at 0 ºC. The mixture was stirred at 0ºC for 30 min, and then sodium azide (1.3 M in H_2O, 8.9 mL, 11.6 mmol) was added dropwise at 0 ºC. The mixture was stirred at 0 ºC for 30 min. Then, the mixture was diluted with Et_2O. The organic layer was collected, washed with a saturated aqueous solution of $NaHCO_3$ (until basic pH), dried ($MgSO_4$),

2017217542 02 Mar 2021


filtered, and concentrated in vacuo to yield title product. The title product was carried as is to the next step.

Step C. (1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol. $CuSO_4$ (91 mg, 0.6 mmol) and (+)-sodium ascorbate (114 mg, 0.6 mmol) were added to a stirred solution of 4-azido-2-(difluoromethoxy)-1-fluorobenzene (1.2 g, 5.8 mmol) and propargyl alcohol (0.4 mL, 7.5 mmol) in distilled water (7.3 mL) and isopropanol (5.7 mL) at room temperature. Upon completion, water (40 mL) was added to the reaction mixture. The reaction mixture was extracted using EtOAc (3 x 60 mL). The combined organics were dried ($MgSO_4$), filtered, and concentrated under vacuum. Purification (FCC, SiO_2, 0-90% EtOAc in hexanes) afforded (1.3 g, 87%).

Method C.

Sodium azide (129 mg, 2.0 mmol) was added to a mixture of 2-(3-(difluoromethoxy)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (380 mg, 1.3 mmol) and $CuOAc_2$ (48 mg, 0.3 mmol) in DMSO (4.5 mL) at room temperature. After 3 hours, propargyl alcohol (0.12 mL, 2.0) was added to the reaction mixture. After 16h, water (20 mL) was added and the mixture was extracted using EtOAc (3 x 30 mL). The combined organics were dried ($MgSO_4$), filtered, and concentrated under vacuum. Purification (FCC, SiO_2, 0-40% EtOAc in hexanes) afforded (14 mg, 0.05, mmol, 4%). MS (ESI): mass calcd. for $C_{10}H_8F_3N_3O_2$, 259.1; m/z found, 259.9 $[M+H]^+$.

Intermediate 7. 2-Bromo-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine.




To a solution of (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6, 50 mg, 0.19 mmol) and 2-bromo-6-fluoropyridine (40.7 mg, 0.23 mmol) in DMF (1.2 mL) at 0 °C was added NaH (60% dispersion in mineral oil, 9.2 mg, 0.23 mmol). The reaction mixture was stirred

02 Mar 2021 2017217542


at 0 °C for 2 h then quenched by the addition of water. The resulting precipitate was filtered to afford the title compound (75 mg, 93%) which was used crude without further purification. MS (ESI): mass calcd. for $C_{15}H_{10}BrF_3N_4O_2$, 413.99; m/z found, 414.0 $[M+H]^+$.

Intermediate 8. (1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 1. MS (ESI): mass calcd. for $C_{10}H_8ClF_2N_3O$, 259.0; m/z found, 260.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.37 (s, 1H), 8.35 (d, *J* = 2.6 Hz, 1H), 8.25 – 8.19 (m, 1H), 7.97 – 7.93 (m, 1H), 7.34 (t, *J* = 54.6 Hz, 1H), 5.25 (s, 2H), 2.72 (s, 1H).

Intermediate 9. (1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol.



The title compound was prepared in a manner analogous to Intermediate 1. MS (ESI): mass calcd. for $C_{10}H_8F_3N_3O$, 243.1; m/z found, 244.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 2.26 (br t, *J* = 5.78 Hz, 1H) 4.91 (d, *J* = 5.32 Hz, 2H) 6.76 - 7.15 (m, 1H) 7.33 (t, *J* = 9.02 Hz, 1H) 7.85 - 7.97 (m, 2H) 8.00 (s, 1H).


Intermediate 10. (1-(2,4-Difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Intermediate 1. MS (ESI): mass calcd. for $C_{10}H_9F_2N_3O$, 225.1; m/z found, 226.2 $[M+H]^+$.

Intermediate 11. (1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 1. MS (ESI) mass calcd. for: $C_{11}H_{10}F_3N_3O$, 257.1; m/z found 258.0. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.98 (t, *J* = 0.7 Hz, 1H), 7.95 – 7.87 (m, 1H), 7.87 – 7.78 (m, 1H), 7.31 (dd, *J* = 9.9, 8.9 Hz, 1H), 4.91 (d, *J* = 0.7 Hz, 2H), 2.05 (td, *J* = 18.6, 1.2 Hz, 3H).

Intermediate 12. (1-(3-(Difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol.



The title compound was prepared in a manner analogous to Intermediate 1, Step C, using 3-(difluoromethyl)aniline. MS (ESI): mass calcd. For $C_{10}H_9F_2N_3O$, 225.1; m/z found, 226.1 $[M+H]^+$.


Intermediate 13. (1-(2,4-Difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol.



The title compound was prepared in a manner analogous to Intermediate 1, Step C, using 2,4-difluoro-5-methylaniline. MS (ESI): mass calcd. For $C_{10}H_9F_2N_3O$, 225.1; m/z found, 226.1 $[M+H]^+$.


2017217542 02 Mar 2021

Intermediate 14. (1-(3-Bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol




The title compound was prepared in a manner analogous to Intermediate 1. MS (ESI): mass calcd. for $C_9H_7BrFN_3O$, 270.98; m/z found, 274.0 $[M+H+2]^+$.

Intermediate 15. (1-(4-Chloro-3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methanol




The title compound was prepared in a manner analogous to Intermediate 1. MS (ESI): mass calcd. for $C_{10}H_{10}ClN_3O_2$, 239.1; m/z found, 240.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 7.97 (s, 1H), 7.49 (d, *J* = 8.5 Hz, 1H), 7.46 (d, *J* = 2.3 Hz, 1H), 7.15 (dd, *J* = 8.5, 2.4 Hz, 1H), 4.90 (s, 2H), 4.00 (s, 3H).

Intermediate 16. 4-(Chloromethyl)-1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazole.



The title compound was prepared in a manner analogous to Intermediate 4. MS (ESI) mass calcd. for: $C_{10}H_9F_2N_3O$, 225.1; m/z found 226.1.


Intermediate 17. (1-(3-(Difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanamine.



4-(Chloromethyl)-1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazole (Intermediate 16, 309.0 mg, 1.27 mmol) was placed in a pressure flask and then dissolved in NH_3 (7M in MeOH (13.73 mL, 7 M, 96.13 mmol). The flask was sealed, and


the reaction was stirred at 45 °C for 20 h. The solvent evaporated under reduced pressure. Purification (FCC, SiO_2, 0-8% MeOH in DCM) afforded the title compound (124.7 mg, 44%). MS (ESI): mass calcd. for $C_{10}H_{10}F_2N_4$, 224.1; m/z found, 225.0 $[M+H]^+$. ^1H NMR (600 MHz, CD_3OD) δ 8.63 (s, 1H), 8.14 – 8.11 (m, 1H), 8.09 – 8.05 (m, 1H), 7.82 – 7.77 (m, 1H), 7.77 – 7.73 (m, 1H), 6.97 (t, *J* = 55.9 Hz, 1H), 4.26 (s, 2H).

Intermediate 18. (1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine.



The title compound was prepared in a manner analogous to Intermediate 17. MS (ESI): mass calcd. for $C_{10}H_9F_3N_4O$, 258.1; m/z found, 259.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ ppm 4.20 (s, 2H) 7.45 (t, *J* = 72.7 Hz, 1H) 7.68 - 7.77 (m, 1H) 7.85 (dt, *J* = 8.8, 3.4 Hz, 1H) 7.98 (dd, *J* = 6.9, 2.7 Hz, 1H) 8.64 (br s, 3H) 8.95 (s, 1H).

Intermediate 19. (1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanamine.




Step A. 1-(4-Chloro-3-(difluoromethyl)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole. To (1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8, 1.65 g, 6.3 mmol) stirring in DCM (16 mL) was slowly added $SOCl_2$ (4 mL, 55 mmol). The mixture was stirred at rt overnight, then poured into a mixture of ice water and K_2CO_3. After all the ice was melted, the layers were separated and the aqueous layer was extracted with DCM (3x). The combined organic layers were washed with brine, dried (Na_2SO_4), then concentrated under reduced pressure to afford an orange solid that was used without purification (1.66 g, 94%).

2017217542 02 Mar 2021

Step B. 2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)isoindoline-1,3-dione. To 1-(4-chloro-3-(difluoromethyl)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole (152 mg, 0.55 mmol) in DMF (2.7 mL) was added phthalimide (96 mg, 0.65 mmol) followed by K_2CO_3 (226 mg, 1.6 mmol). The reaction was stirred at 80 °C for 1 h, then cooled to rt and diluted with EtOAc and H_2O. The layers were separated and the aqueous layer was extracted with DCM (X3), then the combined organic layers were concentrated under reduced pressure to afford an orange solid that was used without purification.

Step C. (1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanamine. To 2-((1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)isoindoline-1,3-dione (212 mg, 0.55 mmol) stirring in EtOH (5 mL) was added hydrazine hydrate (0.03 mL, 0.65 mmol) and the mixture was stirred at reflux (80 °C) for 1 h. The reaction was cooled to rt and concentrated under reduced pressure. Purification (FCC, SiO_2, 10% 2 M NH_3 in MeOH/DCM 0 – 100%) afforded the title compound as pale yellow solid (116 mg, 82%). MS (ESI): mass calcd. for $C_{10}H_9ClF_2N_4$, 258.0; m/z found, 259.0 $[M+H]^+$.


Intermediate 20. (1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine.



The title compound was prepared in a manner analogous to Intermediate 19, steps A – C, using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) in step A. MS (ESI): mass calcd. for $C_{11}H_{11}F_3N_4$, 256.1; m/z found, 257.1 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.48 - 8.43 (m, 1H), 8.06 (dd, *J* = 6.3, 2.8 Hz, 1H), 8.04 - 7.99 (m, 1H), 7.52 - 7.45 (m, 1H), 4.02 (s, 2H), 2.07 (td, *J* = 18.8, 1.1 Hz, 3H).


02 Mar 2021 2017217542

Intermediate 21: (1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine.




The title compound was prepared in a manner analogous to Intermediate 19, Steps A – C, using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) in Step A. MS (ESI) mass calcd. for: $C_{10}H_9F_3N_4$, 242.1; m/z found 243.0 [M+1].

Intermediate 22. (R)-1-(1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol.



The title compound was prepared in a manner analogous to Intermediate 2 using 4-chloro-3-(difluoromethoxy)aniline and in Step A and (R)-(+)-3-butyn-2-ol in Step B. MS (ESI): mass calcd. for $C_{11}H_{10}ClF_2N_3O_2$, 289.7; m/z found, 290.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.76 (s, 1H), 7.98 (d, J = 2.3 Hz, 1H), 7.90 - 7.81 (m, 2H), 7.45 (t, J = 72.8 Hz, 1H), 5.44 (d, J = 4.8 Hz, 1H), 4.92 (qd, J = 6.5, 4.7 Hz, 1H), 1.48 (d, J = 6.5 Hz, 3H).

Intermediate 23. (S)-1-(1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol.




The title compound was prepared in a manner analogous to Intermediate 2 using 4-chloro-3-(difluoromethoxy)aniline and in Step A and (S)-(+)-3-butyn-2-

2017217542 02 Mar 2021


ol in Step B. MS (ESI): mass calcd. for $C_{11}H_{10}ClF_2N_3O_2$, 289.7; m/z found, 290.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.75 (s, 1H), 7.98 (d, J = 2.3 Hz, 1H), 7.91 - 7.79 (m, 2H), 7.45 (t, J = 72.8 Hz, 1H), 5.44 (d, J = 4.8 Hz, 1H), 4.92 (qd, J = 6.5, 4.6 Hz, 1H), 1.47 (d, J = 6.5 Hz, 3H).

Intermediate 24. (R)-1-(1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-amine.



The title compound was made analogous to Intermediate 19 using (R)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 22) in step A.MS (ESI): mass calcd. for $C_{11}H_{11}ClF_2N_4O$, 288.1; m/z found, 289.0 $[M+H]^+$.

Intermediate 25: (1-(5-(Trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methanol.



Step A. *tert*-butyl (5-(Trifluoromethyl)thiophen-2-yl)carbamate.To a solution of 5-(trifluoromethyl)thiophene-2-carboxylic acid (2.5 g, 12.75 mmol) in tert-butyl alcohol (64 mL) was added triethylamine (1.78 mL, 12.75 mmol) followed by diphenylphosphorylazide (2.75 mL, 12.75 mmol). The resulting reaction mixture was heated to 90°C and stirred overnight. The reaction was cooled to room temperature and the solvent was removed under reduced pressure. The resulting residue was redissolved in ethyl acetate (50 mL) and washed with a saturated aqueous solution of $NaHCO_3$, citric acid (10% aq) and brine. The combined organic layers were dried (Na_2SO_4), filtered, and concentrated into a brown oil which was purified via FCC (using 5-20% ethyl acetate/hexanes) to provide the desired product as a white solid (804 mg, 3.01 mmol, 23%). MS (ESI): mass calcd. for $C_{10}H_{12}F_3NO_2S$, 267.2; m/z found, 268.1 $[M+H]^+$. ^1H

2017217542 02 Mar 2021

NMR (500 MHz, $CDCl_3$) δ 7.16 – 7.14 (m, 1H), 6.40 – 6.37 (m, 1H), 1.55 – 1.50 (m, 9H).

Step B. 5-(Trifluoromethyl)thiophen-2-amine HCl salt. To a solution of *tert*-butyl (5-(trifluoromethyl)thiophen-2-yl)carbamate (804 mg, 3.01 mmol) in dioxane (8 mL) was added 4M HCl in dioxane (3.76 mL, 15.04 mmol). The resulting reaction mixture was allowed to stir overnight at room temperature. The reaction mixture was subsequently concentrated into a white solid (under reduced pressure), which was washed with ether to provide the desired product (584 mg, 2.868 mmol, 95.3%). Quantitative yield was assumed and the intermediate was used without further purification. MS (ESI): mass calcd. for $C_5H_4F_3NS$, 203.6; m/z found, 204.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 7.13 – 7.09 (m, 1H), 5.90 – 5.84 (d, J = 4.0 Hz, 1H).


Step C. 2-Azido-5-(trifluoromethyl)thiophene. To a solution of 5-(trifluoromethyl)thiophen-2-amine HCl salt (150 mg, 0.74 mmol) in TFA (0.56 mL, 7.4 mmol), H_2SO_4 (0.118 mL, 2.21 mmol) and water (4 mL) at 0°C was slowly added a 1.3 M aq. solution of sodium nitirite (0.71 mL, 0.92 mmol). The resulting reaction mixture was stirred at 0°C for 30 minutes and then a 1.3 M aq. solution of sodium azide (0.992 mL, 1.29 mmol) in water (4 mL) was added dropwise. The reaction mixture was stirred for an additional 30 minutes and then diluted with ether (10 mL). The organic layer was isolated and washed with saturated $NaHCO_3$ solution (until pH8), dried (Na_2SO_4), filtered, and concentrated under reduced pressure to yield the desired product (142 mg, 0.74 mmol). A quantitative yield was assumed and the crude material was carried forward without further purification.

Step D. (1-(5-(Trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methanol. To a solution of 2-azido-5-(trifluoromethyl)thiophene (150 mg, 0.78 mmol) and propargyl alcohol (0.06 mL, 1.01 mmol) in isopropyl alcohol (1 mL) and water (1 mL) at room temperature was added copper (II) sulfate (14 mg, 0.08 mmol), and sodium ascorbate (15 mg, 0.08 mmol). The resulting reaction mixture was stirred for 3 hours then diluted with water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried ($MgSO_4$), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-90% ethyl acetate in hexanes) afforded the title compound (94

2017217542 02 Mar 2021


mg, 0.38 mmol, 48%). MS (ESI): mass calcd. for $C_8H_6F_3N_3OS$, 249.2; m/z found, 250.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.06 – 7.86 (s, 1H), 7.46 – 7.32 (m, 1H), 7.23 – 7.10 (d, *J* = 4.1 Hz, 1H), 4.98 – 4.76 (s, 2H), 2.79 – 2.63 (s, 1H).

Intermediate 26. (1-(4-Fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanamine.



The title compound was prepared in a manner analogous to Intermediate 19, steps A – C, using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol in Step A. MS (ESI): mass calcd. for $C_{10}H_{11}FN_4$, 206.1; m/z found, 207.0 $[M+H]^+$.

Intermediate 27: (1-(3-(Difluoromethyl)-4-fluorophenyl)-5-iodo-1H-1,2,3-triazol-4-yl)methanol.




Step A. 4-Azido-2-(difluoromethyl)-1-fluorobenzene. The title compound was prepared in a manner analogous to Intermediate 6, Method B, Steps A-B using 2-(difluoromethyl)-1-fluoro-4-nitrobenzene in Step A.

Step B.(1-(3-(Difluoromethyl)-4-fluorophenyl)-5-iodo-1H-1,2,3-triazol-4-yl)methanol. 4-Azido-2-(difluoromethyl)-1-fluorobenzene (336 mg, 1.8 mmol), copper(II) perchlorate hexahydrate (1.3 g, 3.6 mmol) and NaI (1.1 g, 7.2 mmol) were pre-mixed in ACN (8 mL). After 5 minutes, propargyl alcohol (0.14 mL, 2.3 mmol) and DBU (0.27 mL, 1.8 mmol) were added. Upon completion, the reaction mixture was diluted in DCM (40 mL) and NH_4OH (28% NH_3 in water, 50 mL) was added. The crude material was triturated in DCM. The solids were collected by filtration, rinsed with DCM and dried under reduced pressure to yield the title compound (249 mg, 38%). MS (ESI): mass calcd. for $C_{10}H_7F_3IN_3O$, 369.0; m/z found, 369.8 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6)


δ 7.93 – 7.85 (m, 2H), 7.74 – 7.66 (m, 1H), 7.32 (t, *J* = 53.9 Hz, 1H), 5.31 (t, *J* = 5.4 Hz, 1H), 4.54 (d, *J* = 5.4 Hz, 2H).

Intermediate 28. (1-(2-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 6, Method B, using 2-fluoro-1-nitro-3-(trifluoromethyl)benzene in Step A. MS (ESI): mass calcd. for $C_{10}H_7F_4N_3O$, 261.1; m/z found, 261.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.56 – 8.54 (m, 1H), 8.21 – 8.15 (m, 1H), 8.02 – 7.98 (m, 1H), 7.66 (tt, *J* = 8.0, 1.0 Hz, 1H), 5.38 (t, *J* = 5.7 Hz, 1H), 4.64 (dd, *J* = 5.6, 0.8 Hz, 2H).

Intermediate 29. (1-(2-Fluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol.



The title compound was prepared in a manner analogous to Intermediate 6, Method B, Steps B-C, using 2-fluoro-5-methylaniline in Step B. MS (ESI): mass calcd. for $C_{10}H_{10}FN_3O$, 207.1; m/z found, 208.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.40 (dt, *J* = 2.2, 0.7 Hz, 1H), 7.66 – 7.61 (m, 1H), 7.48 – 7.36 (m, 2H), 5.32 (t, *J* = 5.6 Hz, 1H), 4.62 (d, *J* = 5.2 Hz, 2H), 2.40 – 2.37 (m, 3H).

Intermediate 30. (1-(3-(Trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 6, Method B, using 3-(trifluoromethyl)aniline in Step B. MS (ESI): mass calcd. for

2017217542 02 Mar 2021


$C_{10}H_8F_3N_3O$, 243.1; m/z found, 244.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.88 (s, 1H), 8.31 – 8.25 (m, 2H), 7.88 – 7.82 (m, 2H), 5.38 (t, J = 5.6 Hz, 1H), 4.63 (d, J = 5.5 Hz, 2H).

Intermediate 31. (1-(3-Bromophenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 6, Method B, Step B-C using 3-bromoaniline in Step B. ^1H NMR (300 MHz, $CDCl_3$) δ 7.97 (s, 1H), 7.94 (t, J = 1.7 Hz, 1H), 7.68 (dd, J = 8.1, 0.9 Hz, 1H), 7.58 (d, J = 8.6 Hz, 1H), 7.41 (t, J = 8.1 Hz, 1H), 4.90 (s, 2H). OH was not observed.

Intermediate 32. (1-(m-Tolyl)-1H-1,2,3-triazol-4-yl)methanol.



The title compound was prepared in a manner analogous to Intermediate 2 using m-toluidine in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{10}H_{11}N_3O$, 189.2; m/z found, 190.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.64 (d, J = 0.7 Hz, 1H), 7.77 - 7.73 (m, 1H), 7.71 - 7.64 (m, 1H), 7.46 (t, J = 7.8 Hz, 1H), 7.29 (ddt, J = 7.6, 1.7, 0.9 Hz, 1H), 5.31 (t, J = 5.6 Hz, 1H), 4.61 (dd, J = 5.6, 0.7 Hz, 2H), 2.50 (p, J = 1.9 Hz, 3H).


Intermediate 33. (1-(p-Tolyl)-1H-1,2,3-triazol-4-yl)methanol.



The title compound was prepared in a manner analogous to Intermediate 2 using p-toluidine in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{10}H_{11}N_3O$, 189.2; m/z found, 190.1 $[M+H]^+$.


02 Mar 2021 2017217542

Intermediate 34. (1-(4-(Trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using 4-(trifluoromethoxy)aniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{10}H_8F_3N_3O_2$, 259.2; m/z found, 260.1 $[M+H]^+$.

Intermediate 35. (1-(3-(Trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using 3-(trifluoromethoxy)aniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{10}H_8F_3N_3O_2$, 259.2; m/z found, 260.1 $[M+H]^+$.

Intermediate 36. (1-(3,5-Dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol.



The title compound was prepared in a manner analogous to Intermediate 2 using 3,5-dimethylaniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{11}H_{13}N_3O$, 203.2; m/z found, 204.2 $[M+H]^+$.


Intermediate 37. (1-(4-Fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol.



The title compound was prepared in a manner analogous to Intermediate 2 using 4-fluoro-2-methylaniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{10}H_{10}FN_3O$, 207.2; m/z found, 208.1 $[M+H]^+$.


2017217542 02 Mar 2021

Intermediate 38. (1-(2-Methylphenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using o-toluidine in Step A. MS (ESI): mass calcd. for $C_{10}H_{11}N_3O$, 189.2; m/z found, 190.1 $[M+H]^+$.

Intermediate 39. (1-(3,4-Difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using 3,4-difluoroaniline in Step A and propargyl alcohol. MS (ESI): mass calcd. for $C_9H_7F_2N_3O$, 211.2; m/z found, 212.1 $[M+H]^+$.

Intermediate 40. (1-(4-Fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using 4-fluoro-3-methylaniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{10}H_{10}FN_3O$, 207.2; m/z found, 208.1 $[M+H]^+$.

Intermediate 41. (1-(3-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using 3-fluoroaniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for C9H8FN3O, 193.2; m/z found, 194.1 $[M+H]^+$.

Intermediate 42. (1-(3-(Difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using 3-(difluoromethoxy)aniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{10}H_8F_2N_3O_2$, 241.2; m/z found, 242.0 $[M+H]^+$.

Intermediate 43. (1-(4-(Difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using 4-(difluoromethoxy)aniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{10}H_8F_2N_3O_2$, 241.2; m/z found, 242.0 $[M+H]^+$.

Intermediate 44. (1-(3-Isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol.



The title compound was prepared in a manner analogous to Intermediate 2 using 3-isopropylaniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{10}H_8F_2N_3O_2$, 241.2; m/z found, 242.0 $[M+H]^+$.

Intermediate 45. (1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2

02 Mar 2021
2017217542


using 2,2-difluoro-5-aminobenzodioxole in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{10}H_7F_2N_3O_3$, 255.2; m/z found, 256.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.67 (d, J = 0.7 Hz, 1H), 8.07 (d, J = 2.2 Hz, 1H), 7.78 (dd, J = 8.7, 2.2 Hz, 1H), 7.64 (d, J = 8.7 Hz, 1H), 5.36 (t, J = 5.5 Hz, 1H), 4.61 (dd, J = 5.6, 0.7 Hz, 2H).

Intermediate 46. (1-(3-Chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using 3-chloro-2-fluoroaniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_9H_7ClFN_3O$, 227.6; m/z found, 228.0 $[M+H]^+$.

Intermediate 47. (1-(2,5-Difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using 2,5-difluoroaniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_9H_7F_2N_3O$, 211.2; m/z found, 212.1 $[M+H]^+$.

Intermediate 48. (1-(2,3-Difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using 2,3-difluoroaniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_9H_7F_2N_3O$, 211.2; m/z found, 212.1 $[M+H]^+$.

Intermediate 49. (1-(3-Fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using 3-fluoro-2-methylaniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{10}H_{10}FN_3O$, 207.2; m/z found, 208.1 $[M+H]^+$.

Intermediate 50. (1-(2-Fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analogous to Intermediate 2 using 2-fluoro-3-methylaniline in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{12}H_{13}N_3O$, 215.3; m/z found, 216.1 $[M+H]^+$.

Intermediate 51. (1-(2,3-Dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol.



The title compound was prepared in a manner analogous to Intermediate 2 using 5-aminoindan in Step A and propargyl alcohol in Step B. MS (ESI): mass calcd. for $C_{10}H_{10}FN_3O$, 207.2; m/z found, 208.1 $[M+H]^+$.


Intermediate 52. (1-(3-(Difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol.



The title compound was prepared in a manner analogous to Intermediate 1, Step C, using 3-(difluoromethoxy)-4-methylaniline. MS (ESI): mass calcd. for $C_{11}H_{11}F_2N_3O_2$, 255.1; m/z found, 256.0 $[M+H]^+$.


2017217542 02 Mar 2021

Intermediate 53. 5-(((*tert*-Butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine.




To (2-chloropyrimidin-5-yl)methanol (946 mg, 6.5 mmol) stirring in DCM (38 mL) at rt was added imidazole (477 mg, 7 mmol) followed by tert-butyl(chloro)dimethylsilane (1 g, 6.9 mmol). The reaction was stirred at rt for 30 mins, then diluted with water. The layers were separated and the aqueous layer was extracted with DCM (X3), dried (Na_2SO_4), and concentrated under reduced pressure. Purification (FCC, SiO_2, EtOAc/hexanes 0 - 10%) afforded the title compound as a clear, colorless oil that solidified upon standing (1.37 g, 81%). MS (ESI): mass calcd. for $C_{11}H_{19}ClN_2OSi$, 258.1; m/z found, 259.0 $[M+H]^+$.

Intermediate 54. 4-(((*tert*-Butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine.



The title compound was prepared in a manner analogous to Intermediate 53 using (2-chloropyrimidin-4-yl)methanol. MS (ESI): mass calcd. for $C_{11}H_{19}ClN_2OSi$, 258.1; m/z found, 259.0 $[M+H]^+$.

Intermediate 55. *tert*-Butyl (2-chloropyrimidin-4-yl)(methyl)carbamate.




A solution of 2-chloro-N-methylpyrimidin-4-amine (500 mg, 3.4 mmol), di-tert-butyl dicarbonate (1.49 mL, 6.9 mmol), TEA (0.96 mL, 6.9 mmol), DMAP (42.5 mg, 0.34 mmol) in THF (20 mL) was stirred at 70 °C for 3 h. The reation mixture was cooled, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-20% EtOAc in hexanes) afforded the title compound (762 mg, 88%). MS (ESI): mass calcd. for $C_{10}H_{14}ClN_3O_2$, 243.1; m/z found, 244.0

2017217542 02 Mar 2021


[M+H]$^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.51 (d, J = 5.9 Hz, 1H), 7.94 (d, J = 5.9 Hz, 1H), 3.33 (s, 3H), 1.52 (s, 9H).

Intermediate 56. *tert*-Butyl (2-chloro-5-methylpyrimidin-4-yl)(methyl)carbamate.




The title compound was prepared in a manner analogous to Intermediate 55, using 2-chloro-N,5-dimethylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{11}H_{16}ClN_3O_2$, 257.1; m/z found, 258.0 [M+H]$^+$.

Intermediate 57. *tert*-Butyl (2-chloro-5-fluoropyrimidin-4-yl)(2,2-difluoroethyl)carbamate



The title compound was prepared in a manner analogous to Intermediate 55, using 2-chloro-N-(2,2-difluoroethyl)-5-fluoropyrimidin-4-amine. MS (ESI): mass calcd. for $C_{10}H_{13}ClF_3N_3O_2$, 311.1; m/z found, 312.1 [M+H]$^+$. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.92 (d, J = 2.7 Hz, 1H), 6.47 – 6.15 (m, 1H), 4.22 (td, J = 14.8, 3.8 Hz, 2H), 1.44 (s, 9H).

Intermediate 58: *tert*-Butyl ((2-chloropyrimidin-4-yl)methyl)carbamate.




A mixture of 2-chloropyrimidine-4-carbonitrile (1.5 g, 10.7 mmol), di-tert-butyl dicarbonate (2.8 mL, 12.9 mmol) and 10% Pd/C (572 mg, 0.5 mmol) in EtOH (25 mL) was stirred at room temperature under a hydrogen atmosphere (1 atm, balloon). After 4h, the reaction mixture was filtered through a pad of Celite®. The filtrate was concentrated under vacuum. Purification (FCC, SiO_2,

02 Mar 2021 2017217542


0-99% EtOAc) to yield title product (720 mg, 27%). MS (ESI): mass calcd. for $C_{10}H_{14}ClN_3O_2$, 243.7; m/z found, 187.9 $[M\text{-}t\text{-}Bu]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.72 (d, J = 5.1 Hz, 1H), 7.56 (t, J = 6.2 Hz, 1H), 7.39 (d, J = 5.1 Hz, 1H), 4.21 (d, J = 6.0 Hz, 2H), 1.40 (s, 9H).

Intermediate 59. 2-Chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine.



A solution of 2-chloro-5-fluoro-N-methylpyrimidin-4-amine (500 mg, 3 mmol), (2-(chloromethoxy)ethyl)trimethylsilane (0.8 mL, 4.6 mmol), DIPEA (0.8 mL, 4.6 mmol) in DMF (28 mL) was stirred at rt for 16 h. Additional (2-(chloromethoxy)ethyl)trimethylsilane (0.8 mL, 4.6 mmol), DIPEA (0.8 mL, 4.6 mmol) was added and the reaction mixture was stirred for 6 h. To the reaction mixture was added brine (50 mL) and the reaction mix was extracted with EtOAc (3 X 60 mL). The combined organics were dried ($MgSO_4$), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-90% EtOAc in hexanes) afforded the title compound (528 mg, 58 %). MS (ESI): mass calcd. for $C_{11}H_{19}ClFN_3OSi$, 291.1; m/z found, 292.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.27 (d, J = 6.1 Hz, 1H), 4.97 (d, J = 1.4 Hz, 2H), 3.55 – 3.51 (m, 2H), 3.17 (d, J = 2.5 Hz, 3H), 0.90 – 0.85 (m, 2H), -0.03 – -0.05 (m, 9H).

Intermediate 60. 2-Chloro-N-ethyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine.




The title compound was prepared in a manner analgous to Intermediate 59, using 2-chloro-N-ethylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{12}H_{22}ClN_3OSi$, 287.1; m/z found, 288.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.13 (d, J = 6.1 Hz, 1H), 6.79 (d, J = 6.1 Hz, 1H), 4.92 (s, 2H), 3.65 –

2017217542 02 Mar 2021

3.46 (m, 4H), 1.12 (t, *J* = 7.1 Hz, 3H), 0.92 – 0.84 (m, 2H), -0.02 – -0.05 (m, 9H).

Intermediate 61: tert-Butyl methyl((2-(methylsulfonyl)pyrimidin-4-yl)methyl)carbamate.



Step A. N-methyl-1-(2-(methylthio)pyrimidin-4-yl)methanamine. Sodium triacetoxyborohydride (825 mg, 3.9 mmol) was added to a mixture of 2-(methylthio)pyrimidine-4-carbaldehyde (300 mg, 1.9 mmol) and methyl amine (2 M in MeOH, 1.3 mL, 2.5 mmol)) in THF (28 mL) at room temperature. After 16 hours, the reaction mixture was quenched with a saturated aqueous solution of $NaHCO_3$ (50 mL). The mixture was extracted using EtOAc (3 x 75 mL). The combined organics were dried over $MgSO_4$, filtered and concentrated under vacuum. Purification (FCC, SiO_2, 0-90% EtOAc in hexanes followed by 0% DCM to 60% MeOH containing10% 2 M NH_3 in MeOH) afforded the title compound (67 mg, 20%). MS (ESI): mass calcd. for $C_7H_{11}N_3S$, 169.1; m/z found, 170.1 $[M+H]^+$.


Step B. tert-Butyl methyl((2-(methylthio)pyrimidin-4-yl)methyl)carbamate. A mixture of N-methyl-1-(2-(methylthio)pyrimidin-4-yl)methanamine (239 mg, 1.4 mmol), BOC-anhydride (0.9 mL, 4.2 mmol), DMAP (17 mg, 0.1 mmol), TEA (0.4 mL, 2.8 mmol) and THF (8 mL) was allowed to stir at room temperature. After 16 hours, water (30 mL) was added and the mixture was extracted using DCM (3 x 50 mL). The combined organics were dried over $MgSO_4$, filtered and concentrated under vacuum. Purification (FCC, SiO_2, 0-40% EtOAc in hexanes) afforded the title compound (151 mg, 40%). MS (ESI): mass calcd. for $C_{12}H_{19}N_3O_2S$, 269.1; m/z found, 270.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.57 (d, *J* = 5.1 Hz, 1H), 7.03 – 6.94 (m, 1H), 4.39 (s, 2H), 2.89 (s, 3H), 1.48 – 1.21 (m, 9H).

Step C. tert-Butyl methyl((2-(methylsulfonyl)pyrimidin-4-yl)methyl)carbamate. mCPBA (276 mg, 1.2 mmol) was slowly added to a mixture of tert-butyl methyl((2-(methylthio)pyrimidin-4-yl)methyl)carbamate (151 mg, 0.6 mmol) in

2017217542 02 Mar 2021

DCM (6 mL) at 0°C. After 3 hours, complete conversion was observed. The reaction mixture was quenched with saturated aqueous solution of $NaHCO_3$(aq) (60 mL). The mixture was extracted with DCM (3 x 80 mL). The combined organics were dried over $MgSO_4$, filtered and concentrated under vacuum. Purification (FCC, SiO_2, 0-99% EtOAc in hexanes) afforded the title compound (132 mg, 78%). MS (ESI): mass calcd. for $C_{12}H_{19}N_3O_4S$, 301.1; m/z found, 202.1 $[M\text{-}tBu]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 9.05 – 8.99 (m, 1H), 7.68 – 7.58 (m, 1H), 4.59 (s, 2H), 3.40 (s, 3H), 2.94 (s, 3H), 1.51 – 1.19 (m, 9H).

Intermediate 62: 2-Chloro-N-(oxetan-3-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine.




Step A. 2-Chloro-N-(oxetan-3-yl)pyrimidin-4-amine. A mixture of 2,4-dichloropyrimidine (300 mg, 2.0 mmol),3-oxetanamine (147 mg, 2.0 mmol) and DIPEA (0.7 mL, 4.0 mmol) in DMF (17 mL) was stirred at r.t. After 16 hours, conversion was observed. Water (20 mL) was added to the reaction mixture was extracted with EtOAc (3 x 30 mL). The combined organics were dried over $MgSO_4$, filtered and concentrated under vacuum. Purification (FCC, SiO_2, 0-99% EtOAc in hexanes) afforded the title compound. ^1H NMR (500 MHz, DMSO-d_6) δ 8.67 – 8.60 (m, 1H), 8.04 – 7.92 (m, 1H), 6.57 – 6.38 (m, 1H), 4.98 – 4.87 (m, 1H), 4.80 (t, J = 6.7 Hz, 2H), 4.49 – 4.41 (m, 2H).

Step B. 2-Chloro-N-(oxetan-3-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine. Under a nitrogen atmosphere was stirred a mixture of 2-chloro-N-(oxetan-3-yl)pyrimidin-4-amine (374 mg, 2.0 mmol), DIPEA (0.7 mL, 4.0 mmol) (2-(chloromethoxy)ethyl)trimethylsilane (0.7 mL, 4.0 mmol) and DMF (19 mL) at room temperature. After 16 hours, complete conversion was observed. Water (20 mL) was added and the mixture was extracted using EtOAc (3 x 30 mL). The combined organics were dried over $MgSO_4$, filtered and concentrated under vaccum. Purification (FCC, SiO_2, 0-99% EtOAc in

02 Mar 2021
2017217542

hexanes) afforded the title compound (187 mg, 29%). MS (ESI): mass calcd. for $C_{13}H_{22}ClN_3O_2Si$, 315.1; m/z found, 316.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) 8.22 (d, J = 6.1 Hz, 1H), 6.90 – 6.77 (m, 1H), 5.17 – 4.94 (m, 3H), 4.79 – 4.73 (m, 2H), 4.70 – 4.64 (m, 2H), 3.57 – 3.51 (m, 2H), 0.92 – 0.85 (m, 2H), -0.01 – -0.04 (m, 9H).


Intermediate 63: (1-(4-Chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol.



Step A. 4-Chloro-3-(1,1-difluoroethyl)aniline. The title compound was prepared in a manner analogous to Intermediate 3, using 1-(2-chloro-5-nitrophenyl)ethan-1-one in step A and 1-chloro-2-(1,1-difluoroethyl)-4-nitrobenzene in step B. MS (ESI) mass calcd. for $C_8H_8ClF_2N_2O_2$, 191.0; m/z found 192.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 7.22 – 7.12 (m, 1H), 6.96 – 6.87 (d, J = 2.8 Hz, 1H), 6.69 – 6.57 (m, 1H), 3.86 – 3.64 (s, 2H), 2.09 – 1.92 (t, J = 18.5 Hz, 3H).

Step B. (1-(4-Chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol. The title compound was prepared in a manner analogous to Intermediate 1, using 4-chloro-3-(1,1-difluoroethyl)aniline. MS (ESI) mass calcd. for $C_{11}H_{10}ClF_2N_3O$, 273.0; m/z found 274.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.07 – 7.92 (m, 2H), 7.90 – 7.74 (m, 1H), 7.68 – 7.56 (d, J = 8.6 Hz, 1H), 5.00 – 4.79 (s, 2H), 2.19 – 2.01 (t, J = 18.5 Hz, 3H).

Intermediate 64. (1-(3-(1,1-Difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol.




The title compound was prepared in a manner analgous to Intermediate 2, using 3-(1,1-difluoroethyl) aniline. MS (ESI): mass calcd. for $C_{11}H_{11}F_2N_3O$,

02 Mar 2021 2017217542


239.1; m/z found, 240.0 $[M+H]^+$. 1H NMR (500 MHz, CDCl3) δ 8.11 – 7.99 (s, 1H), 7.99 – 7.86 (s, 1H), 7.86 – 7.72 (m, 1H), 7.69 – 7.53 (m, 2H), 5.00 – 4.83 (s, 2H), 2.08 – 1.88 (t, J = 18.2 Hz, 3H).

Example 1. 2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.



To a solution of (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 7, 25.3 mg, 0.097 mmol) in DMF (1.0 mL) at rt was added NaH (60% dispersion in mineral oil) (11.7 mg, 0.29 mmol). The resulting reaction was stirred for 5 min before the addition of 2-chloropyrimidine (14.5 mg, 0.127 mmol). The reaction was stirred at rt for 20 h, and then quenched by the addition of water (0.10 mL). The mixture was diluted with EtOAc (5 mL) and H_2O (5 mL). The layers were separated and the aqueous layer was extracted with EtOAc (3 x 5 mL). The combined organics were washed with H_2O (1 X 5 mL), with brine (1 X 5 mL), dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-60% EtOAc in hexanes) afforded the title compound (19.2 mg, 58%). MS (ESI): mass calcd. for $C_{14}H_{10}ClF_2N_5O$, 337.1; m/z found, 338.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.58 (d, *J* = 4.8 Hz, 2H), 8.18 (s, 1H), 8.02 – 8.00 (m, 1H), 7.92 – 7.86 (m, 1H), 7.63 – 7.59 (m, 1H), 7.14 – 6.84 (m, 2H), 5.71 – 5.65 (m, 2H).

Example 2. N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]pyridin-2-amine.




2017217542 02 Mar 2021

Step A. 1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazole-4-carbaldehyde. To a round bottom flask containing (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1, 150 mg, 0.54 mmol) was added Dess-Martin periodinane (461.6 mg, 1.09 mmol) and DCM (20 mL). The flask was sealed under ambient atmosphere and stirred rapidly at rt for 4 hours. The reaction was quenched with saturated aqueous sodium bicarbonate (2.5 mL) and 10% aqueous sodium thiosulfate (2.5 mL). The biphasic mixture is stirred vigorously until the white milky organic phase became clear and colorless (60 min). The layers were separated and aqueous layers was extracted with DCM (1X). The combined organics were washed with brine, dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-30 % EtOAc in hexanes) afforded the title compound (140 mg, 94 %) as an off white solid. MS (ESI) mass calcd. for: $C_{10}H_6ClF_2N_3O_2$, 273.0; m/z found 274.1 $[M+H]^+$.

Step B. *N*-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine. A solution of 1-(4-chloro-3-(difluoromethoxy)phenyl)-1*H*-1,2,3-triazole-4-carbaldehyde (26 mg, 0.095 mmol) and 2-amino pyridine (10.7 mg, 0.114 mmol) in DCM (5 mL) was charged with 1 N HCl in Et_2O (0.5 mL). The resulting solution was stirred at rt for 10 min then charged with $NaHB(OAc)_3$ (30 mg, 0.143 mmol). The mixture was stirred at rt overnight. The completed reaction was diluted with DCM (5 mL) and quenched with water. The layers were separated and aqueous layer was extracted with DCM (1X). The combined organics were washed with brine, dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-10% 2M NH_3 in MeOH/DCM) afforded the title compound (16 mg, 48%). MS (ESI) mass calcd. for: $C_{15}H_{12}ClF_2N_5O$, 351.1; m/z found 352.0. ^1H NMR (400 MHz, $CDCl_3$) δ 8.17 – 8.05 (m, 1H), 8.00 (s, 1H), 7.69 (d, J = 2.2 Hz, 1H), 7.63 – 7.43 (m, 3H), 6.86 – 6.42 (m, 3H), 5.67 (s, 1H), 4.81 – 4.71 (m, 2H).

Example 3. N-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine.


2017217542 02 Mar 2021



Step A. 4-(Chloromethyl)-1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole. To a suspension of (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5, 1.5 g, 5.7 mmol) in DCM (30 mL) in a flask equipped to vent into 2M Na_2CO_3 was added $SOCl_2$ (15 mL). The reaction turned homogeneous (~5 min) and the clear solution was stirred at rt for 3h. Concentration under reduced pressure afforded 1.5 g of the title compound as an off white solid, which was used without further purification. ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.05 (s, 1H), 8.00 (dd, *J* = 5.8, 2.7 Hz, 1H), 7.99 - 7.94 (m, 1H), 7.42 (t, *J* = 9.1 Hz, 1H), 4.80 (s, 2H).

Step B. *N*-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine. A mixture of 4-(chloromethyl)-1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazole (55 mg, 0.19 mmol), pyrimidin-2-amine (45 mg, 0.47 mmol), K_2CO_3 (130 mg, 0.94 mmol) in DMF (1.5 mL) was heated in a 80 °C heating block for 24 h. The mixture was poured into water (35 mL) and extracted with EtOAc. The solvent was removed under reduced pressure and the residue was loaded onto SiO_2. Purification (FCC, SiO_2, hexanes/EtOAc 0 - 100%) afforded the title compound (13 mg, 19%). MS (ESI): mass calcd. for $C_{14}H_{10}F_4N_6$, 338.1; m/z found, 339.0 $[M+H]^+$. ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.33 (d, *J* = 4.8 Hz, 2H), 7.99 – 7.95 (m, 2H), 7.95 – 7.91 (m, 1H), 7.38 (t, *J* = 9.1 Hz, 1H), 6.64 – 6.59 (m, 1H), 5.87 – 5.80 (m, 1H), 4.83 (d, *J* = 6.2 Hz, 2H).

Example 4. 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine.




To a solution of (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6, 180 mg, 0.69 mmol), pyridin-2-ol (66 mg, 0.69

2017217542 02 Mar 2021

mmol), and triphenylphosphine (182 mg, 0.69 mmol) in THF (4.5 mL) was added DBAD (160 mg, 0.69 mmol). The resulting mixture was stirred at rt. for 3 h. The solvent was removed under reduced pressure. Purification (FCC, SiO_2, heptane/EtOAc (0 to 80%) afforded the title compound (28 mg, 11%). MS (ESI): mass calcd. for $C_{15}H_{11}F_3N_4O_2$, 336.1; m/z found, 337.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.37 - 8.12 (m, 1H), 8.05 (s, 1H), 7.69 (dd, J = 2.5, 6.7 Hz, 1H), 7.66 - 7.51 (m, 2H), 7.34 (t, J = 9.2 Hz, 1H), 6.92 (ddd, J = 0.7, 5.2, 7.1 Hz, 1H), 6.85 - 6.40 (m, 2H), 5.60 (s, 2H). 1-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2(1H)-one was also obtained (75 mg, 32%).


Example 5. 3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine.



To a solution of pyridin-3-ol (11 mg, 0.12 mmol) and K_2CO_3 (64 mg, 0.46 mmol) in DMF (0.7 mL) was added a solution of 1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole (Intermediate 4, 41 mg, 0.14 mmol) in DMF (0.5 mL). The reaction mixture was stirred at room temperature overnight. Upon completion, the reaction mixture was diluted with H_2O and EtOAc. The aqueous layer was further extracted with EtOAc (3X). The combined organics were dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-100% EtOAc in hexanes) afforded title compound (24 mg, 58% yield). MS (ESI): mass calcd. for $C_{15}H_{11}ClF_2N_4O_2$, 352.1; m/z found, 353.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.42 (d, J = 3.0 Hz, 1H), 8.27 (dd, J = 4.6, 1.4 Hz, 1H), 8.14 - 8.04 (m, 1H), 7.78 - 7.69 (m, 1H), 7.66 - 7.60 (m, 1H), 7.60 - 7.56 (m, 1H), 7.40 - 7.33 (m, 1H), 7.31 - 7.21 (m, 1H), 6.64 (t, J = 72.5 Hz, 1H), 5.34 (s, 2H).


02 Mar 2021 2017217542

Example 6. N-((1-(3-(Difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)pyrimidin-2-amine.



(1-(3-(Difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 17, 32.4 mg, 0.145 mmol), 2-chloropyrimidine (21.5 mg, 0.188 mmol), TEA (0.03 mL, 0.217 mmol), and EtOH (0.723 mL) were combined in a microwave vial. The vial was purged with N_2, sealed, and heated in a microwave reactor at 120 °C for 2 h. Then at 150 °C for 10 min. The crude reaction mixture was concentrated under reduced pressure. Purification (FCC, SiO_2, 0-8% MeOH in DCM) afforded the title compound (21.3 mg, 49%). MS (ESI): mass calcd. for $C_{14}H_{12}F_2N_6$, 302.1; m/z found, 303.2 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.33 (d, *J* = 4.8 Hz, 2H), 8.00 (s, 1H), 7.92 – 7.82 (m, 2H), 7.68 – 7.55 (m, 2H), 6.72 (t, *J* = 56.1 Hz, 1H), 6.61 (t, *J* = 4.8 Hz, 1H), 5.66 (s, 1H), 4.83 (d, *J* = 6.2 Hz, 2H).

Example 7. *N*-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-imidazol-2-amine.




To a solution of (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 18, 50 mg, 0.17 mmol) and 2-bromo-1-methyl-1*H*-imidazole in tBuOH (4 mL) was added 2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl (14.4 mg, 0.033 mmol), tris(dibenzylideneacetone)dipalladium(0) (15.5 mg, 0.017 mmol), and potassium tert-butoxide (76 mg, 0.68 mmol) under N_2 atmosphere. The mixture was stirred at 110 ºC for 96 h. The resulting solids were filtered off and the solvent was evaporated under reduced pressure. Purification (FCC, SiO_2, EtOAc /Heptane 0-100%; then MeOH/DCM 0-90%) then further purified (RP HPLC; Stationary phase: C^{18} XBridge 30 x 100 mm 5 µm), Mobile phase:

2017217542 02 Mar 2021


Gradient from 81% 10mM NH_4CO_3H pH 9 solution in Water, 19% CH_3CN to 64% 10mM NH_4CO_3H pH 9 solution in Water, 36% CH_3CN) to afford the title compound (11 mg, 19%) as white solid. MS (ESI): mass calcd. for $C_{14}H_{13}F_3N_6O$, 338.1; m/z found, 339.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 3.38 (s, 3H) 4.13 - 4.31 (m, 1H) 4.70 (d, *J* = 6.24 Hz, 2H) 6.63 (t, *J* = 72.83 Hz, 1H) 6.53 (d, *J* = 1.39 Hz, 1H) 6.69 (d, *J* = 1.39 Hz, 1H) 7.32 (t, *J* = 9.25 Hz, 1H) 7.51 - 7.61 (m, 1H) 7.68 (dd, *J* = 6.70, 2.54 Hz, 1H) 8.08 (s, 1H).

Example 8. 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine.




To a solution of 2-bromo-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine (Intermediate 7, 75 mg, 0.18 mmol) in 1,4-dioxane (2 mL) was added trimethylboroxine (0.03 mL, 0.21 mmol), Cs_2CO_3 (118 mg, 0.36 mmol), and (2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate (15.3 mg, 0.018 mmol) to a sealed tube under N_2 atmosphere. The mixture was heated to 120 ºC for 12 min under microwave irradiation. The mixture was concentrated under reduced pressure. Purification (FCC, SiO_2, EtOAc in heptane from 0-100%) afforded the title compound. The title compound was further purified (RP HPLC, Stationary phase: ^{18}C XBridge 30 x 100 mm 5 μm), Mobile phase: Gradient from 90% 10 mM NH_4CO_3H pH 9 solution in Water, 10% CH_3CN to 0% 10 mM NH_4CO_3H pH 9 solution in Water, 100% CH_3CN) to afford the title compound (39 mg, 61%) HRMS = 350.099. ^1H NMR (500 MHz, $CDCl_3$) δ ppm 2.49 (s, 3 H) 5.59 (s, 2 H) 6.49 - 6.81 (m, 1 H) 6.61 (d, *J* = 8.1 Hz, 1 H) 6.77 (d, *J* = 7.2 Hz, 1 H) 7.35 (t, *J* = 9.2 Hz, 1 H) 7.49 (dd, *J* = 8.2, 7.4 Hz, 1 H) 7.59 (ddd, *J* = 9.0, 3.9, 2.7 Hz, 1 H) 7.70 (dd, *J* = 6.4, 2.6 Hz, 1 H) 8.04 (s, 1 H).

Example 9. 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{13}H_9BrFN_5O$, 349.0; m/z found, 350.0 $[M+H]^+$. ^1H NMR (600 MHz, $CDCl_3$) δ 8.57 (d, J = 4.7 Hz, 2H), 8.09 – 8.08 (m, 1H), 7.99 (dd, J = 5.8, 2.7 Hz, 1H), 7.67 (ddd, J = 8.9, 4.0, 2.6 Hz, 1H), 7.30 – 7.28 (m, 1H), 7.00 (t, J = 4.8 Hz, 1H), 5.68 – 5.65 (m, 2H).

Example 10. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}ClF_2N_5O_2$, 353.0; m/z found, 354.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.57 (d, J = 4.8 Hz, 2H), 8.20 - 8.04 (m, 1H), 7.73 - 7.68 (m, 1H), 7.65 - 7.60 (m, 1H), 7.59 - 7.55 (m, 1H), 7.03 - 6.90 (m, 1H), 6.64 (t, J = 72.5 Hz, 1H), 5.67 (s, 2H).

Example 11. 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol

02 Mar 2021
2017217542


(Intermediate 8) and 2-chloropyridine. MS (ESI): mass calcd. for $C_{15}H_{11}ClF_2N_4O$, 336.1; m/z found, 336.9 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.21 (ddd, *J* = 5.0, 2.0, 0.8 Hz, 1H), 8.12 (s, 1H), 8.02 – 7.99 (m, 1H), 7.92 – 7.87 (m, 1H), 7.64 – 7.58 (m, 2H), 7.14 – 6.85 (m, 1H), 6.95 – 6.90 (m, 1H), 6.81 (dt, *J* = 8.3, 0.9 Hz, 1H), 5.64 – 5.57 (m, 2H).

Example 12. 4-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 4-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}ClF_2N_5O$, 337.1; m/z found, 338.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.85 (s, 1H), 8.48 (d, *J* = 5.8 Hz, 1H), 8.14 (s, 1H), 8.00 (d, *J* = 2.7 Hz, 1H), 7.93 – 7.85 (m, 1H), 7.66 – 7.58 (m, 1H), 7.00 (t, *J* = 54.5 Hz, 1H), 6.81 (dd, *J* = 5.8, 1.2 Hz, 1H), 5.67 (s, 2H).


Example 13. 4-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 4-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}ClF_2N_5O_2$, 353.0; m/z found, 354.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.83 (s, 1H), 8.47 (d, *J* = 5.9 Hz, 1H), 8.10 (s, 1H), 7.73 - 7.67 (m, 1H), 7.64 - 7.59 (m, 1H), 7.59 - 7.54 (m, 1H), 6.80 (dd, *J* = 5.9, 1.2 Hz, 1H), 6.64 (t, *J* = 72.5 Hz, 1H), 5.65 (s, 2H).


2017217542 02 Mar 2021

Example 14. 3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridazine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 3-chloropyridazine. MS (ESI): mass calcd. for $C_{14}H_{10}ClF_2N_5O_2$, 353.0; m/z found, 354.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.47 (d, J = 5.9 Hz, 1H), 8.10 (s, 1H), 7.74 - 7.68 (m, 1H), 7.66 - 7.59 (m, 1H), 7.59 - 7.54 (m, 1H), 6.80 (dd, J = 5.9, 1.2 Hz, 1H), 6.64 (t, J = 72.5 Hz, 1H), 5.65 (s, 2H).


Example 15. 2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloropyridine (Intermediate 15) and 2-chloropyrimidine. . MS (ESI): mass calcd. for $C_{14}H_{12}ClN_5O_2$, 317.1; m/z found, 318.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.57 (d, J = 4.8 Hz, 2H), 8.13 (s, 1H), 7.49 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 2.4 Hz, 1H), 7.16 (dd, J = 8.5, 2.4 Hz, 1H), 7.06 - 6.95 (m, 1H), 5.67 (s, 2H), 3.99 (s, 3H).


02 Mar 2021 2017217542

Example 16. 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}BrFN_5O$, 363.0; m/z found, 363.9 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.38 (s, 2H), 8.07 (s, 1H), 7.98 (dd, J = 5.8, 2.7 Hz, 1H), 7.67 (ddd, J = 8.9, 4.0, 2.6 Hz, 1H), 7.30 – 7.27 (m, 1H), 5.63 (s, 2H), 2.26 (s, 3H).

Example 17. 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}BrFN_5O$, 363.0; m/z found, 363.9 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.40 (d, J = 5.0 Hz, 1H), 8.08 (s, 1H), 7.99 (dd, J = 5.8, 2.6 Hz, 1H), 7.66 (ddd, J = 8.8, 4.0, 2.6 Hz, 1H), 7.31 – 7.28 (m, 1H), 6.87 (d, J = 5.0 Hz, 1H), 5.65 (d, J = 0.7 Hz, 2H), 2.50 (s, 3H).


Example 18. 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4,6-dimethyl-pyrimidine.



02 Mar 2021 2017217542


The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) and 2-chloro-4,6-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}BrFN_5O$, 377.0; m/z found, 378.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.08 (s, 1H), 7.99 (dd, *J* = 5.8, 2.7 Hz, 1H), 7.66 (ddd, *J* = 8.9, 4.0, 2.7 Hz, 1H), 7.33 – 7.27 (m, 1H), 6.73 (s, 1H), 5.64 (d, *J* = 0.8 Hz, 2H), 2.44 (s, 6H).

Example 19. 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{13}H_8BrF_2N_5O$, 367.0; m/z found, 368.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.43 (s, 2H), 8.07 (s, 1H), 7.98 (dd, *J* = 5.8, 2.7 Hz, 1H), 7.67 (ddd, *J* = 8.9, 4.0, 2.6 Hz, 1H), 7.29 (dd, *J* = 8.9, 7.8 Hz, 1H), 5.63 (s, 2H).

Example 20. 2-[[1-(4-Fluoro-3-methoxy-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{12}FN_5O_2$, 301.1; m/z found, 302.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.57 (d, *J* = 4.8 Hz, 2H), 8.09 (s, 1H), 7.46 (dd, *J* = 7.4, 2.5 Hz, 1H), 7.23 - 7.12 (m, 2H), 7.05 - 6.94 (m, 1H), 5.66 (s, 2H), 3.97 (s, 3H).

Example 21. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.39 (d, *J* = 5.0 Hz, 1H), 8.13 (s, 1H), 7.74 - 7.65 (m, 1H), 7.63 - 7.58 (m, 1H), 7.60 - 7.52 (m, 1H), 6.86 (d, *J* = 5.0 Hz, 1H), 6.63 (t, *J* = 72.5 Hz, 1H), 5.64 (s, 2H), 2.48 (s, 3H).

Example 22. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.37 (s, 2H), 8.12 (s, 1H), 7.75 - 7.67 (m, 1H), 7.64 - 7.58 (m, 2H), 7.58 - 7.53 (m, 1H), 6.63 (t, *J* = 72.6 Hz, 1H), 5.62 (s, 2H), 2.25 (s, 3H).


Example 23. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrazine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-fluoropyrazine. MS (ESI): mass calcd. for $C_{14}H_{10}ClF_2N_5O_2$, 353.0; m/z found, 354.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.30 (d, *J* = 1.4 Hz, 1H), 8.19 (d, *J* = 2.8 Hz, 1H), 8.13 (dd, *J* = 2.8, 1.4 Hz, 1H), 8.08 (s, 1H), 7.74 - 7.68 (m, 1H), 7.65 - 7.60 (m, 1H), 7.60 - 7.55 (m, 1H), 6.64 (t, *J* = 72.5 Hz, 1H), 5.61 (s, 2H).

Example 24. *N*-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine.



The title compound was prepared in a manner analogous to Example 3, Step B, using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 21) and 2-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}F_3N_6$, 320.1; m/z found, 321.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 4.82 (d, *J* = 6.01 Hz, 2H), 5.80 (br s, 1H), 6.60 (t, *J* = 4.62 Hz, 1H), 6.75 - 7.15 (m, 1H), 7.30 (br t, *J* = 8.90 Hz, 1H), 7.77 - 7.93 (m, 2H), 7.97 (s, 1H), 8.33 (d, *J* = 4.62 Hz, 2H).

Example 25. 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}F_3N_5O$, 321.1; m/z found, 322.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ

2017217542 02 Mar 2021


5.67 (s, 2H), 6.78 - 7.12 (m, 2H), 7.33 (t, *J* = 9.0 Hz, 1H), 7.82 - 8.01 (m, 2H), 8.14 (s, 1H), 8.58 (d, *J* = 4.6 Hz, 2H).

Example 26. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_3$, 383.1; m/z found, 384.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.24 (s, 2H), 8.15 - 8.08 (m, 1H), 7.74 - 7.67 (m, 1H), 7.66 - 7.59 (m, 1H), 7.59 - 7.55 (m, 1H), 6.63 (t, *J* = 72.5 Hz, 1H), 5.61 (s, 2H), 3.88 (s, 3H).

Example 27. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_2$, 381.1; m/z found, 382.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ .40 (s, 2H), 8.21 - 8.00 (m, 1H), 7.79 - 7.67 (m, 1H), 7.64 - 7.59 (m, 1H), 7.59 - 7.54 (m, 1H), 6.63 (t, *J* = 72.5 Hz, 1H), 5.64 (s, 2H), 2.61 (q, *J* = 7.6 Hz, 2H), 1.26 (t, *J* = 7.6 Hz, 3H).

Example 28. 5-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_9Cl_2F_2N_5O_2$, 387.0; m/z found, 388.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.51 (s, 2H), 8.16 - 8.02 (m, 1H), 7.73 – 7.68 (m, 1H), 7.65 - 7.60 (m, 1H), 7.59 - 7.53 (m, 1H), 6.64 (t, J = 72.5 Hz, 1H), 5.64 (s, 2H).

Example 29. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-chloro-4-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_3$, 383.1; m/z found, 384.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.22 (d, J = 5.7 Hz, 1H), 8.12 (s, 1H), 7.75 – 7.68 (m, 1H), 7.63 - 7.59 (m, 1H), 7.58 - 7.53 (m, 1H), 6.64 (t, J = 72.5 Hz, 1H), 6.43 (d, J = 5.7 Hz, 1H), 5.64 (s, 2H), 3.98 (s, 3H).


Example 30. 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O$, 351.1; m/z found, 352.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.40 (d, *J* = 5.0 Hz, 1H), 8.17 (s, 1H), 8.00 (d, *J* = 2.5 Hz, 1H), 7.90 – 7.86 (m, 1H), 7.60 (d, *J* = 8.7 Hz, 1H), 7.12 – 6.84 (m, 2H), 5.65 (d, *J* = 0.7 Hz, 2H), 2.49 (s, 3H).

Example 31. 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O$, 351.1; m/z found, 352.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.38 (d, *J* = 0.9 Hz, 2H), 8.16 (s, 1H), 8.00 (d, *J* = 2.6 Hz, 1H), 7.92 – 7.84 (m, 1H), 7.66 – 7.55 (m, 1H), 6.99 (t, *J* = 54.6 Hz, 1H), 5.63 (d, *J* = 0.7 Hz, 2H), 2.26 (s, 3H).


Example 32. 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2- chloro-5-ethylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O$, 365.1; m/z found, 366.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.40 (s, 1H), 8.17 (d, *J* = 0.7 Hz, 1H), 8.01 (d, *J* =


2.6 Hz, 1H), 7.92 – 7.86 (m, 1H), 7.63 – 7.59 (m, 1H), 6.99 (t, *J* = 54.5 Hz, 1H), 5.65 (d, *J* = 0.8 Hz, 2H), 2.61 (q, *J* = 7.6 Hz, 3H), 1.27 (t, *J* = 7.6 Hz, 3H).

Example 33. 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}F_3N_5O_2$, 337.1; m/z found, 338.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.58 (d, *J* = 4.9 Hz, 2H), 8.12 (s, 1H), 7.70 (dd, *J* = 2.7, 6.6 Hz, 1H), 7.65 - 7.54 (m, 1H), 7.35 (t, *J* = 9.1 Hz, 1H), 7.02 (t, *J* = 4.7 Hz, 1H), 6.65 (t, *J* = 72.6 Hz, 1H), 5.66 (s, 2H).

Example 34. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrazine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-chloro-5-methylpyrazine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.20 (d, *J* = 1.5 Hz, 1H), 8.11 - 8.04 (m, 1H), 8.01 - 7.94 (m, 1H), 7.74 - 7.68 (m, 1H), 7.65 - 7.58 (m, 1H), 7.59 - 7.55 (m, 1H), 6.64 (t, *J* = 72.5 Hz, 1H), 5.57 (s, 2H), 2.49 (s, 3H).

Example 35. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}ClF_4N_5O_3$, 419.0; m/z found, 420.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.45 (s, 2H), 8.12 (s, 1H), 7.75 - 7.69 (m, 1H), 7.65 - 7.59 (m, 1H), 7.59 - 7.55 (m, 1H), 6.64 (t, *J* = 72.5 Hz, 1H), 6.53 (t, *J* = 71.9 Hz, 1H), 5.65 (s, 2H).


Example 36. *N*-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine.



The title compound was prepared in a manner analogous to Example 6 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 18) and 2-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}F_3N_6O$, 336.1; m/z found, 337.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.33 (d, *J* = 4.9 Hz, 2H), 7.93 (s, 1H), 7.67 (dd, *J* = 2.5, 6.5 Hz, 1H), 7.56 (ddd, *J* = 2.7, 3.9, 9.0 Hz, 1H), 7.33 (t, *J* = 9.2 Hz, 1H), 6.61 (s, 2H), 5.81 - 5.57 (m, 1H), 4.82 (d, *J* = 6.2 Hz, 2H).


02 Mar 2021 2017217542

Example 37. 5-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}ClF_2N_5O$, 337.1; m/z found, 338.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.50 (s, 2H), 8.13 (d, J = 2.7 Hz, 1H), 7.73 – 7.66 (m, 1H), 7.07 – 6.99 (m, 1H), 5.68 – 5.62 (m, 2H), 2.30 (t, J = 2.0 Hz, 3H).

Example 38. 2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O$, 317.1; m/z found, 318.2 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.38 (d, J = 0.9 Hz, 2H), 8.15 – 8.11 (m, 1H), 7.69 (td, J = 8.6, 5.7 Hz, 1H), 7.02 (td, J = 8.7, 1.8 Hz, 1H), 5.64 (d, J = 0.6 Hz, 2H), 2.30 (t, J = 2.0 Hz, 3H), 2.25 (t, J = 0.7 Hz, 3H).

Example 39. 2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O$, 331.1; m/z found, 332.2 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.39 (s, 2H), 8.14 (d, J = 2.9 Hz, 1H), 7.73 – 7.66 (m, 1H), 7.02 (td, J = 8.6, 1.9 Hz, 1H), 5.65 (d, J = 0.7 Hz, 2H), 2.63 – 2.57 (m, 2H), 2.30 (t, J = 2.0 Hz, 3H), 1.26 (t, J = 7.6 Hz, 3H).

Example 40. 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) and 2-chloro-5-ethylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{13}BrFN_5O$, 377.0; m/z found, 380.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.40 (s, 2H), 8.08 (s, 1H), 7.99 (dd, J = 5.8, 2.7 Hz, 1H), 7.67 (ddd, J = 8.9, 4.1, 2.7 Hz, 1H), 7.31 – 7.27 (m, 1H), 5.64 (s, 2H), 2.61 (q, J = 7.6 Hz, 2H), 1.27 (t, J = 7.6 Hz, 3H).

Example 41. 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}BrFN_5O_2$, 379.0; m/z found, 380.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.24 (s, 2H),

2017217542 02 Mar 2021


8.07 (s, 1H), 7.98 (dd, *J* = 5.8, 2.7 Hz, 1H), 7.67 (ddd, *J* = 8.9, 4.1, 2.6 Hz, 1H), 7.31 – 7.27 (m, 1H), 5.60 (d, *J* = 0.7 Hz, 2H), 3.88 (s, 3H).

Example 42. 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-chloro-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) and 2,5-dichloropyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{13}H_8BrClFN_5O$, 383.0; m/z found, 384.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.51 (s, 2H), 8.07 (s, 1H), 7.98 (dd, *J* = 5.8, 2.7 Hz, 1H), 7.67 (ddd, *J* = 8.9, 4.0, 2.6 Hz, 1H), 7.29 (dd, *J* = 9.0, 7.9 Hz, 1H), 5.64 (d, *J* = 0.7 Hz, 2H).

Example 43. 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-isopropyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) and 2-chloro-5-isopropylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{15}BrFN_5O$, 391.0; m/z found, 392.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.42 (d, *J* = 0.5 Hz, 2H), 8.08 (s, 1H), 7.99 (dd, *J* = 5.8, 2.7 Hz, 1H), 7.67 (ddd, *J* = 8.9, 4.0, 2.7 Hz, 1H), 7.31 – 7.28 (m, 1H), 5.64 (d, *J* = 0.7 Hz, 2H), 2.97 – 2.87 (m, 1H), 1.30 (d, *J* = 7.0 Hz, 6H).

Example 44. 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) and 2-chloro-5-(trifluoromethyl)pyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{14}H_8BrF_4N_5O$, 417.0; m/z found, 418.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.82 (d, J = 0.8 Hz, 2H), 8.09 (s, 1H), 7.99 (dd, J = 5.7, 2.7 Hz, 1H), 7.68 (ddd, J = 8.9, 4.0, 2.6 Hz, 1H), 7.29 (dd, J = 8.9, 7.8 Hz, 1H), 5.73 (d, J = 0.6 Hz, 2H).

Example 45. 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-5-(trifluoromethyl)pyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_9ClF_5N_5O$, 405.0; m/z found, 406.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.82 (d, J = 0.8 Hz, 2H), 8.18 (s, 1H), 8.01 (d, J = 2.7 Hz, 1H), 7.89 (dd, J = 8.7, 2.5 Hz, 1H), 7.62 (d, J = 8.6 Hz, 1H), 7.00 (t, J = 54.5 Hz, 1H), 5.74 (d, J = 0.7 Hz, 2H).


Example 46. 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-5-methoxypyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.24 (s, 2H), 8.16 (s, 1H), 8.01 (d, J = 2.6 Hz, 1H), 7.91 – 7.86 (m, 1H), 7.61 (dt, J = 8.7, 1.2 Hz, 1H), 6.99 (t, J = 54.6 Hz, 1H), 5.61 (d, J = 0.7 Hz, 2H), 3.88 (s, 3H).

Example 47. 5-Chloro-2-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2,5-dichloropyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{14}H_9Cl_2F_2N_5O$, 371.0; m/z found, 372.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.51 (s, 2H), 8.16 (s, 1H), 8.01 (d, J = 2.6 Hz, 1H), 7.92 – 7.86 (m, 1H), 7.65 – 7.59 (m, 1H), 7.00 (t, J = 54.5 Hz, 1H), 5.65 (d, J = 0.7 Hz, 2H).

Example 48. 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-5-isopropylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{17}H_{16}ClF_2N_5O$, 379.1; m/z found, 380.1

02 Mar 2021 2017217542


[M+H]$^+$. ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.43 (d, *J* = 0.6 Hz, 2H), 8.17 (s, 1H), 8.01 (d, *J* = 2.6 Hz, 1H), 7.90 – 7.87 (m, 1H), 7.61 (d, *J* = 8.7 Hz, 1H), 6.99 (t, *J* = 54.6 Hz, 1H), 5.65 (d, *J* = 0.7 Hz, 2H), 2.97 – 2.88 (m, 1H), 1.30 (d, *J* = 7.0 Hz, 6H).

Example 49. 5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_9ClF_3N_5O$, 355.0; m/z found, 356.0 [M+H]$^+$. ^{1}H NMR (400 MHz, $CDCl_3$) δ 5.66 (s, 2H), 6.96 (t, *J* = 55.02 Hz, 1H), 7.34 (t, *J* = 9.02 Hz, 1H), 7.77 - 8.03 (m, 2H), 8.13 (s, 1H), 8.52 (s, 2H).

Example 50. 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-5-(trifluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{15}H_9F_6N_5O$, 389.1; m/z found, 390.0 [M+H]$^+$. ^{1}H NMR (400 MHz, $CDCl_3$) δ 5.75 (s, 2H), 6.96 (t, *J* = 54.56 Hz, 1H), 7.35 (t, *J* = 9.02 Hz, 1H), 7.76 - 8.05 (m, 2H), 8.16 (s, 1H), 8.83 (s, 2H).

Example 51. 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-5-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O$, 335.1; m/z found, 336.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 2.27 (s, 3H), 5.65 (s, 2H), 6.96 (t, J = 54.56 Hz, 1H), 7.33 (t, J = 8.90 Hz, 1H), 7.69 - 8.03 (m, 2H), 8.14 (s, 1H), 8.39 (s, 2H).

Example 52. 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-4-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O$, 335.1; m/z found, 336.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 2.50 (s, 3H), 5.67 (s, 2H), 6.96 (t, J = 54.56 Hz, 1H), 6.87 (d, J = 4.85 Hz, 1H), 7.33 (t, J = 9.02 Hz, 1H), 7.86 - 7.93 (m, 1H), 7.96 (dd, J = 5.66, 2.66 Hz, 1H), 8.15 (s, 1H), 8.41 (d, J = 4.85 Hz, 1H).

Example 53. (R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using R/S-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 2) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.1; m/z found, 368.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.54 (d, *J* = 4.8 Hz, 2H), 8.10 - 8.02 (m, 1H), 7.72 - 7.64 (m, 1H), 7.63 - 7.58 (m, 1H), 7.58 - 7.53 (m, 1H), 7.00 - 6.93 (m, 1H), 6.63 (t, *J* = 72.5 Hz, 1H), 6.51 (q, *J* = 6.6 Hz, 1H), 1.85 (d, *J* = 6.6 Hz, 3H).

Example 54. (R*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine.



SFC Purification (Stationary phase: Chiralpak IF 5 μm 250 X 21 mm, Mobile phase: 20% methanol, 80% CO_2) Enantiomeric purity (SFC/ Chiralpak IF): 100%. Retention time: 5.40 min. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.53 (d, *J* = 4.8 Hz, 2H), 8.11 - 7.96 (m, 1H), 7.73 - 7.65 (m, 1H), 7.61 - 7.57 (m, 1H), 7.57 - 7.52 (m, 1H), 7.01 - 6.91 (m, 1H), 6.63 (t, *J* = 72.5 Hz, 1H), 6.51 (q, *J* = 6.6 Hz, 1H), 1.85 (d, *J* = 6.6 Hz, 3H).

Example 55. (S*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine.




SFC Purification (Stationary phase: Chiralpak IF 5 μm 250 X 21 mm, Mobile phase: 20% methanol, 80% CO_2) Enantiomeric purity (SFC/ Chiralpak IF): 99.6%. Retention time: 7.05 min. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.54 (d, *J* = 4.8

02 Mar 2021 2017217542


Hz, 2H), 8.11 - 7.97 (m, 1H), 7.75 - 7.65 (m, 1H), 7.63 - 7.58 (m, 1H), 7.57 - 7.53 (m, 1H), 7.01 - 6.92 (m, 1H), 6.63 (t, *J* = 72.5 Hz, 1H), 6.51 (q, *J* = 6.6 Hz, 1H), 1.85 (d, *J* = 6.6 Hz, 3H).

Example 56. (R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using R/S-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 2) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_2$, 381.1; m/z found, 382.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.35 (s, 2H), 8.09 - 7.99 (m, 1H), 7.74 - 7.66 (m, 1H), 7.62 - 7.57 (m, 1H), 7.57 - 7.52 (m, 1H), 6.84 - 6.42 (m, 2H), 2.24 (s, 3H), 1.84 (d, *J* = 6.6 Hz, 3H). Example 56 was subjected to Chiral SFC purification [Stationary phase: Chiralpak IF (5μm, 4.6 x 250 mm), Mobile phase of 25% MeOH: 75% CO_2] to provide the corresponding single enantiomers (Example 57 and Example 58) where the absolute stereochemistry was not determined. The enantiomeric purity was confirmed by analytical SFC using a Chiralpak IF column (5μm 4.6 x 250 mm), mobile phase of 25% MeOH: 75% CO_2, and a flow rate of 2 mL/min over 7 minutes (Temperature = 35 °C). Elution was monitored following absorbance at 254nm.

Example 57. (R*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine.




Enantiomeric purity (SFC/ Chiralpak IF): 100%. Retention time: 5.93 min. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_2$, 381.1; m/z found, 382.0 $[M+H]^+$. ^1H

2017217542 02 Mar 2021


NMR (400 MHz, $CDCl_3$) δ 8.35 (s, 2H), 8.05 - 8.01 (m, 1H), 7.71 - 7.66 (m, 1H), 7.62 - 7.57 (m, 1H), 7.57 - 7.51 (m, 1H), 6.82 - 6.41 (m, 2H), 2.24 (s, 3H), 1.84 (d, *J* = 6.6 Hz, 3H).

Example 58. (S*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine.



Enantiomeric purity (SFC/ Chiralpak IF): 100%. Retention time: 8.74 min. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_2$, 381.1; m/z found, 382.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.34 (s, 2H), 8.13 - 7.97 (m, 1H), 7.73 - 7.65 (m, 1H), 7.60 - 7.57 (m, 1H), 7.57 - 7.52 (m, 1H), 6.84 - 6.39 (m, 2H), 2.23 (s, 3H), 1.83 (d, *J* = 6.6 Hz, 3H).


Example 59. (R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-4-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using R/S-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 2) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_2$, 381.1; m/z found, 382.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.36 (d, *J* = 5.0 Hz, 1H), 8.04 (d, *J* = 0.7 Hz, 1H), 7.70 - 7.65 (m, 1H), 7.61 - 7.58 (m, 1H), 7.57 - 7.53 (m, 1H), 6.86 - 6.79 (m, 1H), 6.62 (t, *J* = 72.5 Hz, 1H), 6.53 (q, *J* = 6.6 Hz, 1H), 2.47 (s, 3H), 1.83 (d, *J* = 6.6 Hz, 3H).


2017217542 02 Mar 2021

Example 60. (R/S)-5-Chloro-2-[1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using R/S-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 2) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}Cl_2F_2N_5O_2$, 401.0; m/z found, 402.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.47 (s, 2H), 8.02 (d, J = 0.7 Hz, 1H), 7.72 - 7.65 (m, 1H), 7.63 - 7.58 (m, 1H), 7.57 - 7.52 (m, 1H), 6.63 (t, J = 72.5 Hz, 1H), 6.44 (q, J = 6.6 Hz, 1H), 1.85 (d, J = 6.6 Hz, 3H).


Example 61. 5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2,5-dichloropyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{14}H_9ClF_3N_5O_2$, 371.0; m/z found, 372.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 2.01 - 2.06 (m, 1H), 4.08 - 4.15 (m, 1H), 5.64 (s, 2H), 6.64 (t, J = 72.36 Hz, 1H), 7.35 (t, J = 9.13 Hz, 1H), 7.58 (ddd, J = 8.90, 3.81, 2.77 Hz, 1H), 7.69 (dd, J = 6.70, 2.54 Hz, 1H), 8.08 (s, 1H), 8.51 (s, 2H).


2017217542 02 Mar 2021

Example 62. 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-5-(trifluoromethyl)pyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_9F_6N_5O_2$, 405.1; m/z found, 406.1 $[M+H]^+$. ^1H NMR (400MHz, $CDCl_3$) δ 8.81 (s, 2H), 8.13 (s, 1H), 7.69 (dd, J = 2.4, 6.6 Hz, 1H), 7.59 (br d, J = 9.0 Hz, 1H), 7.34 (t, J = 9.2 Hz, 1H), 6.65 (t, J = 72.1 Hz, 1H), 5.72 (s, 2H).


Example 63. 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and and 2-chloro-5-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O_2$, 351.1; m/z found, 352.1 $[M+H]^+$. ^1H NMR (400MHz, $CDCl_3$) δ 8.38 (s, 2H), 8.09 (s, 1H), 7.69 (dd, J = 2.5, 6.5 Hz, 1H), 7.58 (td, J = 3.2, 8.9 Hz, 1H), 7.34 (t, J = 9.2 Hz, 1H), 6.64 (t, J = 72.4 Hz, 1H), 5.83 - 5.41 (m, 2H), 2.26 (s, 3H).


02 Mar 2021 2017217542

Example 64. 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-4-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O_2$, 351.1; m/z found, 352.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.40 (d, J = 5.1 Hz, 1H), 8.11 (s, 1H), 7.70 (dd, J = 2.5, 6.5 Hz, 1H), 7.64 - 7.51 (m, 1H), 7.34 (t, J = 9.2 Hz, 1H), 6.87 (d, J = 5.1 Hz, 1H), 6.65 (t, J = 72.6 Hz, 1H), 5.66 (s, 2H), 2.50 (s, 3H).


Example 65. 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-5-(trifluoromethyl)pyridine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{10}F_6N_4O$, 388.1; m/z found, 389.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 5.66 (s, 2H), 6.73 - 7.14 (m, 2H), 7.33 (t, J = 9.02 Hz, 1H), 7.81 (dd, J = 8.67, 2.43 Hz, 1H), 7.86 - 7.99 (m, 2H), 8.09 (s, 1H), 8.50 (s, 1H).


02 Mar 2021 2017217542

Example 66. 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-5-fluoropyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{14}H_9ClF_3N_5O$, 355.0; m/z found, 356.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.43 (s, 2H), 8.16 (s, 1H), 8.01 (d, J = 2.6 Hz, 1H), 7.91 – 7.86 (m, 1H), 7.64 – 7.60 (m, 1H), 6.99 (t, J = 54.6 Hz, 1H), 5.64 (d, J = 0.7 Hz, 2H).

Example 67. 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-ethylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O$, 363.1; m/z found, 364.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.40 (s, 2H), 8.12 (t, J = 0.7 Hz, 1H), 7.92 – 7.87 (m, 1H), 7.86 – 7.80 (m, 1H), 7.34 – 7.28 (m, 1H), 5.74 – 5.55 (m, 2H), 2.70 – 2.52 (m, 2H), 2.05 (t, J = 18.6, 1.2 Hz, 3H), 1.27 (t, J = 7.6 Hz, 3H).


Example 68. 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-methoxypyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_2$, 365.1; m/z found, 366.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.24 (s, 2H), 8.11 (t, J = 0.7 Hz, 1H), 7.89 (dd, J = 6.2, 2.8 Hz, 1H), 7.82 (s, 1H), 7.30 (dd, J = 9.8, 8.8 Hz, 1H), 5.61 (d, J = 0.7 Hz, 2H), 3.88 (s, 3H), 2.05 (td, J = 18.6, 1.2 Hz, 3H).

Example 69. 5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2,5-dichloropyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{11}ClF_3N_5O$, 369.1; m/z found, 370.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.51 (s, 2H), 8.11 (t, J = 0.7 Hz, 1H), 7.89 (dd, J = 6.2, 2.7 Hz, 1H), 7.84 (d, J = 12.9 Hz, 1H), 7.31 (dd, J = 9.8, 8.9 Hz, 1H), 5.65 (d, J = 0.7 Hz, 2H), 2.05 (td, J = 18.6, 1.2 Hz, 3H).

Example 70. 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-isopropylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{18}H_{18}F_3N_5O$, 377.1; m/z found, 378.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.42 (d, J = 0.5 Hz, 2H), 8.12 (t, J = 0.7

2017217542 02 Mar 2021


Hz, 1H), 7.90 (dd, *J* = 6.2, 2.7 Hz, 1H), 7.87 – 7.81 (m, 1H), 7.35 – 7.27 (m, 1H), 5.64 (s, 2H), 2.92 (t, *J* = 7.0 Hz, 1H), 2.05 (td, *J* = 18.6, 1.2 Hz, 6H), 1.30 (d, *J* = 7.0 Hz, 3H).

Example 71. 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-(trifluoromethyl)pyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{11}F_6N_5O$, 403.1; m/z found, 404.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.85 – 8.78 (m, 2H), 8.13 (s, 1H), 7.93 – 7.87 (m, 1H), 7.87 – 7.81 (m, 1H), 7.36 – 7.28 (m, 1H), 5.74 (s, 2H), 2.05 (td, *J* = 18.6, 1.2 Hz, 3H).


Example 72. 5-Ethyl-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-5-ethylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{13}F_4N_5O$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.40 (t, *J* = 0.7 Hz, 2H), 8.14 (t, *J* = 0.7 Hz, 1H), 8.02 – 7.98 (m, 1H), 7.98 – 7.92 (m, 1H), 7.40 (t, *J* = 9.1 Hz, 1H), 5.65 (d, *J* = 0.7 Hz, 2H), 2.70 – 2.54 (m, 2H), 1.27 (t, *J* = 7.6 Hz, 3H).


02 Mar 2021
2017217542

Example 73. 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-5-methoxypyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O_2$, 369.1; m/z found, 370.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.24 (s, 2H), 8.16 – 8.09 (m, 1H), 8.04 – 7.98 (m, 1H), 7.99 – 7.93 (m, 1H), 7.40 (t, J = 9.2 Hz, 1H), 5.61 (s, 2H), 3.88 (s, 3H).

Example 74. 5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2,5-dichloropyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{14}H_8ClF_4N_5O$, 373.0; m/z found, 374.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.51 (s, 2H), 8.16 – 8.11 (m, 1H), 8.04 – 7.98 (m, 1H), 7.98 – 7.92 (m, 1H), 7.41 (t, J = 9.1 Hz, 1H), 5.65 (d, J = 0.7 Hz, 2H).


Example 75. 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-5-isopropylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{17}H_{15}F_4N_5O$, 381.1; m/z found, 382.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.43 (s, 2H), 8.16 – 8.13 (m, 1H), 8.02 – 7.99 (m, 1H), 7.98 – 7.93 (m, 1H), 7.40 (t, J = 9.1 Hz, 1H), 5.65 (s, 2H), 2.98 – 2.85 (m, 1H), 1.30 (d, J = 7.0 Hz, 6H).

Example 76. 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-5-(trifluoromethyl)pyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_8F_7N_5O$, 407.1; m/z found, 408.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.86 – 8.79 (m, 2H), 8.15 (s, 1H), 8.04 – 7.98 (m, 1H), 7.98 – 7.93 (m, 1H), 7.41 (t, J = 9.1 Hz, 1H), 5.74 (d, J = 0.7 Hz, 2H).

Example 77. 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O$, 349.1; m/z found, 350.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.38 (s, 2H), 8.12 (s, 1H), 7.97 – 7.78

2017217542 02 Mar 2021


(m, 2H), 7.37 – 7.27 (m, 1H), 5.64 (d, *J* = 2.9 Hz, 2H), 2.27 (d, *J* = 2.7 Hz, 3H), 2.17 – 1.94 (m, 3H).

Example 78. 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloropyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O$, 335.1; m/z found, 336.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.58 (d, *J* = 4.7 Hz, 2H), 8.13 (d, *J* = 1.1 Hz, 1H), 7.93 – 7.87 (m, 1H), 7.88 – 7.79 (m, 1H), 7.36 – 7.27 (m, 1H), 7.01 (t, *J* = 4.7 Hz, 1H), 5.67 (d, *J* = 0.9 Hz, 2H), 2.19 – 1.91 (m, 3H).

Example 79. 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-4-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O$, 349.1; m/z found, 350.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.41 (t, *J* = 5.3 Hz, 1H), 8.13 (s, 1H), 7.96 – 7.77 (m, 2H), 7.36 – 7.28 (m, 2H), 6.86 (d, *J* = 5.3 Hz, 1H), 5.66 (d, *J* = 3.5 Hz, 2H), 2.66 – 2.31 (m, 2H), 2.05 (t, *J* = 18.3 Hz, 3H).

Example 80. 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-fluoropyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O$, 353.1; m/z found, 354.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.43 (s, 2H), 8.11 (s, 1H), 7.92 – 7.87 (m, 1H), 7.87 – 7.81 (m, 1H), 7.31 (t, J = 9.4 Hz, 1H), 5.64 (s, 2H), 2.16 – 1.96 (m, 3H).

Example 81. 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-5-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O$, 353.1; m/z found, 354.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.39 (d, J = 1.2 Hz, 2H), 8.13 (s, 1H), 8.04 – 7.92 (m, 2H), 7.40 (t, J = 9.2 Hz, 1H), 5.68 – 5.60 (m, 2H), 2.34 – 2.18 (m, 3H).

Example 82. 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate

2017217542 02 Mar 2021


5) and 2-chloropyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{14}H_9F_4N_5O$, 339.1; m/z found, 340.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.67 – 8.54 (m, 2H), 8.15 (s, 1H), 8.08 – 7.89 (m, 2H), 7.40 (t, *J* = 9.2 Hz, 1H), 7.01 (t, *J* = 4.7 Hz, 1H), 5.68 (d, *J* = 0.8 Hz, 2H).

Example 83. 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-4-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O$, 353.1; m/z found, 354.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.40 (d, *J* = 5.2 Hz, 1H), 8.14 (s, 1H), 8.08 – 7.90 (m, 2H), 7.40 (t, *J* = 9.0 Hz, 1H), 6.87 (d, *J* = 5.1 Hz, 1H), 5.66 (d, *J* = 0.8 Hz, 2H), 2.50 (d, *J* = 2.5 Hz, 3H).


Example 84. 5-Fuoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared analogous to Example 1, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-5-fluoropyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{14}H_8F_5N_5O$, 357.1; m/z found, 358.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.44 (d, *J* = 3.1 Hz, 2H), 8.13 (s, 1H), 8.07 – 7.90 (m, 2H), 7.41 (t, *J* = 9.3 Hz, 1H), 5.64 (d, *J* = 3.0 Hz, 2H).


02 Mar 2021 2017217542

Example 85. 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) and 2-chloro-4,5-dimethylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{13}BrFN_5O$, 377.0; m/z found, 378.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.20 (s, 1H), 8.07 (s, 1H), 7.98 (dd, J = 5.8, 2.7 Hz, 1H), 7.66 (ddd, J = 8.9, 4.1, 2.7 Hz, 1H), 7.30 – 7.27 (m, 1H), 5.62 (d, J = 0.7 Hz, 2H), 2.44 (s, 3H), 2.20 (s, 3H).


Example 86. 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-4,5-dimethylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O$, 365.1; m/z found, 366.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.22 – 8.20 (m, 1H), 8.17 – 8.16 (m, 1H), 8.00 (d, J = 2.6 Hz, 1H), 7.90 – 7.86 (m, 1H), 7.62 – 7.58 (m, 1H), 6.99 (t, J = 54.6 Hz, 1H), 5.63 (d, J = 0.8 Hz, 2H), 2.45 (s, 3H), 2.20 (s, 3H).


02 Mar 2021
2017217542

Example 87. 2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 15) and 2-chloro-5-methoxypyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{14}ClN_5O_3$, 347.1; m/z found, 348.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.24 (s, 2H), 8.15 - 8.04 (m, 1H), 7.49 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 2.4 Hz, 1H), 7.16 (dd, J = 8.5, 2.4 Hz, 1H), 5.60 (s, 2H), 3.99 (s, 3H), 3.88 (s, 3H).

Example 88. 2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 15) and 2-chloro-5-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{14}ClN_5O_2$, 331.1; m/z found, 332.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.38 (s, 2H), 8.23 - 8.08 (m, 1H), 7.49 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 2.3 Hz, 1H), 7.16 (dd, J = 8.5, 2.4 Hz, 1H), 5.63 (s, 2H), 3.99 (s, 3H), 2.26 (s, 3H).


Example 89. 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 12) and 2-chloro-5-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O$, 317.1; m/z found, 318.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.38 (s, 2H), 8.17 (s, 1H), 7.92 – 7.89 (m, 1H), 7.88 – 7.85 (m, 1H), 7.66 – 7.60 (m, 1H), 7.60 – 7.56 (m, 1H), 6.72 (t, *J* = 56.1 Hz, 1H), 5.64 (d, *J* = 0.7 Hz, 2H), 2.28 – 2.23 (m, 3H).

Example 90. 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 12) and 2-chloro-5-methoxypyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O_2$, 333.1; m/z found, 334.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.23 (s, 2H), 8.16 (s, 1H), 7.91 – 7.89 (m, 1H), 7.88 – 7.85 (m, 1H), 7.65 – 7.60 (m, 1H), 7.60 – 7.55 (m, 1H), 6.72 (t, *J* = 56.1 Hz, 1H), 5.61 (d, *J* = 0.7 Hz, 2H), 3.87 (s, 3H).

Example 91. 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 12) and 2-chloro-5-ethylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O$, 331.1; m/z found, 332.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.38 (s, 2H), 8.17 (s, 1H), 7.91 – 7.88 (m, 1H), 7.87 – 7.83 (m, 1H),

2017217542 02 Mar 2021


7.64 – 7.58 (m, 1H), 7.58 – 7.54 (m, 1H), 6.71 (t, *J* = 56.1 Hz, 1H), 5.63 (d, *J* = 0.7 Hz, 2H), 2.59 (q, *J* = 7.7 Hz, 2H), 1.24 (t, *J* = 7.6 Hz, 3H).

Example 92. 5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 12) and 2,5-dichloropyrimidine, using THF instead of DMF MS (ESI): mass calcd. for $C_{14}H_{10}ClF_2N_5O$, 337.1; m/z found, 338.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.50 (s, 2H), 8.17 (s, 1H), 7.92 – 7.88 (m, 1H), 7.88 – 7.85 (m, 1H), 7.66 – 7.61 (m, 1H), 7.61 – 7.57 (m, 1H), 6.72 (t, *J* = 56.1 Hz, 1H), 5.64 (d, *J* = 0.6 Hz, 2H).

Example 93. 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 12) and 2-chloropyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{14}H_{11}F_2N_5O$, 303.1; m/z found, 304.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.56 (d, *J* = 4.8 Hz, 2H), 8.18 (s, 1H), 7.91 – 7.89 (m, 1H), 7.88 – 7.84 (m, 1H), 7.65 – 7.60 (m, 1H), 7.59 – 7.56 (m, 1H), 6.99 (t, *J* = 4.8 Hz, 1H), 6.72 (t, *J* = 56.1 Hz, 1H), 5.66 (d, *J* = 0.7 Hz, 2H).

Example 94. 2-[[1-(5-Bromo-6-methyl-2-pyridyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(5-bromo-6-methylpyridin-2-yl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{14}H_{13}BrN_6O$, 360.0; m/z found 361.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.68 (s, 1H), 8.39 – 8.36 (m, 2H), 8.00 – 7.96 (m, 1H), 7.91 – 7.87 (m, 1H), 5.63 (d, *J* = 0.8 Hz, 2H), 2.68 (s, 3H), 2.25 (s, 3H).

Example 95. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_9ClF_3N_5O_2$, 371.0; m/z found, 372.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.43 (s, 2H), 8.14 - 8.09 (m, 1H), 7.72 - 7.66 (m, 1H), 7.64 - 7.60 (m, 1H), 7.59 - 7.54 (m, 1H), 6.64 (t, *J* = 72.5 Hz, 1H), 5.63 (s, 2H).


Example 96. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-chloro-5-(difluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}ClF_4N_5O_2$, 403.1; m/z found, 404.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.76 - 8.63 (m, 2H), 8.22 - 8.07 (m, 1H), 7.75 - 7.64 (m, 1H), 7.64 - 7.60 (m, 1H), 7.59 - 7.54 (m, 1H), 6.73 (t, *J* = 55.6 Hz, 1H), 6.64 (t, *J* = 72.5 Hz, 1H), 5.71 (s, 2H).

Example 97. N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]oxazol-2-amine.



The title compound was prepared in a manner analogous to Example 2, using 1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazole-4-carbaldehyde and oxazol-2-amine. MS (ESI): mass calcd. for $C_{13}H_{10}ClF_2N_5O_2$, 341.0; m/z found, 342.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.09 – 7.97 (m, 1H), 7.74 – 7.64 (m, 1H), 7.65 – 7.51 (m, 2H), 7.22 – 7.14 (m, 1H), 6.87 – 6.40 (m, 2H), 5.30 (s, 1H), 4.70 (d, *J* = 5.7 Hz, 2H).

Example 98. N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine.




The title compound was prepared in a manner analogous Example 3, using 1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole (Intermediate 4) in Step A and pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for $C_{14}H_{11}ClF_2N_6O$, 352.1; m/z found, 353.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.33 (d, *J* = 4.8 Hz, 2H), 8.00 - 7.92 (m, 1H), 7.72 - 7.68

2017217542 02 Mar 2021


(m, 1H), 7.62 - 7.57 (m, 1H), 7.56 - 7.52 (m, 1H), 6.89 - 6.34 (m, 2H), 4.82 (dd, *J* = 6.2, 0.7 Hz, 2H).

Example 99. *N*-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-4-amine.




The title compound was prepared in a manner analogous to Example 3, using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) in Step A and 1-methyl-1H-pyrazol-4-amine in Step B. MS (ESI): mass calcd. for $C_{14}H_{13}F_3N_6$, 322.1; m/z found, 323.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 3.48 (br s, 1H), 3.80 (s, 3H), 4.37 (s, 2H), 6.75 - 7.10 (m, 2H), 7.17 (s, 1H), 7.32 (br t, *J* = 9.02 Hz, 1H), 7.75 - 8.05 (m, 3H).

Example 100. N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-3-amine.




The title compound was prepared in a manner analogous to Example 3, using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) in Step A and 1-methyl-1H-pyrazol-3-amine in Step B. MS (ESI): mass calcd. for $C_{14}H_{13}F_3N_6$, 322.1; m/z found, 323.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 3.74 (s, 3H), 4.18 (br s, 1H), 4.56 (br s, 2H), 5.58 (br s, 1H), 6.75 - 7.20 (m, 2H), 7.31 (br t, *J* = 9.02 Hz, 1H), 7.72 - 8.17 (m, 3H).

Example 101. *N*-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-3-amine.




The title compound was prepared in a manner analogous to Example 3, using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) in Step A and 1-methyl-1H-pyrazol-3-amine in Step B. MS (ESI): mass calcd. for $C_{14}H_{13}F_3N_6O$, 338.1; m/z found, 339.1 $[M+H]^+$. ^1H NMR (400MHz, $CDCl_3$) δ 7.91 (s, 1H), 7.67 (br d, J = 4.2 Hz, 1H), 7.61 - 7.48 (m, 1H), 7.33 (t, J = 9.5 Hz, 1H), 7.12 (br d, J = 1.6 Hz, 1H), 6.64 (t, J = 72.4 Hz, 1H), 5.57 (d, J = 2.1 Hz, 1H), 4.55 (br s, 2H), 4.20 (br s, 1H), 3.74 (s, 3H).

Example 102. *N*-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-4-amine.




The title compound was prepared in a manner analogous to Example 3, using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) in Step A and 1-methyl-1H-pyrazol-4-amine in Step B. MS (ESI): mass calcd. for $C_{14}H_{13}F_3N_6O$, 338.1; m/z found, 339.1 $[M+H]^+$. ^1H NMR (400MHz, $CDCl_3$) δ 7.86 (s, 1H), 7.68 (br d, J = 4.6 Hz, 1H), 7.61 - 7.47 (m, 1H), 7.33 (s, 1H), 7.17 (s, 1H), 6.97 (s, 1H), 6.87 - 6.40 (m, 1H), 4.36 (s, 2H), 3.80 (d, J = 0.7 Hz, 3H).

Example 103. 3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-2-methoxy-pyridine.




The title compound was prepared in a manner analogous to Example 5 using 1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole (Intermediate 4) and 2-methoxypyridin-3-ol. MS (ESI): mass calcd. for $C_{16}H_{13}ClF_2N_4O_3$, 382.1; m/z found, 383.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.10 (s, 1H), 7.79 (dd, *J* = 5.0, 1.5 Hz, 1H), 7.75 - 7.68 (m, 1H), 7.66 - 7.59 (m, 1H), 7.58 - 7.53 (m, 1H), 7.30 (dd, *J* = 7.8, 1.5 Hz, 1H), 6.85 (dd, *J* = 7.8, 5.0 Hz, 1H), 6.63 (t, *J* = 72.5 Hz, 1H), 5.36 (s, 2H), 4.02 (s, 3H).

Example 104. 5-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-2-methyl-pyridine.




The title compound was prepared in a manner analogous to Example 5 using 1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole (Intermediate 4) and 6-methylpyridin-3-ol. MS (ESI): mass calcd. for $C_{16}H_{13}ClF_2N_4O_2$, 366.1; m/z found, 367.1 $[M+H]^+$. ^1H NMR (400 MHz $CDCl_3$) δ 8.29 (d, *J* = 3.0 Hz, 1H), 8.08 - 7.98 (m, 1H), 7.74 - 7.70 (m, 1H), 7.66 - 7.61 (m, 1H), 7.60 - 7.55 (m, 1H), 7.30 - 7.22 (m, 1H), 7.10 (d, *J* = 8.5 Hz, 1H), 6.64 (t, *J* = 72.5 Hz, 1H), 5.31 (s, 2H), 2.50 (s, 3H).

Example 105. 3-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine.



The title compound was prepared in a manner analogous to Example 5 using 1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole (Intermediate 4) and 3-chloropyridin-2-ol. MS (ESI): mass calcd. for $C_{15}H_{10}Cl_2F_2N_4O_2$, 386.0; m/z found, 387.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.10 (dd, J = 4.9, 1.7 Hz, 1H), 8.09 - 8.08 (m, 1H), 7.74 - 7.70 (m, 1H), 7.67 (dd, J = 7.6, 1.7 Hz, 1H), 7.64 - 7.59 (m, 1H), 7.59 - 7.55 (m, 1H), 6.91 (dd, J = 7.6, 4.9 Hz, 1H), 6.64 (t, J = 72.6 Hz, 1H), 5.68 (s, 2H).


Example 106. 5-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-methoxy-pyridine.



The title compound was prepared in a manner analogous to Example 5 using 1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole (Intermediate 4) and 5-chloro-3-methoxypyridin-2-ol. MS (ESI): mass calcd. for $C_{16}H_{12}Cl_2F_2N_4O_3$, 416.0; m/z found, 417.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.07 (s, 1H), 7.72 (d, J = 2.2 Hz, 1H), 7.71 - 7.68 (m, 1H), 7.62 - 7.58 (m, 1H), 7.57 - 7.53 (m, 1H), 7.06 (d, J = 2.1 Hz, 1H), 6.63 (t, J = 72.6 Hz, 1H), 5.64 (s, 2H), 3.86 (s, 3H).


02 Mar 2021
2017217542

Example 107. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-fluoro-pyridine.



The title compound was prepared in a manner analogous to Example 5 using 1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole (Intermediate 4) and 3-fluoropyridin-2-ol. MS (ESI): mass calcd. for $C_{15}H_{10}ClF_3N_4O_2$, 370.0; m/z found, 371.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.17 - 8.06 (m, 1H), 7.97 (dd, *J* = 5.0, 1.5 Hz, 1H), 7.72 - 7.70 (m, 1H), 7.64 - 7.60 (m, 1H), 7.59 - 7.55 (m, 1H), 7.40 - 7.34 (m, 1H), 6.97 - 6.85 (m, 1H), 6.64 (t, *J* = 72.5 Hz, 1H), 5.68 (s, 2H).


Example 108. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-methoxy-pyridine.



The title compound was prepared in a manner analogous to Example 5 using 1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole (Intermediate 4) and 3-methoxypyridin-2-ol. MS (ESI): mass calcd. for $C_{16}H_{13}ClF_2N_4O_3$, 382.1; m/z found, 383.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.08 (s, 1H), 7.80 - 7.74 (m, 1H), 7.72 - 7.67 (m, 1H), 7.62 - 7.58 (m, 1H), 7.57 - 7.53 (m, 1H), 7.12 - 7.07 (m, 1H), 6.93 - 6.87 (m, 1H), 6.63 (t, *J* = 72.6 Hz, 1H), 5.68 (s, 2H), 3.87 (s, 3H).


02 Mar 2021 2017217542

Example 109. *N*-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 6 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 19) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}ClF_2N_6$, 336.1; m/z found, 337.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.34 (d, J = 4.8 Hz, 2H), 8.00 (s, 1H), 7.98 (d, J = 2.6 Hz, 1H), 7.89 – 7.85 (m, 1H), 7.61 – 7.57 (m, 1H), 6.98 (t, J = 54.6 Hz, 1H), 6.61 (t, J = 4.8 Hz, 1H), 5.69 (s, 1H), 4.83 (dd, J = 6.2, 0.7 Hz, 2H).

Example 110. *N*-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 6 using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 19) and 4-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}ClF_2N_6$, 336.1; m/z found, 337.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.65 (s, 1H), 8.20 (d, J = 6.0 Hz, 1H), 8.02 (s, 1H), 8.00 (d, J = 2.6 Hz, 1H), 7.88 – 7.84 (m, 1H), 7.63 – 7.58 (m, 1H), 6.99 (t, J = 54.5 Hz, 1H), 6.44 (dd, J = 6.0, 1.3 Hz, 1H), 5.54 (s, 1H), 4.81 (d, J = 5.8 Hz, 2H).


Example 111. 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine.



02 Mar 2021 2017217542


The title compound was prepared in a manner analogous to Intermediate 7 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-fluoropyridine. MS (ESI): mass calcd. for $C_{15}H_{11}F_3N_4O$, 320.1; m/z found, 321.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 5.62 (s, 2H), 6.73 - 7.15 (m, 3H), 7.33 (t, *J* = 8.90 Hz, 1H), 7.55 - 7.73 (m, 1H), 7.84 - 8.01 (m, 2H), 8.09 (s, 1H), 8.15 - 8.30 (m, 1H).

Example 112. 5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine.



The title compound was prepared in a manner analogous to Intermediate 7 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 5-chloro-2-fluoropyridine. MS (ESI): mass calcd. for $C_{15}H_{10}ClF_3N_4O$, 354.0; m/z found, 355.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 5.57 (s, 2H), 6.77 (d, *J* = 8.8 Hz, 1H), 6.80 - 7.13 (m, 1H), 7.33 (t, *J* = 9.0 Hz, 1H), 7.56 (dd, *J* = 8.8, 2.5 Hz, 1H), 7.84 - 7.98 (m, 2H), 8.07 (s, 1H), 8.15 (d, *J* = 2.5 Hz, 1H).

Example 113. 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine.




Step A. 2-Bromo-6-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine. The title compound was prepared in a manner analogous to Intermediate 7 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-bromo-6-fluoropyridine.

Step B. 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine. To a solution of 2-bromo-6-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine (25 mg, 0.06 mmol),

2017217542 02 Mar 2021


Cs_2CO_3 (41 mg, 0.12 mmol), in 1,4 dioxane (0.65 mL) was added 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (0.01 mL, 0.07 mmol) and and (2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate (Xphos Palladacycle Gen. 3) (5.3 mg, 0.006 mmol). The reaction mixture was heated under microwave irradiation at 120 °C for 12 minutes. The mixture was concentrated in vacuo. Purification (FCC, SiO_2, EtOAc in heptane from 0-100%). Purification (RP HPLC , Stationary phase: C18 XBridge 30 x 100 mm 5 um, Mobile phase: Gradient from 90% 10mM NH_4CO_3H pH 9 solution in Water, 10% CH_3CN to 0% 10 mM NH_4CO_3H pH 9 solution in Water, 100% CH_3CN) afforded the title compound (46 mg, 68%). MS (ESI): mass calcd. for $C_{16}H_{13}F_3N_4O$, 334.1; m/z found, 335.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 2.49 (s, 3H), 5.60 (s, 2H), 6.61 (d, *J* = 8.3 Hz, 1H), 6.77 (d, *J* = 7.4 Hz, 1H), 6.81 - 7.14 (m, 1H), 7.33 (t, *J* = 9.0 Hz, 1H), 7.49 (t, *J* = 7.6 Hz, 1H), 7.83 - 7.99 (m, 2H), 8.08 (s, 1H).

Example 114. 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-fluoro-5-methylpyridine. MS (ESI): mass calcd. for $C_{16}H_{13}F_3N_4O$, 334.1; m/z found, 335.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 2.27 (s, 3H), 5.58 (s, 2H), 6.73 (d, *J* = 8.3 Hz, 1H), 6.79 - 7.16 (m, 1H), 7.33 (t, *J* = 9.0 Hz, 1H), 7.43 (dd, *J* = 8.4, 1.97 Hz, 1H), 7.84 - 7.97 (m, 2H), 8.01 (s, 1H), 8.08 (s, 1H).


Example 115. 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine.



Step A. 4-Bromo-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine. The title compound was prepared in a manner analogous to Intermediate 7 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 4-bromo-2-fluoropyridine.

Step B. 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine The title compound was prepared in a manner analogous to Example 113 step B, using 4-bromo-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine. MS (ESI): mass calcd. for $C_{16}H_{13}F_3N_4O$, 334.1; m/z found, 335.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 2.31 (s, 3H), 5.60 (s, 2H), 6.63 (s, 1H), 6.76 (d, *J* = 5.1 Hz, 1H), 6.80 - 7.12 (m, 1H), 7.33 (t, *J* = 9.0 Hz, 1H), 7.80 - 7.98 (m, 2H), 8.02 - 8.20 (m, 2H).

Example 116. 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine.




Step A. 4-Bromo-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine. The title compound was prepared in a manner analogous to Intermediate 7 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 4-bromo-2-fluoropyridine.

Step B. 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine The title compound was prepared in a manner analogous to Example 113 step B, using 4-bromo-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine. MS (ESI): mass calcd. for $C_{16}H_{13}F_3N_4O_2$, 350.1; m/z found, 351.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 2.30 (s, 3H), 5.58 (s, 2H), 6.42 - 6.84 (m, 3H), 7.33 (t, *J* = 9.25 Hz, 1H), 7.58

2017217542 02 Mar 2021


(ddd, *J* = 8.96, 3.90, 2.75 Hz, 1H), 7.68 (dd, *J* = 6.65, 2.60 Hz, 1H), 8.02 (s, 1H), 8.05 (d, *J* = 5.20 Hz, 1H).

Example 117. 5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine.



The title compound was prepared in a manner analgous to Example 1 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 5-chloro-2-fluoropyridine. HRMS = 370.044; ^{1}H NMR (500 MHz, $CDCl_3$) δ 5.57 (s, 2H), 6.46 - 6.87 (m, 2H), 7.35 (t, *J* = 9.25 Hz, 1H), 7.49 - 7.63 (m, 2H), 7.70 (dd, *J* = 6.65, 2.60 Hz, 1H), 8.03 (s, 1H), 8.15 (d, *J* = 2.60 Hz, 1H).

Example 118. 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine.




Step A. 5-Chloro-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine. The title compound was prepared in a manner analogous to Intermediate 7 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 5-chloro-2-fluoropyridine.

Step B. 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine The title compound was prepared in a manner analogous to Example 113 step B, using 5-chloro-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine. MS (ESI): mass calcd. for $C_{16}H_{13}F_3N_4O_2$, 350.1; m/z found, 351.1 $[M+H]^+$. ^{1}H NMR (500 MHz, $CDCl_3$) δ 2.26 (s, 3H), 5.56 (s, 2H), 6.44 - 6.81 (m, 2H), 7.33 (t, *J* = 9.25 Hz, 1H), 7.42

2017217542 02 Mar 2021

(dd, *J* = 8.38, 2.02 Hz, 1H), 7.58 (ddd, *J* = 8.81, 3.90, 2.89 Hz, 1H), 7.68 (dd, *J* = 6.65, 2.60 Hz, 1H), 7.94 - 8.01 (m, 1H), 8.03 (s, 1H).


Example 119. 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine.



The title compound was prepared in a manner analogous to Intermediate 7 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-fluoro-5-(trifluoromethyl)pyridine. HRMS= 404.070; ^{1}H NMR (500 MHz, $CDCl_3$) δ 5.65 (s, 2H), 6.45 - 6.81 (m, 1H), 6.89 (d, *J* =8.96 Hz, 1H), 7.34 (t, *J* = 9.25 Hz, 1H), 7.52 - 7.63 (m, 1H), 7.70 (dd, *J* =6.36, 2.60 Hz, 1H), 7.81 (dd, *J* =8.81, 2.17 Hz, 1H), 8.05 (s, 1H), 8.37 - 8.58 (m, 1H).


Example 120- Example 152 may be prepared in a manner analogous to the methods described in the previous examples.

Example 120. 5-Methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.



MS (ESI): mass calcd. for $C_{13}H_{10}F_3N_5OS$, 341.06


Example 121. 5-Methyl-2-((1-(4-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.



MS (ESI): mass calcd. for $C_{13}H_{10}F_3N_5OS$, 341.06


02 Mar 2021
2017217542

Example 122. 2-((1-(3-(Difluoromethyl)-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine.




MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O$, 335.10

Example 123. 2-((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine.




MS (ESI): mass calcd. for $C_{14}H_{12}ClN_5O$, 301.07

Example 124. 2-((1-(4-Chloro-3-(oxetan-3-yl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine.



MS (ESI): mass calcd. for $C_{17}H_{16}ClN_5O_2$, 357.10


Example 125. 2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-fluoro-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine.



MS (ESI): mass calcd. for C15H11ClF3N5O, 369.06


02 Mar 2021
2017217542

Example 126. 2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine.




MS (ESI): mass calcd. for $C_{16}H_{11}ClF_5N_5O$, 419.06

Example 127. 2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine.




MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O$, 365.09

Example 128. 2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylthiazole.



MS (ESI): mass calcd. for $C_{14}H_{11}ClF_2N_4OS$, 356.03.


Example 129. 1-(4-Chloro-3-(difluoromethyl)phenyl)-4-(((5-methyl-1H-imidazol-2-yl)oxy)methyl)-1H-1,2,3-triazole.



MS (ESI): mass calcd. for $C_{14}H_{12}ClF_2N_5O$, 339.07


02 Mar 2021 2017217542

Example 130. 2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyridine.




MS (ESI): mass calcd. for $C_{16}H_{13}ClF_2N_4O_2$, 366.07

Example 131. 2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methylpyridine.




MS (ESI): mass calcd. for $C_{16}H_{13}ClF_2N_4O_2$, 366.07

Example 132. 6-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,3-dimethylpyridine.




MS (ESI): mass calcd. for $C_{17}H_{15}ClF_2N_4O_2$, 380.09

Example 133. 2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methylpyrazine.




MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.06

Example 134. 5-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,3-dimethylpyrazine.




MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_2$, 381.08

Example 135. 5-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyrimidine.




MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.06

Example 136. 6-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,4-dimethylpyridazine.




MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_2$, 381.08

Example 137. 3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(trifluoromethyl)pyridazine.




MS (ESI): mass calcd. for $C_{15}H_9ClF_5N_5O_2$, 421.04r

Example 138. 3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methoxypyridazine.




MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_3$, 383.06

Example 139. 4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyrimidine.




MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.06

Example 140. 4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-(trifluoromethyl)pyrimidine.




MS (ESI): mass calcd. for $C_{15}H_9ClF_5N_5O_2$, 421.04

Example 141. 4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methoxypyrimidine.



MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_3$, 383.06


Example 142. 2-((1-(5-Chloro-6-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine.



2017217542 02 Mar 2021


MS (ESI): mass calcd. for $C_{14}H_{10}ClF_3N_6O$, 370.06

Example 143. 2-((1-(2-(Difluoromethyl)pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine.




MS (ESI): mass calcd. for $C_{14}H_{12}F_2N_6O$, 318.10

Example 144. *N*-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidin-2-amine.




MS (ESI): mass calcd. for $C_{15}H_{13}ClF_2N_6O$, 366.08

Example 145. N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine.



MS (ESI): mass calcd. for $C_{16}H_{15}ClF_2N_6O$, 380.10


Example 146. 3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxypyridine.



MS (ESI): mass calcd. for $C_{16}H_{13}ClF_2N_4O_3$, 382.1


2017217542 02 Mar 2021

Example 147. 4-Chloro-3-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine.




MS (ESI): mass calcd. for $C_{15}H_{10}Cl_2F_2N_4O_2$, 386.0

Example 148. 4-((1-(3-(Difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine.




MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O_3$, 349.1

Example 149. 2-((1-(3-(Difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine.




MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O$, 331.1

Example 150. 5-Methyl-2-((1-(5-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.




MS (ESI): mass calcd. for $C_{14}H_{11}F_3N_6O$, 336.1

Example 151. 2-((1-(5-Bromo-6-fluoropyridin-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine.




MS (ESI): mass calcd. for $C_{13}H_{10}BrFN_6O$, 364.0

Example 152. 5-Methyl-2-((1-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.



MS (ESI): mass calcd. for $C_{13}H_{12}N_6O$, 268.1


Example 153: 5-Chloro-N-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine.



To a solution of 4-(chloromethyl)-1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazole (25 mg, 0.103 mmol) and 2-amino-5-chloropyrimidine (17 mg, 0.13 mmol) in DMF (1.5 mL) was added K_2CO_3 (57 mg, 0.41 mmol). The resulting mixture was stirred at 100 °C for 72 h. The reaction mixture was diluted with water (8 mL) and extracted with EtOAc (3 x 10 mL). The combined organics were dried over Na_2SO_4, filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-80% EtOAc/hexanes) afforded the title compound (6.2 mg, 18%). MS (ESI): mass calcd. for $C_{14}H_{11}ClF_2N_6$, 336.07; m/z found, 337.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.33 – 8.19 (m, 2H), 8.03 – 7.95


(m, 1H), 7.91 – 7.80 (m, 2H), 7.68 – 7.54 (m, 2H), 6.72 (t, *J* = 56.1 Hz, 1H), 5.85 (s, 1H), 4.80 (dd, *J* = 6.2, 0.6 Hz, 2H).

Example 154: N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine.



A solution of (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 19) (35 mg, 0.14 mmol), 2-chloro-5-methylpyrimidine (22.6 mg, 0.18 mmol), and triethylamine (0.06 mL, 0.4 mmol) in EtOH (1 mL) was sealed and heated in a microwave reactor for 1 h at 180 °C, then 200 °C for 1 h. The mixture was concentrated under reduced pressure. Purification (FCC, SiO_2, MeOH/DCM 0 – 8%) afforded the title compound (8.3 mg, 17%). MS (ESI): mass calcd. for $C_{15}H_{13}ClF_2N_6$, 350.1; m/z found, 351.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.19 (s, 2H), 7.99 (s, 1H), 7.97 (d, *J* = 2.6 Hz, 1H), 7.87 (dd, *J* = 8.7, 2.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 6.98 (t, *J* = 54.6 Hz, 1H), 5.69 (s, 1H), 4.81 (d, *J* = 6.2 Hz, 2H), 2.16 (s, 3H).

Example 155: 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine.




To a solution of (1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 12, 50 mg, 0.22 mmol) in THF (1 mL) was added NaH (60% dispersion in mineral oil, 26.6 mg, 0.67 mmol). The mixture was stirred for 5 min, then 2-chloro-4,5-dimethylpyrimidine (38 mg, 0.27 mmol) was added. The reaction was stirred at rt overnight. The mixture was quenched with H_2O, and diluted with EtOAc and H_2O. The layers were separated and the aqueous

2017217542 02 Mar 2021


layer was extracted with EtOAc (3X). The combined organic layers were dried (Na_2SO_4) and concentrated under reduced pressure. Purification (FCC, SiO_2, EtOAc/hexanes 0 – 50%) afforded the title compound (44 mg, 60%). MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O$, 331.1; m/z found, 332.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.23 – 8.12 (m, 2H), 7.93 – 7.83 (m, 2H), 7.67 – 7.54 (m, 2H), 6.72 (t, *J* = 56.0 Hz, 1H), 5.64 (s, 2H), 2.44 (s, 3H), 2.20 (s, 3H).

Example 156: 1-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone.




A solution of (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9, 110 mg, 0.41 mmol), Cs_2CO_3 (535.9 mg, 1.64 mmol), and 1-(2-chloropyrimidin-5-yl)ethan-1-one (83.6 mg, 0.53 mmol) in ACN (0.02 mL) was heated at 110 °C overnight. The reaction mixture was cooled, diluted with EtOAc, and washed with sat. aq. NH_4Cl. The organic layer was dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-50% EtOAc in hexanes) afforded the title compound (12 mg, 8%). MS (ESI): mass calcd. for $C_{16}H_{12}F_3N_5O_2$, 363.1; m/z found, 364.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 9.14 – 9.05 (s, 2H), 8.19 – 8.11 (s, 1H), 7.98 – 7.87 (m, 2H), 7.40 – 7.31 (m, 1H), 7.09 – 6.80 (t, *J* = 54.6 Hz, 1H), 5.80 – 5.71 (s, 2H), 2.66 – 2.57 (s, 3H).

Example 157: (R/S)-1-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol.



A solution of 1-(2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one (Example 156, 14 mg, 0.04 mmol) in DCM/MeOH (15 mL/1 mL) is cool to 0 °C. Sodium borohydride (4.4 mg, 0.12 mmol) was added in a single portion and the reaction mixture was stirred at 0°C for 1h. The completed reaction was quenched with water and extracted into DCM (5 mL X 3). The organic layer is dried (Na_2SO_4), filtered, and concentrated . Purification (FCC, SiO_2, eluting with 0-3% MeOH in DCM) afforded the titled compound (7 mg, 50%). MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_2$, 365.1; m/z found, 366.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.61 – 8.55 (s, 2H), 8.17 – 8.13 (s, 1H), 7.98 – 7.93 (m, 1H), 7.93 – 7.87 (m, 1H), 7.37 – 7.29 (m, 1H), 7.08 – 6.80 (t, *J* = 54.6 Hz, 1H), 5.76 – 5.56 (d, *J* = 0.7 Hz, 2H), 5.10 – 4.86 (m, 1H), 1.64 – 1.50 (d, *J* = 6.5 Hz, 3H). OH proton not observed.


Example 158: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine.



A stirred suspension of (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5, 30 mg, 0.115 mmol), 2-chloropyridine (19.5 mg, 0.172 mmol), Cs_2CO_3 (75 mg, 0.23 mmol) and 2-(di-tert-butylphosphino)biphenyl (69 mg, 0.23 mmol) in toluene (2 mL) was charged with palladium (II) acetate (3 mg, 0.012 mmol). The mixture was stirred at 120 °C for 4 h under a nitrogen atmosphere. The completed reaction was filtered through a pad of diatomaceous earth and washed with EtOAc. The organics

were concentrated under reduced pressure. Purification (FCC, SiO_2, 0-100% EtOAc in Hexanes) afforded the titled compound (18 mg, 47%). MS (ESI): mass calcd. for $C_{15}H_{10}F_4N_4O$, 338.1; m/z found, 339.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.23 – 8.18 (m, 1H), 8.09 (t, *J* = 0.7 Hz, 1H), 8.03 – 7.97 (m, 1H), 7.98 – 7.92 (m, 1H), 7.65 – 7.58 (m, 1H), 7.39 (t, *J* = 9.1 Hz, 1H), 6.95 – 6.89 (m, 1H), 6.85 – 6.78 (m, 1H), 5.61 (d, *J* = 0.7 Hz, 2H).

Example 159: [2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol.




Step A. 4-(((tert-Butyldimethylsilyl)oxy)methyl)-2-((1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine. The title compound was prepared analogous to Example 155, using 4-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine (Intermediate 54).

Step B. [2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol.To a solution of 4-(((tert-butyldimethylsilyl)oxy)methyl)-2-((1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (78 mg, 0.17 mmol) in THF (2 mL) was added TBAF (1 M in THF, 0.2 mL, 0.2 mmol). The reaction was stirred at rt for 15 minutes, then quenched with a saturated solution of NH_4Cl and diluted with EtOAc. The layers were separated and the organic layer was dried (Na_2SO_4) then concentrated under reduced pressure. Purification (FCC, SiO_2, EtOAc/hexanes 0 – 80%) afforded the title compound (26 mg, 39%). MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O_2$, 333.1; m/z found, 334.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.50 (d, *J* = 5.0 Hz, 1H), 8.19 (s, 1H), 7.91 – 7.89 (m, 1H), 7.88 – 7.84 (m, 1H), 7.65 – 7.60 (m, 1H), 7.60 – 7.56 (m, 1H), 7.02 (d, *J* = 5.1 Hz, 1H), 6.72 (t, *J* = 56.1 Hz, 1H), 5.67 (d, *J* = 0.7 Hz, 2H), 4.73 (d, *J* = 4.5 Hz, 2H), 3.33 (t, *J* = 5.4 Hz, 1H).


2017217542 02 Mar 2021

Example 160: [2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol.




The title compound was prepared analogous to Example 159, using 5-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine (Intermediate 53) in Step A. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O_2$, 333.1; m/z found, 334.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.54 (s, 2H), 8.18 (s, 1H), 7.92 – 7.88 (m, 1H), 7.88 – 7.83 (m, 1H), 7.65 – 7.59 (m, 1H), 7.58 – 7.55 (m, 1H), 6.71 (t, *J* = 56.1 Hz, 1H), 5.63 (d, *J* = 0.7 Hz, 2H), 4.67 (s, 2H), 2.88 (s, 1H).

Example 161: 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine.



(1-(3-(Difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 12, 26 mg, 0.12 mmol),2-chloro-5-methylpyrimidin-4-amine (20 mg, 0.14 mmol), and Cs_2CO_3 (113 mg, 0.35 mmol) were dissolved in ACN (0.7 mL) in a microwave vial. The reaction was heated in a microwave reactor at 140 °C for 2 h. The reaction was cooled to rt, diluted with EtOAC and H_2O, then the layers were separated and the aqueous layer was extracted with EtOAc (3X). The combined organic layers were dried (Na_2SO_4), and concentrated under reduced pressure. Purification (FCC, SiO_2, EtOAC/hexanes 0 – 70%) afforded the title compound (13.4 mg, 29%). MS (ESI): mass calcd. for $C_{15}H_{14}F_2N_6O$, 332.1; m/z found, 333.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.15 (s, 1H), 7.93 – 7.82 (m, 3H), 7.66 – 7.54 (m, 2H), 6.71 (t, *J* = 56.1 Hz, 1H), 5.55 (s, 2H), 5.02 (s, 2H), 2.07 – 1.99 (m, 3H).


Example 162: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-4-carboxamide.



Step A: 2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine-4-carboxylic acid. The title compound was prepared in a manner analogous to Example 161, using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and methyl 2-chloropyrimidine-4-carboxylate. MS (ESI): mass calcd. for $C_{15}H_{10}F_3N_5O_3$, 335.1; m/z found, 366.0$[M+H]^+$.

Step B: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-4-carboxamide. To solution of 2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine-4-carboxylic acid (15 mg, 0.041 mmol), methylamine (1.5 mg, 0.045 mmol), EDCI (16 mg, 0.082 mmol), and HOBt (11 mg, 0.082 mmol) in DCM (3 mL) was added DIEA (21 μL, 0.123 mmol). The resulting mixture was stirred at rt overnight. The reaction mixture was diluted with DCM and washed with water and brine. The organic layer was dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-80% EtOAc /Hexanes) afforded the title compound (6.1 mg, 39%). MS (ESI): mass calcd. for $C_{16}H_{13}F_3N_6O_2$, 378.1; m/z found, 379.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.77 (d, *J* = 4.9 Hz, 1H), 8.17 – 8.09 (m, 2H), 7.98 – 7.92 (m, 1H), 7.93 – 7.86 (m, 1H), 7.82 – 7.75 (m, 1H), 7.39 – 7.30 (m, 1H), 6.95 (t, *J* = 54.6 Hz, 1H), 5.70 (d, *J* = 0.6 Hz, 2H), 3.06 (d, *J* = 5.1 Hz, 3H).

Example 163: (R/S) 1-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]ethanamine.



Step. A. (R/S) *tert*-Butyl (1-(2-chloropyrimidin-4-yl)ethyl)carbamate. Under a nitrogen atmosphere was added NaH (60% dispersion in mineral oil, 154 mg, 3.8 mmol) in small batches to a mixture of tert-butyl ((2-chloropyrimidin-4-yl)methyl)carbamate (Intermediate 58, 720 mg, 3.0 mmol) in DMF (50 mL) at room temperature. After 30 minutes, MeI (0.22 mL, 3.5 mmol) was added at 0°C. After 16h, complete conversion was observed. EtOAc (200 mL) was added. The mixture was washed with brine (1x 350 mL). The organic was dried ($MgSO_4$), filtered, and concentrated under vacuum. Purification (FCC, SiO_2, 0-99% EtOAc/hexanes) afforded the title compound (299 mg, 39%). MS (ESI): mass calcd. for $C_{11}H_{16}ClN_3O_2$, 257.1; m/z found, 201.9 $[M\text{-}t\text{-}Bu]^+$.


Step B. (R/S) *tert*-Butyl (1-(2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethyl)carbamate. The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and R/S tert-butyl (1-(2-chloropyrimidin-4-yl)ethyl)carbamate, using THF instead of DMF. MS (ESI): mass calcd. for $C_{21}H_{23}F_3N_6O_4$, 480.1; m/z found, 480.9 $[M+H]^+$.

Step C. (R/S) 1-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]ethanamine as the trifluoroacetic acid salt. TFA (0.04 mL, 0.5 mmol) was added to a mixture of (R/S) tert-butyl (1-(2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethyl)carbamate (13 mg, 0.03 mmol) in DCM (5 mL). Upon completion, the reaction mixture was concentrated under reduced pressure. Purification (HPLC METHOD E) afforded the title compound (3.6 mg, 35%). MS (ESI): mass calcd. for $C_{16}H_{15}F_3N_6O_2$, 380.1; m/z found, 381.0 $[M+H]^+$. ^1H NMR (500 MHz, CD_2Cl_2) δ 8.47 (d, J = 5.1 Hz, 1H), 8.21 (s, 1H), 7.72 (dd, J = 6.7, 2.6 Hz, 1H), 7.60 (ddd, J = 9.0, 3.9, 2.7 Hz, 1H), 7.37 (dd, J = 9.7, 8.9 Hz, 1H),

2017217542 02 Mar 2021


7.03 (d, *J* = 5.0 Hz, 1H), 6.69 (t, *J* = 72.8 Hz, 1H), 5.63 – 5.57 (m, 2H), 4.04 (q, *J* = 6.8 Hz, 1H), 1.39 (d, *J* = 6.7 Hz, 3H).

Example 164: 5-Chloro-2-[[1-(4-fluorophenyl)triazol-4-yl]methoxy]pyrimidine·as the trifluoroacetic acid salt.



A microwave vial was charged with 2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-chloropyrimidine (Example 42, 25 mg, 0.07 mmol), azetidine (0.005 mL, 0.08 mmol), *trans*-bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) (6 mg, 0.007 mmol), molybdenum hexacarbonyl (17 mg, 0.07 mmol), DBU (0.01 mL, 0.08 mmol) and THF (0.5 mL), purged with nitrogen, and heated to 150°C under microwave irradiation for 20 minutes. The reaction mixture was concentrated under vacuum. Purification (FCC, SiO_2, 0-99% EtOAc in hexanes), followed by reversed phase HPLC (METHOD E) afforded the title compound (7 mg, 25%) as a by-product. MS (ESI): mass calcd. for $C_{13}H_9ClFN_5O$, 305.1; m/z found, 306.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.89 (s, 1H), 8.77 – 8.75 (m, 2H), 7.98 – 7.93 (m, 2H), 7.49 – 7.42 (m, 2H), 5.54 (s, 2H).

Example 165: 5-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.



Step A. 5-(Azetidin-1-yl)-2-(methylthio)pyrimidine. A mixture of azetidine (0.03 mL, 0.5 mmol), 5-bromo-2-(methylthio)pyrimidine (100 mg, 0.49 mmol), Xantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) (9.9 mg, 0.02 mmol), $Pd(OAc)_2$ (2 mg, 0.01 mmol) and NaO*t*-Bu (140 mg, 1.5 mmol) in toluene (1.7 mL) was heated at 110°C. After 3h, the reaction mixture was cooled to room temperature and concentrated under vacuum. Purification (FCC, SiO_2, 0-99% EtOAc in hexanes) afforded the title compound (39 mg,


2017217542 02 Mar 2021

44%). MS (ESI): mass calcd. for $C_8H_{11}N_3S$, 181.1; m/z found, 182.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 7.96 (s, 2H), 3.87 (t, J = 7.3 Hz, 4H), 2.45 (s, 3H), 2.40 – 2.32 (m, 2H).

Step B. 5-(Azetidin-1-yl)-2-(methylsulfonyl)pyrimidine. *m*CPBA (1.6 g, 7.3 mmol) was slowly added to a mixture of 5-(azetidin-1-yl)-2-(methylthio)pyrimidine (531 mg, 2.9 mmol) in DCM (12 mL) at 0°C. After 16 hours, the reaction mixture was quenched with a saturated aqueous solution of $NaHCO_3$ (60 mL). The mixture was extracted with DCM (3 x 80 mL). The combined organics were dried ($MgSO_4$), filtered, and concentrated under vacuum. Purification (FCC, SiO_2, 0-99% EtOAc in hexanes) afforded the title compound (290 mg, 46%). MS (ESI): mass calcd. for $C_8H_{11}N_3O_2S$, 213.1; m/z found, 214.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.10 (s, 2H), 4.08 (t, J = 7.5 Hz, 4H), 3.24 (s, 3H), 2.48 – 2.40 (m, 2H).

Step C. 5-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine. The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and using 5-(azetidin-1-yl)-2-(methylsulfonyl)pyrimidine. MS (ESI): mass calcd. for $C_{17}H_{15}F_3N_6O_2$, 392.1; m/z found, 393.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.92 (s, 1H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.92 (s, 2H), 7.87 (ddd, J = 9.0, 4.0, 2.6 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 5.42 (s, 2H), 3.84 (t, J = 7.2 Hz, 4H), 2.38 – 2.29 (m, 2H).

Example 166: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine.




2017217542 02 Mar 2021

Step A. 2-Chloro-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine. A mixture of 2,4-dichloropyrimidine (500 mg, 3.4 mmol), 3,3-difluoropyrrolidine hydrochloride (481 mg, 3.4 mmol) and TEA (0.56 mL, 4.0 mmol) in DCM (23 mL) was stirred at rt. After 3 hours, water (50 mL) was added to the reaction mixture. The mixture was extracted with EtOAc (3 x 75 mL). The combined organics were dried ($MgSO_4$), filtered, and concentrated under vacuum. Purification (FCC, SiO_2, 0-100% EtOAc in hexanes) afforded the title compound (392 mg, 53%). MS (ESI): mass calcd. for $C_8H_8ClF_2N_3$, 219.0; m/z found, 220.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.14 (d, J = 6.0 Hz, 1H), 6.61 (br s, 1H), 3.89 (t, J = 13.0 Hz, 2H), 3.75 – 3.61 (m, 2H).

Step B. 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine. The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine. MS (ESI): mass calcd. for $C_{18}H_{15}F_5N_6O_2$, 442.1; m/z found, 442.9 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.92 (s, 1H), 8.09 (d, J = 5.9 Hz, 1H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.88 (ddd, J = 9.0, 4.0, 2.6 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 6.33 – 6.26 (m, 1H), 5.45 (s, 2H), 3.97 – 3.83 (m, 2H), 3.74 – 3.59 (m, 2H).

Example 167: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine.



Step A: 4-Chloro-5-fluoro-2-(methylsulfonyl)pyrimidine. *m*CPBA (77%, 2.5 g, 11.2 mmol) was slowly added to a mixture of 4-chloro-5-fluoro-2-(methylthio)pyrimidine (1.0 g, 5.6 mmol) in DCM (25 mL) at 0 °C. After 16 hours, the reaction mixture was quenched with a saturated aqueous solution of $NaHCO_3$ (60 mL). The mixture was extracted with DCM (3 x 80 mL). The


2017217542 02 Mar 2021

combined organics were dried ($MgSO_4$), filtered, and concentrated under vacuum. Purification (FCC, SiO_2, 0-99% EtOAc in hexanes) afforded the title compound (1.2 g, 98%). MS (ESI): mass calcd. for $C_5H_4ClFN_2O_2S$, 210.0; m/z found, 211.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 9.26 (d, J = 1.2 Hz, 1H), 3.43 (s, 3H).

Step B. 4-Chloro-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidine. Under a nitrogen atmosphere was added ((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6, 50 mg, 0.2 mmol) to a suspension of NaH (60% dispersion in mineral oil, 15 mg, 0.4 mmol) in THF (2.7 mL). After 5 minutes, 4-chloro-5-fluoro-2-(methylsulfonyl)pyrimidine (49 mg, 0.2 mmol) was added at 0 °C. Upon completion, brine (20 mL) was added and the mixture was extracted with EtOAc (3 x 30 mL). The combined organics were dried ($MgSO_4$), filtered, and concentrated under vacuum. MS (ESI): mass calcd. for $C_{14}H_8ClF_4N_5O_2$, 389.0; m/z found, 390.1 $[M+H]^+$.


Step C. 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine. A microwave vial was charged with 4-chloro-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidine (75 mg, 0.2 mmol), ammonia (2M in MeOH, 1.9 mL, 3.9 mmol) and THF (1.9 mL). The vial was heated to 100 °C under microwave irradiation for 8 hours. The reaction mixture was concentrated under vacuum and the crude material was purified using reversed phase HPLC (Agilent, H_2O/NH_4OH:MeCN gradient) to afford the title compound (14.9 mg, 21%). MS (ESI): mass calcd. for $C_{14}H_{10}F_4N_6O_2$, 370.1; m/z found, 371.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6 δ 8.91 (s, 1H), 8.01 – 7.96 (m, 2H), 7.86 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.55 – 7.23 (m, 3H), 5.35 (s, 2H).

Example 168: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine· as the trifluoroacetic acid salt.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-4-(pyrrolidin-1-yl)pyrimidine. MS (ESI): mass calcd. for $C_{18}H_{17}F_3N_6O_2$, 406.1; m/z found, 406.9 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.97 (s, 1H), 8.07 (d, J = 6.7 Hz, 1H), 8.00 (dd, J = 6.9, 2.7 Hz, 1H), 7.90 – 7.85 (m, 1H), 7.70 (dd, J = 10.2, 9.0 Hz, 1H), 7.40 (t, J = 72.7 Hz, 1H), 6.44 (d, J = 6.7 Hz, 1H), 5.62 (s, 2H), 3.72 – 3.63 (m, 2H), 2.08 – 1.90 (m, 4H).

Example 169: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-4-(piperidin-1-yl)pyrimidine. MS (ESI): mass calcd. for $C_{19}H_{19}F_3N_6O_2$, 420.2; m/z found, 421.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.90 (s, 1H), 8.03 – 7.96 (m, 2H), 7.87 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 6.49 (d, J = 6.2 Hz, 1H), 5.41 (s, 2H), 3.67 – 3.53 (m, 4H), 1.70 – 1.57 (m, 2H), 1.54 – 1.42 (m, 4H).

Example 170: 4-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]morpholine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 4-(2-chloropyrimidin-4-yl) morpholine. MS (ESI): mass calcd. for $C_{18}H_{17}F_3N_6O_3$, 422.1; m/z found, 422.9 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.91 (s, 1H), 8.07 (d, J = 6.1 Hz, 1H), 8.00 (dd, J = 6.9, 2.7 Hz, 1H), 7.87 (ddd, J = 9.0, 4.0, 2.6 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 6.52 (d, J = 6.1 Hz, 1H), 5.43 (s, 2H), 3.69 – 3.54 (m, 8H).

Example 171: 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 163, Steps B-C, using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate (Intermediate 55). MS (ESI): mass calcd. for $C_{15}H_{13}ClF_2N_6O_2$, 382.1; m/z found, 383.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.96 (s, 1H), 8.00 – 7.98 (m, 1H), 7.90 – 7.80 (m, 3H), 7.60 – 7.28 (m, 2H), 6.15 (d, J = 5.9 Hz, 1H), 5.41 (s, 2H), 2.82 – 2.73 (m, 3H).

Example 172: 2-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methoxy-pyrimidine.



Step A. 1-Azido-3-(difluoromethyl)benzene.

Method A. Two solutions, 3-(difluoromethyl)aniline (1.0 g, 7.0 mmol) in 6 N HCl (6N HCl in *i*PrOH, 4.4 mL) and *i*PrOH (5 mL), and sodium nitrite (0.58 g, 8.4 mmol) in H_2O (4 mL) were flowed through a LTF-MS mixer (0.2 mL) at 1 mL/min and 0.4 mL/min, respectively. The outcome was mixed with sodium azide (0.55 g, 8.4 mmol) in H_2O (4 mL) at 0.4 mL/min in a T-piece and flowed through a LTF-VS mixer (1 mL). The mixture was collected over K_2CO_3 (4.8 g, 35 mmol) in *i*PrOH (140 mL). The reaction mixture was extracted into ether and concentrated under reduced pressure. The crude residue was carried forward without purification.

Method B. To 3-(difluoromethyl)aniline (1.47 g, 10.3 mmol) in a round bottom flask was slowly added H_2SO_4 (2 mL, 37.5 mmol) followed by TFA (10 mL, 130.7 mmol). The reaction was cooled to 0 °C, then a solution of $NaNO_2$ (1 g, 15 mmol) in H_2O (10 mL) was added drop-wise with stirring. The reaction was stirred at 0 °C for 40 minutes, then a solution of sodium azide (1.26 g, 19.4 mmol) in H_2O (10 mL) was added drop-wise. The reaction was removed from the ice bath and stirred at rt for 2 h. The mixture was diluted with diethyl ether and basified to pH 12 with a solution of LiOH (4 N). The layers were separated and the aqueous layer was extracted with diethyl ether (3X). The combined organic layers were dried (Na_2SO_4) and concentrated under reduced pressure. The crude residue was carried forward without purification.

Step B. Ethyl 1-(3-(difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazole-4-carboxylate. To a solution of 1-azido-3-(difluoromethyl)benzene (0.59 g, 3.5 mmol) in DMSO (3.5 mL) was added ethyl acetoacetate (0.7 mL, 5.2 mmol) followed by dimethylamine (0.02 mL, 0.17 mmol). The vial was purged with N_2 then sealed and stirred at 70 °C overnight. The reaction was cooled to rt then diluted with EtOAc and H_2O. The layers were separated and the aqueous

2017217542 02 Mar 2021

layer was extracted with EtOAc (3X). The combined organic layers were washed with H_2O (X5), then brine (X3), then dried (Na_2SO_4) and concentrated under reduced pressure. Purification (FCC, SiO_2, EtOAc/hexanes 0 - 50%) afforded the title compound as a pale yellow oil that solidified upon standing (67%). MS (ESI): mass calcd. for $C_{13}H_{13}F_2N_3O_2$, 281.1; m/z found, 282.0 $[M+H]^+$.


Step C. (1-(3-(Difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methanol. To ethyl 1-(3-(difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazole-4-carboxylate (395 mg, 1.4 mmol) stirring in THF at -78 °C was added LAH (1 M in THF, 3.5 mL, 3.5 mmol) drop-wise. The reaction was stirred at -78 °C for 2 h, then warmed to rt and stirred for 1 h. The reaction was cooled to 0 °C and quenched slowly with EtOAc, then the mixture was warmed to rt and diluted with a saturated solution of L(+)-tartaric acid potassium sodium salt (Rochelle salt). The mixture was stirred vigorously for 1 h, then the layers were separated and the aqueous layer was extracted with EtOAc (3X). The combined organic layers were dried (Na_2SO_4) then concentrated under reduced pressure to afford a yellow oil that was used without purification (296 mg, 88%). MS (ESI) mass calcd. for $C_{11}H_{11}F_2N_3O$, 239.1; m/z found 240.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 7.69 - 7.63 (m, 3H), 7.63 - 7.57 (m, 1H), 6.73 (t, J = 56.1 Hz, 1H), 4.83 (s, 2H), 2.40 (s, 3H).

Step D. 2-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methoxy-pyrimidine. To (1-(3-(difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methanol (45 mg, 0.19 mmol) stirring in THF (1 mL) was added NaH (60% dispersion in mineral oil, 22.6 mg, 0.56 mmol) and the reaction was stirred for 5 min. 2-Chloro-5-methoxypyrimidine was then added and the reaction was stirred at rt for 1 h. The reaction was quenched with H_2O, then diluted with EtOAc and H_2O. The layers were separated and the aqueous layer was extracted with EtOAc (3X). The combined organic layers were washed with H_2O (1X), brine (1X), then dried (Na_2SO_4) and concentrated under reduced pressure. Purification (FCC, SiO_2, EtOAc/hexanes 0 - 60%) afforded the title compound (41 mg, 62%). MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ

2017217542 02 Mar 2021

8.24 (s, 2H), 7.71 – 7.56 (m, 4H), 6.73 (t, *J* = 56.1 Hz, 1H), 5.56 (s, 2H), 3.88 (s, 3H), 2.45 (s, 3H).

Example 173: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methyl-pyrimidine.



Step A. 2-(1,1-Difluoroethyl)-1-fluoro-4-nitrobenzene. To a solution of 1-(2-fluoro-5-nitrophenyl)ethanone (3.0 g, 16.5 mmol) stirring in DCM (50 mL) at -78 °C was added DAST (10 mL, 75.7 mmol). The mixture was warmed to rt and stirred for 5 days. The reaction was poured over ice, then the ice was allowed to melt and the layers were separated. The aqueous layer was extracted with DCM (2X), then the combined organic layers were washed with brine, dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, EtOAc/hexanes 0 - 20%) afforded the title compound (2.73 g, 81%). ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.49 (dd, *J* = 6.3, 2.8 Hz, 1H), 8.35 (dt, *J* = 8.9, 3.5 Hz, 1H), 7.31 (t, *J* = 9.3 Hz, 1H), 2.04 (t, *J* = 18.5 Hz, 3H).

Step B. 3-(1,1-Difluoroethyl)-4-fluoroaniline. To 2-(1,1-difluoroethyl)-1-fluoro-4-nitrobenzene (1 g, 4.86 mmol) dissolved in EtOH (30 mL) was added 10% Pd/C (0.52 g, 0.49 mmol). The reaction was placed under an atmosphere of hydrogen and stirred at rt overnight. The reaction mixture was filtered through a pad of Celite®, rinsing with EtOAc, and the filtrate was concentrated under vacuum to afford the title compound that was used without purification (863 mg, 101%). MS (ESI): mass calcd. for $C_8H_8F_3N$, 175.1; m/z found, 176.1 $[M+H]^+$.

Step C. 4-Azido-2-(1,1-difluoroethyl)-1-fluorobenzene. To 3-(1,1-difluoroethyl)-4-fluoroaniline (854 mg, 4.9 mmol) in a round bottom flask was slowly added H_2SO_4 (1 mL, 18.8 mmol) followed by TFA (5 mL, 65.3 mmol). The reaction was cooled to 0 °C, then a solution of $NaNO_2$ (482 mg, 7 mmol) in H_2O (3 mL)

2017217542 02 Mar 2021

was added drop-wise with stirring. The reaction was stirred at 0 °C for 15 minutes, then a solution of sodium azide (594.3 mg, 9 mmol) in H_2O (6 mL) was added drop-wise. The reaction was removed from the ice bath and stirred at rt for 30 min. The mixture was diluted with diethyl ether and basified to pH 12 with a solution of NaOH (3 N). The layers were separated and the aqueous layer was extracted with diethyl ether (3X). The combined organic layers were dried (Na_2SO_4) and concentrated under reduced pressure. The crude residue was carried forward without purification.

Step D. Ethyl 1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxylate. To a solution of 4-azido-2-(1,1-difluoroethyl)-1-fluorobenzene (0.981 g, 4.9 mmol) in DMSO (5 mL) was added ethyl acetoacetate (0.9 mL, 7.3 mmol) followed by dimethylamine (0.025 mL, 0.24 mmol). The vial was purged with N_2 then sealed and stirred at 70 °C for 2 days. The reaction was cooled to rt then diluted with EtOAc and H_2O. The layers were separated and the aqueous layer was extracted with EtOAc (3X). The combined organic layers were washed with H_2O (5X), then brine (3X), then dried (Na_2SO_4) and concentrated under reduced pressure. Purification (FCC, SiO_2, EtOAc/hexanes 0 - 50%) afforded the title compound as a yellow oil that solidified upon standing (1.32 g, 87%). MS (ESI): mass calcd. for $C_{14}H_{14}F_3N_3O_2$, 313.1; m/z found, 314.1 $[M+H]^+$.


Step E. (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methanol.

To ethyl 1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxylate (537 mg, 1.7 mmol) stirring in THF at -78 °C was added LAH (1 M in THF, 4.5 mL, 4.5 mmol) drop-wise. The reaction was stirred at -78 °C for 1 h, then warmed to rt and stirred for 3 h. The reaction was cooled to 0 °C and quenched slowly with EtOAc, then the mixture was warmed to rt and diluted with a saturated solution of potassium sodium tartrate tetrahydrate. The mixture was stirred vigorously for 10 min, then the layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, then dried (Na_2SO_4) and concentrated under reduced pressure to afford a yellow oil that was used without purification. MS (ESI) mass calcd. for $C_{12}H_{12}F_3N_3O$, 271.1; m/z found 272.1 $[M+H]^+$.

2017217542 02 Mar 2021

Step F. 2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methyl-pyrimidine. To (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methanol (25 mg, 0.09 mmol) stirring in THF (0.8 mL) was added NaH (60% dispersion in mineral oil, 12.5 mg, 0.31 mmol) and the reaction was stirred for 5 min. 2-Chloro-5-methylpyrimidine was then added and the reaction was stirred at rt overnight. The reaction was quenched with H_2O, then concentrated under a stream of air. Purification (FCC, SiO_2, EtOAc/hexanes 0 - 80%) afforded the title compound (20 mg, 60%). MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O$, 363.1; m/z found, 364.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.37 (s, 2H), 7.66 (dd, *J* = 6.3, 2.6 Hz, 1H), 7.53 (ddd, *J* = 8.5, 4.1, 2.6 Hz, 1H), 7.32 (t, *J* = 9.4 Hz, 1H), 5.56 (s, 2H), 2.42 (s, 3H), 2.25 (s, 3H), 2.11 – 1.96 (m, 3H).

Example 174: 5-Methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine.



Step A. 5-Methyltetrazolo[1,5-a]pyridine. 2-Methylpyridine *N*-oxide (400 mg, 3.7 mmol), diphenylphosphoryl azide (4 mL, 18.6 mmol), and pyridine (0.6 mL, 7.4 mmol) were combined and purged with nitrogen, sealed, and stirred at 120 °C overnight. The mixture was cooled to rt, then loaded directly onto a silica gel column. Purification (FCC, SiO_2, 10% 2N NH_3 in MeOH/DCM 0 – 5%) afforded the title compound as a white solid (257 mg, 52%). MS (ESI): mass calcd. for $C_6H_6N_4$, 134.1; m/z found, 135.1 $[M+H]^+$.


Step B. (1-(6-Methylpyridin-2-yl)-1H-1,2,3-triazol-4-yl)methanol. To a solution of 5-methyltetrazolo[1,5-a]pyridine (257 mg, 1.9 mmol) and copper (I) trifluoromethanesulfonate benzene complex (96.4 mg, 0.19 mmol) in toluene (7.7 mL) was added propargyl alcohol (0.13 mL, 2.3 mmol). The vial was purged with nitrogen, then sealed and stirred at 100 °C overnight. The mixture was diluted with DCM, washed with water (x1), brine (x1), then dried (Na_2SO_4) and concentrated under reduced pressure to afford a pale orange solid (191

2017217542 02 Mar 2021

mg, 53%). The crude product was used without purification. MS (ESI): mass calcd. for $C_9H_{10}N_4O$, 190.1; m/z found, 191.1 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.68 (s, 1H), 7.96 - 7.88 (m, 2H), 7.37 - 7.33 (m, 1H), 4.77 (d, *J* = 0.7 Hz, 2H), 2.59 (s, 3H).

Step C. 5-Methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine. The title compound was prepared in a manner analgous to Example 1 using(1-(6-methylpyridin-2-yl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{14}H_{14}N_6O$, 282.1; m/z found, 283.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.71 (s, 1H), 8.37 (d, *J* = 0.8 Hz, 2H), 7.96 (d, *J* = 8.1 Hz, 1H), 7.76 (t, *J* = 7.8 Hz, 1H), 7.17 (d, *J* = 7.6 Hz, 1H), 5.63 (d, *J* = 0.7 Hz, 2H), 2.57 (s, 3H), 2.24 (s, 3H).

Example 175: 5-Methyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]pyrimidine.



Step A. 4-Azido-2-methylpyridine. To 4-chloro-2-picoline hydrochloride (600 mg, 3.7 mmol) stirring in H_2O (2.5 mL) was added a solution of NaOH (1 M in H_2O) until the pH measured 7. Sodium azide (476 mg, 7.3 mmol) was then added and the reaction was heated at reflux overnight. The reaction was cooled to rt then extracted with ether (3x). The combined organic layers were dried (Na_2SO_4) and concentrated under reduced pressure to afford a colorless oil that was used without purification.


Step B. (1-(2-Methylpyridin-4-yl)-1H-1,2,3-triazol-4-yl)methanol. 4-Azido-2-methylpyridine (491 mg, 3.7 mmol) was dissolved in a mixture of tBuOH (4.5 mL) and H_2O (4.5 mL). Propargyl alcohol (0.26 mL, 4.4 mmol) was then added, followed by copper (II) sulfate pentahydrate (91 mg, 0.37 mmol) and L-sodium ascorbate (72.5 mg, 0.37 mmol). The reaction was stirred at rt overnight, then diluted with NH_4OH (28% in H_2O) and H_2O. The layers were separated and the aqueous layer was extracted with EtOAc (6x) and DCM

02 Mar 2021 2017217542

(3x). The combined organic layers were washed with brine, dried (Na_2SO_4), and concentrated under reduced pressure to afford the title compound that was used without purification (356 mg, 51%). MS (ESI): mass calcd. for $C_9H_{10}N_4O$, 190.1; m/z found, 191.1 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.66 (s, 1H), 8.61 (d, *J* = 5.7 Hz, 1H), 7.93 - 7.90 (m, 1H), 7.83 (dd, *J* = 5.8, 2.1 Hz, 1H), 4.80 (s, 2H), 2.67 (s, 3H).

Step C. 5-Methyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]pyrimidine. The title compound was prepared in a manner analgous to Example 1 using(1-(2-methylpyridin-4-yl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-methylpyrimidine, using THF instead of DMF. MS (ESI): mass calcd. for $C_{14}H_{14}N_6O$, 282.1; m/z found, 283.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.65 (d, *J* = 5.6 Hz, 1H), 8.38 (d, *J* = 0.8 Hz, 2H), 8.21 (s, 1H), 7.61 (d, *J* = 2.1 Hz, 1H), 7.49 (ddd, *J* = 5.4, 2.1, 0.7 Hz, 1H), 5.64 (d, *J* = 0.7 Hz, 2H), 2.67 (s, 3H), 2.26 (s, 3H).

Example 176: 5-Methyl-2-[[1-(5-methyl-3-pyridyl)triazol-4-yl]methoxy]pyrimidine.




Step A. 3-Azido-5-methylpyridine. To 3-amino-5-methylpyridine (483 mg, 4.5 mmol) in a round bottom flask was slowly added H_2SO_4 (0.9 mL, 17.2 mmol) followed by TFA (4.6 mL, 59.9 mmol). The reaction was cooled to 0 °C, then a solution of $NaNO_2$ (442 mg, 6.4 mmol) in H_2O (3 mL) was added drop-wise with stirring. The reaction was stirred at 0 °C for 15 minutes, then a solution of sodium azide (544 mg, 8.4 mmol) in H_2O (3 mL) was added drop-wise. The reaction was removed from the ice bath and stirred at rt for 30 min. The mixture was diluted with diethyl ether and basified to pH 12 with a solution of NaOH (3 N). The layers were separated and the aqueous layer was extracted with diethyl ether (3X). The combined organic layers were dried (Na_2SO_4) and concentrated under reduced pressure. The crude residue was carried forward without purification.

2017217542 02 Mar 2021

Step B. (1-(5-Methylpyridin-3-yl)-1H-1,2,3-triazol-4-yl)methanol. To 3-azido-5-methylpyridine (599 mg, 4.5 mmol) dissolved in *t*BuOH (6 mL) and H_2O (6 mL) was added propargyl alcohol (0.3 mL, 5.2 mmol) followed by copper (II) sulfate pentahydrate (109 mg, 0.44 mmol) and L-sodium ascorbate (90 mg, 0.45 mmol). The reaction was stirred at rt overnight. In the morning LCMS indicated no conversion. The mixture was basified to pH = 8 with K_2CO_3 (approx. 200 mg, then stirred at rt for an additional 5 h. The reaction was diluted with EtOAc and NH_4OH (28% in H_2O), then the layers were separated and the aqueous layer was extracted with EtOAc (x 3). The combined organic layers were dried (Na_2SO_4) and concentrated under reduced pressure. Purification (FCC, SiO_2, MeOH/DCM 0 – 5%) afforded the title compound (57.5 mg, 6.7%). MS (ESI): mass calcd. for $C_9H_{10}N_4O$, 190.1; m/z found, 191.1 $[M+H]^+$.

Step C. 5-Methyl-2-[[1-(5-methyl-3-pyridyl)triazol-4-yl]methoxy]pyrimidine. The title compound was prepared in a manner analgous to Example 1 using (1-(5-methylpyridin-3-yl)-1H-1,2,3-triazol-4-yl) and 2-chloro-5-methylpyrimidine using THF instead of DMF. MS (ESI): mass calcd. for $C_{14}H_{14}N_6O$, 282.1; m/z found, 283.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.77 (d, *J* = 2.4 Hz, 1H), 8.53 (d, *J* = 1.8 Hz, 1H), 8.38 (s, 2H), 8.19 – 8.13 (m, 1H), 7.97 – 7.94 (m, 1H), 5.65 (s, 2H), 2.47 (s, 3H), 2.26 (s, 3H).


Example 177: 2-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 176, using 2-bromopyridin-4-amine in Step A. MS (ESI): mass calcd. for $C_{13}H_{11}BrN_6O$, 346.0; m/z found, 347.0 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.87 (s, 1H), 8.53 (d, *J* = 5.5 Hz, 1H), 8.46 (s, 2H), 8.24 (d, *J* = 2.0 Hz, 1H), 8.01 (dd, *J* = 5.6, 1.9 Hz, 1H), 5.60 (s, 2H), 2.27 (s, 3H).

2017217542 02 Mar 2021


Example 178: 2-[2-[[1-(3-Cyclobutyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.



Step A. 2-(2-((1-(3-Bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol. The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) and 2-(2-chloropyrimidin-5-yl)propan-2-ol, using THF instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{15}BrN_5O_2$, 407.0; m/z found, 408.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.67 (s, 2H), 8.09 (s, 1H), 7.99 (dd, *J* = 5.8, 2.7 Hz, 1H), 7.67 (ddd, *J* = 8.8, 4.0, 2.7 Hz, 1H), 7.30 - 7.26 (m, 2H), 5.65 (d, *J* = 0.8 Hz, 2H), 1.63 (s, 6H).


Step B. 2-[2-[[1-(3-Cyclobutyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol. To a solution of 2-(2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol (30 mg, 0.07 mmol) in THF (1 mL) was added cyclobutylzinc bromide (0.5 M in THF, 0.3 mL, 0.15 mmol) and Pd(*t*-$Bu_3P)_2$ (1.9 mg, 0.004 mmol). The mixture was stirred at 50 °C overnight. The mixture was purified (FCC, SiO_2, MeOH/DCM 0 - 10%), however the product contained impurities. The compound was re-purified by basic HPLC (Gilson, waters Xbridge 50 x 150 mm, 5-95% MeCN/20 mM NH_4OH over 15 min, 80 mL/min) to afford the title compound (15.8 mg, 56%). MS (ESI): mass calcd. for $C_{20}H_{22}FN_5O_2$, 383.2; m/z found, 384.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.67 (s, 2H), 8.09 (s, 1H), 7.61 (ddd, *J* = 6.3, 2.7, 0.8 Hz, 1H), 7.46 (dddd, *J* = 8.8, 4.2, 2.7, 0.6 Hz, 1H), 7.11 (t, *J* = 9.0 Hz, 1H), 5.65 (d, *J* = 0.7 Hz, 2H), 3.83 – 3.72 (m, 1H), 2.46 – 2.36 (m, 2H), 2.28 – 2.16 (m, 2H), 2.14 – 2.03 (m, 1H), 1.96 – 1.87 (m, 1H), 1.62 (s, 6H).

Example 179: 2-[2-[[1-(4-Fluoro-3-isopropyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.



The title compound was prepared in a manner analogous to Example 178 step B, using 2-(2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol (Example 178, product from Step A) and 2-propylzinc bromide. MS (ESI): mass calcd. for $C_{19}H_{22}FN_5O_2$, 371.2; m/z found, 372.0 $[M+H]^+$.

Example 180: 2-[2-[[1-(3-Cyclopropyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.




To a solution of 2-(2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol (Example 178, product from Step A, 42 mg, 0.1 mmol), K_2CO_3 (43 mg, 0.31 mmol), and RuPhos-Pd-G3 (4.3 mg, 0.005 mmol) was in 1,4-dioxane (1 mL) and water (0.2 mL) was added cyclopropylboronic acid (19.3 mg, 0.23 mmol). The vial was sealed and the reaction was stirred at 100 °C overnight. The reaction was diluted with water, capped with a septum, and left to stand at rt for 9 days. The mixture was then filtered through a plug of silica, rinsing with EtOAc and DCM, then concentrated under reduced pressure. The residue was re-dissolved in MeOH, filtered through a 0.45 µm syringe, and purified by preparatory HPLC (Gilson, waters Xbridge 50 x 150 mm, 5-95% MeCN/20 mM NH4OH over 15 min, 80 mL/min). Fractions containing the pure product was frozen and lyophilized over 2 days to afford the title compound (8 mg, 21%). MS (ESI): mass calcd. for $C_{19}H_{20}FN_5O_2$, 369.2; m/z found, 370.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.67 (s, 2H), 8.04 (s, 1H), 7.42 (ddd, *J* = 8.8, 4.2, 2.8 Hz, 1H),

02 Mar 2021 2017217542


7.28 – 7.27 (m, 1H), 7.14 (t, *J* = 9.1 Hz, 1H), 5.65 (d, *J* = 0.7 Hz, 2H), 2.15 (ddd, *J* = 13.7, 8.6, 5.2 Hz, 1H), 1.76 (s, 1H), 1.63 (s, 6H), 1.11 – 1.05 (m, 2H), 0.81 (dt, *J* = 6.7, 4.8 Hz, 2H).

Example 181: 2-[2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.



To a solution of 2-(2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol (Example 178, product from Step A, 42 mg, 0.1 mmol), K_2CO_3 (44 mg, 0.32 mmol), and RuPhos-Pd-G3 (4.3 mg, 0.005 mmol) in 1,4-dioxane (1.05 mL) was added trimethylboroxine (0.04 mL, 0.3 mmol). The vial was sealed and the reaction was stirred at 90 °C for 3 h. The mixture was then filtered through a plug of silica, rinsing with DCM, and concentrated under reduced pressure. Purification (FCC, SiO_2, MeOH/DCM 0 - 10%) afforded the title compound (20.9 mg, 59%). MS (ESI): mass calcd. for $C_{17}H_{18}FN_5O_2$, 343.1; m/z found, 344.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.67 (s, 2H), 8.06 (s, 1H), 7.59 (ddd, *J* = 6.5, 2.7, 0.9 Hz, 1H), 7.50 – 7.45 (m, 1H), 7.14 (t, *J* = 8.8 Hz, 1H), 5.66 (d, *J* = 0.7 Hz, 2H), 2.37 (d, *J* = 2.0 Hz, 3H), 1.77 (s, 1H), 1.63 (s, 6H).

Example 182: 2-[2-[[1-(3-Ethyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.




A solution of 2-(2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol (Example 178, product from Step A, 32 mg, 0.08 mmol), potassium ethyltrifluoroborate (10.7 mg, 0.08 mmol),

2017217542 02 Mar 2021


potassium phosphate tribasic (50 mg, 0.24 mmol), RuPhos-Pd-G3 (3.3, 0.004 mmol), in 1,4-dioxane (0.5 mL), and water (0.2 mL) was purged with nitrogen, sealed and stirred at 90 °C for 2 days. The reaction was filtered through a plug of silica, rinsing with EtOAc, then evaporated under reduced pressure. The residue was dissolved in MeOH then purified by preparatory HPLC (Gilson, waters Xbridge 50 x 150 mm, 5-95% MeCN/20 mM NH_4OH over 15 min, 80 mL/min), and the fractions containing pure product were frozen and lyophilized over 2 days to afford the title compound (5.7 mg, 20%). MS (ESI): mass calcd. for $C_{18}H_{20}FN_5O_2$, 357.2; m/z found, 358.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.67 (s, 2H), 8.07 (s, 1H), 7.59 (dd, *J* = 6.4, 2.7 Hz, 1H), 7.48 (ddd, *J* = 8.8, 4.2, 2.8 Hz, 1H), 7.14 (t, *J* = 8.9 Hz, 1H), 5.65 (s, 2H), 2.75 (q, *J* = 8.0 Hz, 2H), 1.62 (s, 6H), 1.28 (t, *J* = 7.6 Hz, 3H).

Example 183: 5-Bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 5-bromo-2-chloropyrimidine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{11}BrF_3N_5O$, 413.0; m/z found, 414.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.66 – 8.54 (s, 2H), 8.15 – 8.09 (m, 1H), 7.93 – 7.87 (m, 1H), 7.85 – 7.78 (m, 1H), 7.37 – 7.28 (m, 1H), 5.69 – 5.58 (m, 2H), 2.14 – 1.94 (m, 3H).

Example 184: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1-methylpyrazol-3-yl)pyrimidine.



In a vial a suspension of 5-bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine (Example 183, 25 mg, 0.060 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (15.07 mg, 0.072 mmol), Na_2CO_3 (20 mg, 0.181 mmol) and $PdCl_2$(dppf) (4 mg, 0.006 mmol) in THF/H_2O (3 mL/0.3 mL) was capped and heated under microwave irridiation for 1.5 h at 100 °C. The completed reaction was diluted with EtOAc and washed with water, brine, dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, eluting with 0-50% EtOAc in hexanes) afforded the title compound (13.8 mg, 55%). MS (ESI): mass calcd. for $C_{19}H_{16}F_3N_7O$, 415.1; m/z found, 416.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.96 – 8.90 (s, 2H), 8.17 – 8.12 (s, 1H), 7.94 – 7.87 (m, 1H), 7.87 – 7.79 (m, 1H), 7.46 – 7.39 (d, *J* = 2.3 Hz, 1H), 7.36 – 7.27 (t, *J* = 9.4 Hz, 1H), 6.55 – 6.48 (d, *J* = 2.3 Hz, 1H), 5.74 – 5.67 (d, *J* = 0.7 Hz, 2H), 4.06 – 3.90 (s, 3H), 2.17 – 1.96 (m, 3H).

Example 185: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1H-pyrazol-4-yl)pyrimidine.




Step A: 2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyrimidine. The title compound was prepared in an manner analogous to Example 184 using 5-bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-

2017217542 02 Mar 2021

yl]methoxy]pyrimidine (Example 183) and 1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. MS (ESI): mass calcd. for $C_{23}H_{22}F_3N_7O_2$, 485.2; m/z found, 486.1 $[M+H]^+$.

Step B: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1H-pyrazol-4-yl)pyrimidine. A solution of 2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyrimidine (27 mg, 0.06 mmol) in MeOH(3 mL) was charged with 3M HCl (3 mL) and stirred at rt for 4 hours. The completed reaction was concentrated under reduced pressure and re-suspended in DCM. The organics were washed with sat. aq. $NaHCO_3$, water, then brine. The orgaincs were dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-3% MeOH in DCM) afforded the title compound (15.3 mg, 32%). MS (ESI): mass calcd. for $C_{18}H_{14}F_3N_7O$, 401.1; m/z found, 402.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.73 – 8.68 (s, 2H), 8.36 – 8.32 (s, 1H), 7.99 – 7.94 (m, 1H), 7.92 – 7.83 (m, 2H), 7.39 – 7.32 (t, J = 9.4 Hz, 1H), 5.72 – 5.63 (s, 2H), 3.40 – 3.32 (s, 2H), 2.15 – 1.97 (t, J = 18.6 Hz, 2H).

Example 186: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1H-pyrazol-4-yl)pyrimidine.



Step A: 2-Chloro-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyrimidine. To a flask with 2-chloro-4-(1H-pyrazol-4-yl)pyrimidine (284 mg, 1.6 mmol) and 3,4-dihydro-2H-pyran (661 mg, 7.9 mmol) in THF (9 mL) was charged with TFA (12μL, 0.16 mmol) and stirred at 77°C overnight. The completed reaction was diluted with EtOAc and washed with water, brine, dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-60%


2017217542 02 Mar 2021

EtOAc in hexanes) afforded the title compound (360 mg, 86%). MS (ESI): mass calcd. for $C_{12}H_{13}ClN_4O$, 264.1; m/z found, 265.0 $[M+H]^+$.

Step B: 2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyrimidine. The title compound was prepared in a manner analogous to Example 156 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyrimidine. MS (ESI): mass calcd. for $C_{23}H_{22}F_3N_7O_2$, 485.2; m/z found, 486.1 $[M+H]^+$.

Step C. 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1H-pyrazol-4-yl)pyrimidine. The title compound was prepared in a manner analogous to Example 185, step B, using 2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyrimidine. MS (ESI): mass calcd. for $C_{18}H_{14}F_3N_7O$, 401.1; m/z found, 402.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.52 – 8.44 (d, J = 5.2 Hz, 1H), 8.25 – 8.17 (d, J = 2.6 Hz, 3H), 7.96 – 7.87 (m, 1H), 7.89 – 7.80 (m, 1H), 7.36 – 7.26 (m, 1H), 7.18 – 7.10 (d, J = 5.2 Hz, 1H), 5.76 – 5.64 (s, 2H), 5.34 – 5.25 (s, 1H), 2.11 – 1.98 (m, 3H).

Example 187: 4-(2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine.




To a vial was added 5-bromo-2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 183, 28 mg, 0.07 mmol), morpholine (0.01 mL, 0.08 mmol), NaO*t*Bu (8 mg, 0.08 mmol), 2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate (RuPhos-Pd-G3) (6 mg, 0.01 mmol), 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) (4 mg, 0.01 mmol) in THF (1 mL) under N_2. The resulting reaction mixture was sealed and

2017217542 02 Mar 2021


heated to 85 °C then allowed to stir overnight. The reaction mixture was then cooled to room temperature, filtered through a pad of Celite® and concentrated under reduced pressure. Purification (basic HPLC, Agilent prep system, Waters XBridge C18 5 µm 50x100 mm column, 5-95% MeCN/20 nM NH_4OH over 22 min at 80 mL/min) afforded the title compound (13 mg, 45%). MS (ESI): mass calcd. for $C_{19}H_{19}F_3N_6O_2$, 420.3; m/z found, 421.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.18 – 8.14 (s, 2H), 8.06 – 8.03 (s, 1H), 7.85 – 7.80 (m, 1H), 7.79 – 7.73 (m, 1H), 7.27 – 7.20 (m, 1H), 5.57 – 5.50 (s, 2H), 3.85 – 3.77 (m, 4H), 3.08 – 3.00 (m, 4H), 2.05 – 1.90 (m, 3H).

Example 188: 2-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.



To a solution of 2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 25, 30 mg, 0.09 mmol) in ACN (2 mL) was added azetidine (5.3 mg, 0.09 mmol) and DIPEA (30 mg, 0.23 mmol). The resulting reaction mixture was heated to 90 °C and allowed to stir overnight. The reaction mixture was cooled to room temperature and diluted with EtOAc then washed with NH_4Cl solution. The organic layer was isolated, dried ($MgSO_4$), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-100% ethyl acetate in hexanes) afforded the title compound (19 mg, 0.05 mmol, 57%). MS (ESI): mass calcd. for $C_{17}H_{16}F_2N_6O$, 358.3; m/z found, 359.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.58 – 8.54 (d, J = 4.7 Hz, 2H), 8.05 – 8.01 (t, J = 0.7 Hz, 1H), 7.75 – 7.70 (d, J = 2.5 Hz, 1H), 7.67 – 7.62 (m, 1H), 7.00 – 6.96 (m, 1H), 6.90 – 6.65 (m, 1H), 6.57 – 6.53 (d, J = 8.9 Hz, 1H), 5.68 – 5.62 (d, J = 0.6 Hz, 2H), 4.14 – 4.08 (m, 4H), 2.45 – 2.36 (m, 2H).


Example 189: 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrazine.



Step A. 2-Chloro-5-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrazine. The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2,4-dichloropyrazine. MS (ESI): mass calcd. for $C_{14}H_9Cl_2F_2N_5O_2$, 387.0; m/z found, 388.0 $[M+H]^+$.

Step B. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrazine. To a solution of 2-chloro-5-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrazine (42 mg, 0.108 mmol) in DMSO (0.8 mL) was added CsF (164 mg, 1.1 mmol). The mixture was heated in a sealed reaction vessel to 100 °C for 2.5 h. The reaction mixture was cooled to rt, then diluted with water, ACN and few drops of HCl (1M, aq). Purification (semi-prep RP-HPLC, equipped with Phenomenex C18 Gemini 5 um, 250X4.6 mm ; 5-95% Acetonitrile in water with 0.1% TFA addition) afforded the title compound (8 mg, 20%) after free base with $NaHCO_3$ (aq). MS (ESI): mass calcd. for $C_{14}H_9ClF_3N_5O_2$, 371.0; m/z found, 372.0 $[M+H]^+$. ^1H NMR (400 MHz, CD_3CN) δ 8.47 – 8.36 (m, 1H), 8.27 – 8.19 (m, 1H), 8.10 (dd, *J* = 8.2, 0.7 Hz, 1H), 7.82 – 7.67 (m, 3H), 7.12 (t, *J* = 76 Hz, 1H), 5.59 (s, 2H).

Example 190: 4-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




To a solution of 2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine (Example 382, 25 mg, 0.068 mmol) in ACN (1 mL) at rt, were added isopentyl nitrite (0.0137 ml, 0.1 mmol) and copper(II) chloride (9.6 mg, 1.071 mmol). The mixture was heated to reflux for 3 hours.

2017217542 02 Mar 2021

The reaction mixture was diluted with water (5 mL) and few drops of HCl, filtered through a syringe filter (0.25 um). Purification (semi-prep HPLC (95 % to 5% Water in MeCN with 0.1% TFA addition, Phenomenex C18 Gemini, 5 um, 250X4.6 mm)), afforded the title compound which wasfree based by neutralization with $NaHCO_3$ (aq) and extraction with EtOAc to afford the title compound (7 mg, 27%). MS (ESI): mass calcd. for $C_{14}H_9Cl_2F_2N_5O_2$, 387.0; m/z found, 388.1 $[M+H]^+$. ^1H NMR (400 MHz, CD_3CN) δ 8.55 – 8.48 (m, 1H), 8.45 (t, *J* = 1.3 Hz, 1H), 7.82 – 7.68 (m, 3H), 7.24 – 7.16 (m, 1H), 6.94 (t, *J* = 60 Hz, 1H), 5.63 (s, 1H).


Example 191: 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-fluoro-pyrimidine.



The title compound was prepared in a manner analgous to Example 189, Step B, using 4-chloro-2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 190) using MeCN instead of DMSO. MS (ESI): mass calcd. for $C_{14}H_9ClF_3N_5O_2$, 371.0; m/z found, 372.1 $[M+H]^+$. 1H NMR (500 MHz, $CDCl_3$) δ 8.59 (dd, *J* = 11.5, 5.5 Hz, 1H), 8.15 (s, 1H), 7.73 (d, *J* = 2.1 Hz, 1H), 7.66 – 7.62 (m, 1H), 7.61 – 7.56 (m, 1H), 6.69 (dd, *J* = 5.5, 2.6 Hz, 1H), 6.66 (t, *J* = 72.5 Hz, 1H).

Example 192: 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine.

2017217542 02 Mar 2021




Step A. 2-Chloro-5-(2-fluoroethoxy)pyrimidine. To a mixture of 2-chloropyrimidin-5-ol (1 g, 7.6 mmol) and 1-fluoro-2-iodoethane (1.73 g, 9.9 mmol) in DMF (2.9 mL) was added Cs_2CO_3 (3.2 g, 9.9 mmol). The mixture was stirred vigorously for 3 h. The reaction mixture was diluted with EtOAc (20 mL) and filtered, and the solid was washed with EtOAc (20 mL). The filtrate was washed with water (3x30 mL) and dried (Na_2SO_4) and concentrated. Purification (FCC, SiO_2, DCM/EtOAc) afforded the title compound as a white solid (847 mg, 62.6%). MS (ESI): mass calcd. for $C_6H_6ClFN_2O$, 176.0; m/z found, 171.1$[M+H]^+$.

Step B. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine. The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) (41.2 mg, 0.15 mmol) and 2-chloro-5-(2-fluoroethoxy)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{13}ClF_3N_5O_3$, 415.1; m/z found, 416.1$[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.56 (s, 1H), 8.34 (s, 2H), 7.83 (s, 1H), 7.75 – 7.66 (m, 3H), 6.87 (m, 1H), 5.59 (s, 2H), 4.81-4.80 (m, 1H), 4.71-4.70 (m, 1H), 4.36 – 4.34 (m, 1H), 4.30–4.29 (m, 1H).

Example 193: 2-[[1-[4-Chloro-3-(2-fluoroethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine.

2017217542 02 Mar 2021




Step A. 2-Chloro-5-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)phenol.
A mixture of (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) (110 mg, 0.4 mmol) and *t*BuOK (134 mg, 1.2 mmol) in dry DMSO was stirred at rt for 15 h. The reaction was quenched by adding acetic acid (3 mL). The mixture was subjected to C18 reversed phase HPLC purification (TFA buffered MeCN/water) to afford the title compound as a white solid (18 mg, 20%). MS (ESI): mass calcd. for $C_9H_8ClN_3O_2$, 225.0; m/z found, 226.1$[M+H]^+$.

Step B. (1-(4-Chloro-3-(2-fluoroethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol. To 2-chloro-5-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)phenol (18 mg, 0.08 mg) and Cs_2CO_3 (65 mg, 0.2 mmol) in DMF (0.8mL) was added 1-fluoro-2-iodoethane (16.6 mg, 0.096 mmol). The mixture was stirred at rt for 3 h, and then diluted with EtOAc (30 mL), washed with water 3x20 mL), dried (Na_2SO_4), and concentrated. Purification (FCC, SiO_2, DCM/EtOAc) afforded the title compound (19 mg, 87%). MS (ESI): mass calcd. for $C_{11}H_{11}ClFN_3O_2$, 271.0; m/z found, 272.1$[M+H]^+$.

Step C. 2-[[1-[4-Chloro-3-(2-fluoroethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine. The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(2-fluoroethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}ClFN_5O_3$, 379.1; m/z found, 380.1 $[M+H]^+$. ^1H NMR (600 MHz, CD_3OD) δ 8.39 (s, 1H), 8.25 (s, 2H), 7.52 (t, *J* = 1.1 Hz, 2H), 7.31 (dd, *J* = 8.5, 2.4 Hz, 1H), 5.56 (s, 2H), 4.87 – 4.83 (m, 1H), 4.80 – 4.75 (m, 1H), 4.43 – 4.39 (m, 1H), 4.39 – 4.33 (m, 1H), 3.88 (s, 2H).

Example 194: 2-[[1-[4-Fluoro-3-(3-fluoropropyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine.



Step A. (E)-2-((1-(4-Fluoro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-1-en-1-yl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine. A mixture of 2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine (Example 41, 80 mg, 0.21 mmol), (E)-4,4,5,5-tetramethyl-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-1-en-1-yl)-1,3,2-dioxaborolane (84 mg, 0.31 mmol), $Pd(PPh_3)_4$ (12 mg, 0.01 mmol), and Na_2CO_3 solution (1.0 M, 0.63 mL, 0.62 mmol) in a microwave tube was heated at 110 °C for 20 min under microwave irridiation. The reaction mixture was diluted with EtOAc (10 mL) and washed with water (2x10 mL). The organic phase was dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, hexane/EtOAc) afforded the title compound (68 mg, 73.2%). MS (ESI): mass calcd. for $C_{22}H_{24}FN_5O_4$, 441.2; m/z found, 442.3 $[M+H]^+$.

Step B. 2-((1-(4-Fluoro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine. A solution of (E)-2-((1-(4-fluoro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-1-en-1-yl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine (22 mg, 0.05 mmol) in MeOH (10 mL) was purged with nitrogen. Pd/C (10%, 30 mg) was added. The mixture was purged with hydrogen twice. The mixture was stirred under hydrogen atmosphere at rt for 15 min. The mixture was filtered and the filtrate was concentrated. Purification (FCC, SiO_2, hexane/EtOAc) afforded the title compound (22 mg, 99%). MS (ESI): mass calcd. for $C_{22}H_{26}FN_5O_4$, 443.2; m/z found, 444.3 $[M+H]^+$.


Step C. 3-(2-Fluoro-5-(4-(((5-methoxypyrimidin-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)propan-1-ol. To 2-((1-(4-fluoro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine (22 mg, 0.05 mmol) in MeOH (10 mL) was added concentrated HCl dropwise at rt. The mixture was stirred at rt for 15 min. To the mixture was added 0.1

2017217542 02 Mar 2021

mL of water and the volatiles were removed under reduced pressure and dried under high vacuum. Purification (FCC, SiO_2, DCM/methanol) afforded the title compound. mass calcd. for $C_{17}H_{18}FN_5O_3$, 359.1; m/z found, 360.2 $[M+H]^+$.

Step D. 2-((1-(4-Fluoro-3-(3-fluoropropyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine. To 3-(2-fluoro-5-(4-(((5-methoxypyrimidin-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)propan-1-ol (21 mg, 0.058 mmol) in 0.2 mL of DCM at -78 °C was added (diethylamino)sulfur trifluoride (0.072 mL, 0.6 mmol) with stirring. The reaction was allowed to warm slowly to rt with stirring and concentrated under reduced pressure. Purification (semi-prep RP-HPLC (95 % to 5% Water in MeCN with 0.1% TFA addition, Phenomenex C18 Gemini, 5 um, 250X4.6 mm) afforded the title compound (1.2 mg, 6%) and 2-[[1-[3-(3-chloropropyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine. MS (ESI): mass calcd. for $C_{17}H_{17}F_2N_5O_2$, 361.1; m/z found, 362.2 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.50 (s, 1H), 8.23 (s, 2H), 7.70 (dd, *J* = 6.4, 2.8 Hz, 1H), 7.65 – 7.58 (m, 1H), 7.19 (t, *J* = 9.1 Hz, 1H), 5.45 (s, 2H), 4.45 (t, *J* = 5.9 Hz, 1H), 4.33 (t, *J* = 5.9 Hz, 1H), 3.80 (s, 3H), 2.78 (t, *J* = 7.9 Hz, 2H).


Example 195: 2-[[1-[3-(3-Chloropropyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine.



The title compound was obtained as a by-product from the synthesis of Example 194, step D. (1.3 mg, 6%). MS (ESI): mass calcd. for $C_{17}H_{17}ClFN_5O_2$, 377.1; m/z found, 378.1 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.62 (s, 1H), 8.35 (s, 2H), 7.82 (dd, *J* = 6.3, 2.7 Hz, 1H), 7.78 – 7.71 (m, 1H), 7.31 (t, *J* = 9.1 Hz, 1H), 5.57 (s, 2H), 3.92 (s, 3H), 3.64 (t, *J* = 6.4 Hz, 2H), 2.94 (t, *J* = 7.6 Hz, 2H), 2.15 (ddd, *J* = 7.7, 6.3, 1.3 Hz, 2H).

2017217542 02 Mar 2021

Example 196: 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine.



Step A: 3-(2-Methoxypyrimidin-5-yl)prop-2-yn-1-ol. To a degassed solution of 5-bromo-2-methoxypyrimidine (4.0 g, 21 mmol), trimethylamine (5.9 mL, 42 mmol), $PdCl_2(PPh_3)_2$ (1.5 g, 2.1 mmol) and CuI (0.4 g, 2.1 mmol) in DMF (33 mL) was added prop-2-yn-1-ol (3.1 mL, 53 mmol) was added. The reaction was sealed and heated at 90 °C for 4 hours. The reaction was diluted with brine and extracted with EtOAc (50 mL x 3). The combined organics were dried, filtered, concentrated under reduced pressure. Purification (FCC, SiO2, hexanes/ EtOAc; 4 : 1) afforded the title compound (1.8 g, 52%) MS (ESI): mass calcd. for $C_8H_8N_2O_2$, 164.1; m/z found, $[M+H]^+$ 165.1.

Step B: 3-(2-Methoxypyrimidin-5-yl)propan-1-ol. An ethanol solution (65 mL) of 3-(2-methoxypyrimidin-5-yl)prop-2-yn-1-ol (1.8 g, 11 mmol) was added to Pd/C (10% wt, 583 mg). The reactionmixture was stirred under hydrogen atmosphere (1 atm) for 3 hours. The reaction mixture was filtered through diatomaceous earth and concentrated under reduced pressure to afford the title compound (1.5 g, 81%) MS (ESI): mass calcd. for $C_8H_{12}N_2O_2$, 168.1; m/z found, $[M+H]^+$ 169.1.

Step C: 3-(2-Methoxypyrimidin-5-yl)propyl 4-methylbenzenesulfonate. To a solution of 3-(2-methoxypyrimidin-5-yl)propan-1-ol (450 mg, 2.7 mmol) in DCM (17 mL), were added trimethylamine (1.1 mL, 8.0 mmol) and sulfonyl chloride (1.02 g, 5.35 mmol). The reaction mixture was stirred at rt overnight. The reaction was diluted with $NaHCO_3$ (aq, 25 mL)and the aqueous layers were extracted with EtOAc (30 mL x 3). The combined organic extracts was dried, filtered, and concentrated under reduced pressure. Purification (FCC,

2017217542 02 Mar 2021

SiO_2, hexanes/EtOAc; 5 : 1) afforded the title compound (540 mg, 63%) MS (ESI): mass calcd. for $C_{15}H_{18}N_2O_4S$, 322.1; m/z found, $[M+H]^+$ 323.1.

Step D: 5-(3-Fluoropropyl)-2-methoxypyrimidine. To a solutuion of 3-(2-methoxypyrimidin-5-yl)propyl 4-methylbenzenesulfonate (750 mg, 2.3 mmol) in THF (10 mL) was added TBAF (1.0 M in THF, 3.5 mL, 3.5 mmol). The reaction mixture was heated to 60 °C for 30 min. The reaction mixture was concentrated under reduced pressure. The crude product was diluted with EtOAc (50 mL), washed with $NaHCO_3$ (aq, 30 mL) and brine (30 mL). The combined organics were dried, filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, hexanes EtOAc; 5 : 1) afforded the title compound (290 mg, 73%) MS (ESI): mass calcd. for $C_8H_{11}FN_2O$, 170.1; m/z found, $[M+H]^+$ 171.1.

Step E: 5-(3-Fluoropropyl)pyrimidin-2(1H)-one hydrochloride salt. A solution of 5-(3-fluoropropyl)-2-methoxypyrimidine (250 mg, 1.47 mmol) in HCl (4M in dioxane, 1.1 mL, 4.4 mmol) and water (0.26 mL, 14.7 mmol) was heated to 100 °C for 5 hours. The mixture was concentrated under reduced pressure to afford the title compound as a white HCl salt which was used in next step without further purification. MS (ESI): mass calcd. for $C_7H_9FN_2O$, 156.1; m/z found, $[M+H]^+$ 157.1.


Step F. 2-Chloro-5-(3-fluoropropyl)pyrimidine. A mixture of 5-(3-fluoropropyl)pyrimidin-2(1H)-one hydrochloride (120 mg, 0.62 mmol) in $POCl_3$ (2 mL) was heated at 95 °C for 20 h. The reaction mixture was cooled and concentrated under reduced pressure. The residue was diluted with EtOAc (30 mL) and washed with $NaHCO_3$ (aq, sat. 3x20 mL). The organics were dried, filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, hexane/EtOAc) afforded the title compound (66 mg, 66%). MS (ESI): mass calcd. for $C_7H_8ClFN_2$, 174.0; m/z found, 175.0 $[M+H]^+$.

Step G. 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine. The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-chloro-5-(3 fluoropropyl)pyrimidine. MS (ESI): mass calcd. for $C_{17}H_{15}ClF_3N_5O_2$, 413.1; m/z found, 414.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.45 (s, 2H), 8.17 (s, 1H),

2017217542 02 Mar 2021


7.74 (d, *J* = 2.2 Hz, 1H), 7.67 – 7.56 (m, 2H), 6.68 (t, *J* = 72.5 Hz, 1H), 5.67 (d, *J* = 0.7 Hz, 2H), 4.57 (t, *J* = 5.7 Hz, 1H), 4.46 (t, *J* = 5.7 Hz, 1H), 2.76 (t, *J* = 7.7 Hz, 2H), 2.15 – 1.92 (m, 2H).

Example 197: N-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methyl]-5-fluoro-pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 153 using 2-amino-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}F_3N_6$, 320.1; m/z found, 321.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.23 (d, *J* = 2.2 Hz, 2H), 7.99 (s, 1H), 7.98 – 7.77 (m, 2H), 7.70 – 7.53 (m, 2H), 6.72 (t, *J* = 56.1 Hz, 1H), 5.73 (s, 1H), 4.79 (d, *J* = 6.4 Hz, 2H).

Example 198: N-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 6, using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 26) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{15}FN_6$, 298.1; m/z found, 299.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.52 – 8.50 (m, 1H), 8.18 – 8.14 (m, 2H), 7.88 – 7.83 (m, 1H), 7.75 – 7.69 (m, 1H), 7.40 – 7.30 (m, 2H), 4.58 (d, *J* = 6.1 Hz, 2H), 2.34 – 2.29 (m, 3H), 2.08 – 2.04 (m, 3H).

Example 199: 5-Chloro-N-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-4-methyl-pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 6, using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 26) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}ClFN_6$, 332.1; m/z found, 332.9 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.54 (s, 1H), 8.25 (s, 1H), 7.88 – 7.79 (m, 2H), 7.76 – 7.70 (m, 1H), 7.35 (t, J = 9.1 Hz, 1H), 4.59 (d, J = 6.0 Hz, 2H), 2.36 (s, 3H), 2.32 (d, J = 2.0 Hz, 3H).

Example 200: 5-Chloro-N-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine.



The title compound was prepared in a manner analogous to Example 154 using 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}Cl_2F_2N_6$, 370.0; m/z found, 371.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.26 (s, 2H), 8.00 – 7.95 (m, 2H), 7.90 – 7.83 (m, 1H), 7.62 – 7.55 (m, 1H), 6.98 (t, J = 54.5 Hz, 1H), 5.88 (t, J = 6.4 Hz, 1H), 4.79 (d, J = 6.1 Hz, 2H).

Example 201: N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-4-methyl-pyrimidin-2-amine.




he title compound was prepared in a manner analogous to Example 154 using, using 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}ClF_2N_6$, 350.1; m/z found, 351.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ

2017217542 02 Mar 2021


8.20 (d, *J* = 5.0 Hz, 1H), 8.01 (s, 1H), 7.99 – 7.95 (m, 1H), 7.88 – 7.83 (m, 1H), 7.63 – 7.55 (m, 1H), 6.98 (t, *J* = 54.5 Hz, 1H), 6.52 (d, *J* = 5.0 Hz, 1H), 6.12 (s, 1H), 4.85 (d, *J* = 6.1 Hz, 2H), 2.39 (s, 3H).

Example 202: N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-ethyl-pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 154 using 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}ClF_2N_6$, 364.1; m/z found, 365.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.26 (s, 2H), 8.11 (s, 1H), 7.99 (d, *J* = 2.5 Hz, 1H), 7.85 (dd, *J* = 8.7, 2.5 Hz, 1H), 7.58 (d, *J* = 8.7 Hz, 1H), 7.10 (s, 1H), 6.97 (t, *J* = 54.5 Hz, 1H), 4.89 (d, *J* = 5.5 Hz, 2H), 2.54 (q, *J* = 7.6 Hz, 2H), 1.23 (t, *J* = 7.6 Hz, 3H).

Example 203: N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-methoxy-pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 154 using 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}ClF_2N_6O$, 366.1; m/z found, 367.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.10 (s, 2H), 7.99 – 7.96 (m, 2H), 7.89 – 7.83 (m, 1H), 7.61 – 7.57 (m, 1H), 6.98 (t, *J* = 54.5 Hz, 1H), 5.55 – 5.42 (m, 1H), 4.78 (d, *J* = 6.2 Hz, 2H), 3.81 (s, 3H).

Example 204: N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-(difluoromethyl)pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 154 using 2-chloro-5-difluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}ClF_4N_6$, 386.1; m/z found, 387.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.45 (s, 2H), 8.02 – 7.99 (m, 1H), 7.98 (d, *J* = 2.5 Hz, 1H), 7.89 – 7.84 (m, 1H), 7.60 (dd, *J* = 8.6, 1.0 Hz, 1H), 6.99 (t, *J* = 54.5 Hz, 1H), 6.59 (t, *J* = 56.0 Hz, 1H), 6.05 (s, 1H), 4.86 (d, *J* = 6.2 Hz, 2H).

Example 205: N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 154 using 2-chloro-5-trifluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}ClF_5N_6$, 404.1; m/z found, 405.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.54 (s, 2H), 8.02 (s, 1H), 7.98 (d, *J* = 2.6 Hz, 1H), 7.90 – 7.84 (m, 1H), 7.63 – 7.56 (m, 1H), 6.98 (t, *J* = 54.5 Hz, 1H), 6.43 – 6.31 (m, 1H), 4.87 (d, *J* = 6.0 Hz, 2H).

Example 206: N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 154 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 20). MS (ESI): mass calcd. for $C_{16}H_{15}F_3N_6$, 348.1; m/z found, 349.0 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.46 – 8.44 (m, 1H), 8.20 (d, *J* = 0.7 Hz, 2H), 8.07 – 8.03 (m, 1H), 8.02 – 7.96 (m, 1H), 7.46 (t, *J* = 9.7 Hz, 1H), 4.74 (s, 2H), 2.16 (s, 3H), 2.06 (td, *J* = 18.7, 1.1 Hz, 3H).

Example 207: N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-ethyl-pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 154 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 20) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{17}F_3N_6$, 362.1; m/z found, 363.1 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.45 (s, 1H), 8.22 (s, 2H), 8.07 – 7.95 (m, 2H), 7.45 (t, *J* = 9.6 Hz, 1H), 4.74 (s, 2H), 2.52 (q, *J* = 7.6 Hz, 2H), 2.14 – 1.99 (m, 3H), 1.21 (t, *J* = 7.6 Hz, 3H).

Example 208: N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-isopropyl-pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 154 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 20) and 2-chloro-4-isopropylpyrimidine. MS (ESI): mass calcd. for $C_{18}H_{19}F_3N_6$, 376.2; m/z found, 377.2 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.46 (s, 1H), 8.25 (s, 2H), 8.07 – 8.03 (m, 1H), 8.02 – 7.97 (m, 1H), 7.46 (t, *J* = 9.6 Hz, 1H), 4.75 (d, *J* = 0.7 Hz, 2H), 2.89 – 2.78 (m, 1H), 2.06 (td, *J* = 18.7, 1.1 Hz, 3H), 1.27 (d, *J* = 7.0 Hz, 6H).

Example 209: 5-Cyclopropyl-N-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 154 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 20) and 2-chloro-4-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{18}H_{17}F_3N_6$, 374.1; m/z found, 375.1 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.45 (s, 1H), 8.15 (s, 2H), 8.07 – 8.02 (m, 1H), 8.02 – 7.95 (m, 1H), 7.46 (t, *J* = 9.6 Hz, 1H), 4.74 (s, 2H), 2.13 – 1.99 (m, 3H), 1.84 – 1.73 (m, 1H), 0.99 – 0.88 (m, 2H), 0.68 – 0.60 (m, 2H).

Example 210: N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-4,5-dimethyl-pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 154 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 20) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{17}F_3N_6$, 362.1; m/z found, 363.1 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.44 (s, 1H), 8.07 – 7.96 (m, 3H), 7.49 – 7.42 (m, 1H), 4.74 (s, 2H), 2.35 (s, 3H), 2.14 – 2.11 (m, 3H), 2.11 – 2.00 (m, 3H).

Example 211: N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine.



The title compound was prepared in a manner analogous to Example 154 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 21) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_3N_6$, 334.1; m/z found, 335.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.19 – 8.16 (m, 2H), 7.96 – 7.94 (m, 1H), 7.92 – 7.86 (m, 2H), 7.30 (t, J = 9.0 Hz, 1H), 6.94 (t, J = 54.7 Hz, 1H), 5.52 (s, 1H), 4.87 – 4.75 (m, 2H), 2.21 – 2.07 (m, 3H).


Example 212: 5-Chloro-N-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 154 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 21) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}ClF_3N_6$, 354.1; m/z found, 355.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.27 (s, 2H), 7.97 – 7.94 (m, 1H), 7.94 – 7.85 (m, 2H), 7.31 (t, J = 9.0 Hz, 1H), 6.94 (t, J = 54.5 Hz, 1H), 5.73 (s, 1H), 4.79 (d, J = 6.4 Hz, 2H).

Example 213: N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine.



The title compound was prepared in a manner analogous to Example 154 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 21) and 2-chloro-5-trifluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}F_6N_6$, 388.1; m/z found, 389.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.54 (s, 2H), 7.98 (s, 1H), 7.95 – 7.85 (m, 2H), 7.32 (t, J = 9.0 Hz, 1H), 6.95 (t, J = 54.6 Hz, 1H), 6.16 (s, 1H), 4.86 (d, J = 6.5 Hz, 2H).

Example 214: 2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methylamino]pyrimidin-5-yl]propan-2-ol.




The title compound was prepared in a manner analogous to Example 154 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 21) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{17}H_{17}F_3N_6O$, 378.1; m/z found, 379.0 $[M+H]^+$. ^1H NMR (500 MHz,

2017217542 02 Mar 2021


$CDCl_3$) δ 8.47 (s, 2H), 7.99 – 7.94 (m, 1H), 7.94 – 7.86 (m, 2H), 7.31 (t, *J* = 9.0 Hz, 1H), 6.94 (t, *J* = 54.6 Hz, 1H), 5.66 (s, 1H), 4.87 – 4.77 (m, 2H), 1.58 (s, 6H).

Example 215. N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine



A mixture of (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 21) (69 mg, 0.29 mmol), 2-iodopyridine (0.03 mL, 0.29 mmol), cuprous iodide (27.1 mg, 0.14 mmol), 1-(5,6,7,8-tetrahydroquinolin-8-yl)ethan-1-one (0.045 mL, 0.29 mmol), and Cs_2CO_3 (185.6 mg, 0.57 mmol) in DMF (0.9 mL) under N_2 in a sealed tube was stirred at rt for 16 h. The mixture was concentrated un vacuo. Purification (FCC, EtOAc /heptane from 0- 100%) and re-purification (HPLC, Stationary phase: C18 XBridge 30 x 100 mm 5 um), Mobile phase: Gradient from 90% 10mM NH_4CO_3H pH 9 solution in Water, 10% CH_3CN to 0% 10mM NH_4CO_3H pH 9 solution in Water, 100% CH_3CN) afforded the title compound (12 mg, 13%). MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5$, 319.1; m/z found, 320.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 4.77 (d, *J* = 5.49 Hz, 2H), 5.06 (br s, 1 H), 6.49 (dt, *J* = 8.4, 0.9 Hz, 1H), 6.64 (ddd, *J* = 7.2, 5.0, 0.9 Hz, 1H), 6.77 - 7.09 (m, 1H), 7.31 (t, *J* = 9.1 Hz, 1H), 7.43 (ddd, *J* = 8.5, 6.9, 1.9 Hz, 1H), 7.82 - 7.91 (m, 1H), 7.93 (dd, *J* = 5.6, 2.8 Hz, 1H), 7.96 (s, 1 H), 8.08 - 8.26 (m, 1 H).


Example 216: N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-ethylpyrimidin-2-amine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 153 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 21) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_3N_6$, 348.1; m/z found, 349.0 $[M+H]^+$. ^1H NMR (300 MHz, DMSO-d_6) δ 8.62 (s, 1H), 8.13 (s, 2H), 8.11 – 7.97 (m, 2H), 7.55 (t, J = 9.4 Hz, 1H), 7.45 – 6.88 (m, 2H), 4.53 (d, J = 6.0 Hz, 2H), 2.35 (q, J = 7.5 Hz, 2H), 1.05 (t, J = 7.6 Hz, 3H).

Example 217: N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine.



The title compound was prepared in a manner analogous to Example 153 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 21) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_3N_6$, 348.1; m/z found, 349.0 $[M+H]^+$. ^1H NMR (300 MHz, DMSO-d_6) δ 8.66 (s, 1H), 8.15 (dd, J = 12.0, 4.6 Hz, 2H), 7.99 (s, 1H), 7.62 (t, J = 9.4 Hz, 1H), 7.29 (t, J = 72.0, 1H), 7.24 (t, J = 5.8 Hz, 1H), 4.59 (d, J = 6.0 Hz, 2H), 2.24 (s, 3H), 2.03 (s, 3H).

Example 218: 5-Chloro-N-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methylpyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 21) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_3N_6$, 368.1; m/z found, 369.0 $[M+H]^+$. ^1H NMR (300 MHz, DMSO-d_6) δ 8.70 (s, 1H), 8.24 (s, 1H), 8.15 (dd, J = 10.6, 4.7 Hz, 2H), 7.84 (t, J = 5.6

2017217542 02 Mar 2021

Hz, 1H), 7.63 (t, *J* = 9.4 Hz, 1H), 7.29 (t, *J* = 53.9 Hz, 1H), 4.60 (d, *J* = 5.9 Hz, 2H), 2.36 (s, 3H).


Example 219: N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine.



Step A. 1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazole-4-carbaldehyde. To a solution of (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) (50 mg, 0.21 mmol) and sodium acetate (50.6 mg, 0.62 mmol) stirring in DCM (2 mL) was added pyridinium chlorochromate (PCC) (88.6 mg, 0.41 mmol), and the mixture was stirred at rt for 2 h. The suspension was filtered and the solvent removed under vacuum. The crude product was used without purification.


Step B. N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine. To 1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazole-4-carbaldehyde (42 mg, 0.17 mmol) and 1-methyl-1H-pyrazol-5-amine (18.9 mg, 0.19 mmol) stirring in MeOH (2.2 mL) and AcOH (0.2 mL) was added $NaBH_3CN$, and the mixture was stirred at rt for 90 min. The suspension was filtered and the solvent was removed under vacuum. The residue was purified by HPLC ((Stationary phase: C18 XBridge 30 x 100 mm 5 um), Mobile phase: Gradient from 74% 10mM NH_4CO_3H pH 9 solution in Water, 26% CH_3CN to 58% 10mM NH_4CO_3H pH 9 solution in Water, 42% CH_3CN)) to afford the product (12 mg, 18%). MS (ESI): mass calcd. for $C_{14}H_{13}F_3N_6$, 322.1; m/z found, 323.1 $[M+H]^+$. ^1H NMR (500MHz, $CDCl_3$) δ 8.20 - 7.75 (m, 3H), 7.45 - 7.29 (m, 1H), 7.58 - 7.29 (m, 1H), 7.17 - 6.77 (m, 1H), 5.59 (s, 1H), 4.49 (s, 2H), 4.03 (br s, 1H), 3.68 (s, 3H).

Example 220: N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-imidazol-2-amine




The title compound was prepared in a manner anaolous to Example 7 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 21). MS (ESI): mass calcd. for $C_{14}H_{13}F_3N_6$, 322.1; m/z found, 323.1 $[M+H]^+$. 1H NMR (500MHz, $CDCl_3$) δ 8.12 (s, 1H), 7.95 (dd, *J* = 2.9, 5.8 Hz, 1H), 7.92 - 7.82 (m, 1H), 7.31 (t, *J* = 9.0 Hz, 1H), 6.95 (t, *J* = 54.6 Hz, 1H), 6.71 (d, *J* = 1.7 Hz, 1H), 6.54 (d, *J* = 1.4 Hz, 1H), 4.72 (d, *J* = 6.4 Hz, 2H), 4.19 (br t, *J* = 6.1 Hz, 1H), 3.39 (s, 3H).

Example 221: N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine.



The title compound was prepared in a manner analogous to Example 215 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 18). MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O$, 335.1; m/z found, 336.1 $[M+H]^+$. 1H NMR (500 MHz, $CDCl_3$) δ 4.75 (d, *J* = 6.1 Hz, 2H) 5.05 (br s, 1H) 6.38 - 6.87 (m, 3H) 7.32 (t, *J* = 9.3 Hz, 1H) 7.42 (ddd, *J* = 8.5, 6.9, 1.9 Hz, 1H) 7.50 - 7.61 (m, 1H) 7.67 (dd, *J* = 6.7, 2.6 Hz, 1H) 7.9 (s, 1H) 8.07 - 8.26 (m, 1H).


Example 222: N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidin-2-amine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 153 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 18) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_3N_6O$, 350.1; m/z found, 350.9 $[M+H]^+$. ^1H NMR (300 MHz, DMSO-d_6) δ 8.63 (s, 1H), 8.17 (s, 2H), 8.04 – 7.90 (m, 1H), 7.91 – 7.77 (m, 1H), 7.64 (t, J = 9.6 Hz, 1H), 7.46 – 7.35 (m, 1H), 7.38 (t, J = 72.5 Hz, 1H), 4.59 (d, J = 6.0 Hz, 2H), 2.06 (s, 3H).

Example 223: N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine.



The title compound was prepared in a manner analogous to Example 219 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine (Intermediate 18) in step A. MS (ESI): mass calcd. for $C_{14}H_{13}F_3N_6O$, 338.1; m/z found, 339.1 $[M+H]^+$. ^1H NMR (500MHz, $CDCl_3$) δ 7.88 (s, 1H), 7.69 (dd, J =2.5, 6.5 Hz, 1H), 7.62 - 7.53 (m, 1H), 7.35 (t, J =9.2 Hz, 1H), 7.30 (d, J =1.2 Hz, 1H), 6.65 (t, J =72.8 Hz, 1H), 5.57 (d, J =1.7 Hz, 1H), 4.48 (s, 2H), 3.95 (br s, 1H), 3.68 (s, 3H).

Example 224: N-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethyl]-5-methyl-pyrimidin-2-amine.




The title compound was prepared in a manner analogous to Example 154 using (R)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-amine (Intermediate 24) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}ClF_2N_6O$, 380.1; m/z found, 381.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.17 – 8.11 (d, J = 0.8 Hz, 2H), 7.87 – 7.82 (s, 1H),

2017217542 02 Mar 2021


7.69 – 7.65 (d, *J* = 2.3 Hz, 1H), 7.61 – 7.51 (m, 2H), 6.78 – 6.45 (t, *J* = 72.6 Hz, 1H), 5.46 – 5.36 (m, 2H), 2.17 – 2.10 (t, *J* = 0.7 Hz, 3H), 1.77 – 1.68 (d, *J* = 6.6 Hz, 3H).

Example 225: 5-Chloro-2-[[1-(4-chlorophenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{13}H_9Cl_2N_5O$, 321.0; m/z found, 322.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.49 (s, 2H), 8.09 (s, 1H), 7.71 – 7.63 (m, 2H), 7.53 – 7.45 (m, 2H), 5.62 (d, *J* = 0.7 Hz, 2H).

Example 226: 2-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-trifluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{14}H_9ClF_3N_5O$, 355.0; m/z found, 356.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.82 (d, *J* = 0.8 Hz, 2H), 8.11 (s, 1H), 7.71 – 7.66 (m, 2H), 7.54 – 7.49 (m, 2H), 5.73 (d, *J* = 0.7 Hz, 2H).

Example 227: 2-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}ClF_2N_5O_2$, 353.0; m/z found, 354.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.46 (s, 2H), 8.12 (s, 1H), 7.73 – 7.68 (m, 2H), 7.55 – 7.50 (m, 2H), 6.55 (t, *J* = 71.9 Hz, 1H), 5.67 (d, *J* = 0.7 Hz, 2H).

Example 228: 2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 41) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{13}H_{10}FN_5O$, 271.1; m/z found, 272.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.98 (s, 1H), 8.66 (d, *J* = 4.8 Hz, 2H), 7.87 (dt, *J* = 10.0, 2.3 Hz, 1H), 7.82 (ddd, *J* = 8.0, 2.0, 0.8 Hz, 1H), 7.66 (td, *J* = 8.3, 6.3 Hz, 1H), 7.36 (tdd, *J* = 8.6, 2.6, 0.9 Hz, 1H), 7.20 (t, *J* = 4.8 Hz, 1H), 5.54 (d, *J* = 0.6 Hz, 2H).


Example 229: 5-Fluoro-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 41) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{13}H_9F_2N_5O$, 289.1; m/z found, 290.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.97 (d, *J* = 0.6 Hz,


1H), 8.75 (d, *J* = 0.7 Hz, 2H), 7.86 (dt, *J* = 10.0, 2.3 Hz, 1H), 7.82 (ddd, *J* = 8.1, 2.1, 0.9 Hz, 1H), 7.66 (td, *J* = 8.3, 6.3 Hz, 1H), 7.36 (tdd, *J* = 8.5, 2.5, 0.9 Hz, 1H), 5.52 (d, *J* = 0.6 Hz, 2H).

Example 230: 2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 41) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{14}H_{12}FN_5O_2$, 301.1; m/z found, 302.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.96 (d, *J* = 0.6 Hz, 1H), 8.41 (s, 2H), 7.91 - 7.78 (m, 2H), 7.65 (td, *J* = 8.2, 6.3 Hz, 1H), 7.36 (tdd, *J* = 8.5, 2.5, 0.9 Hz, 1H), 5.47 (d, *J* = 0.5 Hz, 2H), 3.86 (s, 3H).


Example 231: 5-Chloro-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 41) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{13}H_9ClFN_5O$, 305.0; m/z found, 306.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.97 (d, *J* = 0.7 Hz, 1H), 8.77 (s, 2H), 7.86 (dt, *J* = 10.0, 2.3 Hz, 1H), 7.82 (ddd, *J* = 8.1, 2.1, 0.9 Hz, 1H), 7.66 (td, *J* = 8.3, 6.3 Hz, 1H), 7.36 (tdd, *J* = 8.5, 2.5, 0.9 Hz, 1H), 5.55 (d, *J* = 0.5 Hz, 2H).


Example 232: 2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.

2017217542 02 Mar 2021




The title compound was prepared in a manner analogous to Example 1 using (1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 41) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{14}H_{12}FN_5O$, 285.1; m/z found, 286.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.97 (s, 1H), 8.49 (d, J = 0.9 Hz, 2H), 7.87 (dt, J = 10.0, 2.3 Hz, 1H), 7.82 (ddd, J = 8.1, 2.2, 0.9 Hz, 1H), 7.65 (td, J = 8.2, 6.2 Hz, 1H), 7.36 (tdd, J = 8.5, 2.5, 0.9 Hz, 1H), 5.50 (s, 2H), 2.21 (s, 3H).

Example 233: 5-Ethyl-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 41) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}FN_5O$, 299.1; m/z found, 300.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.97 (s, 1H), 8.53 (s, 2H), 7.87 (dt, J = 10.0, 2.3 Hz, 1H), 7.82 (ddd, J = 8.1, 2.0, 0.9 Hz, 1H), 7.65 (td, J = 8.2, 6.2 Hz, 1H), 7.36 (tdd, J = 8.5, 2.5, 0.9 Hz, 1H), 5.50 (s, 2H), 2.57 (q, J = 7.6 Hz, 2H), 1.19 (t, J = 7.6 Hz, 3H).

Example 234: 2-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{14}H_{12}BrN_5O$, 345.0; m/z found,

2017217542 02 Mar 2021


348.0 $[M+H]^+$. ^1H NMR (300 MHz, $CDCl_3$) δ 8.38 (s, 2H), 8.11 (s, 1H), 7.96 – 7.91 (m, 1H), 7.68 (dd, *J* = 8.1, 1.0 Hz, 1H), 7.57 (dd, *J* = 8.0, 0.5 Hz, 1H), 7.39 (t, *J* = 8.1 Hz, 1H), 5.63 (s, 2H), 2.26 (s, 3H).

Example 235: 2-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-bromophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{14}H_{12}BrN_5O$, 345.0; m/z found, 347.9 $[M+H]^+$. ^1H NMR (300 MHz, $CDCl_3$) δ 8.40 (d, *J* = 5.0 Hz, 1H), 8.12 (s, 1H), 7.94 (s, 1H), 7.68 (d, *J* = 8.0 Hz, 1H), 7.57 (d, *J* = 8.1 Hz, 1H), 7.40 (t, *J* = 8.1 Hz, 1H), 6.86 (d, *J* = 5.0 Hz, 1H), 5.65 (s, 2H), 2.49 (s, 3H).

Example 236: 2-[[1-(o-Tolyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 38) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{13}N_5O$, 267.1; m/z found, 268.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.66 (d, *J* = 4.8 Hz, 2H), 8.60 (s, 1H), 7.52 - 7.39 (m, 4H), 7.20 (t, *J* = 4.8 Hz, 1H), 5.53 (s, 2H), 2.15 (s, 3H).

Example 237: 5-Fluoro-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 38) and 2-

2017217542 02 Mar 2021


chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{12}FN_5O$, 285.1; m/z found, 286.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.75 (d, J = 0.7 Hz, 2H), 8.60 (s, 1H), 7.55 - 7.35 (m, 4H), 5.51 (s, 2H), 2.15 (s, 3H).

Example 238: 5-Methoxy-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 38) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{15}N_5O_2$, 297.1; m/z found, 298.1$[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.57 (s, 1H), 8.41 (s, 2H), 7.59 - 7.37 (m, 4H), 5.46 (s, 2H), 3.86 (s, 3H), 2.15 (s, 3H).

Example 239: 5-Chloro-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 38) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{12}ClN_5O$, 301.1; m/z found, 302.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.76 (s, 2H), 8.61 (s, 1H), 7.56 - 7.36 (m, 4H), 5.54 (s, 2H), 2.15 (s, 3H).


Example 240: 5-Methyl-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 38) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{15}N_5O$, 281.1; m/z found, 282.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.58 (s, 1H), 8.49 (d, J = 0.8 Hz, 2H), 7.56 - 7.37 (m, 4H), 5.49 (s, 2H), 2.21 (d, J = 0.8 Hz, 3H), 2.15 (s, 3H).

Example 241: 5-Ethyl-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 38) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{17}N_5O$, 295.1; m/z found, 296.1$[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.58 (s, 1H), 8.52 (d, J = 0.6 Hz, 2H), 7.55 - 7.37 (m, 4H), 5.50 (s, 2H), 2.57 (q, J = 7.6 Hz, 2H), 2.15 (s, 3H), 1.19 (t, J = 7.6 Hz, 3H).


Example 242: 2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(m-Tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{13}N_5O$, 267.1; m/z found, 268.1$[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.89 (s, 1H), 8.66 (d, J = 4.7 Hz, 2H), 7.76 (td, J = 1.8, 0.9 Hz, 1H), 7.70 (dt, J = 7.9, 1.6 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.32 (ddt, J = 7.6, 1.7, 0.9 Hz, 1H), 7.20 (t, J = 4.8 Hz, 1H), 5.52 (s, 2H), 2.42 (d, J = 0.7 Hz, 3H).


2017217542 02 Mar 2021

Example 243: 5-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{15}N_5O$, 281.1; m/z found, 282.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.87 (s, 1H), 8.49 (d, J = 0.9 Hz, 2H), 7.75 (d, J = 1.9 Hz, 1H), 7.69 (dd, J = 8.0, 2.2 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 7.37 - 7.26 (m, 1H), 5.49 (s, 2H), 2.41 (s, 3H), 2.21 (s, 3H).

Example 244: 4-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{15}N_5O$, 281.1; m/z found, 282.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.87 (s, 1H), 8.49 (d, J = 5.0 Hz, 1H), 7.76 (d, J = 2.1 Hz, 1H), 7.70 (dd, J = 8.0, 2.1 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.32 (d, J = 7.6 Hz, 1H), 7.07 (d, J = 4.9 Hz, 1H), 5.50 (s, 2H), 2.42 (d, J = 5.7 Hz, 6H).

Example 245: 5-Ethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2-chloro-5-

02 Mar 2021 2017217542


ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{17}N_5O$, 295.1; m/z found, 296.1[M+H]$^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.87 (s, 1H), 8.53 (d, J = 0.6 Hz, 2H), 7.79 - 7.73 (m, 1H), 7.70 (ddt, J = 8.2, 1.7, 0.8 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.31 (ddt, J = 7.7, 1.8, 0.9 Hz, 1H), 5.55 - 5.41 (m, 2H), 2.57 (q, J = 7.6 Hz, 2H), 2.41 (s, 3H), 1.19 (t, J = 7.6 Hz, 3H).

Example 246: 5-Chloro-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{12}ClN_5O$, 301.1; m/z found, 302.1 [M+H]$^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.88 (s, 1H), 8.77 (s, 2H), 7.75 (dq, J = 2.2, 1.1 Hz, 1H), 7.72 - 7.66 (m, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.32 (ddt, J = 7.6, 1.7, 0.8 Hz, 1H), 5.53 (d, J = 0.6 Hz, 2H), 2.42 (d, J = 0.7 Hz, 3H).


Example 247: 5-Fluoro-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{12}FN_5O$, 285.1; m/z found, 286.1 [M+H]$^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.88 (s, 1H), 8.75 (d, J = 0.7 Hz, 2H), 7.75 (tq, J = 1.5, 0.7 Hz, 1H), 7.69 (ddt, J = 8.1, 2.3, 0.9 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.32 (ddt, J = 7.6, 1.8, 0.9 Hz, 1H), 5.51 (s, 2H), 2.42 (d, J = 0.7 Hz, 3H).


02 Mar 2021
2017217542

Example 248: 5-Methoxy-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{15}N_5O_2$, 297.1; m/z found, 298.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.86 (s, 1H), 8.41 (s, 2H), 7.75 (d, J = 1.9 Hz, 1H), 7.69 (dd, J = 8.1, 2.2 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 7.31 (ddt, J = 7.6, 1.8, 0.9 Hz, 1H), 5.46 (s, 2H), 3.86 (s, 3H), 2.42 (s, 3H).

Example 249: 2-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.



The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{17}H_{19}N_5O_2$, 325.2; m/z found, 326.3 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.72 (d, J = 3.0 Hz, 2H), 8.64 (d, J = 2.9 Hz, 1H), 7.68 (d, J = 2.0 Hz, 1H), 7.62 (dd, J = 8.1, 2.2 Hz, 1H), 7.44 (t, J = 7.8 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H), 4.89 (d, J = 2.8 Hz, 2H), 2.45 (s, 3H), 1.58 (d, J = 3.2 Hz, 6H).


Example 250: 4-(Methoxymethyl)-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{17}N_5O_2$, 311.1; m/z found, 312.2 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.62 (s, 1H), 8.56 (dd, *J* = 5.1, 1.4 Hz, 1H), 7.65 (d, *J* = 2.0 Hz, 1H), 7.60 (dd, *J* = 8.1, 2.1 Hz, 1H), 7.42 (t, *J* = 7.8 Hz, 1H), 7.29 (d, *J* = 7.7 Hz, 1H), 7.20 (d, *J* = 5.1 Hz, 1H), 5.59 (s, 2H), 4.50 (s, 2H), 3.48 (m, *J* = 1.5 Hz, 3H), 2.43 (s, 3H).

Example 251: 4,5-Dimethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{17}N_5O$, 295.1; m/z found, 296.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.85 (s, 1H), 8.30 (d, *J* = 1.0 Hz, 1H), 7.75 (d, *J* = 2.1 Hz, 1H), 7.69 (d, *J* = 8.1 Hz, 1H), 7.47 (t, *J* = 7.8 Hz, 1H), 7.35 - 7.28 (m, 1H), 5.46 (s, 2H), 2.41 (s, 3H), 2.39 (s, 3H), 2.16 (s, 3H).

Example 252: 5-Fluoro-4-methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2-chloro-4-methyl-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}FN_5O$, 299.1; m/z found, 300.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.86 (s, 1H), 8.56 (d, *J* = 1.5 Hz, 1H), 7.76 (d, *J* = 2.1 Hz, 1H), 7.69 (dd, *J* = 7.9, 2.2 Hz, 1H), 7.48 (td, *J* = 7.8, 5.0 Hz, 1H), 7.32 (d, *J* = 7.5 Hz, 1H), 5.48 (s, 2H), 2.44 (d, *J* = 2.6 Hz, 3H), 2.42 (s, 3H).

Example 253: 5-Chloro-4-methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}ClN_5O$, 315.1; m/z found, 316.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.88 (s, 1H), 8.63 (d, J = 1.3 Hz, 1H), 7.76 (s, 1H), 7.69 (d, J = 8.2 Hz, 1H), 7.48 (t, J = 7.7 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 5.51 (s, 2H), 2.43 (d, J = 8.5 Hz, 6H).

Example 254: 5-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 2-chloro-5-methylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{15}H_{16}N_6O$, 296.1; m/z found, 297.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.84 (s, 1H), 7.78 - 7.72 (m, 2H), 7.69 (d, J = 8.6 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 7.37 - 7.25 (m, 1H), 6.76 (s, 2H), 5.33 (s, 2H), 2.41 (s, 3H), 1.92 (d, J = 0.9 Hz, 3H).

Example 255: 1-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone.




The title compound was prepared in a manner analogous to Example 1 using (1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI): mass calcd. for $C_{16}H_{15}N_5O_2$,

2017217542 02 Mar 2021


309.1; m/z found, 310.1 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 9.17 (s, 2H), 8.68 (s, 1H), 7.71 (s, 1H), 7.65 (d, *J* = 8.2 Hz, 1H), 7.47 (t, *J* = 7.9 Hz, 1H), 7.35 (d, *J* = 7.6 Hz, 1H), 5.74 (s, 2H), 2.62 (d, *J* = 3.2 Hz, 3H), 2.48 (s, 3H).

Example 256: 2-[[1-(p-Tolyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 33) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{13}N_5O$, 267.1; m/z found, 268.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.86 (s, 1H), 8.66 (d, *J* = 4.8 Hz, 2H), 7.85 - 7.73 (m, 2H), 7.47 - 7.35 (m, 2H), 7.20 (t, *J* = 4.8 Hz, 1H), 5.52 (s, 2H), 2.38 (s, 3H).

Example 257: 5-Fluoro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 33) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{12}FN_5O$, 285.1; m/z found, 286.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.86 (s, 1H), 8.74 (d, *J* = 0.7 Hz, 2H), 7.84 - 7.72 (m, 2H), 7.44 - 7.34 (m, 2H), 5.57 - 5.43 (m, 2H), 2.38 (s, 3H).


Example 258: 5-Methoxy-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 33) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{15}N_5O_2$, 297.1; m/z found, 298.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.84 (s, 1H), 8.41 (s, 2H), 7.88 - 7.72 (m, 2H), 7.46 - 7.30 (m, 2H), 5.45 (d, J = 0.5 Hz, 2H), 3.86 (s, 3H), 2.38 (s, 3H).

Example 259: 5-Chloro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 33) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{12}ClN_5O$, 301.1; m/z found, 302.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.86 (s, 1H), 8.76 (s, 2H), 7.84 - 7.69 (m, 2H), 7.44 - 7.29 (m, 2H), 5.53 (d, J = 0.5 Hz, 2H), 2.38 (s, 3H).

Example 260: 5-Methyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 33) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{15}N_5O$, 281.1; m/z found, 282.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.84 (d, J = 0.7 Hz, 1H), 8.49 (q, J = 0.7 Hz, 2H), 7.84 - 7.70 (m, 2H), 7.45 - 7.36 (m, 2H), 5.48 (d, J = 0.5 Hz, 2H), 2.38 (s, 3H), 2.21 (d, J = 0.8 Hz, 3H).

Example 261: 5-Ethyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 33) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{17}N_5O$, 295.1; m/z found, 296.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.85 (s, 1H), 8.52 (d, J = 0.6 Hz, 2H), 7.85 - 7.73 (m, 2H), 7.44 - 7.33 (m, 2H), 5.54 - 5.29 (m, 2H), 2.63 - 2.53 (m, 2H), 2.38 (s, 3H), 1.19 (t, J = 7.6 Hz, 3H).

Example 262: 2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 44) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{16}H_{17}N_5O$, 295.1; m/z found, 296.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.93 (s, 1H), 8.67 (d, J = 4.8 Hz, 2H), 7.78 (t, J = 2.0 Hz, 1H), 7.71 (ddd, J = 8.1, 2.4, 1.1 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.42 - 7.33 (m, 1H), 7.20 (t, J = 4.8 Hz, 1H), 5.53 (s, 2H), 3.01 (p, J = 7.0 Hz, 1H), 1.26 (d, J = 6.9 Hz, 6H).


Example 263: 5-Fluoro-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 44) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{16}H_{16}FN_5O$, 313.1; m/z found, 314.1 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.65 (s, 1H), 8.57 (s, 2H), 7.72 (t, *J* = 2.1 Hz, 1H), 7.64 (ddd, *J* = 8.0, 2.3, 1.1 Hz, 1H), 7.49 (t, *J* = 7.9 Hz, 1H), 7.44 - 7.34 (m, 1H), 5.59 (s, 2H), 3.03 (p, *J* = 6.9 Hz, 1H), 1.31 (d, *J* = 6.9 Hz, 6H).

Example 264: 2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 44) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{17}H_{19}N_5O_2$, 325.2; m/z found, 326.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.90 (s, 1H), 8.41 (s, 2H), 7.78 (t, *J* = 2.0 Hz, 1H), 7.71 (ddd, *J* = 8.0, 2.3, 1.1 Hz, 1H), 7.51 (t, *J* = 7.9 Hz, 1H), 7.42 - 7.35 (m, 1H), 5.46 (s, 2H), 3.86 (s, 3H), 3.01 (p, *J* = 6.9 Hz, 1H), 1.26 (d, *J* = 6.9 Hz, 6H).


Example 265: 5-Chloro-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 44) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{16}H_{16}ClN_5O$, 329.1; m/z


found, 330.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.92 (s, 1H), 8.77 (d, J = 0.8 Hz, 2H), 7.77 (d, J = 2.0 Hz, 1H), 7.74 - 7.66 (m, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.39 (d, J = 7.6 Hz, 1H), 5.54 (s, 2H), 3.00 (h, J = 6.9 Hz, 1H), 1.31 - 1.14 (m, 6H).

Example 266: 2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 44) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{19}N_5O$, 309.2; m/z found, 310.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.91 (s, 1H), 8.49 (s, 2H), 7.78 (t, J = 2.0 Hz, 1H), 7.75 - 7.69 (m, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.38 (d, J = 7.7 Hz, 1H), 5.49 (s, 2H), 3.01 (p, J = 6.7 Hz, 1H), 2.21 (s, 3H), 1.26 (d, J = 6.9 Hz, 6H).


Example 267: 5-Ethyl-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 44) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{18}H_{21}N_5O$, 323.2; m/z found, 324.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.92 (s, 1H), 8.53 (s, 2H), 7.78 (t, J = 2.1 Hz, 1H), 7.75 - 7.69 (m, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.43 - 7.36 (m, 1H), 5.50 (s, 2H), 3.02 (q, J = 6.9 Hz, 1H), 2.57 (q, J = 7.6 Hz, 2H), 1.26 (d, J = 6.9 Hz, 6H), 1.19 (t, J = 7.6 Hz, 3H).


2017217542 02 Mar 2021

Example 268: 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.



The title compound was prepared analogous to Example 155, using 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O$, 317.1; m/z found, 318.0 $[M+H]^+$. ^1H NMR (600 MHz, $CDCl_3$) δ 8.40 (d, *J* = 4.9 Hz, 1H), 8.17 (s, 1H), 7.92 – 7.89 (m, 1H), 7.89 – 7.85 (m, 1H), 7.66 – 7.61 (m, 1H), 7.61 – 7.56 (m, 1H), 6.86 (d, *J* = 5.0 Hz, 1H), 6.73 (t, *J* = 56.2 Hz, 1H), 5.67 (d, *J* = 0.8 Hz, 2H), 2.49 (s, 3H).


Example 269: 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine.



The title compound was prepared analogous to Example 155, using 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}F_3N_5O$, 321.1; m/z found, 322.0 $[M+H]^+$. ^1H NMR (600 MHz, $CDCl_3$) δ 8.43 (s, 2H), 8.18 – 8.15 (m, 1H), 7.93 – 7.85 (m, 2H), 7.67 – 7.57 (m, 2H), 6.73 (t, *J* = 56.1 Hz, 1H), 5.65 (d, *J* = 0.7 Hz, 2H).


Example 270: 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine.

2017217542 02 Mar 2021




The title compound was prepared analogous to Example 155, using 2-chloro-4-isopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{17}F_2N_5O$, 345.1; m/z found, 346.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.43 (d, *J* = 5.1 Hz, 1H), 8.18 (s, 1H), 7.92 – 7.89 (m, 1H), 7.88 – 7.84 (m, 1H), 7.65 – 7.60 (m, 1H), 7.59 – 7.55 (m, 1H), 6.86 (d, *J* = 5.1 Hz, 1H), 6.72 (t, *J* = 56.1 Hz, 1H), 5.66 (d, *J* = 0.8 Hz, 2H), 2.96 (hept, *J* = 6.9 Hz, 1H), 1.29 (d, *J* = 6.9 Hz, 6H).

Example 271: 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.



The title compound was prepared analogous to Example 155, using 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.54 (d, *J* = 5.0 Hz, 1H), 8.20 (s, 1H), 7.93 – 7.84 (m, 2H), 7.67 – 7.56 (m, 2H), 7.15 (d, *J* = 5.1 Hz, 1H), 6.72 (t, *J* = 56.1 Hz, 1H), 5.66 (d, *J* = 0.7 Hz, 2H), 4.50 (d, *J* = 0.7 Hz, 2H), 3.49 (s, 3H).


Example 272: 2-[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.



02 Mar 2021 2017217542


The title compound was prepared analogous to Example 155, using 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{17}H_{17}F_2N_5O_2$, 361.1; m/z found, 362.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.68 (s, 2H), 8.18 (s, 1H), 7.94 – 7.84 (m, 2H), 7.68 – 7.56 (m, 2H), 6.73 (t, *J* = 56.1 Hz, 1H), 5.67 (d, *J* = 0.7 Hz, 2H), 1.63 (s, 6H).

Example 273: 5-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using 2-chloro-5-difluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O$, 353.1; m/z found, 354.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.72 (s, 2H), 8.18 (s, 1H), 7.94 – 7.85 (m, 2H), 7.69 – 7.57 (m, 2H), 6.89 – 6.57 (m, 2H), 5.73 (s, 2H).

Example 274: 4-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using 2-chloro-4-difluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O$, 353.1; m/z found, 354.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.76 (d, *J* = 4.9 Hz, 1H), 8.21 (s, 1H), 7.94 – 7.84 (m, 2H), 7.63 (dt, *J* = 16.0, 7.7 Hz, 2H), 7.30 (d, *J* = 4.9 Hz, 1H), 6.88 – 6.34 (m, 2H), 5.71 (d, *J* = 0.7 Hz, 2H).

Example 275: 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine.




The title compound was prepared analogous to Example 155, using 2,-chloro-5-trifluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}F_5N_5O$, 371.1; m/z found, 372.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.82 (d, *J* = 0.8 Hz, 2H), 8.19 (s, 1H), 7.94 – 7.85 (m, 2H), 7.71 – 7.57 (m, 2H), 6.73 (t, *J* = 56.1 Hz, 1H), 5.75 (s, 2H).

Example 276: 5-(Difluoromethoxy)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using 2-chloro-5-difluoromethoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O_2$, 369.1; m/z found, 370.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.48 – 8.43 (m, 2H), 8.21 – 8.14 (m, 1H), 7.96 – 7.84 (m, 2H), 7.69 – 7.57 (m, 2H), 6.89 – 6.34 (m, 2H), 5.67 (d, *J* = 0.7 Hz, 2H).

Example 277: 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine.




The title compound was prepared analogous to Example 155, using 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{16}H_{16}F_2N_6O$, 346.1; m/z found, 347.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.15 (s, 1H), 8.03 (d, *J* = 6.1 Hz, 1H), 7.92 – 7.88 (m, 1H), 7.89 – 7.83 (m, 1H), 7.66 – 7.55 (m, 2H), 6.72 (t, *J* = 56.1 Hz, 1H), 6.13 (d, *J* = 6.1 Hz, 1H), 5.62 (d, *J* = 0.8 Hz, 2H), 3.11 (s, 6H).

Example 278: 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine.



The title compound was prepared analogous to Example 155, using 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O$, 335.1; m/z found, 336.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.26 (d, *J* = 1.2 Hz, 1H), 8.16 (s, 1H), 7.93 – 7.85 (m, 2H), 7.67 – 7.57 (m, 2H), 6.73 (t, *J* = 56.1 Hz, 1H), 5.62 (d, *J* = 0.7 Hz, 2H), 2.49 (d, *J* = 2.5 Hz, 3H).


Example 279: 5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.



02 Mar 2021
2017217542


The title compound was prepared analogous to Example 155, using 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O$, 351.1; m/z found, 352.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.38 (s, 1H), 8.16 (s, 1H), 7.93 – 7.84 (m, 2H), 7.68 – 7.56 (m, 2H), 6.73 (t, *J* = 56.1 Hz, 1H), 5.64 (d, *J* = 0.7 Hz, 2H), 2.56 (s, 3H).

Example 280: 2-Chloro-4-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.



The title compound was prepared analogous to Example 155, using 2,4-dichloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O$, 351.1; m/z found, 352.0 $[M+H]^+$. ^1H NMR (600 MHz, $CDCl_3$) δ 8.24 – 8.19 (m, 1H), 8.17 – 8.14 (m, 1H), 7.95 – 7.91 (m, 1H), 7.89 – 7.85 (m, 1H), 7.68 – 7.63 (m, 1H), 7.62 – 7.60 (m, 1H), 6.74 (t, *J* = 56.1 Hz, 1H), 5.67 (d, *J* = 0.5 Hz, 2H), 2.14 (d, *J* = 0.9 Hz, 3H).

Example 281: 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine.




The title compound was prepared analogous to Example 155, using 2-chloro-N,N,5-trimethylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{17}H_{18}F_2N_6O$, 360.2; m/z found, 361.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.15 (s, 1H),

2017217542 02 Mar 2021


7.90 (s, 1H), 7.87 – 7.82 (m, 1H), 7.67 – 7.53 (m, 2H), 6.72 (t, *J* = 56.1 Hz, 1H), 5.59 (s, 2H), 3.13 (s, 6H), 2.25 (s, 3H).

Example 282: 5-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using 2-chloro-5-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{15}F_2N_5O$, 343.1; m/z found, 344.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.74 (d, *J* = 1.4 Hz, 2H), 8.58 (s, 1H), 8.34 – 8.31 (m, 1H), 8.30 – 8.27 (m, 1H), 8.08 – 8.02 (m, 1H), 8.02 – 7.97 (m, 1H), 7.14 (t, *J* = 56.1 Hz, 1H), 6.06 (s, 2H), 2.29 – 2.21 (m, 1H), 1.47 – 1.41 (m, 2H), 1.15 – 1.09 (m, 2H).

Example 283: 4-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using 2-chloro-4-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{15}F_2N_5O$, 343.1; m/z found, 344.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.31 (dd, *J* = 5.1, 1.1 Hz, 1H), 8.15 (s, 1H), 7.92 – 7.89 (m, 1H), 7.88 – 7.84 (m, 1H), 7.66 – 7.61 (m, 1H), 7.60 – 7.57 (m, 1H), 6.86 (dd, *J* = 5.2, 1.0 Hz, 1H), 6.72 (t, *J* = 56.1 Hz, 1H), 5.61 (s, 2H), 1.96 (ttd, *J* = 8.0, 4.7, 1.0 Hz, 1H), 1.22 – 1.17 (m, 2H), 1.10 – 1.06 (m, 2H).

Example 284: 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine.




The title compound was prepared analogous to Example 155, using 2-chloro-4-cyclopropylpyrimidine 2-chloro-4-(pyrrolidin-1-yl)pyrimidine. MS (ESI): mass calcd. for $C_{18}H_{18}F_2N_6O$, 372.2; m/z found, 373.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.16 (s, 1H), 8.00 (s, 1H), 7.90 (s, 1H), 7.88 – 7.83 (m, 1H), 7.66 – 7.56 (m, 2H), 6.72 (t, *J* = 56.1 Hz, 1H), 6.00 (d, *J* = 5.9 Hz, 1H), 5.62 (s, 2H), 3.63 (s, 2H), 3.42 – 3.27 (m, 2H), 2.11 – 1.89 (m, 4H).

Example 285: 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine.




The title compound was prepared analogous to Example 155, using 2-chloro-4-(piperidin-1-yl)pyrimidine. MS (ESI): mass calcd. for $C_{19}H_{20}F_2N_6O$, 386.2; m/z found, 387.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.15 (s, 1H), 8.01 (d, *J* = 6.1 Hz, 1H), 7.90 (s, 1H), 7.89 – 7.83 (m, 1H), 7.67 – 7.54 (m, 2H), 6.72 (t, *J* = 56.1 Hz, 1H), 6.19 (d, *J* = 6.2 Hz, 1H), 5.59 (d, *J* = 0.8 Hz, 2H), 3.71 – 3.56 (m, 4H), 1.75 – 1.56 (m, 6H).

Example 286: 5-Methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 30) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O$, 335.1; m/z found, 335.9 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 9.10 (s, 1H), 8.51 – 8.49 (m, 2H), 8.33 – 8.26 (m, 2H), 7.92 – 7.82 (m, 2H), 5.52 (s, 2H), 2.22 (t, J = 0.8 Hz, 3H).

Example 287: 5-Ethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 30) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O$, 349.1; m/z found, 349.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 9.10 (s, 1H), 8.54 – 8.52 (m, 2H), 8.32 – 8.30 (m, 1H), 8.30 – 8.26 (m, 1H), 7.90 – 7.83 (m, 2H), 5.52 (s, 2H), 2.58 (q, J = 7.6 Hz, 2H), 1.19 (t, J = 7.6 Hz, 3H).

Example 288: 5-Isopropyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 30) and 2-chloro-5-isopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O$, 363.1; m/z found, 363.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-

02 Mar 2021 2017217542


d_6) δ 9.10 (s, 1H), 8.58 – 8.56 (m, 2H), 8.32 – 8.30 (m, 1H), 8.30 – 8.26 (m, 1H), 7.91 – 7.82 (m, 2H), 5.53 (s, 2H), 2.98 – 2.87 (m, 1H), 1.24 (d, J = 7.0 Hz, 6H).

Example 289: 5-(Difluoromethyl)-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 30) and 2-chloro-5-(difluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}F_5N_5O$, 371.1; m/z found, 371.9 $[M+H]^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 9.13 (s, 1H), 8.91 – 8.90 (m, 2H), 8.32 – 8.30 (m, 1H), 8.29 – 8.26 (m, 1H), 7.91 – 7.83 (m, 2H), 7.16 (t, J = 55.0 Hz, 1H), 5.63 (s, 2H).

Example 290: 4,5-Dimethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 30) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O$, 349.1; m/z found, 349.9 $[M+H]^+$.^{1}H NMR (500 MHz, DMSO-d_6) δ 9.08 (s, 1H), 8.33 – 8.25 (m, 3H), 7.90 – 7.82 (m, 2H), 5.50 (s, 2H), 2.39 (s, 3H), 2.16 (s, 3H).

Example 291: 5-Chloro-4-methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 30) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}ClF_3N_5O$, 369.1; m/z found, 369.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 9.09 (s, 1H), 8.63 (s, 1H), 8.31 – 8.29 (m, 1H), 8.29 – 8.26 (m, 1H), 7.90 – 7.82 (m, 2H), 5.54 (s, 2H), 2.51 (s, 3H).

Example 292: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O$, 317.1; m/z found, 318.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.58 (d, J = 4.8 Hz, 2H), 8.25 – 8.08 (m, 1H), 7.94 – 7.86 (m, 1H), 7.86 – 7.74 (m, 1H), 7.70 – 7.51 (m, 2H), 7.01 (t, J = 4.8 Hz, 1H), 5.68 (d, J = 0.7 Hz, 2H), 1.98 (t, J = 18.2 Hz, 3H).

Example 293: 5-Bromo-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol

02 Mar 2021
2017217542


(Intermediate 64) and 5-bromo-2-chloropyrimidine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{12}BrF_2N_5O$, 395.0; m/z found, 396.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.62 – 8.55 (s, 2H), 8.19 – 8.13 (s, 1H), 7.92 – 7.85 (m, 1H), 7.85 – 7.78 (m, 1H), 7.64 – 7.57 (m, 2H), 5.69 – 5.61 (d, J = 0.7 Hz, 2H), 2.19 – 1.78 (t, J = 18.2 Hz, 3H).

Example 294: 5-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O$, 351.1; m/z found, 352.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.51 (s, 2H), 8.18 – 8.13 (m, 1H), 7.91 – 7.87 (m, 1H), 7.84 – 7.79 (m, 1H), 7.65 – 7.55 (m, 2H), 5.73 – 5.60 (m, 2H), 1.98 (t, J = 18.2 Hz, 3H).

Example 295: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O$, 335.1; m/z found, 336.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.43 (s, 2H), 8.20 – 8.13 (m, 1H), 7.91 – 7.86 (m, 1H), 7.87 – 7.76 (m, 1H), 7.66 – 7.57 (m, 2H), 5.64 (d, J = 0.7 Hz, 2H), 1.98 (t, J = 18.2 Hz, 3H).

Example 296: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O$, 331.1; m/z found, 332.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.40 (d, J = 5.0 Hz, 1H), 8.23 – 8.12 (m, 1H), 7.95 – 7.86 (m, 1H), 7.86 – 7.75 (m, 1H), 7.66 – 7.54 (m, 2H), 6.92 – 6.81 (m, 1H), 5.67 (d, J = 0.8 Hz, 2H), 2.50 (s, 3H), 1.98 (t, J = 18.2 Hz, 3H).

Example 297: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O$, 331.1; m/z found, 332.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.48 – 8.30 (m, 2H), 8.16 (s, 1H), 7.95 – 7.84 (m, 1H), 7.85 – 7.75 (m, 1H), 7.68 – 7.52 (m, 2H), 5.64 (d, J = 0.6 Hz, 2H), 2.26 (s, 3H), 1.97 (t, J = 18.2 Hz, 3H).

Example 298: [2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol.




The title compound was prepared in a manner analogous to Example 159, Steps A-B using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 5-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine (Intermediate 53) in Step A.. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.60 – 8.52 (s, 2H), 8.22 – 8.15 (s, 1H), 7.92 – 7.86 (m, 1H), 7.84 – 7.77 (m, 1H), 7.65 – 7.53 (m, 2H), 5.71 – 5.57 (m, 2H), 4.77 – 4.64 (s, 2H), 2.71 – 2.48 (s, 1H), 2.02 – 1.92 (t, *J* = 18.2 Hz, 3H).

Example 299: [2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol.




The title compound was prepared in a manner analogous to Example 159, Steps A-B using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 4-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine (Intermediate 54) in Step A. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.56 – 8.48 (d, *J* = 5.0 Hz, 1H), 8.23 – 8.15 (m, 1H), 7.93 – 7.85 (m, 1H), 7.86 – 7.76 (m, 1H), 7.65 – 7.54 (m, 2H), 7.07 – 6.96 (m, 1H), 5.71 – 5.64 (m, 2H), 4.78 – 4.68 (d, *J* = 0.7 Hz, 2H), 2.02 – 1.92 (t, *J* = 18.2 Hz, 3H).

Example 300: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{17}H_{17}F_2N_5O_2$, 361.1; m/z found, 362.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.55 (d, *J* = 5.0 Hz, 1H), 8.20 (t, *J* = 0.7 Hz, 1H), 7.91 – 7.87 (m, 1H), 7.86 – 7.78 (m, 1H), 7.64 – 7.56 (m, 2H), 7.16 (dt, *J* = 5.0, 0.8 Hz, 1H), 5.67 (d, *J* = 0.7 Hz, 2H), 4.60 – 4.40 (m, 2H), 3.50 (s, 3H), 1.97 (t, *J* = 18.2 Hz, 3H).

Example 301: 2-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{18}H_{19}F_2N_5O_2$, 375.2; m/z found, 376.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.68 (s, 2H), 8.21 – 8.15 (m, 1H), 7.92 – 7.86 (m, 1H), 7.86 – 7.79 (m, 1H), 7.63 – 7.56 (m, 2H), 5.67 (d, *J* = 0.7 Hz, 2H), 2.12 – 1.88 (m, 3H), 1.63 (s, 6H).

Example 302: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-5-(difluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{13}F_4N_5O$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.77 – 8.66 (m, 2H), 8.25 – 8.11 (m, 1H), 7.96 – 7.87 (m, 1H), 7.87 – 7.77 (m, 1H), 7.66 – 7.55 (m, 2H), 6.73 (t, J = 55.6 Hz, 1H), 5.73 (d, J = 0.7 Hz, 2H), 1.98 (t, J = 18.2 Hz, 3H).


Example 303: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-4-(difluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{13}F_4N_5O$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.76 (d, J = 4.9 Hz, 1H), 8.25 – 8.16 (m, 1H), 7.92 – 7.86 (m, 1H), 7.86 – 7.77 (m, 1H), 7.67 – 7.56 (m, 2H), 7.34 – 7.28 (m, 1H), 6.65 – 6.37 (m, 1H), 5.71 (d, J = 1.3 Hz, 2H), 2.09 – 1.85 (m, 3H).


Example 304: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine.

02 Mar 2021 2017217542




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-4-(trifluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{12}F_5N_5O$, 385.1; m/z found, 386.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.83 (d, J = 4.9 Hz, 1H), 8.22 (t, J = 0.7 Hz, 1H), 7.89 (d, J = 1.0 Hz, 1H), 7.86 – 7.75 (m, 1H), 7.65 – 7.57 (m, 2H), 7.34 (d, J = 4.9 Hz, 1H), 5.73 (d, J = 0.6 Hz, 2H), 1.98 (t, J = 18.2 Hz, 3H).

Example 305: (R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-(2-chloropyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{18}H_{16}F_5N_5O_2$, 429.1; m/z found, 430.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.78 – 8.72 (s, 2H), 8.21 – 8.16 (t, J = 0.7 Hz, 1H), 7.92 – 7.86 (s, 1H), 7.85 – 7.78 (m, 1H), 7.65 – 7.56 (m, 2H), 5.72 – 5.65 (d, J = 0.7 Hz, 2H), 2.70 – 2.59 (s, 1H), 2.04 – 1.92 (t, J = 18.2 Hz, 3H), 1.86 – 1.81 (m, 3H).

Example 306: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.24 (s, 2H), 8.20 – 8.11 (m, 1H), 7.93 – 7.87 (m, 1H), 7.84 – 7.77 (m, 1H), 7.67 – 7.53 (m, 2H), 5.62 (d, *J* = 0.7 Hz, 2H), 3.88 (s, 3H), 1.97 (t, *J* = 18.2 Hz, 3H).

Example 307: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-4-methoxypyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.23 (d, *J* = 5.7 Hz, 1H), 8.16 (t, *J* = 0.7 Hz, 1H), 7.92 – 7.86 (m, 1H), 7.86 – 7.77 (m, 1H), 7.64 – 7.56 (m, 2H), 6.43 (d, *J* = 5.8 Hz, 1H), 5.66 (d, *J* = 0.7 Hz, 2H), 3.99 (s, 3H), 1.98 (t, *J* = 18.2 Hz, 3H).

Example 308: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{13}F_4N_5O_2$, 383.1; m/z found, 384.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.45 (s, 2H), 8.17 (s, 1H), 7.93 – 7.87 (m, 1H), 7.87 – 7.76 (m, 1H), 7.68 – 7.55 (m, 2H), 6.53 (t, *J* = 71.9 Hz, 1H), 5.67 (d, *J* = 0.7 Hz, 2H), 1.98 (t, *J* = 18.2 Hz, 3H).

Example 309: 1-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone.




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI): mass calcd. for $C_{17}H_{15}F_2N_5O_2$, 359.1; m/z found, 360.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 9.16 – 9.05 (s, 2H), 8.24 – 8.16 (s, 1H), 7.93 – 7.88 (d, *J* = 2.0 Hz, 1H), 7.86 – 7.78 (m, 1H), 7.66 – 7.57 (m, 2H), 5.83 – 5.73 (d, *J* = 0.9 Hz, 2H), 2.67 – 2.55 (s, 3H), 2.06 – 1.90 (t, *J* = 18.2 Hz, 3H).

Example 310: (R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol.



The title compound was prepared in a manner analogous to Example 157 using 1-(2-((1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one (Example 309). MS (ESI): mass calcd. for $C_{17}H_{17}F_2N_5O_2$, 361.1; m/z found, 362.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.64 – 8.52 (s, 2H), 8.26 – 8.10 (s, 1H), 7.93 – 7.85 (m, 1H), 7.84 – 7.77 (m, 1H), 7.66 – 7.54 (m, 2H), 5.72 – 5.57 (d, *J* = 0.7 Hz, 2H), 5.03 – 4.88 (m, 1H), 2.23 – 2.10 (s, 1H), 2.07 – 1.88 (t, *J* = 18.3 Hz, 3H), 1.61 – 1.52 (d, *J* = 6.5 Hz, 3H).

Example 311: (R/S)-2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(1-methoxyethyl)pyrimidine.




To a solution of 1-(2-((1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-ol (Example 310, 21 mg, 0.06 mmol) in ACN was added NaH (7 mg, 0.17 mmol) followed by iodomethane (82 mg, 0.58 mmol). The resulting suspension was stirred at rt for 2 h. The completed reaction was diluted with EtOAc and washed with water, brine and dried (Na_2SO_4), filtered, and concentrated under reduced pressure. Purification (FCC, SiO_2, 0-3% MeOH in DCM) afforded the titled compound (9.6 mg, 44%). MS (ESI): mass calcd. for $C_{18}H_{19}F_2N_5O_2$, 375.2; m/z found, 376.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.57 – 8.48 (s, 2H), 8.24 – 8.15 (t, *J* = 0.7 Hz, 1H), 7.92 – 7.86 (m, 1H), 7.86 – 7.78 (m, 1H), 7.67 – 7.53 (m, 2H),

2017217542 02 Mar 2021


5.72 – 5.64 (d, *J* = 0.7 Hz, 2H), 4.40 – 4.29 (m, 1H), 3.35 – 3.21 (s, 3H), 2.08 – 1.88 (t, *J* = 18.2 Hz, 3H), 1.54 – 1.43 (d, *J* = 6.5 Hz, 3H).

Example 312: 5-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O$, 365.1; m/z found, 366.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.39 (s, 1H), 8.17 – 8.14 (m, 1H), 7.90 – 7.87 (m, 1H), 7.84 – 7.79 (m, 1H), 7.62 – 7.57 (m, 2H), 5.64 (d, *J* = 0.7 Hz, 2H), 2.57 (s, 3H), 1.98 (t, *J* = 18.2 Hz, 3H).


Example 313: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O$, 349.1; m/z found, 350.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.26 (d, *J* = 1.2 Hz, 1H), 8.16 (s, 1H), 7.89 (s, 1H), 7.86 – 7.77 (m, 1H), 7.68 – 7.53 (m, 2H), 5.62 (d, *J* = 0.7 Hz, 2H), 2.50 (d, *J* = 2.5 Hz, 3H), 1.98 (t, *J* = 18.2 Hz, 3H).


Example 314: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine.

2017217542 02 Mar 2021




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-5-methylpyrimidin-4-amine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{16}F_2N_6O$, 346.1; m/z found, 347.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.19 – 8.13 (s, 1H), 7.94 – 7.86 (m, 2H), 7.85 – 7.75 (m, 1H), 7.63 – 7.55 (m, 2H), 5.62 – 5.51 (s, 2H), 5.08 – 4.91 (s, 2H), 2.05 – 2.02 (s, 3H), 2.02 – 1.93 (t, *J* = 18.2 Hz, 3H).

Example 315: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 163, Steps B-C using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (Intermediate 59) in step A. MS (ESI): mass calcd. for $C_{16}H_{15}F_3N_6O$, 364.1; m/z found, 365.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.17 – 8.12 (t, *J* = 0.7 Hz, 1H), 7.92 – 7.86 (m, 1H), 7.85 – 7.77 (m, 2H), 7.64 – 7.56 (m, 2H), 5.61 – 5.55 (d, *J* = 0.7 Hz, 2H), 5.15 – 5.10 (s, 1H), 3.11 – 3.05 (d, *J* = 5.0 Hz, 3H), 2.00 – 1.90 (m, 3H).

Example 316: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloropyrimidin-4-amine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{14}F_2N_6O$, 332.1; m/z found, 333.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.22 – 8.11 (t, J = 0.7 Hz, 1H), 8.09 – 7.99 (d, J = 5.7 Hz, 1H), 7.94 – 7.84 (m, 1H), 7.84 – 7.76 (m, 1H), 7.65 – 7.52 (m, 2H), 6.22 – 6.07 (d, J = 5.7 Hz, 1H), 5.65 – 5.50 (d, J = 0.8 Hz, 2H), 5.29 – 5.12 (s, 2H), 2.04 – 1.88 (t, J = 18.2 Hz, 3H).

Example 317: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 163, Steps B-C using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate (Intermediate 55) and (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64). MS (ESI): mass calcd. for $C_{16}H_{16}F_2N_6O$, 346.1; m/z found, 347.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.18 – 8.13 (t, J = 0.7 Hz, 1H), 8.07 – 7.98 (s, 1H), 7.92 – 7.86 (dt, J = 3.0, 1.1 Hz, 1H), 7.85 – 7.78 (m, 1H), 7.63 – 7.55 (m, 2H), 6.07 – 6.02 (d, J = 5.9 Hz, 1H), 5.64 – 5.58 (d, J = 0.8 Hz, 2H), 5.09 – 4.83 (s, 1H), 3.08 – 2.85 (m, 3H), 2.12 – 1.82 (t, J = 18.2 Hz, 3H).

Example 318: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine.




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{17}H_{18}F_2N_6O$, 360.2; m/z found, 361.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.19 – 8.12 (t, J = 0.8 Hz, 1H), 8.06 – 8.00 (d, J = 6.1 Hz, 1H), 7.94 – 7.87 (t, J = 2.1 Hz, 1H), 7.84 – 7.77 (m, 1H), 7.63 – 7.55 (m, 2H), 6.16 – 6.09 (d, J = 6.1 Hz, 1H), 5.64 – 5.59 (d, J = 0.8 Hz, 2H), 3.25 – 2.97 (s, 6H), 2.08 – 1.90 (m, 3H).

Example 319: 5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{18}H_{17}F_2N_5O$, 357.1; m/z found, 358.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.32 (d, J = 0.5 Hz, 2H), 8.17 – 8.15 (m, 1H), 7.90 – 7.87 (m, 1H), 7.81 (d, J = 6.4 Hz, 1H), 7.63 – 7.57 (m, 2H), 5.64 (d, J = 0.7 Hz, 2H), 1.97 (t, J = 18.2 Hz, 3H), 1.89 – 1.77 (m, 1H), 1.07 – 0.98 (m, 2H), 0.75 – 0.64 (m, 2H).

Example 320: 5-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 165, Steps A-C, using 5-bromo-2-((1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 293) and azetidine in Step A. MS (ESI): mass calcd. for $C_{18}H_{18}F_2N_6O$, 372.2; m/z found, 373.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.16 – 8.13 (t, J = 0.7 Hz, 1H), 7.91 – 7.87 (m, 1H), 7.84 – 7.79 (s, 3H), 7.64 – 7.54 (m, 2H), 5.62 – 5.55 (d, J = 0.8 Hz, 2H), 3.97 – 3.86 (t, J = 7.2 Hz, 4H), 2.50 – 2.39 (m, 2H), 2.04 – 1.88 (t, J = 18.2 Hz, 3H).

Example 321: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine.




The title compound was prepared in a manner analogous to Example 165, Steps A-C, using 5-bromo-2-((1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 293) and 3-fluoroazetidine in Step A. MS (ESI): mass calcd. for $C_{18}H_{17}F_3N_6O$, 390.1; m/z found, 391.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.17 – 8.12 (t, J = 0.7 Hz, 1H), 7.91 – 7.86 (m, 3H), 7.85 – 7.77 (m, 1H), 7.64 – 7.55 (m, 2H), 5.62 – 5.56 (d, J = 0.8 Hz, 2H), 5.56 – 5.34 (m, 1H), 4.29 – 4.18 (m, 2H), 4.06 – 3.94 (m, 2H), 2.04 – 1.91 (t, J = 18.2 Hz, 3H).

Example 322: 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 64) and 2-chloro-4-(pyrrolidin-1-yl)pyrimidine using ACN instead of DMF. MS (ESI): mass calcd. for $C_{19}H_{20}F_2N_6O$, 386.2; m/z found, 387.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.17 – 8.14 (s, 1H), 8.02 – 7.98 (d, *J* = 5.9 Hz, 1H), 7.91 – 7.87 (m, 1H), 7.84 – 7.77 (m, 1H), 7.62 – 7.55 (m, 2H), 6.06 – 5.95 (d, *J* = 6.0 Hz, 1H), 5.68 – 5.55 (d, *J* = 0.8 Hz, 2H), 3.76 – 3.54 (m, 2H), 3.47 – 3.27 (m, 2H), 2.10 – 1.88 (m, 7H).

Example 323: 2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 42) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}F_2N_5O_2$, 319.1; m/z found, 320.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.99 (s, 1H), 8.66 (d, *J* = 4.8 Hz, 2H), 7.86 - 7.76 (m, 2H), 7.66 (t, *J* = 8.2 Hz, 1H), 7.48 (d, *J* = 73.5 Hz, 1H), 7.31 (dd, *J* = 7.9, 2.4 Hz, 1H), 7.24 - 7.14 (m, 1H), 5.54 (s, 2H).

Example 324: 2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 42) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}F_3N_5O_2$, 337.1; m/z found, 338.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.98 (s, 1H), 8.75 (d, J = 0.7 Hz, 2H), 7.82 (ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 7.79 (t, J = 2.2 Hz, 1H), 7.66 (t, J = 8.2 Hz, 1H), 7.60 - 7.17 (m, 2H), 5.52 (s, 2H).

Example 325: 2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 42) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O_3$, 349.1; m/z found, 350.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.96 (s, 1H), 8.41 (s, 2H), 7.83 (dd, J = 8.1, 2.2 Hz, 1H), 7.79 (t, J = 2.2 Hz, 1H), 7.66 (t, J = 8.2 Hz, 1H), 7.59 - 7.16 (m, 2H), 5.47 (s, 2H), 3.86 (s, 3H).

Example 326: 5-Chloro-2-[[1-[3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 42) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}ClF_2N_5O_2$, 353.0; m/z found, 354.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.98 (s, 1H), 8.77 (s, 2H), 7.82 (ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 7.79 (t, J = 2.2 Hz, 1H), 7.66 (t, J = 8.2 Hz, 1H), 7.56 - 7.23 (m, 2H), 5.79 - 5.32 (m, 2H).

Example 327: 2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 42) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O_2$, 333.1; m/z found, 334.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.97 (s, 1H), 8.49 (d, J = 0.8 Hz, 2H), 7.83 (ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 7.79 (t, J = 2.2 Hz, 1H), 7.66 (t, J = 8.2 Hz, 1H), 7.56 - 7.22 (m, 2H), 5.62 - 5.21 (m, 2H), 2.21 (d, J = 0.8 Hz, 3H).

Example 328: 2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 42) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.98 (d, J = 0.6 Hz, 1H), 8.53 (d, J = 0.6 Hz, 2H), 7.83 (ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 7.79 (t, J = 2.2 Hz, 1H), 7.66 (t, J = 8.2 Hz, 1H), 7.55 - 7.19 (m, 2H), 5.67 - 5.35 (m, 2H), 2.62 - 2.54 (m, 2H), 1.19 (t, J = 7.6 Hz, 3H).

Example 329: 2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 43) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}F_2N_5O_2$, 319.1; m/z found, 320.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.92 (d, J = 0.6 Hz, 1H), 8.66 (d, J = 4.8 Hz, 2H), 8.05 - 7.91 (m, 2H), 7.52 - 7.16 (m, 4H), 5.53 (d, J = 0.5 Hz, 2H).


Example 330: 2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine.



02 Mar 2021
2017217542


The title compound was prepared in a manner analogous to Example 1 using (1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 43) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}F_3N_5O_2$, 337.1; 338.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.91 (s, 1H), 8.75 (d, J = 0.7 Hz, 2H), 8.01 - 7.92 (m, 2H), 7.52 - 7.17 (m, 3H), 5.52 (s, 2H).

Example 331: 2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 43) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O_3$, 349.1; m/z found, 350.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.89 (s, 1H), 8.41 (s, 2H), 8.02 - 7.94 (m, 2H), 7.53 - 7.16 (m, 3H), 5.46 (d, J = 0.6 Hz, 2H), 3.86 (s, 3H).

Example 332: 5-Chloro-2-[[1-[4-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 43) and 2,5-dichloropyrimidine. ^1H NMR (500 MHz, DMSO-d_6) δ 8.91 (s, 1H), 8.77 (s, 2H), 8.01 - 7.93 (m, 2H), 7.53 - 7.16 (m, 3H), 5.59 - 5.49 (m, 2H).

Example 333: 2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 43) and 2-chloro-5-methylpyrimidine. ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.90 (s, 1H), 8.49 (d, J = 0.8 Hz, 2H), 8.04 - 7.90 (m, 2H), 7.55 - 7.16 (m, 3H), 5.49 (s, 2H), 2.21 (d, J = 0.8 Hz, 3H).

Example 334: 2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 43) and 2-chloro-5-ethylpyrimidine. ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.90 (s, 1H), 8.53 (t, J = 0.6 Hz, 2H), 8.01 - 7.88 (m, 2H), 7.54 - 7.16 (m, 3H), 5.50 (d, J = 0.6 Hz, 2H), 2.57 (q, J = 7.6 Hz, 2H), 1.19 (t, J = 7.6 Hz, 3H).

Example 335: 2-[[1-[4-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 34) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}F_3N_5O_2$, 337.1; m/z found, 338.1 $[M+H]^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.97 (s, 1H), 8.66

2017217542 02 Mar 2021


(d, *J* = 4.8 Hz, 2H), 8.12 - 7.99 (m, 2H), 7.69 - 7.58 (m, 2H), 7.20 (t, *J* = 4.8 Hz, 1H), 5.61 - 5.39 (m, 2H).

Example 336: 5-Fluoro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 34) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_9F_4N_5O_2$, 355.1; m/z found, 356.0 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.74 (s, 1H), 8.57 (s, 2H), 8.03 - 7.94 (m, 2H), 7.57 - 7.44 (m, 2H), 5.44 (s, 2H).

Example 337: 5-Methoxy-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 34) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O_3$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.94 (s, 1H), 8.41 (s, 2H), 8.11 - 8.00 (m, 2H), 7.68 - 7.54 (m, 2H), 5.51 - 5.43 (m, 2H), 3.86 (s, 3H).

Example 338: 5-Chloro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 34) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_9ClF_3N_5O_2$, 371.0; m/z found, 372.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.96 (s, 1H), 8.77 (s, 2H), 8.10 - 8.01 (m, 2H), 7.67 - 7.55 (m, 2H), 5.55 (d, J = 0.6 Hz, 2H).

Example 339: 5-Methyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 34) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O_2$, 351.1; m/z found, 352.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.95 (s, 1H), 8.49 (d, J = 0.7 Hz, 2H), 8.12 - 8.02 (m, 2H), 7.70 - 7.56 (m, 2H), 5.50 (s, 2H), 2.21 (t, J = 0.8 Hz, 3H).

Example 340: 5-Ethyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 34) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_2$, 365.1; m/z found, 366.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.96 (s, 1H),

2017217542 02 Mar 2021


8.53 (s, 2H), 8.16 - 7.97 (m, 2H), 7.70 - 7.51 (m, 2H), 5.58 - 5.41 (m, 2H), 2.57 (q, 2H), 1.19 (t, *J* = 7.6 Hz, 3H).

Example 341: 2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35) and 2-chloropyrimidine. ^{1}H NMR (500 MHz, DMSO-d_6) δ 9.03 (s, 1H), 8.67 (d, *J* = 4.8 Hz, 2H), 8.05 - 7.92 (m, 2H), 7.75 (t, *J* = 8.2 Hz, 1H), 7.52 (d, *J* = 8.3 Hz, 1H), 7.20 (t, *J* = 4.8 Hz, 1H), 5.54 (s, 2H).

Example 342: 5-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O_2$, 351.1; m/z found, 352.1 $[M+H]^+$. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.02 (s, 1H), 8.49 (d, *J* = 0.8 Hz, 2H), 8.04 - 7.96 (m, 2H), 7.78 - 7.68 (m, 1H), 7.52 (ddt, *J* = 8.3, 2.3, 1.2 Hz, 1H), 5.50 (s, 2H), 2.21 (d, *J* = 0.8 Hz, 3H).

Example 343: 5-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35) and 2-chloro-5-methylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{15}H_{13}F_3N_6O_2$, 366.1; m/z found, 367.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.99 (s, 1H), 8.04 - 7.95 (m, 2H), 7.79 - 7.70 (m, 2H), 7.54 - 7.49 (m, 1H), 6.76 (s, 2H), 5.35 (s, 2H), 1.92 (d, J = 0.9 Hz, 3H).

Example 344: 1-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI): mass calcd. for $C_{16}H_{12}F_3N_5O_3$, 379.1; m/z found, 380.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 9.16 (s, 2H), 9.06 (s, 1H), 8.04 - 7.99 (m, 2H), 7.80 - 7.71 (m, 1H), 7.57 - 7.47 (m, 1H), 5.66 (s, 2H), 2.60 (s, 3H).

Example 345: 2-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O_3$, 395.1; m/z found, 396.1 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.76 (s, 1H), 8.72 (s, 2H), 7.94 - 7.85 (m, 2H), 7.69 (t, *J* = 8.2 Hz, 1H), 7.43 (ddt, *J* = 8.3, 2.3, 1.1 Hz, 1H), 5.62 (s, 2H), 1.57 (s, 6H).


Example 346: 4-(Methoxymethyl)-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_3$, 381.1; m/z found, 382.1 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.84 - 8.72 (m, 1H), 8.59 (s, 1H), 7.90 (d, *J* = 9.3 Hz, 2H), 7.71 (d, *J* = 7.9 Hz, 1H), 7.45 (s, 1H), 7.23 (s, 1H), 5.63 (d, *J* = 5.4 Hz, 2H), 4.68 - 4.42 (m, 2H), 3.62 - 3.44 (m, 3H).


Example 347: 4-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.

2017217542 02 Mar 2021




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O_2$, 351.1; m/z found, 352.1[M+H]$^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 9.02 (s, 1H), 8.49 (d, J = 5.0 Hz, 1H), 8.07 - 7.98 (m, 2H), 7.75 (t, J = 8.2 Hz, 1H), 7.58 - 7.51 (m, 1H), 7.08 (d, J = 4.9 Hz, 1H), 5.52 (s, 2H), 2.43 (s, 3H).

Example 348: 5-Fluoro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_9F_4N_5O_2$, 355.1; m/z found, 256.1 [M+H]$^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 9.03 (s, 1H), 8.75 (d, J = 0.7 Hz, 2H), 8.05 - 7.96 (m, 2H), 7.80 - 7.71 (m, 1H), 7.53 (ddq, J = 8.3, 2.2, 1.1 Hz, 1H), 5.53 (d, J = 0.6 Hz, 2H)

Example 349: 5-Methoxy-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O_3$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 9.01 (s, 1H), 8.41 (s, 2H), 8.05 - 7.96 (m, 2H), 7.75 (t, J = 8.2 Hz, 1H), 7.52 (d, J = 8.2 Hz, 1H), 5.48 (s, 2H), 3.86 (s, 3H).

Example 350: 5-Chloro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_9ClF_3N_5O_2$, 371.0; m/z found, 372.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 9.02 (s, 1H), 8.77 (s, 2H), 8.05 - 7.95 (m, 2H), 7.81 - 7.70 (m, 1H), 7.53 (ddt, J = 8.3, 2.2, 1.1 Hz, 1H), 5.55 (s, 2H).

Example 351: 5-Ethyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_2$, 365.1; m/z found, 366.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 9.03 (s, 1H), 8.53 (d, J = 0.8 Hz, 2H), 8.08 - 7.91 (m, 2H), 7.80 - 7.69 (m, 1H), 7.52 (ddt, J = 8.3, 2.2, 1.1 Hz, 1H), 5.52 (s, 2H), 2.58 (q, J = 7.6 Hz, 2H), 1.19 (t, J = 7.6 Hz, 3H).

Example 352: N-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 163, Steps B-C, using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate (Intermediate 55) and (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35). MS (ESI): mass calcd. for $C_{15}H_{13}F_3N_6O_2$, 366.1; m/z found, 367.4 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.69 (s, 1H), 7.97 - 7.84 (m, 2H), 7.80 (s, 1H), 7.69 (dd, J = 10.2, 6.3 Hz, 1H), 7.51 - 7.37 (m, 2H), 6.20 - 6.05 (m, 1H), 5.53 (s, 2H), 2.92 (s, 3H).

Example 353: 2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 153 using using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 35) and 2-chloropyrimidin-4-amine. MS (ESI): mass calcd. for $C_{14}H_{11}F_3N_6O_2$, 352.1; m/z found, 353.3[M+H]$^+$. ^{1}H NMR (400 MHz, CD_3OD) δ 8.72 (s, 1H), 7.95 - 7.82 (m, 3H), 7.69 (dd, *J* = 9.7, 6.9 Hz, 1H), 7.48 - 7.34 (m, 1H), 6.17 (d, *J* = 5.9 Hz, 1H), 5.48 (d, *J* = 3.7 Hz, 2H).

Example 354: 2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 45) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_2N_5O_3$, 347.1; m/z found, 348.0 [M+H]$^+$. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.88 (s, 1H), 8.49 (d, *J* = 0.9 Hz, 2H), 8.08 (d, *J* = 2.2 Hz, 1H), 7.79 (dd, *J* = 8.8, 2.2 Hz, 1H), 7.65 (d, *J* = 8.7 Hz, 1H), 5.49 (s, 2H), 2.21 (d, *J* = 0.7 Hz, 3H).


Example 355: 2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 45) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_9F_2N_5O_3$, 333.1; m/z found, 334.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.91 (s, 1H), 8.67 (d, J = 4.8 Hz, 2H), 8.09 (d, J = 2.2 Hz, 1H), 7.80 (dd, J = 8.7, 2.2 Hz, 1H), 7.65 (d, J = 8.7 Hz, 1H), 7.20 (t, J = 4.8 Hz, 1H), 5.54 (s, 2H).

Example 356: 5-Chloro-2-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 45) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_8ClF_2N_5O_3$, 367.0; m/z found, 368.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.89 (s, 1H), 8.77 (s, 2H), 8.08 (d, J = 2.2 Hz, 1H), 7.79 (dd, J = 8.8, 2.2 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 5.54 (s, 2H).

Example 357: 2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 45) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}F_3N_5O_3$, 365.1; m/z found, 366.0 $[M+H]^+$. ^1H NMR (400 MHz,

02 Mar 2021 2017217542


DMSO-d_6) δ 8.88 (s, 1H), 8.56 (d, J = 1.6 Hz, 1H), 8.08 (d, J = 2.2 Hz, 1H), 7.79 (dd, J = 8.7, 2.2 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 5.49 (s, 2H), 2.44 (d, J = 2.6 Hz, 3H).

Example 358: 2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 45) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_8F_3N_5O_3$, 351.1; m/z found, 352.1 $[M+H]^+$. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.89 (s, 1H), 8.75 (d, J = 0.6 Hz, 2H), 8.08 (d, J = 2.2 Hz, 1H), 7.79 (dd, J = 8.8, 2.2 Hz, 1H), 7.65 (d, J = 8.7 Hz, 1H), 5.52 (s, 2H).

Example 359: 2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 45) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{13}F_2N_5O_3$, 361.1; m/z found, 362.1 $[M+H]^+$. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.87 (s, 1H), 8.30 (s, 1H), 8.08 (d, J = 2.2 Hz, 1H), 7.79 (dd, J = 8.8, 2.2 Hz, 1H), 7.65 (d, J = 8.7 Hz, 1H), 5.47 (s, 2H), 2.39 (s, 3H), 2.16 (s, 3H).

Example 360: 2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 36) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{15}N_5O$, 281.1; m/z found, 282.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.85 (s, 1H), 8.66 (d, J = 4.8 Hz, 2H), 7.59 - 7.44 (m, 2H), 7.20 (t, J = 4.8 Hz, 1H), 7.13 (td, J = 1.5, 0.8 Hz, 1H), 5.52 (s, 2H), 2.37 (d, J = 0.8 Hz, 6H).

Example 361: 2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 36) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}FN_5O$, 299.1; m/z found, 300.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.84 (s, 1H), 8.75 (d, J = 0.6 Hz, 2H), 7.54 (dt, J = 1.4, 0.7 Hz, 2H), 7.14 (dq, J = 1.8, 0.8 Hz, 1H), 5.50 (s, 2H), 2.37 (d, J = 0.7 Hz, 6H).


Example 362: 2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 36) and


2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{16}H_{17}N_5O_2$, 311.1; m/z found, 312.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.82 (s, 1H), 8.41 (s, 2H), 7.54 (dt, *J* = 1.5, 0.7 Hz, 2H), 7.13 (tt, *J* = 1.7, 0.8 Hz, 1H), 5.45 (d, *J* = 0.6 Hz, 2H), 3.86 (s, 3H), 2.37 (d, *J* = 0.7 Hz, 6H).

Example 363: 5-Chloro-2-[[1-(3,5-dimethylphenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 36) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}ClN_5O$, 315.1; m/z found, 316.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.85 (s, 1H), 8.77 (s, 2H), 7.54 (dd, *J* = 1.4, 0.8 Hz, 2H), 7.14 (tt, *J* = 1.6, 0.8 Hz, 1H), 5.53 (d, *J* = 0.5 Hz, 2H), 2.37 (q, *J* = 0.7 Hz, 6H).

Example 364: 2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 36) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{17}N_5O$, 295.1; m/z found, 296.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.83 (s, 1H), 8.49 (d, *J* = 0.8 Hz, 2H), 7.54 (dd, *J* = 1.5, 0.8 Hz, 2H), 7.18 - 7.06 (m, 1H), 5.48 (s, 2H), 2.37 (d, *J* = 0.7 Hz, 6H), 2.21 (t, *J* = 0.7 Hz, 3H).

Example 365: 2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 36) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{19}N_5O$, 309.2; m/z found, 310.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.84 (s, 1H), 8.53 (s, 2H), 7.54 (dt, J = 1.5, 0.7 Hz, 2H), 7.13 (tt, J = 1.6, 0.8 Hz, 1H), 5.49 (s, 2H), 2.57 (q, J = 7.6 Hz, 2H), 1.19 (t, J = 7.6 Hz, 3H).

Example 366: 2-[(1-Indan-5-yltriazol-4-yl)methoxy]-5-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(2,3-dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 51) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{17}N_5O$, 307.1; m/z found, 308.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.82 (s, 1H), 8.49 (d, J = 0.9 Hz, 2H), 7.74 (d, J = 2.0 Hz, 1H), 7.63 (dd, J = 8.1, 2.2 Hz, 1H), 7.41 (d, J = 8.1 Hz, 1H), 5.47 (s, 2H), 2.94 (dt, J = 12.9, 7.4 Hz, 4H), 2.21 (s, 3H), 2.14 - 2.00 (m, 2H).

Example 367: 5-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,3-dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 51) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}ClN_5O$, 327.1; m/z found, 328.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.83 (s, 1H),

2017217542 02 Mar 2021


8.76 (s, 2H), 7.74 (d, *J* = 2.1 Hz, 1H), 7.63 (dd, *J* = 8.1, 2.2 Hz, 1H), 7.41 (d, *J* = 8.1 Hz, 1H), 5.52 (s, 2H), 2.94 (dt, *J* = 12.6, 7.4 Hz, 4H), 2.08 (p, *J* = 7.5 Hz, 2H).

Example 368: 2-[(1-Indan-5-yltriazol-4-yl)methoxy]-4-(methoxymethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,3-dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 51) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{18}H_{19}N_5O_2$, 337.2; m/z found, 338.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.82 (s, 1H), 8.64 (d, *J* = 5.0 Hz, 1H), 7.74 (d, *J* = 2.0 Hz, 1H), 7.63 (dd, *J* = 8.1, 2.2 Hz, 1H), 7.42 (d, *J* = 8.1 Hz, 1H), 7.20 - 7.16 (m, 1H), 5.50 (s, 2H), 4.47 (d, *J* = 0.7 Hz, 2H), 3.40 (s, 3H), 2.94 (dt, *J* = 14.1, 7.3 Hz, 4H), 2.14 - 2.03 (m, 2H).

Example 369: 2-[2-[(1-Indan-5-yltriazol-4-yl)methoxy]pyrimidin-5-yl]propan-2-ol.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,3-dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 51) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{19}H_{21}N_5O_2$, 351.2; m/z found, 352.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.83 (s, 1H), 8.69 (s, 2H), 7.75 (d, *J* = 2.0 Hz, 1H), 7.64 (dd, *J* = 8.1, 2.3 Hz, 1H), 7.41 (d, *J* = 8.1 Hz, 1H), 5.50 (s, 2H), 5.30 (s, 1H), 2.94 (dt, *J* = 13.9, 7.5 Hz, 4H), 2.14 - 2.04 (m, 2H), 1.46 (s, 6H).

Example 370: 4-(Difluoromethyl)-2-[(1-indan-5-yltriazol-4-yl)methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,3-dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 51) and 2-chloro-4-(difluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{17}H_{15}F_2N_5O$, 343.1; m/z found, 344.1[M+H]$^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.90 (d, J = 4.9 Hz, 1H), 8.84 (s, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.63 (dt, J = 8.1, 1.3 Hz, 1H), 7.46 (d, J = 4.9 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 6.96 (t, J = 54.1 Hz, 1H), 5.57 (s, 2H), 2.94 (dt, J = 15.3, 7.4 Hz, 4H), 2.08 (p, J = 7.5 Hz, 2H).

Example 371: 5-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,3-dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 51) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{16}ClN_5O$, 341.1; m/z found, 342.0 [M+H]$^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.82 (s, 1H), 8.62 (s, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.63 (dd, J = 8.1, 2.1 Hz, 1H), 7.41 (d, J = 8.1 Hz, 1H), 5.50 (s, 2H), 2.94 (dt, J = 15.4, 7.4 Hz, 4H), 2.51 (s, 5H), 2.08 (p, J = 7.5 Hz, 2H).

Example 372: 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_2$, 381.1; m/z found, 382.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.98 (s, 1H), 8.30 (d, J = 0.8 Hz, 1H), 7.99 (dd, J = 2.2, 0.7 Hz, 1H), 7.91 - 7.82 (m, 2H), 7.45 (t, J = 72.8 Hz, 1H), 5.54 - 5.37 (m, 2H), 2.38 (s, 3H), 2.16 (s, 3H).

Example 373: 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-isopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{16}ClF_2N_5O_2$, 395.1; m/z found, 396.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 9.01 (s, 1H), 8.56 (s, 2H), 7.99 (d, J = 2.2 Hz, 1H), 7.95 - 7.81 (m, 2H), 7.45 (t, J = 72.8 Hz, 1H), 5.52 (s, 2H), 2.93 (p, J = 7.0 Hz, 1H), 1.24 (d, J = 6.9 Hz, 6H).


Example 374: 2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (R)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 22) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.66 (d, *J* = 3.4 Hz, 1H), 8.58 (d, *J* = 4.7 Hz, 2H), 7.86 (d, *J* = 4.1 Hz, 1H), 7.81 - 7.61 (m, 2H), 7.29 - 6.75 (m, 1H), 6.48 (dt, *J* = 9.5, 4.6 Hz, 1H), 1.82 (dd, *J* = 6.7, 3.4 Hz, 3H).

Example 375: 5-Chloro-2-[(1R)-1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (R)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 22) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}Cl_2F_2N_5O_2$, 401.0; m/z found, 402.0$[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.67 (d, *J* = 0.6 Hz, 1H), 8.58 (d, *J* = 1.2 Hz, 2H), 7.86 (d, *J* = 2.3 Hz, 1H), 7.82 - 7.66 (m, 2H), 7.02 (t, *J* = 72.8 Hz, 1H), 6.41 (dt, *J* = 7.1, 6.3 Hz, 1H), 1.83 (d, *J* = 6.7 Hz, 3H).


Example 376: 2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (R)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 22) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for


$C_{16}H_{14}ClF_2N_5O_2$, 381.1; m/z found, 382.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.96 (d, J = 0.6 Hz, 1H), 8.46 (d, J = 0.8 Hz, 2H), 7.97 (d, J = 2.3 Hz, 1H), 7.91 - 7.80 (m, 2H), 7.43 (t, J = 72.8 Hz, 1H), 6.34 (q, J = 6.6 Hz, 1H), 2.19 (d, J = 0.8 Hz, 3H), 1.73 (d, J = 6.6 Hz, 3H).

Example 377: 2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methoxy-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (R)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 22) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_3$, 397.1; m/z found, 398.1 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.64 (d, J = 0.6 Hz, 1H), 8.30 (s, 2H), 7.86 (d, J = 2.3 Hz, 1H), 7.80 - 7.65 (m, 2H), 7.02 (t, J = 72.8 Hz, 1H), 6.36 (dt, J = 6.8, 6.3 Hz, 1H), 3.88 (s, 3H), 1.80 (d, J = 6.6 Hz, 3H).

Example 378: 2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (S)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 23) (Intermediate 23) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.1; m/z found, 368.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.99 (d, J = 0.6 Hz, 1H), 8.63 (d, J = 4.8 Hz, 2H), 7.98 (d, J

2017217542 02 Mar 2021


= 2.3 Hz, 1H), 7.92 - 7.80 (m, 2H), 7.43 (t, *J* = 72.8 Hz, 1H), 7.16 (t, *J* = 4.8 Hz, 1H), 6.39 (q, *J* = 6.5 Hz, 1H), 1.75 (d, *J* = 6.6 Hz, 3H).

Example 379: 5-Chloro-2-[(1S)-1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (S)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 23) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}Cl_2F_2N_5O_2$, 401.0; m/z found, 402.0$[M+H]^+$. ^{1}H NMR (400 MHz, CD_3OD) δ 8.67 (s, 1H), 8.59 (s, 2H), 7.87 (d, *J* = 2.5 Hz, 1H), 7.80 - 7.65 (m, 2H), 7.02 (t, *J* = 72.8 Hz, 1H), 6.41 (q, *J* = 6.5 Hz, 1H), 1.90 - 1.72 (m, 3H).

Example 380: 2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (S)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 23) and 2-chloro-5-methylpyrimidine. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.96 (s, 1H), 8.46 (d, *J* = 0.8 Hz, 2H), 7.97 (d, *J* = 2.1 Hz, 1H), 7.93 - 7.78 (m, 2H), 7.43 (t, *J* = 72.8 Hz, 1H), 6.34 (q, *J* = 6.6 Hz, 1H), 2.19 (d, *J* = 0.7 Hz, 3H), 1.73 (d, *J* = 6.6 Hz, 3H).

Example 381: 2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methoxy-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (S)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (Intermediate 23) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_3$, 397.1; m/z found, 398.1 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.64 (s, 1H), 8.30 (s, 2H), 7.80 (d, J = 48.2 Hz, 3H), 7.02 (t, J = 72.2 Hz, 1H), 6.36 (s, 1H), 3.88 (s, 3H), 1.81 (s, 3H).

Example 382: 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and 2-chloropyrimidin-4-amine. MS (ESI): mass calcd. for $C_{14}H_{11}ClF_2N_6O_2$, 368.1; m/z found, 369.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.97 – 8.95 (m, 1H), 7.99 – 7.97 (m, 1H), 7.90 (d, J = 5.8 Hz, 1H), 7.88 – 7.83 (m, 2H), 7.44 (t, J = 72.8 Hz, 1H), 6.90 (s, 2H), 6.11 (d, J = 5.8 Hz, 1H), 5.38 (s, 2H).


Example 383: [2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol.



Step A. 2-Chloro-4-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)pyrimidine. The title compound was prepared in a manner analogous to Intermediate 59, using (2-chloropyrimidin-4-yl)methanol and (2-(chloromethoxy)ethyl)trimethylsilane. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.77 (d, J = 5.0 Hz, 1H), 7.60 – 7.55 (m, 1H), 4.77 (s, 2H), 4.65 – 4.62 (m, 2H), 3.64 – 3.56 (m, 2H), 0.87 – 0.80 (m, 2H), 0.00 – -0.03 (s, 9H).

Step B. [2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol .The title compound was prepared in a manner analogous to Example 163, Steps B-C, using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) and chloro-4-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)pyrimidine and using THF instead of DMF in Step B. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_3$, 383.1; m/z found, 384.1 $[M+H]^+$. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.00 (s, 1H), 8.62 (d, J = 5.0 Hz, 1H), 8.00 – 7.97 (m, 1H), 7.89 – 7.83 (m, 2H), 7.44 (t, J = 72.8 Hz, 1H), 7.25 – 7.23 (m, 1H), 5.63 (t, J = 5.7 Hz, 1H), 5.53 (s, 2H), 4.51 (d, J = 5.3 Hz, 2H).


Example 384: 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using 2-chloro-4-(methoxymethyl)pyrimidine and (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1). MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_3$, 397.1; m/z found, 398.1 $[M+H]^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 9.00 - 8.99 (m, 1H), 8.64 (d, J = 5.0 Hz, 1H), 7.99 – 7.97 (m, 1H), 7.89 – 7.83 (m, 2H), 7.44 (t, J = 72.8 Hz, 1H), 7.18 (dt, J = 5.0, 0.7 Hz, 1H), 5.54 (s, 2H), 4.49 – 4.46 (m, 2H), 3.40 (s, 3H).


2017217542 02 Mar 2021

Example 385: 2-[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(difluoromethoxy)-4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-(2-chloropyrimidin-5-yl)propan-2-ol, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{17}H_{16}ClF_2N_5O_3$, 411.1; m/z found, 412.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.79 – 8.61 (s, 2H), 8.16 – 8.10 (s, 1H), 7.74 – 7.68 (d, J = 2.2 Hz, 1H), 7.66 – 7.54 (m, 2H), 6.80 – 6.46 (t, J = 72.5 Hz, 2H), 5.71 – 5.61 (s, 2H), 1.65 – 1.59 (s, 6H).

Example 386: 2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-isopropoxypyrimidine.




The title compound was prepared in a manner analogous to Example 155 using 2-chloro-4-isopropoxypyrimidine and (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1). MS (ESI): mass calcd. for $C_{17}H_{16}ClF_2N_5O_3$, 411.1; m/z found, 412.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 9.00 (s, 1H), 8.31 (d, J = 5.7 Hz, 1H), 8.01 – 7.97 (m, 1H), 7.90 – 7.83 (m, 2H), 7.44 (t, J = 72.8 Hz, 1H), 6.53 (d, J = 5.7 Hz, 1H), 5.51 (s, 2H), 5.33 – 5.25 (m, 1H), 1.29 (d, J = 6.2 Hz, 6H).

Example 387: Methyl 2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine-4-carboxylate.




The title compound was prepared in a manner analogous to Example 155 using methyl 2-chloropyrimidine-4-carboxylate and (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1). MS (ESI): mass calcd. for $C_{16}H_{12}ClF_2N_5O_4$, 411.1; m/z found, 412.1 $[M+H]^+$.

Example 388: 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-N-(2,2-difluoroethyl)-5-fluoro-pyrimidin-4-amine·as the trifluoroacetic acid salt.



The title compound was prepared in a manner analogous to Example 163, Steps B-C using tert-butyl (2-chloro-5-fluoropyrimidin-4-yl)(2,2-difluoroethyl)carbamate (Intermediate 57) and (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1). MS (ESI): mass calcd. for $C_{16}H_{12}ClF_5N_6O_2$, 450.1; m/z found, 451.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.97 (s, 1H), 8.19 – 8.12 (m, 1H), 8.07 (d, J = 3.3 Hz, 1H), 8.00 – 7.97 (m, 1H), 7.90 – 7.82 (m, 2H), 7.44 (t, J = 72.8 Hz, 1H), 6.33 – 5.99 (m, 1H), 5.42 (s, 2H).

Example 389: 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine· as the trifluoroacetic acid salt.




The title compound was prepared in a manner analogous to Example 163, Steps B-C, using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-

02 Mar 2021
2017217542

yl)methanol (Intermediate 1) and 2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (Intermediate 59) in Step A. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_3N_6O_2$, 400.1; m/z found, 401.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.98 (s, 1H), 8.01 – 7.84 (m, 5H), 7.46 (t, J = 72.8 Hz, 1H), 5.43 (s, 2H), 2.87 (d, J = 4.6 Hz, 3H).


Example 390: 2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine.



Step A. 4-Chloro-2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidine. The title compound was prepared in a manner analogous to Example 167 using 4-chloro-5-fluoro-2-(methylsulfonyl)pyrimidine and (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) in Step B. MS (ESI): mass calcd. for $C_{14}H_8Cl_2F_3N_5O_2$, 405.0; m/z found, 406.0 $[M+H]^+$.

Step B. 2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine. The title compound was prepared in a manner analogous to Example 167, Step C. MS (ESI): mass calcd. for $C_{14}H_{10}ClF_3N_6O_2$, 386.1; m/z found, 387.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.96 (s, 1H), 8.00 – 7.96 (m, 2H), 7.89 – 7.83 (m, 2H), 7.44 (t, J = 72.8 Hz, 1H), 7.34 (s, 2H), 5.36 (s, 2H).

Example 391: 5-(Azetidin-1-yl)-2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.




The title compound was prepared in a manner analogous to Example 165, Steps A-C using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-

02 Mar 2021 2017217542


yl)methanol (Intermediate 1) in Step C. MS (ESI): mass calcd. for $C_{17}H_{15}ClF_2N_6O_2$, 408.1; m/z found, 409.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.98 – 8.96 (m, 1H), 8.00 – 7.97 (m, 1H), 7.92 (s, 2H), 7.89 – 7.83 (m, 2H), 7.45 (t, J = 72.8 Hz, 1H), 5.45 – 5.41 (m, 2H), 3.84 (t, J = 7.2 Hz, 4H), 2.39 – 2.29 (m, 2H).

Example 392: 2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine.



The title compound was prepared in a manner analogous to Example 165, Steps A-C using 3-fluoroazetidine in Step A and (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) in Step C. MS (ESI): mass calcd. for $C_{17}H_{14}ClF_3N_6O_2$, 426.1; m/z found, 427.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.97 (s, 1H), 8.03 – 7.96 (m, 3H), 7.90 – 7.82 (m, 2H), 7.44 (t, J = 72.8 Hz, 1H), 5.60 – 5.38 (m, 3H), 4.25 – 4.14 (m, 2H), 4.00 – 3.88 (m, 2H).

Example 393: 2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3,3-difluoroazetidin-1-yl)pyrimidine.




The title compound was prepared in a manner analogous to Example 165, Steps A-C using 3,3-difluoroazetidine in Step A and (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 1) in Step C. MS (ESI): mass calcd. for $C_{17}H_{13}ClF_4N_6O_2$, 444.1; m/z found, 445.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.98 (s, 1H), 8.09 (s, 2H), 8.00 –

2017217542 02 Mar 2021


7.97 (m, 1H), 7.90 – 7.83 (m, 2H), 7.44 (t, *J* = 72.8 Hz, 1H), 5.46 (s, 2H), 4.34 (t, *J* = 12.3 Hz, 4H).

Example 394: 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-6-fluoro-pyridine.



The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2,6-difluoropyridine. MS (ESI): mass calcd. for $C_{15}H_{10}ClF_3N_4O_2$, 370.0; m/z found, 371.0 $[M+H]^+$. ^1H NMR (500 MHz, CD_3CN) δ 8.42 (s, 1H), 7.84 (q, *J* = 8.1 Hz, 1H), 7.80 – 7.76 (m, 1H), 7.76 – 7.67 (m, 2H), 6.93 (t, *J* = 73.0 Hz, 1H), 6.70 (ddd, *J* = 53.8, 7.9, 2.0 Hz, 2H), 5.50 (s, 2H).


Example 395: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-(trifluoromethyl)pyridine.



The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-fluoro-6-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for $C_{16}H_{10}F_6N_4O_2$, 404.1; m/z found, 404.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.92 (s, 1H), 8.04 – 8.00 (m, 1H), 7.98 (dd, *J* = 6.9, 2.6 Hz, 1H), 7.85 (ddd, *J* = 9.0, 3.9, 2.6 Hz, 1H), 7.69 (dd, *J* = 10.2, 9.0 Hz, 1H), 7.56 – 7.24 (m, 2H), 7.23 – 7.20 (m, 1H), 5.53 (s, 2H).


02 Mar 2021 2017217542

Example 396: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrazine.



The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and using 2-chloro-5-methylpyrazine. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O_2$, 351.1; m/z found, 351.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.95 (s, 1H), 8.25 (d, J = 1.4 Hz, 1H), 8.14 – 8.12 (m, 1H), 7.99 (dd, J = 6.9, 2.6 Hz, 1H), 7.87 (ddd, J = 9.0, 3.9, 2.6 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 5.50 (s, 2H), 2.42 (s, 3H).


Example 397: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(2-thienyl)pyrazine.



The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and using 2-chloro-5-(thiophen-2-yl)pyrazine. MS (ESI): mass calcd. for $C_{18}H_{12}F_3N_5O_2S$, 419.1; m/z found, 419.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.97 (s, 1H), 8.83 (d, J = 1.4 Hz, 1H), 8.34 (d, J = 1.4 Hz, 1H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.87 (ddd, J = 9.0, 3.9, 2.6 Hz, 1H), 7.79 (dd, J = 3.6, 1.1 Hz, 1H), 7.69 (dd, J = 10.2, 9.0 Hz, 1H), 7.65 (dd, J = 5.1, 1.1 Hz, 1H), 7.39 (t, J = 72.7 Hz, 1H), 7.19 (dd, J = 5.1, 3.6 Hz, 1H), 5.58 (s, 2H).


Example 398: 5-Bromo-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.

2017217542 02 Mar 2021




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 5-bromo-2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_9BrF_3N_5O$, 399.0; m/z found, 399.9 $[M+H]^+$. ^1H NMR (300 MHz, DMSO-d_6 δ 9.00 (s, 1H), 8.82 (s, 2H), 8.18 (dd, J = 12.7, 4.6 Hz, 2H), 7.66 (t, J = 9.3 Hz, 1H), 7.31 (t, J = 53.9 Hz, 1H), 5.54 (s, 2H).

Example 399: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_2$, 365.1; m/z found, 366.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.55 (d, J = 5.0 Hz, 1H), 8.17 (s, 1H), 7.98 – 7.85 (m, 2H), 7.33 (s, 1H), 7.16 (d, J = 5.1 Hz, 1H), 7.10 – 6.79 (m, 1H), 5.66 (d, J = 0.7 Hz, 2H), 4.50 (d, J = 0.8 Hz, 2H), 3.50 (s, 3H).


Example 400: [2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 159, Steps A-B using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 4-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine (Intermediate 54) in Step A.. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O_2$, 351.1; m/z found, 352.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.56 – 8.45 (d, *J* = 5.0 Hz, 1H), 8.20 – 8.11 (s, 1H), 7.99 – 7.93 (dd, *J* = 5.8, 2.7 Hz, 1H), 7.93 – 7.87 (ddd, *J* = 8.1, 4.2, 2.9 Hz, 1H), 7.37 – 7.29 (tt, *J* = 9.0, 1.1 Hz, 1H), 7.10 – 6.79 (m, 2H), 5.74 – 5.63 (m, 2H), 4.81 – 4.66 (m, 2H).

Example 401: 2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O_2$, 379.1; m/z found, 380.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.68 (s, 2H), 8.17 – 8.13 (m, 1H), 7.98 – 7.88 (m, 2H), 7.37 – 7.29 (m, 1H), 6.95 (t, *J* = 54.6 Hz, 1H), 5.67 (d, *J* = 0.7 Hz, 2H), 1.63 (s, 6H).


Example 402: 4-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-4-(difluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}F_5N_5O$, 371.1; m/z found, 372.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.79 – 8.74 (m, 1H), 8.20 – 8.15 (m, 1H), 7.97 – 7.93 (m, 1H), 7.93 – 7.87 (m, 1H), 7.38 – 7.28 (m, 2H), 7.09 – 6.83 (m, 1H), 6.63 – 6.37 (m, 1H), 5.75 – 5.68 (m, 2H).

Example 403: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-4-trifluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_9F_6N_5O$, 389.1; m/z found, 390.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.83 (d, J = 4.8 Hz, 1H), 8.19 (t, J = 0.6 Hz, 1H), 7.98 – 7.85 (m, 2H), 7.39 – 7.30 (m, 2H), 6.95 (t, J = 54.6 Hz, 1H), 5.72 (d, J = 0.6 Hz, 2H).

Example 404: (R/S)-2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol

2017217542 02 Mar 2021


(Intermediate 9) and 2-(2-chloropyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{17}H_{13}F_6N_5O_2$, 433.1; m/z found, 434.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.78 – 8.71 (s, 2H), 8.16 – 8.12 (t, *J* = 0.7 Hz, 1H), 7.98 – 7.93 (d, *J* = 5.4 Hz, 1H), 7.93 – 7.87 (m, 1H), 7.38 – 7.29 (t, *J* = 9.0 Hz, 1H), 7.08 – 6.79 (t, *J* = 54.6 Hz, 1H), 5.73 – 5.67 (d, *J* = 0.7 Hz, 2H), 2.59 – 2.51 (s, 1H), 1.87 – 1.80 (m, 3H).

Example 405: 5-(Difluoromethoxy)-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}F_5N_5O_2$, 387.1; m/z found, 388.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.45 (t, *J* = 0.8 Hz, 2H), 8.14 (t, *J* = 0.7 Hz, 1H), 8.01 – 7.86 (m, 2H), 7.33 (t, *J* = 9.0 Hz, 1H), 6.95 (t, *J* = 54.6 Hz, 1H), 6.53 (t, *J* = 71.9 Hz, 1H), 5.66 (d, *J* = 0.7 Hz, 2H).

Example 406: 5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}ClF_3N_5O$, 369.1; m/z found, 370.0 $[M+H]^+$. ^1H NMR (500 MHz,

2017217542 02 Mar 2021


$CDCl_3$) δ 8.39 (s, 2H), 8.12 (s, 1H), 7.99 – 7.86 (m, 2H), 7.39 – 7.29 (m, 1H), 6.95 (t, *J* = 54.6 Hz, 1H), 5.64 (d, *J* = 0.7 Hz, 2H), 2.57 (s, 3H).

Example 407: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O$, 353.1; m/z found, 354.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.26 (d, *J* = 1.2 Hz, 1H), 8.12 (t, *J* = 0.7 Hz, 1H), 7.97 – 7.87 (m, 2H), 7.33 (t, *J* = 9.0 Hz, 1H), 6.95 (t, *J* = 54.6 Hz, 1H), 5.62 (d, *J* = 0.7 Hz, 2H), 2.50 (d, *J* = 2.5 Hz, 3H).

Example 408: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O$, 349.1; m/z found, 350.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.21 (d, *J* = 0.9 Hz, 1H), 8.13 (t, *J* = 0.8 Hz, 1H), 7.98 – 7.85 (m, 2H), 7.32 (s, 1H), 6.95 (t, *J* = 54.6 Hz, 1H), 5.66 – 5.59 (m, 2H), 2.45 (s, 3H), 2.20 (s, 3H).

Example 409: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-5-carboxamide.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-N-methylpyrimidine-5-carboxamide, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{13}F_3N_6O_2$, 378.1; m/z found, 379.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 9.05 – 8.95 (m, 2H), 8.42 – 8.34 (d, *J* = 0.9 Hz, 1H), 8.05 – 8.00 (m, 1H), 8.00 – 7.91 (m, 1H), 7.40 – 7.35 (m, 1H), 7.12 – 6.85 (t, *J* = 54.5 Hz, 1H), 5.76 – 5.66 (s, 2H), 3.03 – 2.87 (m, 3H).

Example 410: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidine-4-carboxamide.




The title compound was prepared in a manner analogous to Example 162, Steps A-B, using dimethylamine in Step B. MS (ESI): mass calcd. for $C_{17}H_{15}F_3N_6O_2$, 392.1; m/z found, 393.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.69 (d, *J* = 4.9 Hz, 1H), 8.21 (s, 1H), 7.98 (dd, *J* = 5.9, 2.6 Hz, 1H), 7.94 – 7.86 (m, 1H), 7.37 – 7.29 (m, 1H), 7.22 (d, *J* = 4.9 Hz, 1H), 6.95 (t, *J* = 54.6 Hz, 1H), 5.72 – 5.62 (m, 2H), 3.14 (s, 3H), 3.09 (s, 3H).

Example 411: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methoxy-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-4-methoxy-5-methylpyrimidine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_2$, 365.1; m/z found, 366.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.14 – 8.10 (s, 1H), 8.05 – 8.00 (d, J = 1.2 Hz, 1H), 7.97 – 7.92 (dd, J = 5.8, 2.6 Hz, 1H), 7.92 – 7.86 (m, 1H), 7.36 – 7.29 (m, 1H), 7.08 – 6.82 (t, J = 54.6 Hz, 1H), 5.64 – 5.60 (d, J = 0.6 Hz, 2H), 4.07 – 3.90 (s, 3H), 2.12 – 2.02 (m, 3H).

Example 412: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloropyrimidin-4-amine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{14}H_{11}F_3N_6O$, 336.1; m/z found, 337.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.17 – 8.09 (s, 1H), 8.09 – 8.01 (m, 1H), 7.99 – 7.84 (m, 2H), 7.38 – 7.28 (m, 1H), 7.10 – 6.76 (t, J = 54.6 Hz, 1H), 6.19 – 6.09 (m, 1H), 5.63 – 5.54 (m, 2H), 5.08 – 4.89 (s, 2H).

Example 413: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 163, Steps B-C using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate (Intermediate 55) and (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9). MS (ESI): mass calcd. for $C_{15}H_{13}F_3N_6O$, 350.1; m/z found, 351.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.14 – 8.10 (s, 1H), 8.07 – 7.98 (d, J = 7.4 Hz, 1H), 7.98 – 7.92 (m, 1H), 7.93 – 7.85 (m, 1H), 7.36 – 7.28 (m, 1H), 7.07 – 6.81 (t, J = 54.6 Hz, 1H), 6.08 – 6.02 (d, J = 5.9 Hz, 1H), 5.64 – 5.55 (s, 2H), 5.14 – 4.91 (m, 1H), 3.04 – 2.86 (d, J = 4.8 Hz, 3H).


Example 414: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine.



The title compound was prepared in a manner analogous to 163, Steps B-C using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (Intermediate 59) in Step A. MS (ESI): mass calcd. for $C_{15}H_{12}F_4N_6O$, 368.1; m/z found, 369.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.16 – 8.09 (d, J = 0.8 Hz, 1H), 7.98 – 7.92 (m, 1H), 7.92 – 7.86 (m, 1H), 7.85 – 7.78 (m, 1H), 7.37 – 7.28 (m, 1H), 7.11 – 6.77 (t, J = 54.6 Hz, 1H), 5.64 – 5.50 (m, 2H), 5.26 – 5.01 (s, 1H), 3.14 – 2.98 (m, 3H).


Example 415: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine.

2017217542 02 Mar 2021




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{16}H_{15}F_3N_6O$, 364.1; m/z found, 365.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.14 – 8.09 (t, *J* = 0.8 Hz, 1H), 8.06 – 8.01 (d, *J* = 6.1 Hz, 1H), 7.97 – 7.92 (m, 1H), 7.92 – 7.86 (m, 1H), 7.35 – 7.28 (m, 1H), 7.08 – 6.81 (t, *J* = 54.6 Hz, 1H), 6.16 – 6.08 (d, *J* = 6.1 Hz, 1H), 5.64 – 5.58 (d, *J* = 0.8 Hz, 2H), 3.21 – 3.04 (s, 6H).

Example 416: 2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine.




The title compound was made in an analogous manner to Example 187 using 5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 398) and 3-fluoroazetidine hydrochloride. MS (ESI): mass calcd. for $C_{17}H_{14}F_4N_6O$, 394.3; m/z found, 395.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.18 – 8.15 (s, 1H), 8.00 – 7.97 (m, 1H), 7.97 – 7.92 (m, 1H), 7.92 – 7.89 (s, 2H), 7.40 – 7.33 (m, 1H), 7.14 – 6.84 (m, 1H), 5.67 – 5.61 (s, 2H), 5.60 – 5.39 (m, 1H), 4.34 – 4.22 (m, 2H), 4.11 – 3.98 (m, 2H).

Example 417: 5-(Azetidin-1-yl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.



The title compound was made in an analogous manner to Example 187 using 5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 398) and azetidine. MS (ESI): mass calcd. for $C_{17}H_{15}F_3N_6O$, 376.3; m/z found, 377.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.18 – 8.12 (s, 1H), 8.01 – 7.97 (m, 1H), 7.96 – 7.91 (m, 1H), 7.88 – 7.83 (s, 2H), 7.40 – 7.32 (m, 1H), 7.14 – 6.83 (t, *J* = 54.6 Hz, 1H), 5.66 – 5.58 (s, 2H), 4.02 – 3.87 (m, 4H), 2.55 – 2.43 (m, 2H).


Example 418: 2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1-yl)pyrimidine.



The title compound was made in an analogous manner to Example 187 using 5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 398) and 3-methoxyazetidine hydrochloride. MS (ESI): mass calcd. for $C_{18}H_{17}F_3N_6O_2$, 406.3; m/z found, 407.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.12 – 8.09 (s, 1H), 7.97 – 7.92 (m, 1H), 7.92 – 7.87 (m, 1H), 7.86 – 7.81 (s, 2H), 7.35 – 7.29 (m, 1H), 7.07 – 6.81 (m, 1H), 5.62 – 5.56 (d, *J* = 0.7 Hz, 2H), 4.43 – 4.36 (m, 1H), 4.19 – 4.11 (m, 2H), 3.79 – 3.68 (m, 2H), 3.37 – 3.31 (s, 3H).


Example 419: 5-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.

02 Mar 2021 2017217542




The title compound was made in an analogous manner to Example 187 using 5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 398) and 3,3-difluoroazetidine hydrochloride. MS (ESI): mass calcd. for $C_{17}H_{13}F_5N_6O$, 412.3; m/z found, 413.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.13 – 8.11 (s, 1H), 7.96 – 7.93 (m, 1H), 7.93 – 7.88 (s, 3H), 7.36 – 7.30 (m, 1H), 7.07 – 6.82 (m, 1H), 5.62 – 5.57 (d, *J* = 0.8 Hz, 2H), 4.33 – 4.22 (m, 4H).

Example 420: 2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoro-3-methylazetidin-1-yl)pyrimidine.




The title compound was made in an analogous manner to Example 187 using 5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 398) and 3-fluoro-3-methylazetidine hydrochloride. MS (ESI): mass calcd. for $C_{18}H_{16}F_4N_6O$, 408.3; m/z found, 409.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.13 – 8.10 (t, *J* = 0.7 Hz, 1H), 7.96 – 7.92 (m, 1H), 7.92 – 7.88 (m, 1H), 7.88 – 7.85 (s, 2H), 7.35 – 7.29 (m, 1H), 7.06 – 6.83 (t, *J* = 54.6 Hz, 1H), 5.62 – 5.56 (d, *J* = 0.7 Hz, 2H), 4.06 – 3.98 (m, 2H), 3.98 – 3.89 (m, 2H), 1.76 – 1.67 (d, *J* = 21.8 Hz, 3H).

Example 421: 2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-(difluoromethyl)azetidin-1-yl)pyrimidine.




The title compound was made in an analogous manner to Example 187 using 5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 398) and 3-(difluoromethyl)azetidine hydrochloride. MS (ESI): mass calcd. for $C_{18}H_{15}F_5N_6O$, 426.3; m/z found, 427.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.13 – 8.09 (m, 1H), 7.96 – 7.93 (dd, *J* = 5.8, 2.8 Hz, 1H), 7.92 – 7.87 (m, 1H), 7.87 – 7.83 (s, 2H), 7.35 – 7.29 (m, 1H), 7.07 – 6.83 (t, *J* = 54.6 Hz, 1H), 6.20 – 5.94 (m, 1H), 5.61 – 5.56 (d, *J* = 0.8 Hz, 2H), 4.07 – 4.00 (m, 2H), 3.94 – 3.89 (dd, *J* = 7.6, 5.3 Hz, 2H), 3.26 – 3.14 (m, 1H).

Example 422: 2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3,3-difluoropyrrolidin-1-yl)pyrimidine.




The title compound was made in an analogous manner to Example 187 using 5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 398) and 3,3-difluoropyrrolidine hydrochloride. MS (ESI): mass calcd. for $C_{18}H_{15}F_5N_6O$, 426.3; m/z found, 427.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.15 – 8.11 (d, *J* = 0.8 Hz, 1H), 7.99 – 7.95 (m, 3H), 7.94 – 7.89 (m, 1H), 7.37 – 7.31 (m, 1H), 7.09 – 6.84 (m, 1H), 5.63 – 5.60 (s, 2H), 3.72 – 3.63 (m, 2H), 3.58 – 3.52 (m, 2H), 2.60 – 2.50 (m, 2H).

Example 423: 5-Cyclopropyl-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{14}F_3N_5O$, 361.1; m/z found, 362.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.32 (d, J = 0.6 Hz, 2H), 8.12 (t, J = 0.7 Hz, 1H), 7.96 – 7.87 (m, 2H), 7.32 (t, J = 9.0 Hz, 1H), 6.95 (t, J = 54.6 Hz, 1H), 5.63 (d, J = 0.7 Hz, 2H), 1.88 – 1.78 (m, 1H), 1.07 – 0.99 (m, 2H), 0.75 – 0.64 (m, 2H).


Example 424: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(2-furyl)pyrimidine.



The title compound was prepared in a manner analogous to Example 153 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-4-(furan-2-yl)pyrimidine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{18}H_{12}F_3N_5O_2$, 387.1; m/z found, 388.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.62 – 8.52 (d, J = 5.1 Hz, 1H), 8.25 – 8.15 (s, 1H), 7.98 – 7.93 (m, 1H), 7.92 – 7.87 (m, 1H), 7.66 – 7.58 (m, 1H), 7.39 – 7.28 (m, 3H), 7.08 – 6.80 (t, J = 54.6 Hz, 1H), 6.64 – 6.56 (m, 1H), 5.76 – 5.67 (s, 2H).


02 Mar 2021 2017217542

Example 425: 2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]-5-iodo-triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethyl)-4-fluorophenyl)-5-iodo-1H-1,2,3-triazol-4-yl)methanol (Intermediate 27) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_3IN_5O$, 461.0; m/z found, 461.8 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.51 – 8.49 (m, 2H), 7.99 – 7.91 (m, 2H), 7.75 – 7.67 (m, 1H), 7.33 (t, J = 53.9 Hz, 1H), 5.44 (s, 2H), 2.22 (s, 3H).

Example 426: [3H]-2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl-5-t)methoxy)-5-methylpyrimidine.




A solution of 2-((1-(3-(difluoromethyl)-4-fluorophenyl)-5-iodo-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine (Example 425, 5 mg, 0.01 mmol), Pd/C 10% (9 mg, 0.008 mmol), DMF (1 ml), DIPEA (0.018 mL, 0.1 mmol), and tritium gas (760 mm Hg) was stirred for 30 minutes. The resulting product was dissolved in ethanol and filtered. The labile tritium was removed by rotovap three times. Purification (HPLC-C-18 column using gradient A: 0.1 % TFA, B: 100 % CH_3CN, A to 100 % B in 60 min., U.V. 250 nm, flow 6 ml/min) afforded the title compound.

Example 427: 3-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine.




The title compound was prepared analogous to Example 158 using 2-chloro-3-fluoropyridine. MS (ESI): mass calcd. for $C_{15}H_9F_5N_4O$, 356.1; m/z found, 357.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.11 (s, 1H), 8.04 – 7.92 (m, 3H), 7.44 – 7.33 (m, 2H), 6.95 – 6.88 (m, 1H), 5.69 (d, J = 0.7 Hz, 2H).

Example 428: 5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine.



The title compound was prepared analogous to Example 158 using 2, 5-dichloropyridine. MS (ESI): mass calcd. for $C_{15}H_9ClF_4N_4O$, 372.0; m/z found, 373.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.16 – 8.12 (m, 1H), 8.10 – 8.04 (m, 1H), 8.03 – 7.91 (m, 2H), 7.60 – 7.53 (m, 1H), 7.40 (t, J = 9.1 Hz, 1H), 6.81 – 6.72 (m, 1H), 5.57 (d, J = 0.6 Hz, 2H).

Example 429: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine.




The title compound was prepared analogous to Example 158 using 2-chloro-4-methylpyridine. MS (ESI): mass calcd. for $C_{16}H_{12}F_4N_4O$, 352.1; m/z found, 353.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.08 – 8.03 (m, 2H), 8.00 – 7.97

2017217542 02 Mar 2021


(m, 1H), 7.97 – 7.92 (m, 1H), 7.39 (t, *J* = 9.1 Hz, 1H), 6.75 (d, *J* = 5.2 Hz, 1H), 6.62 (d, *J* = 1.4 Hz, 1H), 5.59 (d, *J* = 0.7 Hz, 2H), 2.31 (s, 3H).

Example 430: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine.




The title compound was prepared analogous to Example 158 using 2-chloro-6-methylpyridine. MS (ESI): mass calcd. for $C_{16}H_{12}F_4N_4O$, 352.1; m/z found, 353.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.07 (t, *J* = 0.7 Hz, 1H), 8.02 – 7.98 (m, 1H), 7.97 – 7.92 (m, 1H), 7.52 – 7.46 (m, 1H), 7.39 (t, *J* = 9.1 Hz, 1H), 6.88 – 6.70 (m, 1H), 6.68 – 6.54 (m, 1H), 5.60 (d, *J* = 0.7 Hz, 2H), 2.48 (t, *J* = 0.7 Hz, 3H).

Example 431: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine.




The title compound was prepared analogous to Example 158 using 2-chloro-5-methylpyridine. MS (ESI): mass calcd. for $C_{16}H_{12}F_4N_4O$, 352.1; m/z found, 353.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.09 – 8.05 (m, 1H), 8.03 – 7.97 (m, 2H), 7.98 – 7.93 (m, 1H), 7.45 – 7.36 (m, 2H), 6.72 (d, *J* = 8.4 Hz, 1H), 5.69 – 5.48 (m, 2H), 2.26 (s, 3H).

Example 432: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine.




The title compound was prepared analogous to Example 158 using 2-chloro-5-trifluoromethylpyridine. MS (ESI): mass calcd. for $C_{16}H_9F_7N_4O$, 406.1; m/z found, 407.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.50 (d, J = 1.3 Hz, 1H), 8.09 (t, J = 0.6 Hz, 1H), 8.03 – 7.98 (m, 1H), 7.98 – 7.93 (m, 1H), 7.85 – 7.78 (m, 1H), 7.40 (t, J = 9.1 Hz, 1H), 6.91 – 6.88 (m, 1H), 5.66 (d, J = 0.6 Hz, 2H).

Example 433: 2-[6-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-3-pyridyl]propan-2-ol.



The title compound was prepared analogous to Example 158 using 2-(6-chloropyridin-3-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{18}H_{16}F_4N_4O_2$, 396.1; m/z found, 397.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.34 – 8.27 (m, 1H), 8.10 (s, 1H), 8.03 – 7.98 (m, 1H), 7.98 – 7.93 (m, 1H), 7.80 – 7.72 (m, 1H), 7.39 (t, J = 9.1 Hz, 1H), 6.78 (dd, J = 8.6, 0.8 Hz, 1H), 5.59 (s, 2H), 1.60 (s, 6H).


Example 434: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrazine.



02 Mar 2021 2017217542


The title compound was prepared analogous to Example 155, using (1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloropyrazine. MS (ESI): mass calcd. for $C_{14}H_9F_4N_5O$, 339.1; m/z found, 340.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.38 – 8.27 (m, 1H), 8.30 – 8.07 (m, 2H), 8.07 – 7.93 (m, 2H), 7.41 (t, J = 9.6 Hz, 1H), 7.26 (s, 1H), 5.62 (s, 2H).

Example 435: 2-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.



The title compound was prepared analogous to Example 155, using (1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{17}H_{15}F_4N_5O_2$, 397.1; m/z found, 398.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.68 (s, 2H), 8.15 (s, 1H), 7.99 (d, J = 20.7 Hz, 2H), 7.50 – 7.28 (m, 1H), 5.82 – 5.58 (m, 2H), 1.78 – 1.44 (m, 6H).


Example 436: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine.



The title compound was prepared in a manner analogous to Example 311 using 2-(2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol (Example 435). MS (ESI): mass calcd. for $C_{18}H_{17}F_4N_5O_2$, 411.1; m/z found, 412.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$)


δ 8.64 – 8.53 (s, 2H), 8.20 – 8.13 (t, *J* = 0.7 Hz, 1H), 8.03 – 7.99 (m, 1H), 7.98 – 7.94 (m, 1H), 7.46 – 7.36 (t, *J* = 9.1 Hz, 1H), 5.72 – 5.63 (d, *J* = 0.7 Hz, 2H), 3.16 – 3.08 (s, 3H), 1.59 – 1.51 (s, 6H).

Example 437: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(methoxymethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 153 using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-5-(methoxymethyl)pyrimidine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{13}F_4N_5O_2$, 383.1; m/z found, 384.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.60 – 8.48 (s, 2H), 8.21 – 8.10 (m, 1H), 8.02 – 7.98 (m, 1H), 7.98 – 7.92 (m, 1H), 7.46 – 7.35 (t, *J* = 9.1 Hz, 1H), 5.74 – 5.61 (d, *J* = 0.8 Hz, 2H), 4.50 – 4.33 (s, 2H), 3.49 – 3.36 (s, 3H).

Example 438: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{13}F_4N_5O_2$, 383.1; m/z found, 384.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.55 (d, *J* = 5.0 Hz, 1H), 8.17 (t, *J* = 0.8 Hz, 1H), 8.03 – 7.98 (m, 1H), 7.98 – 7.92 (m, 1H), 7.40 (t, *J* = 9.2 Hz, 1H), 7.16 (dt, *J* = 5.0, 0.7 Hz, 1H), 5.66 (d, *J* = 0.7 Hz, 2H), 4.50 (d, *J* = 0.7 Hz, 2H), 3.50 (s, 3H).

Example 439: 5-(Difluoromethyl)-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 5). MS (ESI): mass calcd. for $C_{15}H_9F_6N_5O$, 389.1; m/z found, 390.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.72 (t, J = 1.3 Hz, 2H), 8.15 (t, J = 0.7 Hz, 1H), 8.04 – 7.98 (m, 1H), 7.99 – 7.92 (m, 1H), 7.41 (t, J = 9.1 Hz, 1H), 6.73 (t, J = 55.6 Hz, 1H), 5.72 (d, J = 0.7 Hz, 2H).

Example 440: 4-(Difluoromethyl)-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-4-(difluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{15}H_9F_6N_5O$, 389.1; m/z found, 390.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.77 (d, J = 5.0 Hz, 1H), 8.18 (s, 1H), 8.05 – 7.98 (m, 1H), 7.98 – 7.92 (m, 1H), 7.41 (t, J = 9.0 Hz, 1H), 7.31 (d, J = 5.0 Hz, 1H), 6.51 (t, J = 54.7 Hz, 1H), 5.71 (d, J = 0.9 Hz, 2H).

Example 441: (R/S)-1,1,1-Trifluoro-2-[2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.



The title compound was prepared in a manner analogous to Example 153 using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-(2-chloropyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{17}H_{12}F_7N_5O_2$, 451.1; m/z found, 452.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.78 – 8.73 (s, 2H), 8.18 – 8.11 (s, 1H), 8.05 – 7.98 (m, 1H), 7.98 – 7.92 (d, *J* = 9.0 Hz, 1H), 7.45 – 7.37 (t, *J* = 9.1 Hz, 1H), 5.73 – 5.66 (d, *J* = 0.7 Hz, 2H), 2.68 – 2.60 (d, *J* = 17.8 Hz, 1H), 1.85 – 1.81 (d, *J* = 1.1 Hz, 3H).


Example 442: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-4-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O_2$, 369.1; m/z found, 370.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.23 (d, *J* = 5.7 Hz, 1H), 8.14 (s, 1H), 8.08 – 7.87 (m, 2H), 7.40 (t, *J* = 9.1 Hz, 1H), 6.44 (d, *J* = 5.9 Hz, 1H), 5.66 (s, 2H), 3.99 (s, 3H).


Example 443: 5-Ethoxy-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.

2017217542 02 Mar 2021




The title compound was prepared analogous to Example 155, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-5-ethoxypyrimidine. MS (ESI): mass calcd. for $C_{16}H_{13}F_4N_5O_2$, 383.1; m/z found, 384.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.23 (s, 2H), 8.12 (s, 1H), 8.06 – 7.91 (m, 2H), 7.40 (t, *J* = 9.2 Hz, 1H), 5.61 (d, *J* = 0.7 Hz, 2H), 4.09 (q, *J* = 7.0 Hz, 2H), 1.44 (t, *J* = 6.9 Hz, 3H).

Example 444: 5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2,5 dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}ClF_4N_5O$, 387.1; m/z found, 388.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.39 (s, 1H), 8.13 (s, 1H), 8.11 – 7.90 (m, 2H), 7.41 (t, *J* = 9.1 Hz, 1H), 5.64 (d, *J* = 3.5 Hz, 2H), 2.68 – 2.50 (m, 3H).

Example 445: 5-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}F_5N_5O$, 371.1; m/z found, 372.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.26 (d, *J* = 1.2 Hz, 1H), 8.12 (t, *J* = 0.7 Hz, 1H), 8.06 – 7.90 (m, 2H), 7.40 (t, *J* = 9.1 Hz, 1H), 5.62 (d, *J* = 0.7 Hz, 2H), 2.50 (d, *J* = 2.5 Hz, 3H).

Example 446: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{13}F_4N_5O$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.19 – 8.10 (m, 1H), 8.06 – 7.89 (m, 2H), 7.40 (t, *J* = 9.1 Hz, 1H), 6.74 (s, 1H), 5.65 (d, *J* = 0.8 Hz, 2H), 2.44 (d, *J* = 0.5 Hz, 6H).


Example 447: 1-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone.



02 Mar 2021 2017217542


The title compound was prepared analogous to Example 155, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI): mass calcd. for $C_{16}H_{11}F_4N_5O_2$, 381.1; m/z found, 382.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 9.19 – 9.07 (d, *J* = 1.8 Hz, 2H), 8.22 – 8.11 (s, 1H), 8.07 – 7.91 (m, 2H), 7.47 – 7.37 (t, *J* = 9.1 Hz, 1H), 5.82 – 5.71 (s, 2H), 2.73 – 2.52 (s, 3H).

Example 448: (R/S)-1-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol.



The title compound was prepared in a manner analogous to Example 157 using 1-(2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one (Example 447). MS (ESI): mass calcd. for $C_{16}H_{13}F_4N_5O_2$, 383.1; m/z found, 384.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.62 – 8.53 (s, 2H), 8.19 – 8.13 (s, 1H), 8.04 – 7.99 (m, 1H), 7.99 – 7.92 (m, 1H), 7.44 – 7.35 (t, *J* = 9.1 Hz, 1H), 5.69 – 5.59 (d, *J* = 0.8 Hz, 2H), 5.02 – 4.88 (m, 1H), 2.41 – 2.17 (s, 1H), 1.62 – 1.49 (d, *J* = 6.5 Hz, 3H).

Example 449: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 163, Steps B-C using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate (Intermediate 55) and (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 5). MS (ESI): mass calcd. for $C_{15}H_{12}F_4N_6O$,

2017217542 02 Mar 2021


368.1; m/z found, 369.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.23 – 8.09 (s, 1H), 8.09 – 7.99 (m, 2H), 7.98 – 7.89 (dt, *J* = 8.8, 3.4 Hz, 1H), 7.46 – 7.34 (t, *J* = 9.2 Hz, 1H), 6.17 – 5.99 (d, *J* = 6.0 Hz, 1H), 5.69 – 5.54 (s, 2H), 5.34 – 5.08 (s, 1H), 3.05 – 2.91 (d, *J* = 4.4 Hz, 3H).

Example 450: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine.



The title compound was prepared analogous to Example 155, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{16}H_{14}F_4N_6O$, 382.1; m/z found, 383.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.17 – 8.12 (s, 1H), 8.08 – 7.98 (t, *J* = 6.7 Hz, 2H), 7.98 – 7.90 (m, 1H), 7.44 – 7.33 (t, *J* = 9.1 Hz, 1H), 6.17 – 6.10 (d, *J* = 6.1 Hz, 1H), 5.64 – 5.58 (d, *J* = 0.8 Hz, 2H), 3.19 – 3.06 (s, 6H).

Example 451: 5-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 163, Steps B-C using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (Intermediate 59) in step A. MS (ESI): mass calcd. for $C_{15}H_{11}F_5N_6O$, 386.1; m/z found, 387.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.17 – 8.10 (s, 1H), 8.06 – 7.98 (m, 1H), 7.98 – 7.89

2017217542 02 Mar 2021


(m, 1H), 7.85 – 7.78 (d, *J* = 3.0 Hz, 1H), 7.46 – 7.34 (t, *J* = 9.0 Hz, 1H), 5.62 – 5.54 (d, *J* = 0.8 Hz, 2H), 5.20 – 5.04 (s, 1H), 3.20 – 2.96 (m, 3H).

Example 452: 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-5-carboxamide.



The title compound was prepared in a manner analogous to Example 153 using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-N-methylpyrimidine-5-carboxamide, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{12}F_4N_6O_2$, 396.1; m/z found, 397.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 9.00 – 8.98 (s, 2H), 8.44 – 8.38 (s, 1H), 8.12 – 8.07 (m, 1H), 8.07 – 8.00 (m, 1H), 7.49 – 7.41 (t, *J* = 9.2 Hz, 1H), 5.77 – 5.67 (s, 2H), 3.03 – 2.90 (s, 3H).


Example 453: 5-Cyclopropyl-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{13}F_4N_5O$, 379.1; m/z found, 380.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.32 (d, *J* = 0.6 Hz, 2H), 8.14 – 8.12 (m, 1H), 8.02 – 7.98 (m, 1H), 7.98 – 7.92 (m, 1H), 7.40 (t, *J* = 9.1 Hz, 1H), 5.64 (d, *J* = 0.7 Hz, 2H), 1.90 – 1.76 (m, 1H), 1.09 – 0.97 (m, 2H), 0.75 – 0.65 (m, 2H).


2017217542 02 Mar 2021

Example 454: 5-Bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.




The title compound was made analogous to Example 156, using (1-(4-fluoro-3-(trifluoromethyl)phenyl)-1*H*-1,2,3-triazol-4-yl)methanol (Intermediate 5) and 2,5-dibromopyrimidine. MS (ESI): mass calcd. for $C_{14}H_8BrF_4N_5O$, 418.3; m/z found, 419.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.67 – 8.61 (s, 2H), 8.20 – 8.15 (s, 1H), 8.07 – 8.02 (m, 1H), 8.02 – 7.96 (m, 1H), 7.48 – 7.40 (m, 1H), 5.72 – 5.65 (d, *J* = 0.6 Hz, 2H).

Example 455: 2-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine.




The title compound was made in an analogous manner to Example 187 using 5-bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 454) and 3-fluoroazetidine hydrochloride. MS (ESI): mass calcd. for $C_{17}H_{13}F_5N_6O$, 412.3; m/z found, 413.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.08 – 8.02 (s, 1H), 7.96 – 7.90 (m, 1H), 7.90 – 7.84 (m, 1H), 7.82 – 7.76 (s, 2H), 7.37 – 7.27 (m, 1H), 5.54 – 5.49 (m, 2H), 5.48 – 5.26 (m, 1H), 4.23 – 4.11 (m, 2H), 3.99 – 3.84 (m, 2H).

Example 456: 4-(2-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine.




The title compound was made in an analogous manner to Example 187 using 5-bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 454). MS (ESI): mass calcd. for $C_{18}H_{16}F_4N_6O_2$, 424.3; m/z found, 425.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.19 – 8.13 (s, 2H), 8.07 – 8.04 (s, 1H), 7.95 – 7.91 (m, 1H), 7.91 – 7.85 (m, 1H), 7.36 – 7.29 (m, 1H), 5.57 – 5.51 (s, 2H), 3.85 – 3.76 (m, 4H), 3.08 – 3.00 (m, 4H).

Example 457: 5-(Azetidin-1-yl)-2-((1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methylpyrimidine.




The title compound was made in an analogous manner to Example 187 using 5-chloro-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methylpyrimidine (Example 444) and azetidine. MS (ESI): mass calcd. for $C_{18}H_{16}F_4N_6O$, 408.3; m/z found, 409.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.18 – 8.15 (s, 1H), 8.06 – 8.02 (m, 1H), 8.01 – 7.96 (m, 1H), 7.76 – 7.72 (s, 1H), 7.47 – 7.40 (m, 1H), 5.66 – 5.59 (s, 2H), 3.96 – 3.88 (m, 4H), 2.44 – 2.42 (s, 3H), 2.42 – 2.36 (m, 2H).

Example 458: 2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethyl-4-methylpyrimidin-5-amine.




The title compound was made in an analogous manner to Example 187 using 5-chloro-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methylpyrimidine (Example 444) and ethylamine. MS (ESI): mass calcd. for $C_{17}H_{16}F_4N_6O$, 396.3; m/z found, 397.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.19 – 8.15 (s, 1H), 8.07 – 8.02 (dd, *J* = 5.8, 2.7 Hz, 1H), 8.01 – 7.95 (m, 1H), 7.86 – 7.84 (s, 1H), 7.47 – 7.39 (m, 1H), 5.65 – 5.59 (s, 2H), 3.26 – 3.17 (m, 2H), 3.16 – 3.08 (s, 1H), 2.42 – 2.38 (s, 3H), 1.39 – 1.33 (m, 3H).

Example 459: 2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethylpyrimidin-5-amine.




The title compound was made in an analogous manner to Example 187 using 5-bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 454) and ethylamine. MS (ESI): mass calcd. for $C_{16}H_{14}F_4N_6O$, 382.3; m/z found, 383.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.06 – 8.04 (s, 1H), 7.95 – 7.92 (m, 1H), 7.92 – 7.91 (s, 2H), 7.90 – 7.85 (m, 1H), 7.35 – 7.28 (m, 1H), 5.53 – 5.49 (s, 2H), 3.31 – 3.20 (s, 1H), 3.14 – 3.04 (m, 2H), 1.24 – 1.20 (m, 3H).

Example 460: 2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1-yl)pyrimidine.




The title compound was made in an analogous manner to Example 187 using 5-bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine (Example 454) and 3-methoxyazetidine hydrochloride. MS (ESI): mass calcd. for $C_{18}H_{16}F_4N_6O_2$, 424.3; m/z found, 425.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.14 – 8.10 (s, 1H), 8.02 – 7.98 (m, 1H), 7.98 – 7.92 (m, 1H), 7.86 – 7.82 (s, 2H), 7.43 – 7.36 (m, 1H), 5.63 – 5.53 (s, 2H), 4.42 – 4.34 (m, 1H), 4.18 – 4.11 (m, 2H), 3.77 – 3.70 (m, 2H), 3.38 – 3.29 (s, 3H).

Example 461: 5-Chloro-2-[[1-[2-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using 2,5-dichloropyrimidine and (1-(2-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 28). MS (ESI): mass calcd. for $C_{14}H_8ClF_4N_5O$, 373.0; m/z found, 373.9 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.82 (d, J = 2.1 Hz, 1H), 8.77 (s, 2H), 8.25 – 8.17 (m, 1H), 8.05 – 7.99 (m, 1H), 7.70 – 7.64 (m, 1H), 5.57 (s, 2H).


Example 462: 4-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-6-methyl-pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 155 using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 40) and 4-chloro-6-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}FN_5O$, 299.1; m/z found, 300.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.85 (s, 1H), 8.72 (d, J = 1.1 Hz, 1H), 7.90 – 7.86 (m, 1H), 7.78 – 7.72 (m, 1H), 7.38 (t, J = 9.1 Hz, 1H), 6.88 - 6.86 (m, 1H), 5.55 (s, 2H), 2.39 (s, 3H), 2.34 (d, J = 2.1 Hz, 3H).

Example 463: 5-Chloro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 49) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}ClFN_5O$, 319.1; m/z found, 320.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.77 (s, 2H), 8.65 (s, 1H), 7.52 - 7.41 (m, 2H), 7.38 - 7.33 (m, 1H), 5.54 (s, 2H), 2.25 - 1.93 (m, 3H).

Example 464: 2-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 49) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}FN_5O$, 299.1; m/z found, 300.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.63 (s, 1H),

2017217542 02 Mar 2021


8.49 (d, *J* = 0.8 Hz, 2H), 7.51 - 7.41 (m, 2H), 7.35 (dd, *J* = 6.8, 1.9 Hz, 1H), 5.49 (s, 2H), 2.21 (d, *J* = 0.8 Hz, 3H), 2.05 (d, *J* = 2.2 Hz, 3H).

Example 465: 5-Fluoro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 49) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O$, 317.1; m/z found, 318.1 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.41 - 8.35 (m, 2H), 7.42 (td, *J* = 8.2, 5.9 Hz, 1H), 7.32 (td, *J* = 8.9, 8.3, 1.3 Hz, 1H), 7.26 (dd, *J* = 7.9, 1.3 Hz, 1H), 5.58 (d, *J* = 1.8 Hz, 2H), 2.48 (d, *J* = 2.6 Hz, 3H), 2.09 (d, *J* = 2.2 Hz, 3H).


Example 466: 2-[2-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 49) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{17}H_{18}FN_5O_2$, 343.1; m/z found, 344.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.69 (s, 2H), 8.65 (d, *J* = 4.5 Hz, 1H), 7.53 - 7.42 (m, 2H), 7.36 (d, *J* = 7.4 Hz, 1H), 5.52 (s, 2H), 5.32 (s, 1H), 2.07 (s, 3H), 1.47 (d, *J* = 6.6 Hz, 6H).


Example 467: 2-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.

2017217542 02 Mar 2021




The title compound was prepared in a manner analogous to Example 1 using (1-(2-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 50) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}FN_5O$, 299.1; m/z found, 300.1[M+H]$^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.66 (d, J = 2.0 Hz, 1H), 8.49 (t, J = 0.7 Hz, 2H), 7.68 - 7.60 (m, 1H), 7.55 - 7.45 (m, 1H), 7.33 (t, J = 7.8 Hz, 1H), 5.50 (s, 2H), 2.36 (d, J = 2.3 Hz, 3H), 2.21 (t, J = 0.7 Hz, 3H).

Example 468: 5-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(2-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 50) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}ClFN_5O$, 319.1; m/z found, 320.1 [M+H]$^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.77 (s, 2H), 8.69 (d, J = 2.1 Hz, 1H), 7.63 (td, J = 7.6, 1.8 Hz, 1H), 7.57 - 7.46 (m, 1H), 7.33 (td, J = 7.8, 1.0 Hz, 1H), 5.55 (s, 2H), 2.36 (d, J = 2.2 Hz, 3H).


Example 469: 2-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(2-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 50) and 2-chloro-5-(trifluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O$, 353.1; m/z found, 354.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 9.12 (q, J = 0.8 Hz, 2H), 8.73 (d, J = 2.1 Hz, 1H), 7.68 - 7.60 (m, 1H), 7.51 (tdd, J = 7.0, 1.8, 0.9 Hz, 1H), 7.33 (td, J = 7.8, 1.0 Hz, 1H), 5.66 (s, 2H), 2.36 (d, J = 2.1 Hz, 3H).

Example 470: 5-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(2-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 50) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}ClFN_5O$, 333.1; m/z found, 334.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.68 (d, J = 2.1 Hz, 1H), 8.62 (d, J = 1.5 Hz, 1H), 7.63 (t, J = 7.5 Hz, 1H), 7.51 (t, J = 7.3 Hz, 1H), 7.33 (t, J = 7.8 Hz, 1H), 5.53 (d, J = 1.5 Hz, 2H), 2.50 (m , 3H), 2.36 (d, J = 2.1 Hz, 3H).


Example 471: 5-(Difluoromethoxy)-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(2-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 50) and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI): mass calcd. for


$C_{15}H_{12}F_3N_5O_2$, 351.1; m/z found, 352.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.70 (d, J = 2.1 Hz, 1H), 8.65 (s, 2H), 7.68 - 7.59 (m, 1H), 7.55 - 7.47 (m, 1H), 7.45 - 7.03 (m, 2H), 5.54 (s, 2H), 2.36 (d, J = 2.2 Hz, 3H).

Example 472: 2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 40) and 2-chloropyrimidin-4-amine. MS (ESI): mass calcd. for $C_{14}H_{13}FN_6O$, 300.1; m/z found, 301.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.82 (s, 1H), 7.89 (t, J = 6.4 Hz, 2H), 7.75 (dt, J = 7.6, 3.4 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 6.92 (s, 2H), 6.11 (d, J = 5.7 Hz, 1H), 5.35 (s, 2H), 2.33 (d, J = 2.0 Hz, 3H).

Example 473: 2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{12}FN_5O$, 285.1; m/z found, 286.1 $[M+H]^+$. ^1H NMR (600 MHz, DMSO-d_6) δ 8.87 (s, 1H), 8.67 (d, J = 4.8 Hz, 2H), 7.90 (ddd, J = 6.7, 2.8, 0.9 Hz, 1H), 7.81 - 7.71 (m, 1H), 7.38 (t, J = 9.1 Hz, 1H), 7.20 (t, J = 4.8 Hz, 1H), 5.52 (s, 2H), 2.33 (d, J = 2.0 Hz, 3H).

Example 474: 5-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 40) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}F_2N_5O$, 303.1; m/z found, 304.1 $[M+H]^+$. ^1H NMR (600 MHz, DMSO-d_6) δ 8.86 (s, 1H), 8.75 (d, J = 0.6 Hz, 2H), 7.93 - 7.85 (m, 1H), 7.76 (dt, J = 7.9, 3.6 Hz, 1H), 7.39 (t, J = 9.1 Hz, 1H), 5.51 (s, 2H), 2.33 (d, J = 2.1 Hz, 3H).

Example 475: 2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 40) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}FN_5O_2$, 315.1; m/z found, 316.1 $[M+H]^+$. ^1H NMR (600 MHz, DMSO-d_6) δ 8.84 (s, 1H), 8.41 (s, 2H), 7.89 (dd, J = 6.6, 2.7 Hz, 1H), 7.76 (dt, J = 8.4, 3.6 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 5.45 (s, 2H), 3.86 (s, 3H), 2.33 (d, J = 2.1 Hz, 3H).


Example 476: 5-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 40) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}ClFN_5O$, 319.1; m/z found, 320.0 $[M+H]^+$. ^1H NMR (600 MHz, DMSO-d_6) δ 8.86 (s, 1H), 8.77 (s, 2H), 7.95 - 7.86 (m, 1H), 7.76 (dt, J = 7.5, 3.6 Hz, 1H), 7.39 (t, J = 9.1 Hz, 1H), 5.53 (s, 2H), 2.33 (d, J = 2.0 Hz, 3H).


02 Mar 2021 2017217542

Example 477: 2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 40) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}FN_5O$, 299.1; m/z found, 300.2 $[M+H]^+$. ^1H NMR (600 MHz, DMSO-d_6) δ 8.85 (s, 1H), 8.49 (d, J = 0.8 Hz, 2H), 7.89 (ddd, J = 6.6, 2.8, 0.9 Hz, 1H), 7.83 - 7.71 (m, 1H), 7.38 (t, J = 9.1 Hz, 1H), 5.48 (s, 2H), 2.33 (d, J = 2.0 Hz, 3H), 2.21 (t, J = 0.8 Hz, 3H).

Example 478: 5-Ethyl-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 40) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{16}FN_5O$, 313.1; m/z found, 314.1 $[M+H]^+$. ^1H NMR (600 MHz, DMSO-d_6) δ 8.86 (s, 1H), 8.53 (s, 2H), 7.90 (dd, J = 6.8, 2.7 Hz, 1H), 7.76 (dt, J = 8.2, 3.6 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 5.49 (s, 2H), 2.57 (q, J = 7.6 Hz, 2H), 2.33 (d, J = 2.0 Hz, 3H), 1.19 (t, J = 7.6 Hz, 3H).

Example 479: 2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 40) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{16}FN_5O_2$, 329.1; m/z found, 330.0[M+H]$^+$. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.85 (s, 1H), 8.64 (d, J = 5.0 Hz, 1H), 7.88 (ddd, J = 6.5, 2.7, 0.9 Hz, 1H), 7.75 (ddd, J = 8.9, 4.3, 3.0 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 7.24 - 7.12 (m, 1H), 5.51 (s, 2H), 4.47 (d, J = 0.7 Hz, 2H), 3.40 (s, 3H), 2.33 (d, J = 2.1 Hz, 3H).

Example 480: 2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 40) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{16}FN_5O$, 313.1; m/z found, 314.1 [M+H]$^+$. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.82 (s, 1H), 8.30 (s, 1H), 7.89 (dd, J = 6.7, 2.9 Hz, 1H), 7.75 (dt, J = 7.5, 3.5 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 5.46 (s, 2H), 2.38 (s, 3H), 2.33 (d, J = 2.0 Hz, 3H), 2.16 (s, 3H).

Example 481: 5-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 40) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O$, 317.1; m/z found, 318.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.84 (s, 1H), 8.56 (d, J = 1.5 Hz, 1H), 7.88 (dd, J = 6.8, 2.9 Hz, 1H), 7.75 (dt, J = 8.1, 3.8 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 5.48 (s, 2H), 2.44 (d, J = 2.5 Hz, 3H), 2.33 (d, J = 2.0 Hz, 3H).

Example 482: 5-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 40) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}ClFN_5O$, 333.1; m/z found, 334.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.84 (s, 1H), 8.62 (s, 1H), 7.88 (dd, J = 6.8, 2.8 Hz, 1H), 7.75 (dt, J = 8.9, 3.6 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 5.51 (s, 2H), 2.51 (m, J = 1.3 Hz, 3H), 2.33 (d, J = 2.2 Hz, 3H).

Example 483: 5-(2-Fluoroethoxy)-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 192, Steps A – B, using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 40) in Step B. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.2 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.29 (s, 2H), 8.05 (s,

2017217542 02 Mar 2021


1H), 7.64 – 7.53 (m, 1H), 7.51 – 7.42 (m, 1H), 7.14 (t, *J* = 8.8 Hz, 1H), 5.60 (d, *J* = 0.8 Hz, 2H), 4.88 – 4.76 (m, 1H), 4.76 – 4.65 (m, 1H), 4.36 – 4.27 (m, 1H), 4.27 – 4.18 (m, 1H), 2.36 (d, *J* = 2.0 Hz, 3H).

Example 484: 2-[[1-(2-Fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(2-fluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 29) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}FN_5O$, 299.1; m/z found, 300.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.67 (d, *J* = 2.0 Hz, 1H), 8.51 – 8.47 (m, 2H), 7.68 – 7.64 (m, 1H), 7.48 – 7.38 (m, 2H), 5.49 (s, 2H), 2.38 (s, 3H), 2.21 (t, *J* = 0.8 Hz, 3H).

Example 485: 5-Chloro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(2-fluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 29) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}ClFN_5O$, 333.1; m/z found, 333.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.69 (d, *J* = 2.0 Hz, 1H), 8.62 (s, 1H), 7.68 – 7.64 (m, 1H), 7.48 – 7.39 (m, 2H), 5.52 (s, 2H), 2.38 (s, 3H).


Example 486: 5-Fluoro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 155 using (1-(2-fluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 29) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O$, 317.1; m/z found, 317.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.68 (d, J = 2.0 Hz, 1H), 8.57 (d, J = 1.5 Hz, 1H), 7.68 – 7.64 (m, 1H), 7.48 – 7.38 (m, 2H), 5.49 (s, 2H), 2.44 (d, J = 2.5 Hz, 3H), 2.38 (s, 3H).

Example 487: 5-Fluoro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 37) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}F_2N_5O$, 303.1; m/z found, 304.1 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.56 (d, J = 0.6 Hz, 2H), 8.35 (d, J = 0.5 Hz, 1H), 7.42 (dd, J = 8.7, 5.2 Hz, 1H), 7.22 (ddd, J = 9.3, 2.9, 0.9 Hz, 1H), 7.14 (dddd, J = 8.7, 8.0, 2.9, 0.7 Hz, 1H), 5.60 (d, J = 0.5 Hz, 2H), 2.16 (s, 3H).


Example 488: 2-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 37) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}FN_5O_2$, 315.1; m/z found, 316.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.56 (s, 1H),


8.41 (s, 2H), 7.51 (dd, *J* = 8.7, 5.4 Hz, 1H), 7.39 (dd, *J* = 9.6, 2.9 Hz, 1H), 7.26 (td, *J* = 8.5, 2.9 Hz, 1H), 5.46 (s, 2H), 3.86 (s, 3H), 2.13 (s, 3H).

Example 489: 5-Chloro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 37) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}ClFN_5O$, 319.1; m/z found, 320.0 $[M+H]^+$.

Example 490: 2-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 37) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{14}FN_5O$, 299.1; m/z found, 300.2$[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.43 (d, *J* = 0.9 Hz, 2H), 8.34 (s, 1H), 7.41 (dd, *J* = 8.7, 5.2 Hz, 1H), 7.20 (dd, *J* = 9.5, 3.1 Hz, 1H), 7.12 (td, *J* = 8.4, 2.9 Hz, 1H), 5.58 (s, 2H), 2.25 (d, *J* = 0.8 Hz, 3H), 2.15 (s, 3H).

Example 491: 5-Ethyl-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(4-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 37) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{16}FN_5O$, 313.1; m/z found, 314.1 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.45 (d, *J* = 0.7 Hz, 2H), 8.35 (s, 1H), 7.41 (dd, *J* = 8.7, 5.2 Hz, 1H), 7.20 (ddd, *J* = 9.3, 2.9, 0.8 Hz, 1H), 7.12 (dddd, *J* = 8.8, 8.0, 2.9, 0.7 Hz, 1H), 5.68 - 5.47 (m, 2H), 2.62 (q, *J* = 7.6 Hz, 2H), 2.15 (s, 3H), 1.24 (t, *J* = 7.6 Hz, 3H).

Example 492: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{14}H_9F_4N_5O_2$, 355.1; m/z found, 355.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.96 (s, 1H), 8.76 – 8.74 (m, 2H), 8.00 (dd, *J* = 6.9, 2.6 Hz, 1H), 7.87 (ddd, *J* = 9.0, 4.0, 2.7 Hz, 1H), 7.68 (dd, *J* = 10.2, 9.0 Hz, 1H), 7.39 (t, *J* = 72.8 Hz, 1H), 5.52 (s, 2H).

Example 493: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol

02 Mar 2021
2017217542


(Intermediate 6) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O_2$, 369.1; m/z found, 369.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.94 (s, 1H), 8.57 (d, J = 1.5 Hz, 1H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.87 (ddd, J = 9.0, 3.9, 2.7 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 5.50 (s, 2H), 2.44 (d, J = 2.6 Hz, 3H).

Example 494: 5-Bromo-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 5-bromo-2-chloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_9BrF_3N_5O_2$, 415.0; m/z found, 416 $[M+H]^+$. ^1H NMR (300 MHz, DMSO-d_6 δ 8.95 (s, 1H), 8.81 (s, 2H), 7.99 (dd, J = 6.8, 2.1 Hz, 1H), 7.92 – 7.82 (m, 1H), 7.68 (t, J = 9.6 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 5.54 (s, 2H).


Example 495: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-ethyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-4-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_2$, 365.1; m/z found, 365.9 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.95 (s, 1H), 8.51 (d, J = 5.0 Hz, 1H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.88 (ddd, J = 9.0, 4.0, 2.6 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J =


72.8 Hz, 1H), 7.08 (d, *J* = 5.0 Hz, 1H), 5.52 (s, 2H), 2.71 (q, *J* = 7.6 Hz, 2H), 1.22 (t, *J* = 7.6 Hz, 3H).

Example 496: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-4-isopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O_2$, 379.1; m/z found, 379.9 $[M+H]^+$. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.95 (s, 1H), 8.53 (d, *J* = 5.1 Hz, 1H), 8.00 (dd, *J* = 6.9, 2.6 Hz, 1H), 7.88 (ddd, *J* = 9.0, 3.9, 2.6 Hz, 1H), 7.68 (dd, *J* = 10.2, 9.0 Hz, 1H), 7.39 (t, *J* = 72.8 Hz, 1H), 7.10 (d, *J* = 5.1 Hz, 1H), 5.52 (s, 2H), 2.95 (hept, *J* = 7.0 Hz, 1H), 1.22 (d, *J* = 6.9 Hz, 6H).


Example 497: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine·as the trifluoroacetic acid salt.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-4-methoxypyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O_3$, 367.1; m/z found, 368.2 $[M+H]^+$. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.96 (s, 1H), 8.34 (d, *J* = 5.7 Hz, 1H), 8.01 (dd, *J* = 6.9, 2.6 Hz, 1H), 7.88 (ddd, *J* = 9.0, 4.0, 2.6 Hz, 1H), 7.69 (dd, *J* = 10.2, 9.0 Hz, 1H), 7.40 (t, *J* = 72.7 Hz, 1H), 6.62 (d, *J* = 5.7 Hz, 1H), 5.53 (s, 2H), 3.91 (s, 3H).


2017217542 02 Mar 2021

Example 498: [2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol.




The title compound was prepared in a manner analogous to Example 163, Steps B-C, using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-4-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)pyrimidine (Example 383, product from Step A). MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O_3$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.94 (s, 1H), 8.62 (d, J = 5.0 Hz, 1H), 8.00 (dd, J = 7.0, 2.6 Hz, 1H), 7.87 (ddd, J = 9.0, 4.0, 2.6 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 7.26 – 7.22 (m, 1H), 5.63 (t, J = 5.8 Hz, 1H), 5.52 (s, 2H), 4.51 (d, J = 5.7 Hz, 2H).

Example 499: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_3$, 381.1; m/z found, 381.9 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.95 (s, 1H), 8.64 (d, J = 5.0 Hz, 1H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.90 – 7.84 (m, 1H), 7.69 (dd, J = 10.2, 9.0 Hz, 1H), 7.40 (t, J = 72.8 Hz, 1H), 7.20 – 7.17 (m, 1H), 5.53 (s, 2H), 4.48 (s, 2H), 3.41 (s, 3H).

Example 500: 2-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-(2-chloropyrimidin-5-yl)propan-2-ol, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O_3$, 395.1; m/z found, 396.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.70 – 8.65 (s, 2H), 8.12 – 8.08 (t, *J* = 0.7 Hz, 1H), 7.71 – 7.67 (dd, *J* = 6.6, 2.6 Hz, 1H), 7.61 – 7.55 (m, 1H), 7.38 – 7.30 (t, *J* = 9.2 Hz, 1H), 6.80 – 6.48 (t, *J* = 72.6 Hz, 1H), 5.72 – 5.61 (d, *J* = 0.7 Hz, 2H), 1.70 – 1.60 (s, 6H).

Example 501: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloropyrimidin-4-amine. MS (ESI): mass calcd. for $C_{14}H_{11}F_3N_6O_2$, 352.1; m/z found, 352.9 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.91 (s, 1H), 7.99 (dd, *J* = 6.9, 2.6 Hz, 1H), 7.91 – 7.83 (m, 2H), 7.68 (dd, *J* = 10.2, 9.0 Hz, 1H), 7.39 (t, *J* = 72.8 Hz, 1H), 6.92 (s, 2H), 6.11 (d, *J* = 5.7 Hz, 1H), 5.37 (s, 2H).

Example 502: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-amine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloropyrimidin-5-amine. MS (ESI): mass calcd. for $C_{14}H_{11}F_3N_6O_2$, 352.1; m/z found, 352.9 $[M+H]^+$. ^1H NMR (400 MHz, CD_2Cl_2) δ 8.17 – 8.01 (m, 3H), 7.73 – 7.67 (m, 1H), 7.62 – 7.55 (m, 1H), 7.40 – 7.32 (m, 1H), 6.68 (t, *J* = 72.8 Hz, 1H), 5.50 (s, 2H).

Example 503: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 163, Steps B-C using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate (Intermediate 55) and (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) in Step A. MS (ESI): mass calcd. for $C_{15}H_{13}F_3N_6O_2$, 366.1; m/z found, 366.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.90 (s, 1H), 8.00 (dd, *J* = 7.0, 2.6 Hz, 1H), 7.89 – 7.79 (m, 2H), 7.67 (dd, *J* = 10.2, 9.0 Hz, 1H), 7.55 – 7.22 (m, 2H), 6.14 (d, *J* = 5.9 Hz, 1H), 5.40 (s, 2H), 2.81 – 2.74 (m, 3H).


Example 504: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethylpyrimidin-4-amine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 163 Steps B-C, using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-N-ethyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (Intermediate 60) in Step A. MS (ESI): mass calcd. for $C_{16}H_{15}F_3N_6O_2$, 380.1; m/z found, 381.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.91 (s, 1H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.90 – 7.80 (m, 2H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.59 – 7.20 (m, 2H), 6.13 (d, J = 5.9 Hz, 1H), 5.39 (s, 2H), 1.11 (t, J = 7.2 Hz, 3H).

Example 505: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{16}H_{15}F_3N_6O_2$, 380.1; m/z found, 380.9 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.91 (s, 1H), 8.03 – 7.98 (m, 2H), 7.88 (ddd, J = 9.0, 4.0, 2.6 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 6.36 (d, J = 6.1 Hz, 1H), 5.43 (s, 2H), 3.05 (s, 6H).

Example 506: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-phenyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol

2017217542 02 Mar 2021


(Intermediate 6) and (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-4-phenylpyrimidine. MS (ESI): mass calcd. for $C_{20}H_{14}F_3N_5O_2$, 413.1; m/z found, 413.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 9.00 (s, 1H), 8.72 (d, J = 5.2 Hz, 1H), 8.25 – 8.21 (m, 2H), 8.01 (dd, J = 6.9, 2.6 Hz, 1H), 7.88 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 7.78 (d, J = 5.2 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.61 – 7.23 (m, 4H), 5.65 (s, 2H).

Example 507: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine.



The title compound was prepared in a manner analogous to Example 165 using 3-fluoroazetidine hydrochloride in Step A. MS (ESI): mass calcd. for $C_{17}H_{14}F_4N_6O_2$, 410.1; m/z found, 411.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.92 (s, 1H), 8.02 – 7.98 (m, 3H), 7.87 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 5.59 – 5.38 (m, 3H), 4.26 – 4.14 (m, 2H), 4.00 – 3.88 (m, 2H).


Example 508: 5-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 165 using 3,3-difluoroazetidine hydrochloride in Step A. MS (ESI): mass calcd. for $C_{17}H_{13}F_5N_6O_2$, 428.1; m/z found, 429.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.93 (s, 1H), 8.08 (s, 2H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.87 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 5.45 (s, 2H), 4.34 (t, J = 12.3 Hz, 4H).


2017217542 02 Mar 2021

Example 509: 4-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 166 using azetidine in Step A. MS (ESI): mass calcd. for $C_{17}H_{15}F_3N_6O_2$, 392.1; m/z found, 392.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.89 (s, 1H), 8.02 – 7.98 (m, 2H), 7.87 (ddd, J = 9.0, 3.9, 2.7 Hz, 1H), 7.67 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 6.04 (d, J = 5.8 Hz, 1H), 5.40 (s, 2H), 4.02 (t, J = 7.6 Hz, 4H), 2.39 – 2.31 (m, 2H).

Example 510: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3-fluoroazetidin-1-yl)pyrimidine.




The title compound was prepared in a manner analogous to Example 166 using 3-fluoroazetidine hydrochloride in Step A. MS (ESI): mass calcd. for $C_{17}H_{14}F_4N_6O_2$, 410.1; m/z found, 410.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.90 (s, 1H), 8.06 (d, J = 5.8 Hz, 1H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.87 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 7.67 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 6.16 (d, J = 5.8 Hz, 1H), 5.60 – 5.41 (m, 3H), 4.41 – 4.31 (m, 2H), 4.14 – 4.04 (m, 2H).

Example 511: 4-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 166 using 3,3-difluoroazetidine hydrochloride in Step A. MS (ESI): mass calcd. for $C_{17}H_{13}F_5N_6O_2$, 428.1; m/z found, 428.9 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.92 (s, 1H), 8.15 (d, J = 5.7 Hz, 1H), 8.02 – 7.98 (m, 1H), 7.90 – 7.85 (m, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 6.28 (d, J = 5.8 Hz, 1H), 5.45 (s, 2H), 4.49 (t, J = 12.4 Hz, 4H).

Example 512: (R)-2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-[(3R)-3-fluoropyrrolidin-1-yl]pyrimidine.




The title compound was prepared in a manner analogous to Example 166 using (R)-3-fluoropyrrolidine hydrochloride in Step A. MS (ESI): mass calcd. for $C_{18}H_{16}F_4N_6O_2$, 424.1; m/z found, 424.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.91 (s, 1H), 8.04 (d, J = 5.9 Hz, 1H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.87 (ddd, J = 9.0, 4.0, 2.7 Hz, 1H), 7.67 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 6.30 – 6.19 (m, 1H), 5.55 – 5.34 (m, 3H), 3.95 – 3.36 (m, 4H), 2.35 – 2.02 (m, 2H).

Example 513: 5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}ClF_3N_5O_2$, 385.1; m/z found, 385.9 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.94 (s, 1H), 8.62 (s, 1H), 8.01 – 7.97 (m, 1H), 7.90 – 7.84 (m, 1H), 7.72 – 7.64 (m, 1H), 7.39 (t, J = 72.8 Hz, 1H), 5.53 (s, 2H).

Example 514: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine·as the trifluoroacetic acid salt.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-5-methylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{15}H_{13}F_3N_6O_2$, 366.1; m/z found, 366.9 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 9.03 (s, 1H), 7.99 – 7.95 (m, 1H), 7.95 – 7.92 (m, 1H), 7.88 – 7.82 (m, 1H), 7.72 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.7 Hz, 1H), 5.59 (s, 2H), 2.02 – 1.97 (m, 3H).


Example 515: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 163, Steps B-C using tert-butyl (2-chloro-5-methylpyrimidin-4-yl)(methyl)carbamate (Intermediate 56) and (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) in Step A. MS (ESI): mass calcd. for $C_{16}H_{15}F_3N_6O_2$, 380.1; m/z found, 381.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.95 (s, 1H), 7.99 (dd, J = 6.9, 2.7 Hz, 1H), 7.87 (ddd, J = 9.0, 3.9, 2.6 Hz, 1H), 7.84 – 7.82 (m, 1H), 7.69 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.7 Hz, 1H), 5.63 (s, 2H), 3.01 (d, J = 4.5 Hz, 3H), 2.00 – 1.97 (m, 3H).

Example 516: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-N,N,5-trimethylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{17}H_{17}F_3N_6O_2$, 394.1; m/z found, 395.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.90 (s, 1H), 8.00 (dd, J = 6.9, 2.7 Hz, 1H), 7.87 (ddd, J = 9.0, 4.0, 2.6 Hz, 1H), 7.84 – 7.82 (m, 1H), 7.67 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 5.40 (s, 2H), 3.07 (s, 6H), 2.22 (d, J = 0.9 Hz, 3H).


Example 517: N-(2,2-Difluoroethyl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidin-4-amine·as the trifluoroacetic acid salt.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 163, Steps B-C using tert-butyl (2-chloro-5-fluoropyrimidin-4-yl)(2,2-difluoroethyl)carbamate (Intermediate 57) and (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) in Step A. MS (ESI): mass calcd. for $C_{16}H_{12}F_6N_6O_2$, 434.1; m/z found, 435.2 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.92 (s, 1H), 8.19 – 8.12 (m, 1H), 8.07 (d, J = 3.3 Hz, 1H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.88 (ddd, J = 9.0, 3.9, 2.6 Hz, 1H), 7.69 (dd, J = 10.2, 9.0 Hz, 1H), 7.40 (t, J = 72.8 Hz, 1H), 6.34 – 6.00 (m, 1H), 5.42 (s, 2H).

Example 518: 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine·as the trifluoroacetic acid salt.



The title compound was prepared in a manner analogous to Example 163, Steps B-C, using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6) and 2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (Intermediate 59) in Step A. MS (ESI): mass calcd. for $C_{15}H_{12}F_4N_6O_2$, 384.1; m/z found, 385.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.91 (s, 1H), 8.01 – 7.97 (m, 2H), 7.94 – 7.85 (m, 2H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 5.43 (s, 2H), 2.87 (d, J = 4.6 Hz, 3H).


Example 519: N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 167 using 4-chloro-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-


yl)methoxy)-5-fluoropyrimidine and cyclopropylamine in Step C. MS (ESI): mass calcd. for $C_{17}H_{14}F_4N_6O_2$, 411.1; m/z found, 410.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.91 (s, 1H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.95 (d, J = 3.5 Hz, 1H), 7.90 – 7.84 (m, 2H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 5.40 (s, 2H), 2.85 – 2.75 (m, 1H), 0.74 – 0.67 (m, 2H), 0.60 – 0.53 (m, 2H).

Example 520: 1-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)-N-methylmethanamine.



The title compound was prepared in a manner analogous to Example 163, Steps B-C, using tert-butyl methyl((2-(methylsulfonyl)pyrimidin-4-yl)methyl)carbamate (Intermediate 61) and (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 6). MS (ESI): mass calcd. for $C_{16}H_{15}F_3N_6O_2$, 380.1; m/z found, 381.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.97 (s, 1H), 8.57 (d, J = 5.0 Hz, 1H), 8.00 (dd, J = 6.9, 2.6 Hz, 1H), 7.87 (ddd, J = 9.0, 4.0, 2.6 Hz, 1H), 7.68 (dd, J = 10.2, 9.0 Hz, 1H), 7.39 (t, J = 72.8 Hz, 1H), 7.21 (d, J = 5.0 Hz, 1H), 5.52 (s, 2H), 3.69 (s, 2H), 2.29 (s, 3H).


Example 521: 2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine.



02 Mar 2021 2017217542


The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 52) and 2-chloro-4-amino-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{16}F_2N_6O_2$, 362.1; m/z found, 363.2[M+H]$^+$. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.88 (s, 1H), 7.93 - 7.66 (m, 2H), 7.61 - 7.10 (m, 3H), 6.76 (s, 2H), 5.35 (s, 2H), 2.29 (s, 3H), 1.92 (s, 3H).

Example 522: 1-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone.



The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 52) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI): mass calcd. for $C_{17}H_{15}F_2N_5O_3$, 375.1; m/z found, 376.1 [M+H]$^+$. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.15 (s, 2H), 8.97 (s, 1H), 7.79 - 7.67 (m, 2H), 7.60 - 7.13 (m, 2H), 5.65 (s, 2H), 2.59 (s, 3H), 2.30 (s, 3H).

Example 523: 2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 52) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.0 [M+H]$^+$. ^{1}H NMR (400 MHz, DMSO-d_6)

2017217542 02 Mar 2021


δ 8.92 (s, 1H), 8.49 (d, *J* = 4.8 Hz, 1H), 7.80 - 7.67 (m, 2H), 7.57 - 7.14 (m, 2H), 7.07 (d, *J* = 5.1 Hz, 1H), 5.51 (s, 2H), 2.43 (s, 3H), 2.30 (s, 3H).

Example 524: 2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 52) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.93 (d, *J* = 2.7 Hz, 1H), 8.50 (d, *J* = 7.9 Hz, 2H), 7.84 - 7.68 (m, 2H), 7.61 - 7.10 (m, 2H), 5.50 (d, *J* = 2.5 Hz, 2H), 2.30 (s, 2H), 2.21 (s, 2H).

Example 525: 5-Bromo-2-[[1-[3-(difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 52) and 2-chloro-5-bromopyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}BrF_2N_5O_2$, 411.0; m/z found, 412.1 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.71 (s, 2H), 8.68 (s, 1H), 7.69 (d, *J* = 2.1 Hz, 1H), 7.65 (dd, *J* = 8.2, 2.2 Hz, 1H), 7.50 (d, *J* = 8.2 Hz, 1H), 6.97 (t, *J* = 73.6 Hz, 1H), 5.62 (s, 2H), 2.37 (s, 3H).

Example 526: 2-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 52) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{18}H_{19}F_2N_5O_3$, 391.1; m/z found, 392.1 $[M+H]^+$.

Example 527: 2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 52) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{17}H_{17}F_2N_5O_3$, 377.1; m/z found, 378.2 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.67 (s, 1H), 8.59 (d, *J* = 5.1 Hz, 1H), 7.71 - 7.57 (m, 2H), 7.49 (d, *J* = 8.3 Hz, 1H), 7.23 (d, *J* = 5.1 Hz, 1H), 6.98 (t, *J* = 73.7 Hz, 1H), 5.62 (s, 2H), 4.53 (s, 2H), 3.50 (s, 3H), 2.37 (s, 3H).

Example 528: 2-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 172, Steps A through D, using 2-chloro-4,5-dimethylpyrimidine in Step D. MS (ESI): mass calcd. for $C_{17}H_{17}F_2N_5O$, 345.1; m/z found, 346.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.19 (d, *J* = 0.9 Hz, 1H), 7.71 – 7.56 (m, 4H), 6.73 (t, *J* = 56.1 Hz, 1H), 5.57 (s, 2H), 2.44 (s, 3H), 2.43 (s, 3H), 2.19 (s, 3H).

Example 529: 5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 172, Steps A through D, using 2,5-dichloropyrimidine in Step D. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O$, 351.1; m/z found, 352.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.50 (s, 2H), 7.72 – 7.54 (m, 4H), 6.73 (t, *J* = 56.1 Hz, 1H), 5.59 (s, 2H), 2.45 (s, 3H).


Example 530: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for


$C_{16}H_{14}ClF_2N_5O$, 365.1; m/z found, 366.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.38 (d, *J* = 0.8 Hz, 2H), 8.20 – 8.09 (m, 1H), 7.97 (d, *J* = 2.6 Hz, 1H), 7.84 – 7.76 (m, 1H), 7.65 – 7.58 (m, 1H), 5.64 (d, *J* = 0.7 Hz, 2H), 2.26 (t, *J* = 0.7 Hz, 3H), 2.09 (t, *J* = 18.5 Hz, 3H).

Example 531: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O$, 365.1; m/z found, 366.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.40 (d, *J* = 5.0 Hz, 1H), 8.16 (s, 1H), 7.97 (d, *J* = 2.6 Hz, 1H), 7.85 – 7.74 (m, 1H), 7.61 (d, *J* = 8.6 Hz, 1H), 6.92 – 6.80 (m, 1H), 5.66 (d, *J* = 0.7 Hz, 2H), 2.56 – 2.43 (m, 3H), 2.18 – 1.97 (m, 3H).


Example 532: 2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.



The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{18}H_{18}ClF_2N_5O_2$, 409.1; m/z found, 410.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.68 (d, *J* = 1.4 Hz, 2H), 8.20 – 8.13 (m, 1H), 7.98 (d, *J* = 2.5


Hz, 1H), 7.84 – 7.74 (m, 1H), 7.61 (d, *J* = 8.6 Hz, 1H), 5.67 (t, *J* = 0.9 Hz, 2H), 2.20 – 1.99 (m, 3H), 1.70 – 1.59 (m, 6H).

Example 533: [2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol.



The title compound was prepared in a manner analogous to Example 159, Steps A-B using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 5-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine (Intermediate 53) in Step A. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_2$, 381.1; m/z found, 382.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.60 – 8.54 (s, 2H), 8.18 – 8.12 (t, *J* = 0.7 Hz, 1H), 8.00 – 7.94 (d, *J* = 2.6 Hz, 1H), 7.83 – 7.75 (m, 1H), 7.65 – 7.57 (m, 1H), 5.70 – 5.63 (d, *J* = 0.7 Hz, 2H), 4.75 – 4.66 (m, 2H), 2.16 – 2.03 (t, *J* = 18.5 Hz, 3H), 1.90 – 1.57 (s, 1H).


Example 534: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{17}H_{16}ClF_2N_5O_2$, 395.1; m/z found, 396.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.55 (d, *J* = 5.0 Hz, 1H), 8.18 (t, *J* = 0.7 Hz, 1H), 7.97 (d, *J* = 2.6 Hz, 1H), 7.82 – 7.76 (m, 1H), 7.61 (d, *J* = 8.6 Hz, 1H), 7.16 (d, *J* = 5.0 Hz, 1H), 5.66 (d, *J* = 0.7 Hz, 2H), 4.50 (d, *J* = 0.7 Hz, 2H), 3.50 (s, 3H), 2.29 – 1.90 (m, 3H).


2017217542 02 Mar 2021

Example 535: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-4-difluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{12}ClF_4N_5O$, 401.1; m/z found, 402.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.75 – 8.68 (m, 2H), 8.16 (s, 1H), 7.97 (d, J = 2.7 Hz, 1H), 7.84 – 7.76 (m, 1H), 7.62 (d, J = 8.6 Hz, 1H), 6.73 (t, J = 55.6 Hz, 1H), 5.72 (d, J = 0.7 Hz, 2H), 2.09 (t, J = 18.5 Hz, 3H).

Example 536: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-4-(difluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{12}ClF_4N_5O$, 401.1; m/z found, 402.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.76 (d, J = 4.9 Hz, 1H), 8.19 (s, 1H), 8.07 – 7.93 (m, 1H), 7.87 – 7.74 (m, 1H), 7.62 (d, J = 8.7 Hz, 1H), 7.31 (d, J = 5.0 Hz, 1H), 6.51 (t, J = 54.7 Hz, 1H), 5.71 (s, 2H), 2.20 – 1.99 (m, 3H).

Example 537: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-5-trifluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{11}ClF_5N_5O$, 419.1; m/z found, 420.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.89 – 8.76 (m, 2H), 8.23 – 8.08 (m, 1H), 7.97 (d, J = 2.6 Hz, 1H), 7.85 – 7.75 (m, 1H), 7.70 – 7.57 (m, 1H), 5.74 (d, J = 0.7 Hz, 2H), 2.09 (t, J = 18.5 Hz, 3H).

Example 538: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-4-trifluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{11}ClF_5N_5O$, 419.1; m/z found, 420.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.83 (d, J = 4.8 Hz, 1H), 8.21 (s, 1H), 7.97 (d, J = 2.6 Hz, 1H), 7.79 (dd, J = 8.6, 2.6 Hz, 1H), 7.62 (d, J = 8.6 Hz, 1H), 7.34 (d, J = 4.9 Hz, 1H), 5.72 (d, J = 0.7 Hz, 2H), 2.09 (t, J = 18.5 Hz, 3H).

Example 539: (R/S)-2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol.




The title compound was prepared in a manner analogous to Example 153 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-(2-chloropyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{18}H_{15}ClF_5N_5O_2$, 463.1; m/z found, 464.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.77 – 8.71 (s, 2H), 8.20 – 8.13 (s, 1H), 8.01 – 7.95 (d, *J* = 2.6 Hz, 1H), 7.83 – 7.75 (m, 1H), 7.64 – 7.58 (d, *J* = 8.6 Hz, 1H), 5.72 – 5.65 (d, *J* = 0.8 Hz, 2H), 2.16 – 2.03 (t, *J* = 18.5 Hz, 3H), 1.87 – 1.78 (m, 3H).

Example 540: [2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol.




The title compound was prepared in a manner analogous to Example 159, Steps A-B using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 4-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine (Intermediate 54) in Step A.. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_2$, 381.1; m/z found, 382.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.55 – 8.48 (d, *J* = 5.0 Hz, 1H), 8.21 – 8.12 (s, 1H), 8.00 – 7.95 (d, *J* = 2.6 Hz, 1H), 7.84 – 7.75 (m, 1H), 7.65 – 7.57 (d, *J* = 8.6 Hz, 1H), 7.07 – 6.98 (d, *J* = 5.0 Hz, 1H), 5.73 – 5.62 (d, *J* = 0.7 Hz, 2H), 4.80 – 4.68 (d, *J* = 0.7 Hz, 2H), 2.18 – 1.99 (m, 3H).

Example 541: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-4-methoxypyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_2$, 381.1; m/z found, 382.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.23 (d, J = 5.7 Hz, 1H), 8.15 (s, 1H), 7.97 (d, J = 2.6 Hz, 1H), 7.86 – 7.73 (m, 1H), 7.61 (d, J = 8.6 Hz, 1H), 6.43 (d, J = 5.7 Hz, 1H), 5.65 (d, J = 0.7 Hz, 2H), 3.99 (s, 3H), 2.20 – 1.99 (m, 3H).

Example 542: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-5-difluoromethoxypyrimidine. MS (ESI): mass calcd. for $C_{16}H_{12}ClF_4N_5O_2$, 417.1; m/z found, 418.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.53 – 8.41 (m, 2H), 8.15 (s, 1H), 7.98 (d, J = 2.6 Hz, 1H), 7.80 (dd, J = 8.6, 2.6 Hz, 1H), 7.62 (d, J = 8.6 Hz, 1H), 6.53 (t, J = 71.9 Hz, 1H), 5.66 (d, J = 0.7 Hz, 2H), 2.09 (t, J = 18.5 Hz, 3H).

Example 543: 5-Chloro-2-[[1-[4-chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{13}Cl_2F_2N_5O$, 399.0; m/z found, 400.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.39 (s, 1H), 8.14 (s, 1H), 7.97 (d, *J* = 2.6 Hz, 1H), 7.79 (dd, *J* = 8.6, 2.6 Hz, 1H), 7.61 (d, *J* = 8.6 Hz, 1H), 5.69 – 5.57 (m, 2H), 2.57 (s, 3H), 2.09 (t, *J* = 18.5 Hz, 3H).

Example 544: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{13}ClF_3N_5O$, 383.1; m/z found, 384.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.26 (d, *J* = 1.2 Hz, 1H), 8.14 (t, *J* = 0.7 Hz, 1H), 7.97 (d, *J* = 2.6 Hz, 1H), 7.86 – 7.75 (m, 1H), 7.61 (d, *J* = 8.6 Hz, 1H), 5.62 (d, *J* = 0.7 Hz, 2H), 2.50 (d, *J* = 2.5 Hz, 3H), 2.09 (t, *J* = 18.5 Hz, 3H).

Example 545: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{16}ClF_2N_5O$, 379.1; m/z found, 380.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.20 (d, J = 0.9 Hz, 1H), 8.15 (s, 1H), 7.97 (d, J = 2.6 Hz, 1H), 7.79 (dd, J = 8.6, 2.6 Hz, 1H), 7.61 (d, J = 8.6 Hz, 1H), 5.63 (d, J = 0.8 Hz, 2H), 2.44 (s, 3H), 2.20 (s, 3H), 2.09 (t, J = 18.5 Hz, 3H).

Example 546: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4,6-dimethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-4,6-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{16}ClF_2N_5O$, 379.1; m/z found, 380.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.16 (t, J = 0.8 Hz, 1H), 7.97 (d, J = 2.6 Hz, 1H), 7.79 (dd, J = 8.6, 2.6 Hz, 1H), 7.61 (d, J = 8.7 Hz, 1H), 6.73 (s, 1H), 5.65 (d, J = 0.8 Hz, 2H), 2.52 – 2.31 (m, 6H), 2.09 (t, J = 18.5 Hz, 3H).

Example 547: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 153 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloropyrimidin-4-amine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{13}ClF_2N_6O$, 366.1; m/z found, 367.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.21 – 8.11 (t, *J* = 0.8 Hz, 1H), 8.11 – 8.02 (d, *J* = 5.7 Hz, 1H), 8.00 – 7.95 (d, *J* = 2.6 Hz, 1H), 7.86 – 7.72 (m, 1H), 7.66 – 7.54 (d, *J* = 8.6 Hz, 1H), 6.25 – 6.00 (d, *J* = 5.7 Hz, 1H), 5.70 – 5.44 (d, *J* = 0.7 Hz, 2H), 5.20 – 4.99 (s, 2H), 2.21 – 1.96 (t, *J* = 18.5 Hz, 3H).

Example 548: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 163, Steps B-C using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate (Intermediate 55) and (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63). MS (ESI): mass calcd. for $C_{16}H_{15}ClF_2N_6O$, 380.1; m/z found, 381.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.20 – 8.16 (s, 1H), 8.07 – 7.96 (m, 2H), 7.82 – 7.76 (m, 1H), 7.64 – 7.57 (d, *J* = 8.6 Hz, 1H), 6.10 – 6.07 (d, *J* = 5.9 Hz, 1H), 5.67 – 5.57 (s, 2H), 5.40 – 5.26 (s, 1H), 3.05 – 2.91 (s, 3H), 2.18 – 2.00 (t, *J* = 18.5 Hz, 3H).

Example 549: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 163, Steps B-C using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (Intermediate 59) in step A. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_3N_6O$, 398.1; m/z found, 399.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.16 – 8.11 (s, 1H), 8.01 – 7.94 (d, J = 2.6 Hz, 1H), 7.86 – 7.73 (m, 2H), 7.66 – 7.56 (d, J = 8.6 Hz, 1H), 5.63 – 5.51 (s, 2H), 5.19 – 5.03 (s, 1H), 3.15 – 3.04 (d, J = 5.0 Hz, 3H), 2.21 – 1.97 (m, 3H).

Example 550: 1-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone.




The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI): mass calcd. for $C_{17}H_{14}ClF_2N_5O_2$, 393.1; m/z found, 394.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 9.18 – 9.05 (m, 2H), 8.25 – 8.14 (s, 1H), 8.04 – 7.92 (m, 1H), 7.88 – 7.75 (m, 1H), 7.70 – 7.58 (m, 1H), 5.83 – 5.70 (m, 2H), 2.69 – 2.57 (m, 3H), 2.23 – 2.00 (m, 3H).

Example 551: (R/S)-1-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol.




The title compound was prepared in a manner analogous to Example 157 using 1-(2-((1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one (Example 550). MS (ESI): mass calcd. for $C_{17}H_{16}ClF_2N_5O_2$, 395.1; m/z found, 396.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.62 – 8.55 (d, J = 0.6 Hz, 2H), 8.18 – 8.14 (t, J = 0.7 Hz, 1H), 8.00 – 7.96 (d, J = 2.6 Hz, 1H), 7.83 – 7.76 (m, 1H), 7.65 – 7.57 (d, J = 8.6 Hz, 1H), 5.71 – 5.62 (d, J = 0.8 Hz, 2H), 5.03 – 4.92 (q, J = 6.5 Hz, 1H), 2.20 – 2.01 (t, J = 18.4 Hz, 3H), 1.62 – 1.50 (d, J = 6.5 Hz, 3H).

Example 552: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-cyclopropyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{18}H_{16}ClF_2N_5O$, 391.1; m/z found, 392.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.32 (d, J = 0.5 Hz, 2H), 8.14 (t, J = 0.7 Hz, 1H), 7.97 (d, J = 2.6 Hz, 1H), 7.83 – 7.77 (m, 1H), 7.61 (d, J = 8.6 Hz, 1H), 5.63 (d, J = 0.7 Hz, 2H), 2.09 (t, J = 18.5 Hz, 3H), 1.88 – 1.78 (m, 1H), 1.07 – 0.98 (m, 2H), 0.74 – 0.67 (m, 2H).

Example 553: 2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine.



The title compound was prepared in a manner analogous to Example 153 using (1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 63) and 2-chloro-4-(pyrrolidin-1-yl)pyrimidine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{19}H_{19}ClF_2N_6O$, 420.1; m/z found, 421.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.16 – 8.11 (t, J = 0.7 Hz, 1H), 8.02 – 7.98 (d, J = 5.9 Hz, 1H), 7.98 – 7.96 (d, J = 2.6 Hz, 1H), 7.82 – 7.74 (dd, J = 8.6, 2.7 Hz, 1H), 7.64 – 7.55 (d, J = 8.6 Hz, 1H), 6.03 – 5.97 (d, J = 5.9 Hz, 1H), 5.63 – 5.57 (d, J = 0.8 Hz, 2H), 3.72 – 3.53 (m, 2H), 3.43 – 3.26 (m, 2H), 2.17 – 1.92 (m, 7H).


Example 554: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine.



The title compound was prepared in a manner analogous to Example 158 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloropyridine. MS (ESI): mass calcd. for $C_{16}H_{13}F_3N_4O$, 334.1; m/z found, 335.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.29 – 8.12 (m, 1H), 8.13 – 7.99 (m, 1H), 7.96 – 7.80 (m, 2H), 7.68 – 7.53 (m, 1H), 7.42 – 7.22 (m, 1H), 7.05 – 6.70 (m, 2H), 5.72 – 5.50 (m, 2H), 2.23 – 1.82 (m, 3H).


2017217542 02 Mar 2021

Example 555: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-3-fluoro-pyridine.




The title compound was prepared in a manner analogous to Example 158 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-3-fluoropyridine. MS (ESI): mass calcd. for $C_{16}H_{12}F_4N_4O$, 352.1; m/z found, 353.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.11 (s, 1H), 8.02 – 7.96 (m, 1H), 7.95 – 7.87 (m, 1H), 7.88 – 7.81 (m, 1H), 7.43 – 7.26 (m, 2H), 6.98 – 6.87 (m, 1H), 5.68 (d, J = 2.0 Hz, 2H), 2.05 (t, J = 18.4, 1.6 Hz, 3H).

Example 556: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine.




The title compound was prepared in a manner analogous to Example 158 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-6-methylpyridine. MS (ESI): mass calcd. for $C_{17}H_{15}F_3N_4O$, 348.1; m/z found, 349.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.09 – 8.03 (m, 1H), 7.93 – 7.85 (m, 1H), 7.86 – 7.78 (m, 1H), 7.54 – 7.41 (m, 1H), 7.36 – 7.26 (m, 1H), 6.81 – 6.73 (m, 1H), 6.64 – 6.51 (m, 1H), 5.59 (d, J = 0.7 Hz, 2H), 2.48 (t, J = 0.6 Hz, 3H), 2.05 (td, J = 18.6, 1.2 Hz, 3H).

Example 557: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine.




The title compound was prepared in a manner analogous to Example 158 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-4-methylpyridine. MS (ESI): mass calcd. for $C_{17}H_{15}F_3N_4O$, 348.1; m/z found, 349.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.15 – 8.01 (m, 1H), 7.97 – 7.76 (m, 2H), 7.39 – 7.22 (m, 2H), 6.83 – 6.58 (m, 2H), 5.68 – 5.49 (m, 2H), 2.31 (s, 3H), 2.20 – 1.90 (m, 3H).

Example 558: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine.



The title compound was prepared in a manner analogous to Example 158 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-methylpyridine. MS (ESI): mass calcd. for $C_{17}H_{15}F_3N_4O$, 348.1; m/z found, 349.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.13 – 8.04 (m, 1H), 8.05 – 7.96 (m, 1H), 7.96 – 7.75 (m, 2H), 7.49 – 7.35 (m, 1H), 7.36 – 7.21 (m, 1H), 6.81 – 6.63 (m, 1H), 5.57 (d, *J* = 4.0 Hz, 2H), 2.27 (d, *J* = 3.6 Hz, 3H), 2.05 (t, 3H).


Example 559: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine.



02 Mar 2021 2017217542


The title compound was prepared in a manner analogous to Example 158 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-trifluoromethylpyridine. MS (ESI): mass calcd. for $C_{17}H_{12}F_6N_4O$, 402.1; m/z found, 403.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.60 – 8.39 (m, 1H), 8.23 – 8.02 (m, 1H), 8.01 – 7.74 (m, 2H), 7.43 – 7.22 (m, 2H), 7.03 – 6.84 (m, 1H), 5.65 (s, 2H), 2.05 (t, *J* = 18.4 Hz, 3H).

Example 560: 6-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-2,3-dimethyl-pyridine.



The title compound was prepared in a manner analogous to Example 158 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5,6-dimethylpyridine. MS (ESI): mass calcd. for $C_{18}H_{17}F_3N_4O$, 362.1; m/z found, 363.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.06 (s, 1H), 7.98 – 7.76 (m, 2H), 7.42 – 7.26 (m, 2H), 6.64 – 6.51 (m, 1H), 5.57 (d, *J* = 2.5 Hz, 2H), 2.43 (s, 3H), 2.20 (s, 3H), 2.03 (t, 3H).

Example 561: 3-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-2-methoxy-pyridine.




The title compound was prepared in a manner analogous to Example 153, using 4-(chloromethyl)-1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazole (Intermediate 20, product from Step A) and 2-methoxypyridin-3-ol (24 mg, 0.189 mmol) and stirred at rt overnight. MS (ESI): mass calcd. for $C_{17}H_{15}F_3N_4O_2$, 364.1; m/z found, 365.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.09 (t, *J* = 0.7 Hz, 1H), 7.92 – 7.88 (m, 1H), 7.86 – 7.80 (m, 1H), 7.81 – 7.77

2017217542 02 Mar 2021


(m, 1H), 7.34 – 7.28 (m, 2H), 6.91 – 6.78 (m, 1H), 5.46 – 5.28 (m, 2H), 4.03 (s, 3H), 2.05 (t, *J* = 18.6, 1.2 Hz, 3H).

Example 562: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-(difluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{12}F_5N_5O$, 385.1; m/z found, 386.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.76 – 8.67 (m, 2H), 8.13 (s, 1H), 7.94 – 7.87 (m, 1H), 7.87 – 7.81 (m, 1H), 7.32 (t, *J* = 9.4 Hz, 1H), 6.73 (t, *J* = 55.6 Hz, 1H), 5.78 – 5.68 (m, 2H), 2.12 – 1.96 (m, 3H).

Example 563: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-4-(difluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{12}F_5N_5O$, 385.1; m/z found, 386.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.76 (d, *J* = 4.9 Hz, 1H), 8.16 (t, *J* = 0.7 Hz, 1H), 7.93 – 7.87 (m, 1H), 7.87 – 7.79 (m, 1H), 7.36 – 7.28 (m, 2H), 6.50 (t, *J* = 54.7 Hz, 1H), 5.70 (d, *J* = 0.7 Hz, 2H), 2.05 (td, *J* = 18.6, 1.1 Hz, 3H).

Example 564: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-3-trifluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{11}F_6N_5O$, 403.1; m/z found, 404.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.83 (d, J = 4.8 Hz, 1H), 8.18 (s, 1H), 7.95 – 7.86 (m, 1H), 7.87 – 7.78 (m, 1H), 7.38 – 7.28 (m, 2H), 5.78 – 5.66 (m, 2H), 2.05 (t, J = 18.6, 1.2 Hz, 3H).

Example 565: (R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-(2-chloropyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{18}H_{15}F_6N_5O_2$, 447.1; m/z found, 448.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.79 – 8.70 (s, 2H), 8.17 – 8.08 (t, J = 0.7 Hz, 1H), 7.94 – 7.88 (m, 1H), 7.88 – 7.78 (m, 1H), 7.35 – 7.27 (m, 1H), 5.74 – 5.65 (d, J = 0.7 Hz, 2H), 2.77 – 2.56 (s, 1H), 2.11 – 1.99 (m, 3H), 1.86 – 1.79 (m, 3H).

Example 566: 2-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{18}H_{18}F_3N_5O_2$, 393.1; m/z found, 394.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.68 (s, 2H), 8.13 (s, 1H), 7.95 – 7.79 (m, 2H), 7.37 – 7.27 (m, 1H), 5.67 (d, J = 0.7 Hz, 2H), 2.15 – 1.97 (m, 3H), 1.63 (s, 6H).

Example 567: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 311 using 2-(2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol (Example 566). MS (ESI): mass calcd. for $C_{19}H_{20}F_3N_5O_2$, 407.2; m/z found, 408.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.62 – 8.56 (s, 2H), 8.16 – 8.09 (t, J = 0.7 Hz, 1H), 7.93 – 7.87 (m, 1H), 7.87 – 7.80 (m, 1H), 7.35 – 7.28 (m, 1H), 5.72 – 5.63 (d, J = 0.7 Hz, 2H), 3.18 – 3.09 (s, 3H), 2.14 – 1.97 (m, 3H), 1.56 – 1.55 (s, 6H).

Example 568: [2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol.




The title compound was prepared in a manner analogous to Example 159, Steps A-B using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 4-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine (Intermediate 54) in Step A. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_2$, 365.1; m/z found, 366.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.60 – 8.43 (d, J = 5.0 Hz, 1H), 8.19 – 8.11 (s, 1H), 7.95 – 7.87 (dd, J = 6.2, 2.7 Hz, 1H), 7.87 – 7.76 (m, 1H), 7.34 – 7.28 (m, 1H), 7.07 – 6.94 (d, J = 5.0 Hz, 1H), 5.74 – 5.62 (d, J = 0.7 Hz, 2H), 4.84 – 4.67 (d, J = 0.8 Hz, 2H), 2.15 – 1.92 (m, 3H).

Example 569: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(methoxymethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-(methoxymethyl)pyrimidine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O_2$, 379.1; m/z found, 380.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.56 – 8.52 (s, 2H), 8.14 – 8.09 (t, J = 0.7 Hz, 1H), 7.92 – 7.87 (m, 1H), 7.87 – 7.78 (m, 1H), 7.35 – 7.27 (m, 1H), 5.70 – 5.64 (d, J = 0.7 Hz, 2H), 4.45 – 4.37 (s, 2H), 3.45 – 3.39 (s, 3H), 2.12 – 1.97 (m, 3H).

Example 570: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O_2$, 379.1; m/z found, 380.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.55 (d, *J* = 5.0 Hz, 1H), 8.15 (t, *J* = 0.8 Hz, 1H), 7.92 – 7.86 (m, 1H), 7.86 – 7.80 (m, 1H), 7.31 (t, *J* = 10.0, 8.8 Hz, 1H), 7.16 (d, *J* = 5.1 Hz, 1H), 5.66 (d, *J* = 0.7 Hz, 2H), 4.50 (d, *J* = 0.7 Hz, 2H), 3.50 (s, 3H), 2.05 (t, *J* = 18.6, 1.2 Hz, 3H).

Example 571: [2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol.




The title compound was prepared in a manner analogous to Example 159, Steps A-B using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 5-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine (Intermediate 53) in Step A. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_2$, 365.1; m/z found, 366.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.61 – 8.56 (s, 2H), 8.15 – 8.10 (t, *J* = 0.7 Hz, 1H), 7.93 – 7.86 (m, 1H), 7.86 – 7.81 (m, 1H), 7.34 – 7.27 (m, 1H), 5.70 – 5.65 (d, *J* = 0.7 Hz, 2H), 4.75 – 4.67 (m, 2H), 2.16 – 1.95 (m, 3H).

Example 572: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{12}F_5N_5O_2$, 401.1; m/z found, 402.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.45 (s, 2H), 8.12 (s, 1H), 7.92 – 7.88 (m, 1H), 7.87 – 7.80 (m, 1H), 7.31 (t, J = 9.4 Hz, 1H), 6.53 (t, J = 71.9 Hz, 1H), 5.66 (d, J = 0.7 Hz, 2H), 2.05 (t, J = 18.6, 1.2 Hz, 3H).

Example 573: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O$, 363.1; m/z found, 364.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.20 (d, J = 1.0 Hz, 1H), 8.12 (d, J = 0.7 Hz, 1H), 7.91 – 7.87 (m, 1H), 7.86 – 7.80 (m, 1H), 7.30 (t, J = 9.4 Hz, 1H), 5.73 – 5.55 (m, 2H), 2.44 (s, 3H), 2.20 (s, 3H), 2.05 (td, J = 18.5, 1.2 Hz, 3H).

Example 574: 5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{13}ClF_3N_5O$, 383.1; m/z found, 384.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.39 (s, 1H), 8.15 – 8.07 (m, 1H), 7.89 (dd, *J* = 6.2, 2.7 Hz, 1H), 7.87 – 7.80 (m, 1H), 7.31 (t, *J* = 9.4 Hz, 1H), 5.73 – 5.56 (m, 2H), 2.68 – 2.52 (m, 3H), 2.15 – 1.91 (m, 3H).

Example 575: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{13}F_4N_5O$, 367.1; m/z found, 368.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.26 (d, *J* = 1.2 Hz, 1H), 8.11 (t, *J* = 0.7 Hz, 1H), 7.94 – 7.86 (m, 1H), 7.86 – 7.78 (m, 1H), 7.31 (t, *J* = 9.4 Hz, 1H), 5.62 (d, *J* = 0.8 Hz, 2H), 2.49 (d, *J* = 2.5 Hz, 3H), 2.05 (td, *J* = 18.7, 1.2 Hz, 3H).

Example 576: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-methylpyrimidin-4-amine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{15}F_3N_6O$, 364.1; m/z found, 365.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.16 – 8.05 (m, 1H), 7.93 – 7.87 (m, 1H), 7.86 – 7.80 (m, 1H), 7.37 – 7.27 (m, 2H), 5.56 (d, J = 0.8 Hz, 2H), 4.98 – 4.81 (m, 2H), 2.15 – 1.94 (m, 6H).

Example 577: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine.




Step A: tert-Butyl (2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)(methyl)carbamate. The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and tert-butyl (2-chloro-5-methylpyrimidin-4-yl)(methyl)carbamate, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{22}H_{25}F_3N_6O_5$, 478.2; m/z found, 479.1 $[M+H]^+$.

Step B: tert-Butyl (2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)(methyl)carbamate. To a vial with tert-butyl (2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidin-4-yl)(methyl)carbamate in DCM (3mL) was added TFA (0.5mL). The reaction mixture was stirred at rt overnight. The completed reaction was concentrated under reduced pressure. Purification (FCC, SiO_2,


eluting with 0-3% 2M NH_3 in MeOH in DCM) afforded the title compound (17.9 mg, 41%) over the two step process. MS (ESI): mass calcd. for $C_{17}H_{17}F_3N_6O$, 378.1; m/z found, 379.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.14 – 8.08 (t, *J* = 0.8 Hz, 1H), 7.92 – 7.87 (m, 1H), 7.85 – 7.79 (m, 1H), 7.79 – 7.76 (d, *J* = 1.1 Hz, 1H), 7.34 – 7.27 (m, 1H), 5.64 – 5.56 (d, *J* = 0.7 Hz, 2H), 4.75 – 4.59 (s, 1H), 3.13 – 3.03 (d, *J* = 4.8 Hz, 3H), 2.10 – 1.99 (m, 3H), 1.99 – 1.95 (d, *J* = 1.0 Hz, 3H).

Example 578: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 163, Steps B-C using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (Intermediate 59) in Step A. MS (ESI): mass calcd. for $C_{16}H_{14}F_4N_6O$, 382.1; m/z found, 383.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.14 – 8.07 (d, *J* = 2.4 Hz, 1H), 7.95 – 7.87 (m, 1H), 7.86 – 7.78 (m, 2H), 7.36 – 7.22 (m, 1H), 5.61 – 5.52 (d, *J* = 2.4 Hz, 2H), 5.22 – 5.08 (s, 1H), 3.16 – 3.02 (m, 3H), 2.17 – 1.90 (m, 3H).


Example 579: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol


(Intermediate 11) and 2-chloro-N,N,5-trimethylpyrimidin-4-amine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{18}H_{19}F_3N_6O$, 392.2; m/z found, 393.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.10 (s, 1H), 7.92 – 7.87 (m, 1H), 7.86 – 7.79 (m, 2H), 7.33 – 7.27 (m, 1H), 5.58 (s, 2H), 3.13 (s, 6H), 2.25 (s, 3H), 2.13 – 1.96 (m, 3H).

Example 580: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloropyrimidin-4-amine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{15}H_{13}F_3N_6O$, 350.1; m/z found, 351.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.26 – 7.99 (m, 2H), 7.99 – 7.68 (m, 2H), 7.49 – 7.03 (m, 1H), 6.36 – 5.98 (m, 1H), 5.75 – 5.49 (d, *J* = 3.0 Hz, 2H), 5.20 – 4.89 (s, 2H), 2.28 – 1.91 (m, 3H).

Example 581: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 163, Steps B-C using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate (Intermediate 55) and (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11). MS (ESI): mass calcd. for $C_{16}H_{15}F_3N_6O$, 364.1; m/z found, 365.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.17 – 8.05 (s,

2017217542 02 Mar 2021


1H), 8.09 – 7.95 (s, 1H), 7.96 – 7.87 (m, 1H), 7.87 – 7.76 (m, 1H), 7.38 – 7.27 (m, 1H), 6.15 – 5.98 (d, *J* = 5.7 Hz, 1H), 5.71 – 5.51 (s, 2H), 5.27 – 4.95 (s, 1H), 3.05 – 2.86 (d, *J* = 4.8 Hz, 3H), 2.12 – 1.93 (m, 3H).

Example 582: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{17}H_{17}F_3N_6O$, 378.1; m/z found, 379.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.15 – 8.08 (t, *J* = 0.8 Hz, 1H), 8.07 – 7.98 (d, *J* = 6.0 Hz, 1H), 7.94 – 7.86 (m, 1H), 7.86 – 7.78 (m, 1H), 7.34 – 7.26 (m, 1H), 6.18 – 6.08 (d, *J* = 6.1 Hz, 1H), 5.66 – 5.54 (d, *J* = 0.7 Hz, 2H), 3.22 – 3.03 (s, 6H), 2.15 – 1.95 (m, 3H).

Example 583: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine-5-carbonitrile.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-cyanopyrimidine, using ACN instead of DMF, employing microwave heating at 140 °C for 90 min. MS (ESI): mass calcd. for $C_{16}H_{11}F_3N_6O$, 360.1; m/z found, 361.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ

2017217542 02 Mar 2021


8.85 (s, 2H), 8.16 – 8.09 (m, 1H), 7.92 – 7.86 (m, 1H), 7.86 – 7.81 (m, 1H), 7.38 – 7.29 (m, 1H), 5.74 (d, *J* = 0.6 Hz, 2H), 2.17 – 1.91 (m, 3H).

Example 584: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methylsulfonyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-(methylsulfonyl)pyrimidine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_3S$, 413.1; m/z found, 414.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 9.05 (s, 2H), 8.21 – 8.05 (m, 1H), 7.92 – 7.88 (m, 1H), 7.87 – 7.81 (m, 1H), 7.33 (t, *J* = 9.3 Hz, 1H), 5.84 – 5.68 (m, 2H), 3.15 (s, 3H), 2.18 – 1.92 (m, 3H).

Example 585: 1-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI): mass calcd. for $C_{17}H_{14}F_3N_5O_2$, 377.1; m/z found, 378.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 9.15 – 9.06 (s, 2H), 8.19 – 8.10 (s, 1H), 7.94 – 7.87 (m, 1H), 7.87 – 7.80 (m, 1H), 7.38 – 7.28 (m, 1H), 5.81 – 5.71 (m, 2H), 2.65 – 2.55 (s, 3H), 2.16 – 1.94 (m, 3H).

Example 586: (R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol.




The title compound was prepared in a manner analogous to Example 157 using 1-(2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one (Example 585). MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O_2$, 379.1; m/z found, 380.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.61 – 8.52 (s, 2H), 8.17 – 8.10 (s, 1H), 7.93 – 7.86 (m, 1H), 7.86 – 7.79 (m, 1H), 7.35 – 7.28 (m, 1H), 5.69 – 5.60 (d, J = 0.7 Hz, 2H), 5.03 – 4.92 (m, 1H), 2.12 – 1.97 (m, 3H), 1.61 – 1.50 (d, J = 6.5 Hz, 3H).

Example 587: 5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{18}H_{16}F_3N_5O$, 375.1; m/z found, 376.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.34 – 8.29 (m, 2H), 8.13 – 8.08 (m, 1H), 7.92 – 7.86 (m, 1H), 7.86 – 7.79 (m, 1H), 7.34 – 7.27 (m, 1H), 5.63 (d, J = 0.7 Hz, 2H), 2.16 – 1.94 (m, 3H), 1.91 – 1.74 (m, 1H), 1.09 – 0.97 (m, 2H), 0.78 – 0.63 (m, 2H).

Example 588: 5-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 165, Step A, using 5-bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine (Example 183) and azetidine. MS (ESI): mass calcd. for $C_{18}H_{17}F_3N_6O$, 390.1; m/z found, 391.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.12 – 8.07 (t, *J* = 0.7 Hz, 1H), 7.93 – 7.87 (m, 1H), 7.87 – 7.78 (s, 3H), 7.35 – 7.27 (m, 1H), 5.62 – 5.54 (d, *J* = 0.7 Hz, 2H), 3.98 – 3.86 (t, *J* = 7.2 Hz, 4H), 2.53 – 2.39 (m, 2H), 2.16 – 1.97 (m, 3H).

Example 589: 2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine.




The title compound was made in an analogous manner to Example 187 using 3-fluoroazetidine hydrochloride. MS (ESI): mass calcd. for $C_{18}H_{16}F_4N_6O$, 408.3; m/z found, 409.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.05 – 8.02 (s, 1H), 7.84 – 7.80 (m, 1H), 7.80 – 7.79 (s, 2H), 7.78 – 7.73 (m, 1H), 7.26 – 7.20 (m, 1H), 5.54 – 5.49 (s, 2H), 5.49 – 5.28 (m, 1H), 4.23 – 4.11 (m, 2H), 3.98 – 3.86 (m, 2H), 2.05 – 1.91 (m, 3H).

Example 590: 2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N,N-dimethylpyrimidin-5-amine.




The title compound was made in an analogous manner to Example 187 using dimethylamine hydrochloride. MS (ESI): mass calcd. for $C_{17}H_{17}F_3N_6O$, 378.3; m/z found, 379.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.05 – 8.03 (m, 1H), 8.03 – 8.01 (s, 2H), 7.84 – 7.80 (dd, *J* = 6.3, 2.7 Hz, 1H), 7.78 – 7.73 (m, 1H), 7.26 – 7.20 (m, 1H), 5.53 – 5.50 (d, *J* = 0.7 Hz, 2H), 2.89 – 2.83 (s, 6H), 2.05 – 1.90 (m, 3H).

Example 591: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-4-(pyrrolidin-1-yl)pyrimidine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{19}H_{19}F_3N_6O$, 404.2; m/z found, 405.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.12 – 8.08 (t, *J* = 0.8 Hz, 1H), 8.02 – 7.96 (m, 1H), 7.91 – 7.86 (m, 1H), 7.84 – 7.79 (m, 1H), 7.33 – 7.27 (m, 1H), 6.04 – 5.96 (d, *J* = 6.0 Hz, 1H), 5.65 – 5.57 (d, *J* = 0.8 Hz, 2H), 3.80 – 3.22 (d, *J* = 110.6 Hz, 4H), 2.13 – 1.94 (m, 7H).

Example 592: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 153 using (1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 11) and 2-chloro-4-(piperidin-1-yl)pyrimidine, using ACN instead of DMF. MS (ESI): mass calcd. for $C_{20}H_{21}F_3N_6O$, 418.2; m/z found, 419.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.15 – 8.07 (s, 1H), 8.07 – 7.97 (d, J = 6.1 Hz, 1H), 7.95 – 7.86 (m, 1H), 7.86 – 7.78 (m, 1H), 7.34 – 7.27 (m, 1H), 6.22 – 6.15 (d, J = 6.2 Hz, 1H), 5.61 – 5.54 (d, J = 0.8 Hz, 2H), 3.73 – 3.53 (s, 4H), 2.13 – 1.98 (m, 3H), 1.75 – 1.65 (m, 2H), 1.65 – 1.56 (m, 4H).

Example 593: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-ethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 173, Steps A through F, using 2-chloro-5-ethylpyrimidine in Step F. MS (ESI): mass calcd. for $C_{18}H_{18}F_3N_5O$, 377.1; m/z found, 378.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.39 (s, 2H), 7.66 (dd, J = 6.3, 2.6 Hz, 1H), 7.57 – 7.51 (m, 1H), 7.32 (t, J = 9.3 Hz, 1H), 5.57 (s, 2H), 2.60 (q, J = 7.6 Hz, 2H), 2.42 (s, 3H), 2.04 (td, J = 18.6, 1.1 Hz, 3H), 1.25 (t, J = 7.6 Hz, 3H).

Example 594: 5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 173, Steps A through F, using 2-chloro-5-cyclopropylpyrimidine in Step F. MS (ESI): mass calcd. for $C_{19}H_{18}F_3N_5O$, 389.1; m/z found, 390.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.30 (s, 2H), 7.66 (dd, *J* = 6.3, 2.6 Hz, 1H), 7.55 – 7.51 (m, 1H), 7.34 – 7.29 (m, 1H), 5.56 (s, 2H), 2.41 (s, 3H), 2.04 (td, *J* = 18.6, 1.1 Hz, 3H), 1.82 (tt, *J* = 8.5, 5.1 Hz, 1H), 1.04 – 0.97 (m, 2H), 0.73 – 0.63 (m, 2H).

Example 595: 2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 173, Steps A through F, using 2-chloro-4,5-dimethylpyrimidine in Step F. MS (ESI): mass calcd. for $C_{18}H_{18}F_3N_5O$, 377.1; m/z found, 378.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.19 (s, 1H), 7.66 (dd, *J* = 6.4, 2.6 Hz, 1H), 7.53 (ddd, *J* = 8.6, 4.1, 2.8 Hz, 1H), 7.35 – 7.29 (m, 1H), 5.56 (s, 2H), 2.45 – 2.40 (m, 6H), 2.19 (s, 3H), 2.04 (td, *J* = 18.6, 1.2 Hz, 3H).

Example 596: 5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 173, Steps A through F, using 2,5-dichloro-4-methylpyrimidine in Step F. MS (ESI): mass calcd. for $C_{17}H_{15}ClF_3N_5O$, 397.1; m/z found398.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.37 (s, 1H), 7.66 (dd, *J* = 6.3, 2.6 Hz, 1H), 7.53 (ddd, *J* = 8.6, 4.1, 2.7 Hz, 1H), 7.33 (t, *J* = 9.3 Hz, 1H), 5.56 (s, 2H), 2.55 (s, 3H), 2.42 (s, 3H), 2.04 (td, *J* = 18.6, 1.2 Hz, 3H).

Example 597: 2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 39) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{13}H_9F_2N_5O$, 289.1; m/z found, 290.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.94 (d, *J* = 0.6 Hz, 1H), 8.66 (d, *J* = 4.8 Hz, 2H), 8.13 (ddd, *J* = 11.4, 7.0, 2.7 Hz, 1H), 7.83 (dddd, *J* = 9.0, 4.1, 2.6, 1.6 Hz, 1H), 7.71 (dt, *J* = 10.4, 8.8 Hz, 1H), 7.20 (t, *J* = 4.8 Hz, 1H), 5.53 (d, *J* = 0.6 Hz, 2H).


Example 598: 2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine.



02 Mar 2021 2017217542


The title compound was prepared in a manner analogous to Example 1 using (1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 39) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{13}H_8F_3N_5O$, 307.1; m/z found, 308.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.93 (s, 1H), 8.75 (d, J = 0.6 Hz, 2H), 8.13 (ddd, J = 11.5, 7.0, 2.7 Hz, 1H), 7.83 (dt, J = 8.3, 2.9 Hz, 1H), 7.71 (dt, J = 10.4, 8.8 Hz, 1H), 5.52 (s, 2H).

Example 599: 2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 39) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}F_2N_5O_2$, 319.1; m/z found, 320.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.92 (s, 1H), 8.41 (s, 2H), 8.13 (ddd, J = 11.4, 7.0, 2.6 Hz, 1H), 7.83 (dddd, J = 9.0, 4.1, 2.6, 1.6 Hz, 1H), 7.71 (dt, J = 10.4, 8.8 Hz, 1H), 5.47 (d, J = 0.6 Hz, 2H), 3.86 (s, 3H).


Example 600: 5-Chloro-2-[[1-(3,4-difluorophenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 39) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{13}H_8ClF_2N_5O$, 323.0; m/z found, 324.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.93 (s, 1H), 8.77 (s, 2H), 8.13 (ddd, J = 11.5, 7.0, 2.7 Hz, 1H), 7.83 (dtt, J = 8.1, 2.6, 1.5 Hz, 1H), 7.71 (dt, J = 10.4, 8.8 Hz, 1H), 5.54 (d, J = 0.5 Hz, 2H).


02 Mar 2021
2017217542

Example 601: 2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 39) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}F_2N_5O$, 303.1; m/z found, 304.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.93 (d, J = 0.6 Hz, 1H), 8.49 (d, J = 0.8 Hz, 2H), 8.13 (ddd, J = 11.5, 7.0, 2.7 Hz, 1H), 7.83 (dddd, J = 9.1, 4.1, 2.6, 1.6 Hz, 1H), 7.71 (dt, J = 10.3, 8.8 Hz, 1H), 5.49 (d, J = 0.6 Hz, 2H), 2.21 (d, J = 0.8 Hz, 3H).

Example 602: 2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 39) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O$, 317.1; m/z found, 318.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.93 (s, 1H), 8.52 (d, J = 0.6 Hz, 2H), 8.13 (ddd, J = 11.5, 7.1, 2.7 Hz, 1H), 7.87 - 7.80 (m, 1H), 7.71 (dt, J = 10.4, 8.8 Hz, 1H), 5.50 (d, J = 0.6 Hz, 2H), 2.62 - 2.54 (m, 2H), 1.19 (t, J = 7.6 Hz, 3H).

Example 603: 2-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,5-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 47) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}F_2N_5O$, 303.1; m/z found, 304.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.73 (s, 1H), 8.49 (d, J = 1.0 Hz, 2H), 7.85 (s, 1H), 7.66 (td, J = 9.9, 4.9 Hz, 1H), 7.51 (s, 1H), 5.50 (s, 2H), 2.21 (d, J = 0.9 Hz, 3H).

Example 604: 2-[2-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.



The title compound was prepared in a manner analogous to Example 1 using (1-(2,5-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 47) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.73 (s, 1H), 8.69 (d, J = 1.1 Hz, 1H), 7.92 - 7.81 (m, 1H), 7.66 (td, J = 9.7, 4.6 Hz, 1H), 7.52 (d, J = 8.5 Hz, 1H), 5.53 (s, 2H), 5.32 (s, 1H), 1.47 (s, 6H).

Example 605: 5-Chloro-2-[[1-(2,3-difluorophenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,3-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 48) and

2017217542 02 Mar 2021


2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{13}H_8ClF_2N_5O$, 323.0; m/z found, 324.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.86 - 8.66 (m, 2H), 7.71 (s, 2H), 7.48 (s, 1H), 5.56 (d, J = 1.5 Hz, 2H).

Example 606: 2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,3-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 48) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{13}H_8F_3N_5O$, 307.1; m/z found, 308.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.83 - 8.70 (m, 3H), 7.69 (dddd, J = 11.8, 8.9, 5.5, 1.6 Hz, 2H), 7.54 - 7.42 (m, 1H), 5.54 (s, 2H).

Example 607: 2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,3-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 48) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{13}H_9F_2N_5O$, 289.1; m/z found, 290.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.77 (d, J = 2.0 Hz, 1H), 8.66 (d, J = 4.8 Hz, 2H), 7.76 - 7.64 (m, 2H), 7.53 - 7.43 (m, 1H), 7.20 (t, J = 4.8 Hz, 1H), 5.55 (s, 2H).

Example 608: 2-[2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.




The title compound was prepared in a manner analogous to Example 1 using (1-(2,3-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 48) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.2 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.70 (s, 2H), 8.58 (d, *J* = 2.4 Hz, 1H), 7.68 (ddt, *J* = 8.1, 6.3, 1.8 Hz, 1H), 7.49 (dddd, *J* = 10.1, 8.8, 7.3, 1.7 Hz, 1H), 7.40 (tdd, *J* = 8.4, 5.2, 2.0 Hz, 1H), 5.63 (d, *J* = 2.5 Hz, 2H), 1.56 (d, *J* = 2.7 Hz, 6H).

Example 609: 2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine.



The title compound was prepared in a manner analogous to Example 1 using (1-(2,3-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 48) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}F_3N_5O$, 321.1; m/z found, 322.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 8.92 - 8.50 (m, 2H), 7.79 - 7.63 (m, 2H), 7.48 (s, 1H), 5.49 (d, *J* = 12.0 Hz, 2H), 2.37 (s, 3H).


Example 610: 2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.



2017217542 02 Mar 2021


The title compound was prepared in a manner analogous to Example 1 using (1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 46) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}ClFN_5O$, 319.1; m/z found, 320.0 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.55 (d, *J* = 2.5 Hz, 1H), 8.45 (t, *J* = 0.8 Hz, 2H), 7.81 (ddd, *J* = 8.2, 6.6, 1.6 Hz, 1H), 7.69 (ddd, *J* = 8.3, 6.8, 1.6 Hz, 1H), 7.40 (td, *J* = 8.2, 1.6 Hz, 1H), 5.60 (d, *J* = 0.6 Hz, 2H), 2.27 (t, *J* = 0.8 Hz, 3H).

Example 611: 2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 46) and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{13}H_9ClFN_5O$, 305.0; m/z found, 306.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.78 (d, *J* = 2.3 Hz, 1H), 8.67 (dd, *J* = 4.8, 1.6 Hz, 2H), 7.92 - 7.79 (m, 2H), 7.57 - 7.43 (m, 1H), 7.28 - 7.15 (m, 1H), 5.55 (d, *J* = 1.5 Hz, 2H).

Example 612: 5-Chloro-2-[[1-(3-chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 46) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{13}H_8Cl_2FN_5O$, 339.0; m/z found, 341.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.78 (d, *J* = 5.8 Hz, 2H), 7.84 (q, *J* = 8.0, 7.6 Hz, 3H), 7.58 - 7.40 (m, 1H), 5.56 (s, 2H).

Example 613: 2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 46) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}ClF_2N_5O$, 337.1; m/z found, 338.0 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.76 (d, J = 2.2 Hz, 1H), 8.57 (d, J = 1.6 Hz, 1H), 7.84 (dt, J = 7.9, 6.4 Hz, 2H), 7.53 - 7.45 (m, 1H), 5.51 (s, 2H), 2.44 (d, J = 2.6 Hz, 3H).

Example 614: 2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 46) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for $C_{13}H_8ClF_2N_5O$, 323.0; m/z found, 324.0 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.57 (d, J = 4.1 Hz, 3H), 7.81 (ddd, J = 8.2, 6.6, 1.7 Hz, 1H), 7.69 (ddd, J = 8.4, 6.7, 1.6 Hz, 1H), 7.41 (td, J = 8.2, 1.7 Hz, 1H), 5.61 (s, 2H).

Example 615: 2-[2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 46) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{16}H_{15}ClFN_5O_2$, 363.1; m/z found, 364.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.77 (d, J = 2.1 Hz, 1H), 8.69 (s, 2H), 7.84 (dddd, J = 11.7, 8.3, 6.8, 1.6 Hz, 2H), 7.48 (td, J = 8.2, 1.5 Hz, 1H), 5.53 (s, 2H), 5.32 (s, 1H), 1.46 (s, 6H).

Example 616: [2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]methanol.



The title compound was prepared analogous to Example 160, steps A – B, using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) in step A. MS (ESI): mass calcd. for $C_{14}H_{11}BrFN_5O_2$, 379.0; m/z found, 380.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.55 (s, 2H), 8.09 (s, 1H), 7.98 (dd, J = 5.8, 2.6 Hz, 1H), 7.66 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 7.29 – 7.25 (m, 1H), 5.64 (d, J = 0.7 Hz, 2H), 4.69 (s, 2H).


Example 617: [2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-4-yl]methanol.



2017217542 02 Mar 2021


The title compound was prepared analogous to Example 159, steps A – B, using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) in step A. MS (ESI): mass calcd. for $C_{14}H_{11}BrFN_5O_2$, 379.0; m/z found, 380.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.51 (d, *J* = 5.0 Hz, 1H), 8.09 (s, 1H), 7.98 (dd, *J* = 5.8, 2.7 Hz, 1H), 7.66 (ddd, *J* = 8.8, 4.0, 2.6 Hz, 1H), 7.29 – 7.26 (m, 1H), 7.02 (d, *J* = 5.0 Hz, 1H), 5.66 (d, *J* = 0.7 Hz, 2H), 4.75 – 4.70 (m, 2H), 3.25 (s, 1H).

Example 618: 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine.



The title compound was prepared in a manner analogous to Example 192, Steps A – B, using 1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 14) in Step B. MS (ESI): mass calcd. for $C_{15}H_{12}BrF_2N_5O_2$, 411.0; m/z found,412.0 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.37 (s, 1H), 8.32 (s, 2H), 8.09 (dd, *J* = 5.8, 2.7 Hz, 1H), 7.78 (ddd, *J* = 8.9, 4.2, 2.7 Hz, 1H), 7.35 (dd, *J* = 8.9, 7.9 Hz, 1H), 5.59 (s, 2H), 4.86 – 4.79 (m, 1H), 4.75 – 4.68 (m, 1H), 4.38 – 4.32 (m, 1H), 4.31 – 4.25 (m, 1H).

Example 619: 2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-chloro-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloropyrimidine. MS (ESI): mass calcd. for $C_{13}H_9ClFN_5O$, 305.0; m/z found, 306.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.57 (d, *J* = 4.7 Hz, 2H), 8.11 – 8.06 (m, 1H), 7.84

2017217542 02 Mar 2021


(dd, *J* = 6.2, 2.7 Hz, 1H), 7.62 (ddd, *J* = 8.9, 4.0, 2.7 Hz, 1H), 7.31 (t, *J* = 8.6 Hz, 1H), 7.00 (t, *J* = 4.8 Hz, 1H), 5.66 (d, *J* = 0.7 Hz, 2H).

Example 620: 2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-chloro-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{14}H_{11}ClFN_5O$, 319.1; m/z found, 320.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.38 (d, *J* = 0.7 Hz, 2H), 8.07 (s, 1H), 7.84 (dd, *J* = 6.3, 2.7 Hz, 1H), 7.61 (ddd, *J* = 8.9, 4.0, 2.7 Hz, 1H), 7.30 (t, *J* = 8.6 Hz, 1H), 5.63 (d, *J* = 0.7 Hz, 2H), 2.26 (s, 3H).

Example 621: 2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(3-chloro-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}ClFN_5O$, 333.1; m/z found, 334.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.39 (s, 2H), 8.08 (s, 1H), 7.84 (dd, *J* = 6.2, 2.7 Hz, 1H), 7.61 (ddd, *J* = 8.9, 4.0, 2.7 Hz, 1H), 7.30 (t, *J* = 8.6 Hz, 1H), 5.63 (s, 2H), 2.60 (q, *J* = 7.6 Hz, 2H), 1.26 (t, *J* = 7.6 Hz, 3H).

Example 622: 2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(3-chloro-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}ClFN_5O_2$, 349.1; m/z found, 350.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.54 (d, *J* = 5.0 Hz, 1H), 8.11 (s, 1H), 7.84 (dd, *J* = 6.2, 2.7 Hz, 1H), 7.61 (ddd, *J* = 8.9, 3.9, 2.7 Hz, 1H), 7.30 (t, *J* = 8.6 Hz, 1H), 7.15 (d, *J* = 5.0 Hz, 1H), 5.65 (s, 2H), 4.50 (s, 2H), 3.50 (s, 3H).


Example 623: 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-4-isopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{16}ClF_2N_5O$, 379.1; m/z found, 380.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.43 (d, *J* = 5.1 Hz, 1H), 8.18 (s, 1H), 8.00 (d, *J* = 2.6 Hz, 1H), 7.89 – 7.86 (m, 1H), 7.62 – 7.57 (m, 1H), 7.11 – 6.85 (m, 2H), 5.66 (s, 2H), 2.97 (hept, *J* = 6.9 Hz, 1H), 1.30 (d, *J* = 6.9 Hz, 6H).


Example 624: [2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol.

2017217542 02 Mar 2021




The title compound was prepared analogous to Example 160, steps A – B, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) in step A. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.1; m/z found, 368.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.58 (s, 2H), 8.17 (s, 1H), 8.01 (d, *J* = 2.6 Hz, 1H), 7.89 (dd, *J* = 8.7, 2.6 Hz, 1H), 7.66 – 7.56 (m, 1H), 6.99 (t, *J* = 54.5 Hz, 1H), 5.68 (d, *J* = 0.7 Hz, 2H), 4.71 (d, *J* = 5.6 Hz, 2H), 1.78 (t, *J* = 5.5 Hz, 1H).

Example 625: [2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol.




The title compound was prepared analogous to Example 159, Steps A – B, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) in Step A. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O_2$, 367.1; m/z found, 368.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.51 (d, *J* = 5.0 Hz, 1H), 8.19 (s, 1H), 8.00 (d, *J* = 2.6 Hz, 1H), 7.92 – 7.83 (m, 1H), 7.64 – 7.56 (m, 1H), 7.11 – 6.85 (m, 2H), 5.67 (s, 2H), 4.72 (s, 2H).

Example 626: 2-[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.




The title compound was prepared analogous to Example 155, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{17}H_{16}ClF_2N_5O_2$, 395.1; m/z found, 396.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.66 (s, 2H), 8.19 (s, 1H), 8.01 (d, *J* = 2.6 Hz, 1H), 7.88 (dd, *J* = 8.7, 2.6 Hz, 1H), 7.60 (dd, *J* = 8.6, 1.2 Hz, 1H), 6.98 (t, *J* = 54.5 Hz, 1H), 5.65 – 5.63 (m, 2H), 1.61 (s, 6H).

Example 627: 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{14}ClF_2N_5O_2$, 381.1; m/z found, 382.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.55 (d, *J* = 5.0 Hz, 1H), 8.21 (s, 1H), 8.00 (d, *J* = 2.6 Hz, 1H), 7.91 – 7.86 (m, 1H), 7.63 – 7.58 (m, 1H), 7.15 (d, *J* = 5.0 Hz, 1H), 6.99 (t, *J* = 54.5 Hz, 1H), 5.66 (s, 2H), 4.50 (s, 2H), 3.50 (s, 3H).

Example 628: 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-4-difluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}ClF_4N_5O$, 387.1; m/z found, 388.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.76 (d, *J* = 4.9 Hz, 1H), 8.20 (s, 1H), 8.01 (d, *J* = 2.6 Hz, 1H), 7.91 – 7.85 (m, 1H), 7.64 – 7.57 (m, 1H), 7.30 (d, *J* = 4.9 Hz, 1H), 6.99 (t, *J* = 54.5 Hz, 1H), 6.50 (t, *J* = 54.7 Hz, 1H), 5.71 (d, *J* = 0.6 Hz, 2H).

Example 629: 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine.




The title compound was prepared analogous to Example 155, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{16}H_{15}ClF_2N_6O$, 380.1; m/z found, 381.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.15 (s, 1H), 8.06 – 7.98 (m, 2H), 7.91 – 7.82 (m, 1H), 7.60 (dt, *J* = 8.7, 1.2 Hz, 1H), 6.99 (t, *J* = 54.6 Hz, 1H), 6.13 (d, *J* = 6.1 Hz, 1H), 5.61 (d, *J* = 0.8 Hz, 2H), 3.11 (s, 6H).

Example 630: 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-cyclopropyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{14}ClF_2N_5O$, 377.1; m/z found, 378.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.32 (s, 2H), 8.16 (s, 1H), 8.00 (d, *J* = 2.6 Hz, 1H), 7.91 – 7.87 (m, 1H), 7.64 – 7.58 (m, 1H), 6.99 (t, *J* = 54.5 Hz, 1H), 5.64 (s, 2H), 1.83 (tt, *J* = 8.4, 5.1 Hz, 1H), 1.02 (ddd, *J* = 8.3, 6.4, 4.8 Hz, 2H), 0.70 (ddd, *J* = 7.3, 5.7, 4.4 Hz, 2H).

Example 631: 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-cyclopropyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-4-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{14}ClF_2N_5O$, 377.1; m/z found, 378.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.32 – 8.29 (m, 1H), 8.16 – 8.12 (m, 1H), 8.02 – 7.98 (m, 1H), 7.89 – 7.84 (m, 1H), 7.60 (dd, *J* = 8.5, 1.2 Hz, 1H), 7.10 – 6.84 (m, 2H), 5.60 (s, 2H), 2.00 – 1.90 (m, 1H), 1.22 – 1.16 (m, 2H), 1.08 (ddd, *J* = 6.7, 3.0, 1.6 Hz, 2H).

Example 632: 2-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 161, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8). (ESI): mass calcd. for $C_{15}H_{13}ClF_2N_6O$, 366.1; m/z found, 366.9 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.15 (d, *J* = 1.2 Hz, 1H), 8.00 (d, *J* = 2.6 Hz, 1H), 7.92 – 7.84 (m, 2H), 7.62 – 7.56 (m, 1H), 6.98 (t, *J* = 54.6 Hz, 1H), 5.60 – 5.54 (m, 2H), 4.91 (s, 2H), 2.07 – 2.01 (m, 3H).

Example 633: 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine.




The title compound was prepared analogous to Example 155, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-N,N,5-trimethylpyrimidin-4-amine. MS (ESI): mass calcd. for $C_{17}H_{17}ClF_2N_6O$, 394.1; m/z found, 395.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.14 (s, 1H), 8.04 – 7.97 (m, 1H), 7.90 – 7.80 (m, 2H), 7.62 – 7.56 (m, 1H), 6.99 (t, *J* = 54.6 Hz, 1H), 5.59 (s, 2H), 3.13 (s, 6H), 2.25 (s, 3H).

Example 634: 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-4-(pyrrolidin-1-yl)pyrimidine. MS (ESI): mass calcd. for $C_{18}H_{17}ClF_2N_6O$, 406.1; m/z found, 407.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.15 (s, 1H), 8.03 – 7.98 (m, 2H), 7.90 – 7.84 (m, 1H), 7.60 (dt, *J* = 8.6, 1.2 Hz, 1H), 6.99 (t, *J* = 54.6 Hz, 1H), 6.00 (d, *J* = 6.0 Hz, 1H), 5.61 (d, *J* = 0.8 Hz, 2H), 3.62 (s, 2H), 3.35 (s, 2H), 2.00 (s, 4H).

Example 635: 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) and 2-chloro-4-(piperidin-1-yl)pyrimidine. MS (ESI): mass calcd. for $C_{19}H_{19}ClF_2N_6O$, 420.1; m/z found, 421.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.15 (s, 1H), 8.06 – 7.96 (m, 2H), 7.91 – 7.80 (m, 1H), 7.68 – 7.52 (m, 1H), 6.98 (t, *J* = 54.6 Hz, 1H), 6.19 (d, *J* = 6.1 Hz, 1H), 5.58 (s, 2H), 3.73 – 3.48 (m, 4H), 1.73 – 1.56 (m, 6H).

Example 636: 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine.




The title compound was prepared in a manner analogous to Example 192, Steps A – B, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) in Step B. MS (ESI): mass calcd. for $C_{16}H_{13}ClF_3N_5O_2$, 399.1; m/z found, 400.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.29 (s, 2H), 8.16 (s, 1H), 8.01 (d, *J* = 2.5 Hz, 1H), 7.89 (dd, *J* = 8.7, 2.7 Hz, 1H), 7.61 (d, *J* = 8.7 Hz, 1H), 6.99 (t, *J* = 54.5 Hz, 1H), 5.62 (d, *J* = 0.7 Hz, 2H), 4.90 – 4.77 (m, 1H), 4.76 – 4.66 (m, 1H), 4.37 – 4.27 (m, 1H), 4.27 – 4.18 (m, 1H). ^{19}F NMR (376 MHz, $CDCl_3$) δ -115.87 (s), -116.02 (s).

Example 637: 2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine.




The title compound was prepared in a manner analogous to Example 196, Steps A – G, using (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 8) in step G. MS (ESI): mass calcd. for $C_{17}H_{15}ClF_3N_5O$, 397.1; m/z found, 398.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.42 (s, 2H), 8.18 (s, 1H), 8.01 (d, *J* = 2.7 Hz, 1H), 7.92 – 7.86 (m, 1H), 7.61 (d, *J* = 8.7 Hz, 1H), 6.99 (t, *J* = 54.5 Hz, 1H), 5.65 (d, *J* = 0.7 Hz, 1H), 4.55 (t, *J* = 5.7 Hz, 0H), 4.43 (t, *J* = 5.7 Hz, 0H), 2.78 – 2.63 (m, 1H), 2.10 – 1.92 (m, 1H).

Example 638: 2-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine.




Made in an analogous manner to Example 188 using 2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine (Example 51). MS (ESI): mass calcd. for $C_{18}H_{18}F_2N_6O$, 372.3; m/z found, 373.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.41 – 8.34 (d, *J* = 0.9 Hz, 2H), 8.05 – 8.00 (s, 1H), 7.74 – 7.70 (d, *J* = 2.5 Hz, 1H), 7.67 – 7.62 (m, 1H), 6.91 – 6.64 (m, 1H), 6.58 – 6.51 (d, *J* = 8.8 Hz, 1H), 5.64 – 5.58 (d, *J* = 0.6 Hz, 2H), 4.15 – 4.07 (m, 4H), 2.45 – 2.35 (m, 2H), 2.29 – 2.21 (m, 3H).

Example 639: 2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-isopropyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-chloro-5-isopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{17}F_2N_5O$, 345.1; m/z found, 346.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.42 (s, 2H), 8.14 (d, *J* = 2.8 Hz, 1H), 7.74 – 7.65 (m, 1H), 7.02 (td, *J* = 8.8, 1.8 Hz, 1H), 5.65 (d, *J* = 0.7 Hz, 2H), 2.91 (hept, *J* = 6.8 Hz, 1H), 2.30 (t, *J* = 2.0 Hz, 3H), 1.29 (d, *J* = 7.0 Hz, 6H).

Example 640: 2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-isopropyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-chloro-4-isopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{17}F_2N_5O$, 345.1; m/z found, 346.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.42 (d, *J* = 5.1 Hz, 1H), 8.13 (d, *J* = 2.9 Hz, 1H), 7.71 – 7.64 (m, 1H), 7.04 – 6.97 (m, 1H), 6.85 (d, *J* = 5.1 Hz, 1H), 5.66 (d, *J* = 0.7 Hz, 2H), 2.95 (hept, *J* = 6.9 Hz, 1H), 2.28 (t, *J* = 2.0 Hz, 3H), 1.28 (d, *J* = 6.9 Hz, 6H).

Example 641: 5-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-chloro-5-difluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O$, 353.1; m/z found, 354.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.71 (t, *J* = 1.2 Hz, 2H), 8.15 (d, *J* = 2.8 Hz, 1H), 7.74 – 7.66 (m, 1H), 7.03 (td, *J* = 8.6, 1.8 Hz, 1H), 6.72 (t, *J* = 55.6 Hz, 1H), 5.72 (s, 2H), 2.30 (t, *J* = 2.1 Hz, 3H).

Example 642: 4-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-chloro-4-difluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O$, 353.1; m/z found, 354.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.75 (d, *J* = 4.9 Hz, 1H), 8.16 (d, *J* = 2.8 Hz, 1H), 7.75 – 7.64 (m, 1H), 7.29 (d, *J* = 4.9 Hz, 1H), 7.10 – 6.96 (m, 1H), 6.49 (t, *J* = 54.7 Hz, 1H), 5.71 (s, 2H), 2.30 (t, *J* = 2.1 Hz, 3H).

Example 643: 2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-chloro-5-trifluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{10}F_5N_5O$, 371.1; m/z found, 372.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.81 (d, *J* = 0.9 Hz, 2H), 8.16 (d, *J* = 2.8 Hz, 1H), 7.70 (td, *J* = 8.7, 5.6 Hz, 1H), 7.03 (td, *J* = 8.7, 1.8 Hz, 1H), 5.74 (s, 2H), 2.30 (t, *J* = 2.1 Hz, 3H).

Example 644: 2-[2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. for $C_{17}H_{17}F_2N_5O_2$, 361.1; m/z found, 362.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.67 (s, 2H), 8.14 (d, *J* = 2.8 Hz, 1H), 7.69 (td, *J* = 8.6, 5.7 Hz, 1H), 7.02 (td, *J* = 8.7, 1.9 Hz, 1H), 5.67 (s, 2H), 2.30 (s, 3H), 1.62 (s, 6H).

Example 645: 2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O_2$, 347.1; m/z found, 348.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.54 (d, *J* = 5.0 Hz, 1H), 8.14 (d, *J* = 2.8 Hz, 1H), 7.68 (dddd, *J* = 9.1, 8.4, 5.7, 0.8 Hz, 1H), 7.14 (dt, *J* = 5.0, 0.7 Hz, 1H), 7.01 (td, *J* = 8.7, 1.8 Hz, 1H), 5.65 (d, *J* = 0.7 Hz, 2H), 4.49 (d, *J* = 0.7 Hz, 2H), 3.49 (s, 3H), 2.29 (t, *J* = 2.1 Hz, 3H).

Example 646: 5-(Difluoromethoxy)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O_2$, 369.1; m/z found, 370.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.44 (s, 2H), 8.14 (d, *J* = 2.7 Hz, 1H), 7.74 – 7.65 (m, 1H), 7.02 (td, *J* = 8.7, 1.8 Hz, 1H), 6.52 (t, *J* = 71.9 Hz, 1H), 5.66 (d, *J* = 0.6 Hz, 2H), 2.30 (t, *J* = 2.1 Hz, 3H).

Example 647: 5-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{15}F_2N_5O$, 343.1; m/z found, 344.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.31 (s, 2H), 8.12 (d, *J* = 2.8 Hz, 1H), 7.68 (td, *J* = 8.7, 5.7 Hz, 1H), 7.01 (td, *J* = 8.7, 1.8 Hz, 1H), 5.63 (s, 2H), 2.29 (t, *J* = 2.0 Hz, 3H), 1.82 (tt, *J* = 8.4, 5.1 Hz, 1H), 1.01 (ddd, *J* = 8.4, 6.4, 4.9 Hz, 2H), 0.72 – 0.66 (m, 2H).

Example 648: 4-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-chloro-4-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{15}F_2N_5O$, 343.1; m/z found, 344.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.29 (d, *J* = 5.1 Hz, 1H), 8.10 (d, *J* = 2.7 Hz, 1H), 7.68 (td, *J* = 8.7, 5.7 Hz, 1H), 7.01 (td, *J* = 8.7, 1.8 Hz, 1H), 6.85 (d, *J* = 5.1 Hz, 1H), 5.60 (s, 2H), 2.29 (t, *J* = 2.1 Hz, 3H), 1.94 (tt, *J* = 8.1, 4.6 Hz, 1H), 1.22 – 1.16 (m, 2H), 1.10 – 1.03 (m, 2H).

Example 649: 2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}F_3N_5O$, 335.1; m/z found, 336.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.25 (d, *J* = 1.2 Hz, 1H), 8.13 (d, *J* = 2.7 Hz, 1H), 7.76 – 7.64 (m, 1H), 7.06 – 6.95 (m, 1H), 5.67 – 5.57 (m, 2H), 2.49 (d, *J* = 2.5 Hz, 3H), 2.30 (t, *J* = 2.0 Hz, 3H).

Example 650: 5-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O$, 351.1; m/z found, 352.0 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.38 (s, 1H), 8.13 (d, *J* = 2.6 Hz, 1H), 7.76 – 7.63 (m, 1H), 7.06 – 6.99 (m, 1H), 5.66 – 5.60 (m, 2H), 2.56 (s, 3H), 2.30 (t, *J* = 2.0 Hz, 3H).

Example 651: 2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 161, using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 10). MS (ESI): mass calcd. for $C_{15}H_{14}F_2N_6O$, 332.1; m/z found, 333.1 $[M+H]^+$. ^1H NMR (500 MHz, CD_3OD) δ 8.46 (d, *J* = 2.3 Hz, 1H), 7.72 (s, 1H), 7.65 (td, *J* = 8.6, 5.6 Hz, 1H), 7.15 (td, *J* = 8.8, 1.8 Hz, 1H), 5.46 (s, 2H), 2.30 (t, *J* = 2.0 Hz, 3H), 1.99 (s, 3H).

Example 652: 2-[[1-[3-(Difluoromethyl)-2,4-difluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine.




02 Mar 2021 2017217542

Step A. 1-(3-(Difluoromethyl)-2,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol.The title compound was prepared in a manner analogous toIntermediate 5 using 3-(difluoromethyl)-2,4-difluoroaniline in step A, and 1-azido-3-(difluoromethyl)-2,4-difluorobenzene and a reaction temperature of 60 °C in step B.


Step B. 2-[[1-[3-(Difluoromethyl)-2,4-difluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine. The title compound was prepared analogous to Example 155, using (1-(3-(difluoromethyl)-2,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-trifluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_8F_7N_5O$, 407.1; m/z found, 408.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.82 (s, 2H), 8.22 (d, *J* = 2.7 Hz, 1H), 8.14 – 8.05 (m, 1H), 7.24 – 7.16 (m, 1H), 7.00 (t, *J* = 52.9 Hz, 1H), 5.74 (s, 2H).

Example 653: 5-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 13) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for $C_{14}H_{10}ClF_2N_5O$, 337.1; m/z found,338.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.49 (s, 2H), 8.14 (d, *J* = 2.5 Hz, 1H), 7.77 (t, *J* = 8.0 Hz, 1H), 7.00 (t, *J* = 9.7 Hz, 1H), 5.63 (s, 2H), 2.32 (s, 3H).


Example 654: 2-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine.



02 Mar 2021 2017217542


The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 13) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{13}F_2N_5O$, 317.1; m/z found, 318.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.37 (s, 2H), 8.14 (d, *J* = 2.7 Hz, 1H), 7.77 (t, *J* = 8.0 Hz, 1H), 6.99 (dd, *J* = 10.6, 8.9 Hz, 1H), 5.63 (s, 2H), 2.32 (s, 3H), 2.25 (s, 3H).

Example 655: 2-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 13) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for $C_{16}H_{15}F_2N_5O$, 331.1; m/z found, 332.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.38 (s, 2H), 8.14 (d, *J* = 2.8 Hz, 1H), 7.80 – 7.74 (m, 1H), 6.98 (dd, *J* = 10.6, 8.9 Hz, 1H), 5.63 (d, *J* = 0.6 Hz, 2H), 2.59 (q, *J* = 7.6 Hz, 2H), 2.36 – 2.25 (m, 3H), 1.25 (t, *J* = 7.6 Hz, 3H).


Example 656: 5-(Difluoromethyl)-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 13) and 2-chloro-5-difluoromethylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O$, 353.1; m/z found, 354.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.70 (s, 2H),


8.16 (d, *J* = 2.7 Hz, 1H), 7.77 (t, *J* = 7.5 Hz, 1H), 7.00 (dd, *J* = 10.7, 8.9 Hz, 1H), 6.72 (t, *J* = 55.6 Hz, 1H), 5.71 (d, *J* = 0.7 Hz, 2H), 2.37 – 2.26 (m, 3H).

Example 657: 5-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 13) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{15}H_{12}ClF_2N_5O$, 351.1; m/z found, 352.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.36 (s, 1H), 8.14 (d, *J* = 2.7 Hz, 1H), 7.82 – 7.70 (m, 1H), 6.99 (dd, *J* = 10.6, 8.9 Hz, 1H), 5.62 (s, 2H), 2.55 (s, 3H), 2.33 – 2.29 (m, 3H).

Example 658: 5-Cyclopropyl-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 155, using (1-(2,4-difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 13) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): mass calcd. for $C_{17}H_{15}F_2N_5O$, 343.1; m/z found, 344.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.31 (s, 2H), 8.14 (d, *J* = 2.7 Hz, 1H), 7.77 (t, *J* = 7.8 Hz, 1H), 6.99 (dd, *J* = 10.6, 8.9 Hz, 1H), 5.63 (s, 2H), 2.33 – 2.31 (m, 3H), 1.82 (tt, *J* = 8.5, 5.2 Hz, 1H), 1.04 – 0.99 (m, 2H), 0.69 (dt, *J* = 6.4, 4.9 Hz, 2H).

Example 659: 5-Chloro-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 174, steps A – C, using 2,5-dichloropyrimidine in step C. MS (ESI): mass calcd. for $C_{13}H_{11}ClN_6O$, 302.1; m/z found, 303.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.71 (s, 1H), 8.49 (s, 2H), 7.96 (d, *J* = 8.1 Hz, 1H), 7.77 (t, *J* = 7.8 Hz, 1H), 7.18 (d, *J* = 7.6 Hz, 1H), 5.64 (d, *J* = 0.7 Hz, 2H), 2.57 (s, 3H).

Example 660: 5-Ethyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 174, steps A – C, using 2-chloro-5-ethylpyrimidine in step C. MS (ESI): mass calcd. for $C_{15}H_{16}N_6O$, 296.1; m/z found, 297.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.71 (s, 1H), 8.39 (d, *J* = 0.6 Hz, 2H), 7.96 (d, *J* = 8.1 Hz, 1H), 7.76 (t, *J* = 7.8 Hz, 1H), 7.17 (d, *J* = 7.5 Hz, 1H), 5.64 (d, *J* = 0.7 Hz, 2H), 2.65 – 2.53 (m, 5H), 1.25 (t, *J* = 7.6 Hz, 3H).


Example 661: 5-Chloro-4-methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared in a manner analogous to Example 174, Steps A – C, using 2,5-dichloro-4-methylpyrimidine in Step C. MS (ESI): mass


calcd. for $C_{14}H_{13}ClN_6O$, 316.1; m/z found, 317.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.71 (s, 1H), 8.38 (s, 1H), 7.97 (d, *J* = 8.1 Hz, 1H), 7.77 (t, *J* = 7.8 Hz, 1H), 7.18 (d, *J* = 7.3 Hz, 1H), 5.63 (d, *J* = 0.7 Hz, 2H), 2.57 (s, 3H), 2.56 (s, 3H).

Example 662: 5-Methyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared analogous to Example 174, steps A – C, using 4-methylpyridine *N*-oxide in Step A, 7-methyltetrazolo[1,5-a]pyridine in Step B, and (1-(4-methylpyridin-2-yl)-1H-1,2,3-triazol-4-yl)methanol in Step C. MS (ESI): mass calcd. for $C_{14}H_{14}N_6O$, 282.1; m/z found, 283.0 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.66 (s, 1H), 8.37 (s, 2H), 8.32 (d, *J* = 5.0 Hz, 1H), 8.04 – 7.98 (m, 1H), 7.17 – 7.12 (m, 1H), 5.63 (s, 2H), 2.47 (s, 3H), 2.24 (s, 3H).


Example 663: 5-Ethyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine.



The title compound was prepared analogous to Example 174, Steps A – C, using 4-methylpyridine *N*-oxide in Step A, 7-methyltetrazolo[1,5-a]pyridine in Step B, and (1-(4-methylpyridin-2-yl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-ethylpyrimidine in Step C. MS (ESI): mass calcd. for $C_{15}H_{16}N_6O$, 296.1; m/z found, 297.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.69 – 8.64 (m, 1H), 8.40 – 8.37 (m, 2H), 8.33 (d, *J* = 5.0 Hz, 1H), 8.04 – 8.01 (m, 1H), 7.17 – 7.12 (m, 1H), 5.67 – 5.60 (m, 2H), 2.59 (q, *J* = 7.4 Hz, 2H), 2.47 (s, 3H), 1.25 (t, *J* = 7.6 Hz, 3H).


2017217542 02 Mar 2021

Example 664: 5-Ethyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared analogous to Example 175, steps A – C, using 2-chloro-5-ethylpyrimidine in step C. MS (ESI): mass calcd. for $C_{15}H_{16}N_6O$, 296.1; m/z found, 297.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.65 (d, *J* = 5.5 Hz, 1H), 8.40 (s, 2H), 8.21 (s, 1H), 7.61 (d, *J* = 2.1 Hz, 1H), 7.51 – 7.47 (m, 1H), 5.65 (s, 2H), 2.67 (s, 3H), 2.61 (q, *J* = 7.6 Hz, 2H), 1.27 (t, *J* = 7.6 Hz, 3H).

Example 665: 2-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine.




The title compound was prepared analogous to Example 177, steps A – C, using 2-chloro-5-ethylpyrimidine in step C. MS (ESI): mass calcd. for $C_{14}H_{13}BrN_6O$, 360.0; m/z found, 361.0 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ 8.88 (s, 1H), 8.53 (d, *J* = 5.5 Hz, 1H), 8.48 (s, 2H), 8.24 (d, *J* = 2.0 Hz, 1H), 8.01 (dd, *J* = 5.5, 2.1 Hz, 1H), 5.61 (s, 2H), 2.64 (q, *J* = 7.7 Hz, 2H), 1.26 (t, *J* = 7.6 Hz, 3H).

Example 666: 5-Methyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 177, steps A – C, using 4-amino-2-(trifluoromethyl)pyridine in step A, 4-azido-2-(trifluoromethyl)pyridine in step B, and (1-(2-(trifluoromethyl)pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methanol in step C. MS (ESI): mass calcd. for $C_{14}H_{11}F_3N_6O$, 336.1; m/z found, 337.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.90 (d, *J* = 5.4 Hz, 1H), 8.39 (d, *J* = 0.8 Hz, 2H), 8.30 – 8.28 (m, 1H), 8.12 (d, *J* = 2.1 Hz, 1H), 7.92 (dd, *J* = 5.4, 2.0 Hz, 1H), 5.66 (d, *J* = 0.8 Hz, 2H), 2.27 (s, 3H).

Example 667: 5-Ethyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-yl]methoxy]pyrimidine.




The title compound was prepared in a manner analogous to Example 177, Steps A – C, using 4-amino-2-(trifluoromethyl)pyridine in step A, 4-azido-2-(trifluoromethyl)pyridine in step B, and (1-(2-(trifluoromethyl)pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-ethylpyrimidine in step C. MS (ESI): mass calcd. for $C_{15}H_{13}F_3N_6O$, 350.1; m/z found, 351.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.90 (d, *J* = 5.4 Hz, 1H), 8.42 – 8.39 (m, 2H), 8.30 (t, *J* = 0.7 Hz, 1H), 8.13 (d, *J* = 2.0 Hz, 1H), 7.92 (dd, *J* = 5.4, 2.1 Hz, 1H), 5.67 (d, *J* = 0.8 Hz, 2H), 2.62 (q, *J* = 7.7 Hz, 2H), 1.27 (t, *J* = 7.6 Hz, 3H).

Example 668: 5-Fluoro-4-methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.




The title compound was prepared in a manner analogous to Example 155 using (1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. for $C_{13}H_9F_4N_5OS$, 359.3; m/z found, 360.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.28 – 8.23 (s, 1H), 8.11 – 8.05 (s, 1H), 7.42 – 7.37 (m, 1H), 7.19 – 7.15 (m, 1H), 5.62 – 5.57 (s, 2H), 2.53 – 2.45 (d, *J* = 2.4 Hz, 3H).

Example 669: 5-Methoxy-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.



The title compound was prepared in a manner analogous to Example 155 using (1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for $C_{13}H_{10}F_3N_5O_2S$, 357.3; m/z found, 358.1 $[M+H]^+$. ^1H NMR (500 MHz, $CDCl_3$) δ 8.26 – 8.22 (s, 2H), 8.09 – 8.06 (d, *J* = 0.9 Hz, 1H), 7.40 – 7.37 (m, 1H), 7.19 – 7.15 (m, 1H), 5.62 – 5.56 (s, 2H), 3.91 – 3.85 (m, 3H).


Example 670: 5-(Trifluoromethyl)-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.



2017217542 02 Mar 2021

The title compound was prepared in a manner analogous to Example 155 using (1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-5-(trifluoromethyl)pyrimidine. MS (ESI): mass calcd. for $C_{13}H_7F_6N_5OS$, 395.3; m/z found, 396.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ 8.85 – 8.80 (d, *J* = 0.9 Hz, 2H), 8.12 – 8.09 (m, 1H), 7.42 – 7.38 (m, 1H), 7.22 – 7.17 (m, 1H), 5.74 – 5.70 (d, *J* = 0.7 Hz, 2H).


Example 671: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-(oxetan-3-yl)pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 159, using (1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and 2-chloro-N-(oxetan-3-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (Intermediate 62) in Step A. MS (ESI): mass calcd. for $C_{17}H_{15}F_3N_6O_3$, 408.1; m/z found, 409.2 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 8.91 (s, 1H), 8.26 – 8.17 (m, 1H), 8.00 (dd, *J* = 7.0, 2.6 Hz, 1H), 7.97 – 7.91 (m, 1H), 7.87 (ddd, *J* = 8.9, 3.9, 2.6 Hz, 1H), 7.68 (dd, *J* = 10.2, 9.0 Hz, 1H), 7.40 (t, *J* = 72.8 Hz, 1H), 6.24 – 6.16 (m, 1H), 5.38 (s, 2H), 5.00 – 4.86 (m, 1H), 4.79 (t, *J* = 6.7 Hz, 2H), 4.45 (t, *J* = 6.1 Hz, 2H).


Examples 672-689, 693-698, 700-716 may be prepared in a manner analogous to the previously described examples.

Example 672: 5-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine.




MS (ESI): mass calcd. for $C_{18}H_{16}F_3N_5O_2$, 391.1

Example 673: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyridine.




MS (ESI): mass calcd. for $C_{18}H_{15}F_4N_5O_2$, 409.1

Example 674: 5-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine.



MS (ESI): mass calcd. for $C_{18}H_{14}F_5N_5O_2$, 427.1


Example 675: 2-(Azetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine.



2017217542 02 Mar 2021


MS (ESI): mass calcd. for $C_{18}H_{16}F_3N_5O_2$, 391.1

Example 676: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(3-fluoroazetidin-1-yl)pyridine.




MS (ESI): mass calcd. for $C_{18}H_{15}F_4N_5O_2$, 409.1

Example 677: 2-(3,3-Difluoroazetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine.




MS (ESI): mass calcd. for $C_{18}H_{14}F_5N_5O_2$, 427.1

Example 678: 4-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine.




MS (ESI): mass calcd. for $C_{18}H_{16}F_3N_5O_2$, 391.1

Example 679: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(3-fluoroazetidin-1-yl)pyridine.




MS (ESI): mass calcd. for $C_{18}H_{15}F_4N_5O_2$, 409.1

Example 680: 4-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine.




MS (ESI): mass calcd. for $C_{18}H_{14}F_5N_5O_2$, 427.1

Example 681: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrrol-2-yl)pyrimidine .




MS (ESI): mass calcd. for $C_{18}H_{13}F_3N_6O_2$, 402.1

Example 682: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine.




MS (ESI): mass calcd. for $C_{17}H_{12}F_3N_7O_2$, 403.1

Example 683: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrrol-2-yl)pyrimidine.




MS (ESI): mass calcd. for $C_{18}H_{13}F_3N_6O_2$, 402.1

Example 684: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine.




MS (ESI): mass calcd. for $C_{17}H_{12}F_3N_7O_2$, 403.1

Example 685: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethyl-5-fluoropyrimidin-4-amine.




MS (ESI): mass calcd. for $C_{16}H_{14}F_4N_6O_2$, 398.1

Example 686: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoro-N-(oxetan-3-yl)pyrimidin-4-amine.



MS (ESI): mass calcd. for $C_{17}H_{14}F_4N_6O_3$, 426.1


Example 687: N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine.



MS (ESI): mass calcd. for $C_{18}H_{14}F_6N_6O_2$, 460.1


Example 688: N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine.

2017217542 02 Mar 2021




MS (ESI): mass calcd. for $C_{17}H_{15}F_3N_6O_2$, 392.1

Example 689: N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine.



MS (ESI): mass calcd. for $C_{18}H_{15}F_5N_6O_2$, 442.1

Example 690: N-Cyclopropyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-N-cyclopropylpyrimidine-4-amine. MS (ESI): mass calcd. for $C_{17}H_{15}F_3N_6O$, 376.1; m/z found, 377.1 [M+H]+. ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.16 – 8.09 (m, 2H), 7.96 – 7.92 (m, 1H), 7.92 – 7.86 (m, 1H), 7.35 – 7.29 (m, 1H), 7.08 – 6.79 (t, J = 54.6 Hz, 1H), 6.44 – 6.33 (s, 1H), 5.59

2017217542 02 Mar 2021


– 5.53 (d, *J* = 0.8 Hz, 2H), 5.43 – 5.32 (s, 1H), 2.66 – 2.51 (s, 1H), 0.93 – 0.76 (m, 2H), 0.66 – 0.54 (m, 2H).

Example 691: N-Ethyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine.



The title compound was prepared in a manner analogous to Example 171, Steps A-B, (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-N-ethyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (Intermediate 60) in Step A. MS (ESI): mass calcd. for $C_{18}H_{21}F_3N_6O$, 394.2; m/z found, 365.1 [M+H]+. ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.15 – 8.10 (s, 1H), 8.09 – 7.97 (d, J = 11.8 Hz, 1H), 7.97 – 7.92 (d, J = 5.5 Hz, 1H), 7.92 – 7.87 (s, 1H), 7.36 – 7.28 (t, J = 9.0 Hz, 1H), 7.08 – 6.82 (t, J = 54.6 Hz, 1H), 6.07 – 5.99 (d, J = 5.8 Hz, 1H), 5.63 – 5.54 (s, 2H), 5.00 – 4.81 (s, 1H), 3.48 – 3.29 (m, 2H), 1.30 – 1.22 (t, J = 7.1 Hz, 3H).

Example 692: 2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(2-methyl-1H-imidazol-1-yl)pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol

02 Mar 2021 2017217542


(Intermediate 9) and 2-chloro-4-(2-methyl-1H-imidazol-1-yl)pyrimidine. MS (ESI): mass calcd. for $C_{18}H_{14}F_3N_7O$, 401.1; m/z found, 402.1 [M+H]+. ^1H NMR (500 MHz, $CDCl_3$) d 8.48 – 8.42 (d, J = 5.7 Hz, 1H), 8.12 – 8.06 (s, 1H), 7.97 – 7.93 (d, J = 5.3 Hz, 1H), 7.93 – 7.88 (m, 2H), 7.39 – 7.30 (t, J = 8.9 Hz, 1H), 7.09 – 6.83 (m, 2H), 6.78 – 6.61 (m, 1H), 5.78 – 5.62 (s, 2H), 2.96 – 2.80 (s, 3H).

Example 693: 2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(2-methyl-1H-imidazol-1-yl)pyrimidine.




MS (ESI): mass calcd. for $C_{18}H_{14}F_3N_7O$, 401.1

Example 694: 2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine.




MS (ESI): mass calcd. for $C_{17}H_{12}F_3N_7O$, 387.1

Example 695: 2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine.




MS (ESI): mass calcd. for $C_{17}H_{12}F_3N_7O$, 387.1

Example 696: 4-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.




MS (ESI): mass calcd. for $C_{16}H_{12}F_5N_5O$, 385.1

Example 697: 4-((Difluoromethoxy)methyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.




MS (ESI): mass calcd. for $C_{16}H_{12}F_5N_5O_2$, 401.1

Example 698: 2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-1-yl)pyrimidine.




MS (ESI): mass calcd. for $C_{17}H_{12}F_3N_7O$, 387.1

Example 699: 2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-1-yl)pyrimidine.




The title compound was prepared in a manner analogous to Example 1 using (1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 9) and 2-chloro-4-(pyrazol-1-yl)pyrimidine. MS (ESI): mass calcd. for $C_{17}H_{12}F_3N_7O$, 387.1; m/z found, 388.0 [M+H]+. ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.66 – 8.60 (m, 1H), 8.60 – 8.54 (d, J = 5.5 Hz, 1H), 8.21 – 8.13 (s, 1H), 8.00 – 7.93 (m, 1H), 7.93 – 7.85 (m, 1H), 7.84 – 7.77 (m, 1H), 7.65 – 7.56 (d, J = 5.5 Hz, 1H), 7.37 – 7.30 (m, 1H), 7.10 – 6.81 (t, J = 54.6 Hz, 1H), 6.56 – 6.47 (m, 1H), 5.76 – 5.67 (m, 2H).

Example 700: (E)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one oxime.




MS (ESI): mass calcd. for $C_{16}H_{13}F_3N_6O_2$, 378.1

Example 701: 5-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.




MS (ESI): mass calcd. for $C_{16}H_{12}F_5N_5O$, 385.1

Example 702: (Z)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-one oxime.




MS (ESI): mass calcd. for $C_{16}H_{13}F_3N_6O_2$, 378.1

Example 703: (2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-yl)methanol.




MS (ESI): mass calcd. for $C_{15}H_{11}F_4N_5O_3$, 385.1

Example 704: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)-5-fluoropyrimidine.




MS (ESI): mass calcd. for $C_{16}H_{11}F_6N_5O_3$, 435.1

Example 705: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)pyrimidine.




MS (ESI): mass calcd. for $C_{16}H_{12}F_5N_5O_3$, 417.1

Example 706: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoro-4-((trifluoromethoxy)methyl)pyrimidine.



MS (ESI): mass calcd. for $C_{16}H_{10}F_7N_5O_3$, 453.1


Example 707: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((trifluoromethoxy)methyl)pyrimidine.



2017217542 02 Mar 2021


MS (ESI): mass calcd. for $C_{16}H_{11}F_6N_5O_3$, 435.1

Example 708: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(methoxymethyl-d2)pyrimidine.




MS (ESI): mass calcd. for $C_{16}H_{12}D_2F_3N_5O_3$, 383.1

Example 709: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((methoxy-d3)methyl-d2)pyrimidine.




MS (ESI): mass calcd. for $C_{16}H_9D_5F_3N_5O_3$, 386.1

Example 710: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((methoxy-d3)methyl)pyrimidine.




MS (ESI): mass calcd. for $C_{16}H_{11}D_3F_3N_5O_3$, 384.1

Example 711: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(ethoxymethyl)pyrimidine.




MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O_3$, 395.1

Example 712: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1-methoxyethyl)pyrimidine.




MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O_3$, 395.1

Example 713: 1-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-ol.



MS (ESI): mass calcd. for $C_{16}H_{14}F_3N_5O_3$, 381.1


Example 714: 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(2-methoxypropan-2-yl)pyrimidine.



MS (ESI): mass calcd. for $C_{18}H_{18}F_3N_5O_3$, 409.1


2017217542 02 Mar 2021

Example 715: 2-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)propan-2-ol.



MS (ESI): mass calcd. for $C_{17}H_{16}F_3N_5O_3$, 395.1

Example 716: 4-((2,2-Difluoroethoxy)methyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.



MS (ESI): mass calcd. for $C_{17}H_{14}F_5N_5O_3$, 431.1

2017217542 02 Mar 2021

BIOLOGICAL ASSAYS

Effects of Test Articles on Cloned Human NR1/NR2B Ion Channels Expressed in Mammalian Cells

NMDA receptors are ion channels that are highly permeable to Ca^{2+} ions, rendering it possible to monitor NMDA receptor function using cell-based calcium flux assay. In this assay, co-agonists glutamate and glycine are added to cells heterologously expressing human GluN1/ GluN2B NMDA receptors to initiate cellular Ca^{2+} influx. The time course of the changes in intracellular calcium is measured using a fluorescent dye and a FLIPR (Fluorometric Imaging Plate Reader) device.

Twenty four hours before measurements, the expression of the NMDA receptors in the stable cell line is induced with Tet-On inducible system in the presence of a non-selective NMDA receptor blocker. On the day of the experiment, cell culture media is carefully washed and the cells are loaded with Calcium 5 Dye Kit (Molecular Devices) in dye loading buffer containing 149 mM NaCl, 4 mM KCl, 2 mM $CaCl_2$, and 1.5 mM $MgCl_2$,10 mM HEPES and 5 mM D-glucose; pH 7.4. After 1h incubation at the room temperature, the dye is washed away with the assay buffer (149 mM NaCl (standard assay) or 150 mM (HTS assay), 4 mM KCl (standard assay) or 3 mM (HTS assay), 2 mM $CaCl_2$, 0.01 mM EDTA, 10 mM HEPES and 5 mM D-glucose; pH 7.4) In the FLIPR TETRA reader, various concentrations of the test compounds are added to the cells for 5 min while fluorescence is monitored to detect potential agonist activity. Next, co-agonists, glutamate and glycine are added for another 5 minutes. The concentration of glutamate corresponding to ~EC_{80} (standard assay) or EC_{40} (HTS assay) is used to maximize the assay's signal window or the ability to detect NMDA receptor antagonists and negative allosteric modulators, respectively. A saturating concentration (10 μM) of glycine is also present in the assay. A non-selective NMDA receptor antagonist, (+)MK-801 is used as a positive control for antagonist activity. The

2017217542 02 Mar 2021

fluorescent signal in the presence of test compounds is quantified and normalized to the signal defined by the appropriate control wells.

Table 5.

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
1	2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	0.049
2	N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]pyridin-2-amine;	0.213
3	N-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;	2.800
4	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;	0.392
5	3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine;	0.333
6	N-((1-(3-(Difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)pyrimidin-2-amine;	10.573
7	N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-imidazol-2-amine;	1.870
8	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine;	0.022
9	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.020
10	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.010

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
11	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine;	1.200
12	4-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	2.230
13	4-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.879
14	3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridazine;	0.401
15	2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.699
16	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.001
17	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.010
18	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4,6-dimethyl-pyrimidine;	0.082
19	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	0.056
20	2-[[1-(4-Fluoro-3-methoxy-phenyl)triazol-4-yl]methoxy]pyrimidine;	1.000
21	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.002
22	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.002

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
23	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrazine;	0.456
24	N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;	0.824
25	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.050
26	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.003
27	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.009
28	5-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.002
29	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;	0.011
30	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.004
31	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.001
32	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.002
33	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.018
34	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrazine;	0.159

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
35	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;	0.006
36	N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;	0.351
37	5-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.053
38	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.027
39	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.015
40	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.001
41	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.000
42	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-chloro-pyrimidine;	0.003
43	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;	0.005
44	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;	0.005
45	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;	0.004
46	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.001

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
47	5-Chloro-2-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.003
48	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;	0.008
49	5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.003
50	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;	0.007
51	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.001
52	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.008
53	(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;	0.026
54	(R*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;	4.640
55	(S*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;	0.008
56	(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;	0.028

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
57	(R*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;	0.338
58	(S*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;	0.007
59	(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-4-methyl-pyrimidine;	0.040
60	(R/S)-5-Chloro-2-[1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;	0.032
61	5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.003
62	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;	0.007
63	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.003
64	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.007
65	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine;	0.056
66	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	0.052
67	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.015

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
68	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.007
69	5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.009
70	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;	0.044
71	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;	0.040
72	5-Ethyl-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.010
73	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.008
74	5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.016
75	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;	0.026
76	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;	0.035
77	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.004
78	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.060

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
79	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.007
80	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	0.032
81	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.003
82	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.126
83	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.020
84	5-Fuoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.072
85	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;	0.003
86	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;	0.004
87	2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.012
88	2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.019
89	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.011
90	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.012

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
91	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.004
92	5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.019
93	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.493
94	2-[[1-(5-Bromo-6-methyl-2-pyridyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	2.910
95	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	0.023
96	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine;	0.008
97	N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]oxazol-2-amine;	0.106
98	N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;	0.331
99	N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-4-amine;	5.050
100	N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-3-amine;	0.894
101	N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-3-amine;	0.374
102	N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-4-amine;	3.250

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
103	3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-2-methoxy-pyridine;	0.064
104	5-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-2-methyl-pyridine;	0.729
105	3-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine;	0.059
106	5-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-methoxy-pyridine;	0.276
107	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-fluoro-pyridine;	0.119
108	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-methoxy-pyridine;	0.114
109	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;	1.260
110	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-4-amine;	7.570
111	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;	0.684
112	5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;	0.056
113	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine;	0.038
114	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine;	0.021

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
115	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine;	0.170
116	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine;	0.102
117	5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;	0.073
118	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine;	0.026
119	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine;	0.114
120	5-Methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	0.005
121	5-Methyl-2-((1-(4-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	NT
122	2-((1-(3-(Difluoromethyl)-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;	NT
123	2-((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;	NT
124	2-((1-(4-Chloro-3-(oxetan-3-yl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;	NT
125	2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-fluoro-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;	NT
126	2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;	NT

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
127	2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;	NT
128	2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylthiazole;	NT
129	1-(4-Chloro-3-(difluoromethyl)phenyl)-4-(((5-methyl-1H-imidazol-2-yl)oxy)methyl)-1H-1,2,3-triazole;	NT
130	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyridine;	NT
131	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methylpyridine;	NT
132	6-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,3-dimethylpyridine;	NT
133	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methylpyrazine;	NT
134	5-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,3-dimethylpyrazine;	NT
135	5-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyrimidine;	NT
136	6-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,4-dimethylpyridazine;	NT
137	3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(trifluoromethyl)pyridazine;	NT
138	3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methoxypyridazine;	NT

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
139	4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyrimidine;	NT
140	4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-(trifluoromethyl)pyrimidine;	NT
141	4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methoxypyrimidine;	NT
142	2-((1-(5-Chloro-6-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;	NT
143	2-((1-(2-(Difluoromethyl)pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;	NT
144	N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidin-2-amine;	NT
145	N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine;	NT
146	3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxypyridine;	NT
147	4-Chloro-3-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;	NT
148	4-((1-(3-(Difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine;	NT
149	2-((1-(3-(Difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;	0.952
150	5-Methyl-2-((1-(5-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	NT

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
151	2-((1-(5-Bromo-6-fluoropyridin-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;	NT
152	5-Methyl-2-((1-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	NT
153	5-Chloro-N-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;	0.216
154	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine;	0.030
155	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;	0.006
156	1-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;	0.005
157	(R/S)-1-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;	0.018
158	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine;	3.040
159	[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;	0.408
160	[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;	0.173
161	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;	0.055
162	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-4-carboxamide;	>2.99

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
163	(R/S) 1-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]ethanamine;	1.400
164	5-Chloro-2-[[1-(4-fluorophenyl)triazol-4-yl]methoxy]pyrimidine;	0.371
165	5-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.016
166	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine;	0.144
167	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine;	0.013
168	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;	0.008
169	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine;	0.031
170	4-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]morpholine;	0.260
171	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;	0.006
172	2-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.468
173	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.465
174	5-Methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;	>2.99

02 Mar 2021 2017217542

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
175	5-Methyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]pyrimidine;	0.655
176	5-Methyl-2-[[1-(5-methyl-3-pyridyl)triazol-4-yl]methoxy]pyrimidine;	0.929
177	2-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.172
178	2-[2-[[1-(3-Cyclobutyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.349
179	2-[2-[[1-(4-Fluoro-3-isopropyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.029
180	2-[2-[[1-(3-Cyclopropyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.133
181	2-[2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.097
182	2-[2-[[1-(3-Ethyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.027
183	5-Bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.009
184	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1-methylpyrazol-3-yl)pyrimidine;	0.309
185	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1H-pyrazol-4-yl)pyrimidine;	0.166
186	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1H-pyrazol-4-yl)pyrimidine;	1.360

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
187	4-(2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine;	0.088
188	2-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	4.580
189	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrazine;	1.460
190	4-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.026
191	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-fluoro-pyrimidine;	0.023
192	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine;	0.030
193	2-[[1-[4-Chloro-3-(2-fluoroethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.089
194	2-[[1-[4-Fluoro-3-(3-fluoropropyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.061
195	2-[[1-[3-(3-Chloropropyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.136
196	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine;	0.024
197	N-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methyl]-5-fluoro-pyrimidin-2-amine;	0.652
198	N-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine;	0.147

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
199	5-Chloro-N-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-4-methyl-pyrimidin-2-amine;	0.051
200	5-Chloro-N-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;	0.131
201	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-4-methyl-pyrimidin-2-amine;	0.100
202	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-ethyl-pyrimidin-2-amine;	0.044
203	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-methoxy-pyrimidin-2-amine;	0.030
204	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-(difluoromethyl)pyrimidin-2-amine;	0.240
205	N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine;	0.616
206	N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine;	0.219
207	N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-ethyl-pyrimidin-2-amine;	0.128
208	N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-isopropyl-pyrimidin-2-amine;	0.581
209	5-Cyclopropyl-N-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;	0.104
210	N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-4,5-dimethyl-pyrimidin-2-amine;	0.050

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
211	N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine;	0.049
212	5-Chloro-N-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;	0.074
213	N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine;	0.108
214	2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methylamino]pyrimidin-5-yl]propan-2-ol;	0.654
215	N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine;	0.986
216	N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-ethylpyrimidin-2-amine;	0.026
217	N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine;	0.012
218	5-Chloro-N-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methylpyrimidin-2-amine;	0.011
219	N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine;	>10
220	N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-imidazol-2-amine;	3.650
221	N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine;	0.724
222	N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidin-2-amine;	0.064

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
223	N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine; and	11.801
224	N-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethyl]-5-methyl-pyrimidin-2-amine;	0.121
225	5-Chloro-2-[[1-(4-chlorophenyl)triazol-4-yl]methoxy]pyrimidine;	0.070
226	2-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;	0.155
227	2-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;	0.151
228	2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]pyrimidine;	5.649
229	5-Fluoro-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine;	2.980
230	2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.275
231	5-Chloro-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine;	0.389
232	2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.205
233	5-Ethyl-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine;	0.075

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
234	2-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.022
235	2-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;	NT
236	2-[[1-(o-Tolyl)triazol-4-yl]methoxy]pyrimidine;	>10
237	5-Fluoro-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;	16.600
238	5-Methoxy-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;	5.990
239	5-Chloro-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;	4.800
240	5-Methyl-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;	5.580
241	5-Ethyl-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;	1.460
242	2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidine;	0.647
243	5-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.014
244	4-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.191
245	5-Ethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.010

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
246	5-Chloro-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.033
247	5-Fluoro-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.340
248	5-Methoxy-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.009
249	2-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.289
250	4-(Methoxymethyl)-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.249
251	4,5-Dimethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.002
252	5-Fluoro-4-methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.065
253	5-Chloro-4-methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.007
254	5-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidin-4-amine;	0.151
255	1-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;	0.224
256	2-[[1-(p-Tolyl)triazol-4-yl]methoxy]pyrimidine;	4.420
257	5-Fluoro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;	2.690

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
258	5-Methoxy-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.225
259	5-Chloro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.711
260	5-Methyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.271
261	5-Ethyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;	0.093
262	2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]pyrimidine;	0.358
263	5-Fluoro-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine;	0.227
264	2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.006
265	5-Chloro-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine;	0.016
266	2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.010
267	5-Ethyl-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine;	0.012
268	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.134
269	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	0.325

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
270	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine;	0.617
271	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.360
272	2-[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.173
273	5-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.027
274	4-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.813
275	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;	0.025
276	5-(Difluoromethoxy)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.031
277	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;	0.041
278	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;	0.042
279	5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.003
280	2-Chloro-4-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.173

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
281	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine;	0.130
282	5-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.011
283	4-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.169
284	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;	0.094
285	2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine;	0.299
286	5-Methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.012
287	5-Ethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.005
288	5-Isopropyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.040
289	5-(Difluoromethyl)-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.037
290	4,5-Dimethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.007
291	5-Chloro-4-methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.009

02 Mar 2021 2017217542

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
292	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.105
293	5-Bromo-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.039
294	5-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.003
295	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	0.061
296	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.012
297	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.005
298	[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;	0.034
299	[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;	0.049
300	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.008
301	2-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.119
302	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine;	0.002
303	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine;	0.085

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
304	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine;	0.711
305	(R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol;	0.496
306	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.003
307	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;	0.033
308	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;	0.003
309	1-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;	0.010
310	(R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;	0.037
311	(R/S)-2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(1-methoxyethyl)pyrimidine;	1.580
312	5-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.004
313	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;	0.005
314	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;	0.006
315	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;	0.158

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
316	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;	0.183
317	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;	0.026
318	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;	0.026
319	5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.015
320	5-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.061
321	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine;	0.104
322	2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;	0.011
323	2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.788
324	2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	0.494
325	2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.027
326	5-Chloro-2-[[1-[3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.069
327	2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.015

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
328	2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.029
329	2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.854
330	2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	0.752
331	2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.098
332	5-Chloro-2-[[1-[4-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.200
333	2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.087
334	2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.051
335	2-[[1-[4-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	3.120
336	5-Fluoro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	11.301
337	5-Methoxy-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	>10
338	5-Chloro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	9.049
339	5-Methyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	1.130

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
340	5-Ethyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.794
341	2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.538
342	5-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.017
343	5-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;	0.040
344	1-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;	0.062
345	2-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.284
346	4-(Methoxymethyl)-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.202
347	4-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.137
348	5-Fluoro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.447
349	5-Methoxy-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.013
350	5-Chloro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.050
351	5-Ethyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.015

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
352	N-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;	0.068
353	2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;	0.525
354	2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.073
355	2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]pyrimidine;	0.238
356	5-Chloro-2-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]pyrimidine;	0.185
357	2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;	0.350
358	2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	0.726
359	2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;	0.009
360	2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]pyrimidine;	0.791
361	2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	0.587
362	2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.032
363	5-Chloro-2-[[1-(3,5-dimethylphenyl)triazol-4-yl]methoxy]pyrimidine;	0.118

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
364	2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.027
365	2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.022
366	2-[(1-Indan-5-yltriazol-4-yl)methoxy]-5-methyl-pyrimidine;	0.020
367	5-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]pyrimidine;	0.053
368	2-[(1-Indan-5-yltriazol-4-yl)methoxy]-4-(methoxymethyl)pyrimidine;	0.114
369	2-[2-[(1-Indan-5-yltriazol-4-yl)methoxy]pyrimidin-5-yl]propan-2-ol;	0.175
370	4-(Difluoromethyl)-2-[(1-indan-5-yltriazol-4-yl)methoxy]pyrimidine;	0.397
371	5-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]-4-methyl-pyrimidine;	0.039
372	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;	0.008
373	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;	0.010
374	2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;	0.011

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
375	5-Chloro-2-[(1R)-1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;	0.010
376	2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;	0.011
377	2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methoxy-pyrimidine;	0.010
378	2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;	2.300
379	5-Chloro-2-[(1S)-1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;	0.575
380	2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;	0.237
381	2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methoxy-pyrimidine;	0.196
382	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;	0.021
383	[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;	0.008
384	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.018

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
385	2-[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.028
386	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-isopropoxypyrimidine;	0.504
387	Methyl 2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine-4-carboxylate;	0.068
388	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-N-(2,2-difluoroethyl)-5-fluoro-pyrimidin-4-amine;	0.842
389	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;	0.033
390	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine;	0.006
391	5-(Azetidin-1-yl)-2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	0.022
392	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine;	0.017
393	2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3,3-difluoroazetidin-1-yl)pyrimidine;	0.037
394	2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-6-fluoro-pyridine;	0.437

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
395	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-(trifluoromethyl)pyridine;	0.919
396	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrazine;	0.647
397	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(2-thienyl)pyrazine;	10.700
398	5-Bromo-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.003
399	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.023
400	[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;	0.036
401	2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.017
402	4-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.051
403	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine;	0.199
404	(R/S)-2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol;	0.482
405	5-(Difluoromethoxy)-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.003
406	5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.001

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
407	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;	0.001
408	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;	0.002
409	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-5-carboxamide;	0.149
410	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidine-4-carboxamide;	>2.99
411	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methoxy-5-methyl-pyrimidine;	0.021
412	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;	0.124
413	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;	0.015
414	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;	0.122
415	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;	0.008
416	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine;	0.010
417	5-(Azetidin-1-yl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	0.006

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
418	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1-yl)pyrimidine;	0.271
419	5-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	0.029
420	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoro-3-methylazetidin-1-yl)pyrimidine;	0.260
421	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-(difluoromethyl)azetidin-1-yl)pyrimidine;	0.227
422	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3,3-difluoropyrrolidin-1-yl)pyrimidine;	0.068
423	5-Cyclopropyl-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.005
424	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(2-furyl)pyrimidine;	0.141
425	2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]-5-iodo-triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.394
426	[3H]-2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl-5-t)methoxy)-5-methylpyrimidine;	
427	3-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine;	0.897

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
428	5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine;	0.796
429	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine;	0.665
430	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine;	0.110
431	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine;	0.101
432	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine;	0.528
433	2-[6-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-3-pyridyl]propan-2-ol;	1.114
434	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrazine;	6.390
435	2-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.098
436	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine;	3.260
437	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(methoxymethyl)pyrimidine;	0.071
438	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.094
439	5-(Difluoromethyl)-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.013

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
440	4-(Difluoromethyl)-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.098
441	(R/S)-1,1,1-Trifluoro-2-[2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.412
442	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;	0.072
443	5-Ethoxy-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.004
444	5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.013
445	5-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.006
446	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;	0.001
447	1-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;	0.014
448	(R/S)-1-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;	0.031
449	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;	0.034

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
450	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;	0.030
451	5-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;	0.298
452	2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-5-carboxamide;	0.218
453	5-Cyclopropyl-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.022
454	5-Bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	0.013
455	2-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine;	0.034
456	4-(2-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine;	0.500
457	5-(Azetidin-1-yl)-2-((1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methylpyrimidine;	0.296
458	2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethyl-4-methylpyrimidin-5-amine;	0.439
459	2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethylpyrimidin-5-amine;	0.126

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
460	2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1-yl)pyrimidine;	0.726
461	5-Chloro-2-[[1-[2-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;	0.070
462	4-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-6-methyl-pyrimidine;	3.030
463	5-Chloro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.647
464	2-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.515
465	5-Fluoro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;	3.720
466	2-[2-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	7.010
467	2-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.711
468	5-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	1.250
469	2-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;	1.058
470	5-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.659

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
471	5-(Difluoromethoxy)-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	1.729
472	2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-4-amine;	0.149
473	2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.072
474	5-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.022
475	2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.001
476	5-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.002
477	2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.001
478	5-Ethyl-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.001
479	2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.036
480	2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;	0.001
481	5-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.002
482	5-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.001

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
483	5-(2-Fluoroethoxy)-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.007
484	2-[[1-(2-Fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	1.000
485	5-Chloro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;	1.010
486	5-Fluoro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;	>2.99
487	5-Fluoro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	16.199
488	2-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	2.650
489	5-Chloro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	4.420
490	2-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	2.440
491	5-Ethyl-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	1.170
492	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	0.026
493	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;	0.004
494	5-Bromo-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.003

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
495	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-ethyl-pyrimidine;	0.010
496	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine;	0.114
497	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;	0.028
498	[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;	0.019
499	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.016
500	2-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.068
501	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;	0.052
502	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-amine;	0.136
503	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;	0.008
504	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethylpyrimidin-4-amine;	0.007
505	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;	0.007
506	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-phenyl-pyrimidine;	9.750

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
507	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine;	0.008
508	5-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.019
509	4-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.003
510	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3-fluoroazetidin-1-yl)pyrimidine;	0.025
511	4-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.041
512	(R)-2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-[(3R)-3-fluoropyrrolidin-1-yl]pyrimidine;	0.308
513	5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.004
514	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;	0.005
515	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine;	0.099
516	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine;	0.017
517	N-(2,2-Difluoroethyl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidin-4-amine;	0.912

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
518	2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;	0.092
519	N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine;	0.204
520	1-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)-N-methylmethanamine;	0.672
521	2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;	0.021
522	1-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;	0.093
523	2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.114
524	2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.028
525	5-Bromo-2-[[1-[3-(difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.040
526	2-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.425
527	2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.132
528	2-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;	0.752

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
529	5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine;	1.320
530	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.005
531	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.017
532	2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.081
533	[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;	0.017
534	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.003
535	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine;	0.009
536	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine;	0.067
537	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;	0.016
538	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine;	0.318
539	(R/S)-2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol;	0.450
540	[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;	0.019

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
541	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;	0.012
542	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;	0.012
543	5-Chloro-2-[[1-[4-chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.015
544	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;	0.015
545	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;	0.006
546	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4,6-dimethyl-pyrimidine;	0.024
547	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;	0.033
548	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;	0.055
549	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;	0.094
550	1-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;	0.016
551	(R/S)-1-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;	0.014

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
552	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-cyclopropyl-pyrimidine;	0.086
553	2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;	0.043
554	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;	1.640
555	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-3-fluoro-pyridine;	0.265
556	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine;	0.098
557	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine;	0.246
558	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine;	0.125
559	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine;	0.812
560	6-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-2,3-dimethyl-pyridine;	0.052
561	3-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-2-methoxy-pyridine;	0.476
562	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine;	0.014
563	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine;	0.048

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
564	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine;	0.272
565	(R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol;	0.308
566	2-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.008
567	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine;	4.630
568	[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;	0.025
569	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(methoxymethyl)pyrimidine;	0.089
570	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.011
571	[2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;	0.021
572	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;	0.025
573	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;	0.019
574	5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.010
575	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;	0.006

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
576	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;	0.017
577	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine;	0.128
578	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;	0.140
579	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine;	0.087
580	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;	0.088
581	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;	0.033
582	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;	0.028
583	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine-5-carbonitrile;	0.067
584	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methylsulfonyl-pyrimidine;	0.199
585	1-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;	0.011
586	(R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;	0.014
587	5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.041

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
588	5-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;	0.034
589	2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine;	0.013
590	2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N,N-dimethylpyrimidin-5-amine;	0.039
591	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;	0.016
592	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine;	0.271
593	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.486
594	5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine;	0.171
595	2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;	0.706
596	5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.601
597	2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]pyrimidine;	2.100
598	2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	1.450
599	2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;	0.034

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
600	5-Chloro-2-[[1-(3,4-difluorophenyl)triazol-4-yl]methoxy]pyrimidine;	0.238
601	2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.048
602	2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.023
603	2-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	10.430
604	2-[2-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	79.708
605	5-Chloro-2-[[1-(2,3-difluorophenyl)triazol-4-yl]methoxy]pyrimidine;	4.360
606	2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	17.499
607	2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]pyrimidine;	3.425
608	2-[2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	>10
609	2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;	15.900
610	2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	1.034
611	2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine;	>10

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
612	5-Chloro-2-[[1-(3-chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine;	1.737
613	2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;	1.441
614	2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;	4.032
615	2-[2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	4.658
616	[2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;	0.030
617	[2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;	0.041
618	2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine;	0.006
619	2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.217
620	2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.008
621	2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.003
622	2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.066
623	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine;	0.129

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
624	[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;	0.020
625	[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;	0.017
626	2-[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.067
627	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.038
628	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine;	0.042
629	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;	0.007
630	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-cyclopropyl-pyrimidine;	0.013
631	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-cyclopropyl-pyrimidine;	0.042
632	2-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;	0.004
633	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine;	0.057
634	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;	0.012
635	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine;	0.169

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
636	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine;	0.010
637	2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine;	0.011
638	2-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;	0.511
639	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;	0.052
640	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-isopropyl-pyrimidine;	1.980
641	5-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.111
642	4-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	2.210
643	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;	0.200
644	2-[2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;	0.967
645	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;	0.799
646	5-(Difluoromethoxy)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.099
647	5-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.034

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
648	4-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.592
649	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;	0.152
650	5-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.005
651	2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;	0.262
652	2-[[1-[3-(Difluoromethyl)-2,4-difluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;	0.112
653	5-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	1.490
654	2-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;	0.979
655	2-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.507
656	5-(Difluoromethyl)-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	1.510
657	5-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;	0.781
658	5-Cyclopropyl-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;	0.424
659	5-Chloro-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;	>2.99

02 Mar 2021 2017217542

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
660	5-Ethyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;	>2.99
661	5-Chloro-4-methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;	>2.99
662	5-Methyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;	>2.99
663	5-Ethyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;	2.450
664	5-Ethyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]pyrimidine;	0.169
665	2-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;	0.261
666	5-Methyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-yl]methoxy]pyrimidine;	0.668
667	5-Ethyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-yl]methoxy]pyrimidine;	0.184
668	5-Fluoro-4-methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	0.008
669	5-Methoxy-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	0.004
670	5-(Trifluoromethyl)-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	0.063
671	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-(oxetan-3-yl)pyrimidin-4-amine;	0.126

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
672	5-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;	NT
673	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyridine;	NT
674	5-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;	NT
675	2-(Azetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;	NT
676	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(3-fluoroazetidin-1-yl)pyridine;	NT
677	2-(3,3-Difluoroazetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;	NT
678	4-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;	NT
679	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(3-fluoroazetidin-1-yl)pyridine;	NT
680	4-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;	NT
681	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrrol-2-yl)pyrimidine;	0.681
682	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine;	NT

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
683	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrrol-2-yl)pyrimidine;	NT
684	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine;	NT
685	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethyl-5-fluoropyrimidin-4-amine;	NT
686	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoro-N-(oxetan-3-yl)pyrimidin-4-amine;	NT
687	N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine;	NT
688	N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine;	NT
689	N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine;	NT
690	N-Cyclopropyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine;	0.008
691	N-Ethyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine;	0.006
692	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(2-methyl-1H-imidazol-1-yl)pyrimidine;	1.580

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
693	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(2-methyl-1H-imidazol-1-yl)pyrimidine;	NT
694	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine;	NT
695	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine;	NT
696	4-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	0.958
697	4-((Difluoromethoxy)methyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	NT
698	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-1-yl)pyrimidine;	NT
699	2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-1-yl)pyrimidine;	0.389
700	(E)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one oxime;	NT
701	5-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;	0.958
702	(Z)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-one oxime;	NT

2017217542 02 Mar 2021

Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
703	(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-yl)methanol;	NT
704	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)-5-fluoropyrimidine;	NT
705	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)pyrimidine;	NT
706	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoro-4-((trifluoromethoxy)methyl)pyrimidine;	NT
707	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((trifluoromethoxy)methyl)pyrimidine;	NT
708	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(methoxymethyl-d2)pyrimidine;	NT
709	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((methoxy-d3)methyl-d2)pyrimidine;	NT
710	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((methoxy-d3)methyl)pyrimidine;	NT
711	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(ethoxymethyl)pyrimidine;	0.043
712	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1-methoxyethyl)pyrimidine;	NT

2017217542 02 Mar 2021


Ex #.	Compound Name	NR2B IC_{50} (μM) standard assay
713	1-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-ol;	NT
714	2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(2-methoxypropan-2-yl)pyrimidine;	NT
715	2-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)propan-2-ol; and	NT
716	4-((2,2-Difluoroethoxy)methyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine.	0.049

NT means not tested.

2017217542 30 Apr 2021

What is claimed:

1. A compound having the structure of Formula (I):



(I)

,

or a pharmaceutically acceptable salt thereof,

wherein:

Ar^1 is selected from the group consisting of:

(a) phenyl substituted with one substituent selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}perhaloalkyl, and OC_{1-6}perhaloalkyl; phenyl substituted with two or three substituents each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, C_{3-6}cycloalkyl, and azetidinyl;

(b) pyridinyl; pyridinyl substituted with one or two members each independently selected from the group consisting of: halo, CH_3, CF_3, and CF_2H; and

(c) thienyl substituted with CF_3; 2,2-difluorobenzo[d][1,3]dioxol-5-yl; or 2,3-dihydro-1H-inden-5-yl;

R^1 is H, halo, or CH_3;

R^2 is H or CH_3; and

Ar^3 is selected from the group consisting of:

(a) pyridinyl; pyridinyl substituted with one or two substituents each independently selected from the group consisting of: Cl, F, CH_3, OCH_3, CF_3, and $C(CH_3)_2OH$; azetidin-1-yl; 3-fluoroazetidin-1-yl; and 3,3-difluoroazetidin-1-yl;

(b) pyridazinyl; pyridazinyl substituted with one or two substituents each independently selected from the group consisting of: CH_3, OCH_3, and CF_3;

(c) pyrimidin-4-yl; pyrimidin-4-yl substituted with one or two substituents each independently selected from the group consisting of: Cl, CH_3, CF_3, and OCH_3; pyrimidin-2-yl; pyrimidin-2-yl substituted with one or two members each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}alkyl substituted with OH or OCH_3, $C(OH)(CH_3)(CF_3)$, CH_2OCHF_2, CH_2OCF_3, $CH_2OCH_2CH_3$, $CH(NH_2)CH_3$, $CH_2NH(CH_3)$, C_{1-6}perhaloalkyl,


OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, C(=N-OH)(CH_3), NH_2, NH(CH_3), N(CH_3)$_2$, NH(CH_2CH_3), NH(CH_2CHF_2), NH(cyclopropyl), NH(difluorocyclobutyl), NH-oxetanyl, CN, C(=O)CH_3, C(=O)NH(CH_3), C(=O)N(CH_3)$_2$, SO_2CH_3, CO_2CH_3, cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholinyl, 1H-pyrrol-2-yl, 2-furyl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-pyrazol-1-yl, 2-methyl-1H-imidazol-1-yl, 1-methylpyrazol-3-yl, and phenyl;

(d) 5-fluoro-pyrazin-2-yl; 5-methylpyrazin-2-yl; 6-methylpyrazin-2-yl; pyrazin-2-yl; 5-(thien-2-yl)pyrazin-2-yl; and 2,3-dimethylpyrazin-5-yl; and

(e) 5-methyl-1H-imidazol-2-yl; and 5-methylthiazol-2-yl;

with the proviso that the compound is other than 5-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyridine.

2. A compound having the structure of Formula (II):



(II)

or a pharmaceutically acceptable salt thereof,

wherein:

$Ar^{1'}$ is phenyl substituted with C_{1-3}perhaloalkyl; or phenyl substituted with two substituents each independently selected from the group consisting of: halo, C_{1-3}alkyl, C_{1-3}perhaloalkyl, and OC_{1-3}perhaloalkyl;

$R^{2'}$ is H or CH_3; and

Ar^2 is selected from the group consisting of:

(a) pyridin-2-yl; pyridazin-3-yl; pyrimidin-4-yl; pyrimidin-2-yl; pyrimidin-2-yl substituted with one or two substituents each independently selected from the group consisting of halo, C_{1-3}alkyl, $C(CH_3)_2OH$, C_{1-3}perhaloalkyl, OCH_3, and cyclopropyl; and

(b) 1-methyl-imidazol-2-yl; oxazol-2-yl; 1-methyl-pyrazol-4-yl; 1-methyl-pyrazol-3-yl; or 1-methyl-1H-pyrazol-5-yl.

2017217542 30 Apr 2021

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

Ar^1 is selected from the group consisting of:

(a) phenyl substituted with one substituent selected from the group consisting of: F, Br, I, C_{1-6}alkyl, C_{1-6}perhaloalkyl, and OC_{1-6}perhaloalkyl; phenyl substituted with two or three substituents each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, C_{3-6}cycloalkyl, and azetidinyl;

(b) pyridinyl; pyridinyl substituted with one or two members each independently selected from the group consisting of: halo, CH_3, CF_3, and CF_2H; and

(c) thienyl substituted with CF_3; 2,2-difluorobenzo[d][1,3]dioxol-5-yl; or 2,3-dihydro-1H-inden-5-yl;

R^1 is H, halo, or CH_3;

R^2 is H or CH_3; and

Ar^3 is selected from the group consisting of:

(a) pyridinyl; pyridinyl substituted with one or two substituents each independently selected from the group consisting of: Cl, F, CH_3, OCH_3, CF_3, and $C(CH_3)_2OH$; azetidin-1-yl; 3-fluoroazetidin-1-yl; and 3,3-difluoroazetidin-1-yl;

(b) pyridazinyl; pyridazinyl substituted with one or two substituents each independently selected from the group consisting of: CH_3, OCH_3, and CF_3;

(c) pyrimidin-4-yl; pyrimidin-4-yl substituted with one or two substituents each independently selected from the group consisting of: Cl, CH_3, CF_3, and OCH_3; pyrimidin-2-yl; pyrimidin-2-yl substituted with one or two members each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}alkyl substituted with OH or OCH_3, $C(OH)(CH_3)(CF_3)$, CH_2OCHF_2, CH_2OCF_3, $CH_2OCH_2CH_3$, $CH(NH_2)CH_3$, $CH_2NH(CH_3)$, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, $C(=N\text{-}OH)(CH_3)$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, $NH(CH_2CH_3)$, $NH(CH_2CHF_2)$, NH(cyclopropyl), NH(difluorocyclobutyl), NH-oxetanyl, CN, $C(=O)CH_3$, $C(=O)NH(CH_3)$, $C(=O)N(CH_3)_2$, SO_2CH_3, CO_2CH_3, cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholinyl, 1H-pyrrol-2-yl, 2-

2017217542 30 Apr 2021

furyl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-pyrazol-1-yl, 2-methyl-1H-imidazol-1-yl, 1-methylpyrazol-3-yl, and phenyl;

(d) 5-fluoro-pyrazin-2-yl; 5-methylpyrazin-2-yl; 6-methylpyrazin-2-yl; pyrazin-2-yl; 5-(thien-2-yl)pyrazin-2-yl, and 2,3-dimethylpyrazin-5-yl; and

(e) 5-methyl-1H-imidazol-2-yl; and 5-methylthiazol-2-yl.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

Ar^1 is phenyl substituted with two substituents each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, C_{3-6}cycloalkyl, and azetidinyl;

R^1 is H, halo, or CH_3;

R^2 is H or CH_3; and

Ar^3 is pyrimidin-4-yl; pyrimidin-4-yl substituted with one or two substituents each independently selected from the group consisting of: Cl, CH_3, CF_3, and OCH_3; pyrimidin-2-yl; pyrimidin-2-yl substituted with one or two members each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}alkyl substituted with OH or OCH_3, $C(OH)(CH_3)(CF_3)$, CH_2OCHF_2, CH_2OCF_3, $CH_2OCH_2CH_3$, $CH(NH_2)CH_3$, $CH_2NH(CH_3)$, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, $C(=N\text{-}OH)(CH_3)$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, $NH(CH_2CH_3)$, $NH(CH_2CHF_2)$, NH(cyclopropyl), NH(difluorocyclobutyl), NH-oxetanyl, CN, $C(=O)CH_3$, $C(=O)NH(CH_3)$, $C(=O)N(CH_3)_2$, SO_2CH_3, CO_2CH_3, cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholinyl, 1H-pyrrol-2-yl, 2-furyl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-pyrazol-1-yl, 2-methyl-1H-imidazol-1-yl, 1-methylpyrazol-3-yl, and phenyl.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is H, F, I or CH_3.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is H.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ar^1 is phenyl substituted with:

30 Apr 2021
2017217542

a) one substituent selected from the group consisting of: Br, Cl, F, CH_3, CF_3, CHF_2, CF_2CH_3, $CH(CH_3)_2$, $OCHF_2$, and OCF_3; or

b) two substituents each independently selected from the group consisting of: Br, Cl, F, CH_3, CH_2CH_3, $CH(CH_3)_2$, CF_3, CF_2H, CF_2CH_3, $CH_2CH_2CH_2Cl$, $CH_2CH_2CH_2F$, OCH_3, OCF_2H, OCH_2CH_2F, cyclopropyl, and azetidin-1-yl.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ar^1 is

a) 3-bromophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-isopropylphenyl, 3-(trifluoromethyl)phenyl, 3-(difluoromethyl)phenyl, 3-(1,1-difluoroethyl)phenyl, 3-(trifluoromethoxy)phenyl, 4-(trifluoromethoxy)phenyl, 3-(difluoromethoxy)phenyl, or 4-(difluoromethoxy)phenyl; or

b) 2,4-difluoro-5-methyl-phenyl, 3-(difluoromethyl)-2,4-difluoro-phenyl, or 2,4-difluoro-3-methyl-phenyl; or

c) 6-methyl-pyridin-2-yl, 2-methyl-pyridin-4-yl, 5-methyl-pyridin-3-yl, 4-methyl-pyridin-2-yl, 2-bromo-pyridin-4-yl, 2-(trifluoromethyl)-pyridin-4-yl, 5-chloro-6-(trifluoromethyl)pyridin-2-yl, 2-(difluoromethyl)pyridin-4-yl, 5-(trifluoromethyl)pyridin-2-yl, 5-bromo-6-fluoropyridin-3-yl, or pyridin-4-yl; or

d) 6-methyl-pyridin-2-yl, 2-methyl-pyridin-4-yl, 5-methyl-pyridin-3-yl, 4-methyl-pyridin-2-yl, 2-bromo-pyridin-4-yl, 2-(trifluoromethyl)-pyridin-4-yl, 2,2-difluorobenzo[d][1,3]dioxol-5-yl, 5-(trifluoromethyl)thiophen-2-yl, or 2,3-dihydro-1H-inden-5-yl; or

e) 4-chloro-3-(difluoromethoxy)phenyl, 3-(difluoromethyl)-4-fluoro-phenyl, 4-chloro-3-(1,1-difluoroethyl)phenyl, 3-(1,1-difluoroethyl)-4-fluoro-phenyl, 3-(difluoromethoxy)-4-fluoro-phenyl, 4-chloro-3-(difluoromethyl)phenyl, 4-chloro-3-(2-fluoroethoxy)phenyl, 3-(3-chloropropyl)-4-fluoro-phenyl, or 5-(trifluoromethyl)thiophen-2-yl.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ar^3 is

a) pyridin-2-yl, 3-fluoro-pyridin-2-yl, 6-fluoro-pyridin-2-yl, 3-chloro-pyridin-2-yl, 5-chloro-pyridin-2-yl, 4-methyl-pyridin-2-yl, 5-methyl-pyridin-2-yl,


2017217542 30 Apr 2021

6-methyl-pyridin-2-yl, 5-(trifluoromethyl)pyridin-2-yl, 6-(trifluoromethyl)pyridin-2-yl, pyridin-3-yl, 3-methoxy-pyridin-2-yl, 2-methoxy-pyridin-3-yl, 2-methyl-pyridin-5-yl, 2,3-dimethyl-pyridin-2-yl, 5-chloro-3-methoxy-pyridin-2-yl, or 2-chloro-5-methyl-pyridin-4-yl; or

b) pyrimidin-2-yl; or pyrimidin-2-yl substituted with one or two members each independently selected from the group consisting of: halo, C_{1-3}alkyl, C_{1-3}alkyl substituted with OH or OCH_3, $C(OH)(CH_3)(CF_3)$, $CH(NH_2)CH_3$, $CH_2NH(CH_3)$, C_{1-3}perhaloalkyl, OC_{1-3}alkyl, OC_{1-3}perhaloalkyl, NH_2, $NH(CH_3)$, $N(CH_3)_2$, $NH(CH_2CH_3)$, $NH(CH_2CHF_2)$, CN, $C(=O)CH_3$, $C(=O)NH(CH_3)$, $C(=O)N(CH_3)_2$, SO_2CH_3, CO_2CH_3, cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholinyl, 2-furyl, 1H-pyrazol-4-yl, and 1-methylpyrazol-3-yl; or

c) pyrimidin-2-yl substituted with one or two members each independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}alkyl substituted with OH or CH_3, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, and azetidine-1-yl.

10. The compound of claim 1 having the structure of Formula (IA)



(IA)

or a pharmaceutically acceptable salt thereof,


wherein

Ar^1 is phenyl substituted with two substituents each independently selected from the group consisting of: halo, C_{1-3}perhaloalkyl, and OC_{1-3}perhaloalkyl; and

Ar^3 is selected from the group consisting of: pyridin-2-yl, pyridin-3-yl, 3-chloro-pyridin-2-yl, 5-chloro-pyridin-2-yl, 3-fluoro-pyridin-2-yl, 6-fluoro-pyridin-2-yl, 4-methyl-pyridin-2-yl, 2-methyl-pyridin-5-yl, 5-methyl-pyridin-2-yl, 6-methyl-pyridin-2-yl, 2,3-dimethyl-pyridin-6-yl, 2-chloro-5-methylpyridin-4-yl, 3-methoxy-pyridin-2-yl, 2-methoxy-pyridin-3-yl, 2-(pyridin-3-yl)propan-2-ol, 5-chloro-3-methoxy-pyridin-2-yl, 5-(trifluoromethyl)pyridin-2-yl, 6-(trifluoromethyl)pyridin-2-yl,

pyridazin-3-yl, pyrazin-2-yl, 5-methylpyrazin-2-yl, 5-fluoro-pyrazin-2-yl, and 5-(thien-2-yl)pyrazin-2-yl.

11. The compound of claim 1 having the structure of Formula (IB):



(IB)

or a pharmaceutically acceptable salt thereof,

wherein

Ar^1 is phenyl substituted with two substituents each independently selected from the group consisting of: halo, C_{1-3}alkyl, C_{1-3}perhaloalkyl, OCH_3, and OC_{1-3}perhaloalkyl;

R^1 is selected from the group consisting of: H, F, I, and CH_3;

R^2 is H or CH_3;

n is 0, 1, or 2; and

each R^4 is independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{1-6}alkyl substituted with OH or OCH_3, $C(OH)(CH_3)(CF_3)$, $CH(NH_2)CH_3$, $CH_2NH(CH_3)$, C_{1-6}perhaloalkyl, OC_{1-6}alkyl, OC_{1-6}perhaloalkyl, NH_2, $NH(CH_3)$, $N(CH_3)_2$, $NH(CH_2CH_3)$, $NH(CH_2CHF_2)$, CN, $C(=O)CH_3$, $C(=O)NH(CH_3)$, $C(=O)N(CH_3)_2$, SO_2CH_3, CO_2CH_3, cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholinyl, 2-furyl, 1H-pyrazol-4-yl, and 1-methylpyrazol-3-yl.

12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein

Ar^1 is selected from the group consisting of: 4-chloro-3-(difluoromethoxy)phenyl, 3-(difluoromethoxy)-4-fluoro-phenyl, 3-(difluoromethoxy)-4-methyl-phenyl, 4-chloro-3-(1,1-difluoroethyl)phenyl, 3-(1,1-difluoroethyl)-4-fluoro-phenyl, 4-chloro-3-(2-fluoroethoxy)phenyl, 3-(3-chloropropyl)-4-fluoro-phenyl, 4-fluoro-3-(3-fluoropropyl)phenyl, 3-bromo-4-fluoro-phenyl, 2-fluoro-3-(trifluoromethyl)phenyl, 3-(difluoromethyl)-4-fluoro-phenyl, 4-chloro-3-(difluoromethyl)phenyl, 4-chloro-3-methoxy-phenyl, 4-fluoro-3-isopropyl-

2017217542 30 Apr 2021

phenyl, 3-chloro-4-fluoro-phenyl, 3-ethyl-4-fluoro-phenyl, 3,4-difluorophenyl, 4-fluoro-3-methyl-phenyl, and 3,5-dimethylphenyl;


R^1 is H;

R^2 is H;

n is 1 or 2; and

each R^4 is independently selected from the group consisting of: Cl, F, C_{1-3}alkyl, C_{1-3}perhaloalkyl, CH_2OH, CH_2OCH_3, $C(CH_3)_2(OH)$, OCH_3, OC_{1-3}perhaloalkyl, $C(=O)CH_3$, and azetidine-1-yl.

13. The compound of claim 1 having the structure of Formula (IC):



(IC)

or a pharmaceutically acceptable salt thereof,


wherein

Ar^1 is selected from the group consisting of: 2-bromo-pyridin-4-yl, 6-methyl-pyridin-2-yl, 4-methyl-pyridin-2-yl, 2-methyl-pyridin-4-yl, 5-methyl-pyridin-3-yl, 2-(trifluoromethyl)-pyridin-4-yl, 5-(trifluoromethyl)pyridin-2-yl, 5-chloro-6-(trifluoromethyl)pyridin-2-yl, 5-bromo-6-methyl-pyridin-2-yl, 5-bromo-6-fluoropyridin-3-yl, and 5-(trifluoromethyl)-2-thienyl;

R^6 is selected from the group consisting of: Cl, F, CH_3, CH_2CH_3, CF_3, and OCH_3; and

R^7 is H or CH_3.

14. The compound of claim 1 having the structure of Formula (ID):



(ID)

or a pharmaceutically acceptable salt thereof,

wherein


Ar^1 is phenyl substituted with one substituent selected from the group consisting of: Br, Cl, F, C_{1-3}alkyl, C_{1-3}perhaloalkyl, and OC_{1-3}perhaloalkyl;

n is 0, 1, or 2; and

2017217542 30 Apr 2021

each R^4 is independently selected from the group consisting of: Br, Cl, F, C_{1-3}alkyl, C_{1-3}perhaloalkyl, OCH_3, $OCHF_2$, CH_2OH, CH_2OCH_3, $CH(CH_3)(OH)$, $C(OH)(CH_3)_2$, $C(OCH_3)(CH_3)_2$, $C(OH)(CH_3)(CF_3)$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, $C(=O)CH_3$, cyclopropyl, azetidine-1-yl, 3-fluoroazetidin-1-yl, pyrrolidin-1-yl, and piperidin-1-yl.

15. The compound of claim 2 having the structure of Formula (IIA):



(IIA)


or a pharmaceutically acceptable salt thereof,

wherein:

$Ar^{1'}$ is selected from the group consisting of: 4-chloro-3-(difluoromethoxy)phenyl, 3-(difluoromethoxy)-4-fluoro-phenyl, 4-fluoro-3-(trifluoromethyl)phenyl, 3-(difluoromethyl)-4-fluoro-phenyl, and 4-chloro-3-(difluoromethyl)phenyl; and

Ar^2 is selected from the group consisting of: oxazol-2-yl, pyrimidin-4-yl, 1-methyl-pyrazol-3-yl, 1-methyl-imidazol-2-yl, and 1-methyl-pyrazol-4-yl.

16. The compound of claim 2 having the structure of Formula (IIB):



(IIB)

or a pharmaceutically acceptable salt thereof,

wherein:

$Ar^{1'}$ is selected from the group consisting of: 3-(difluoromethyl)phenyl, 4-fluoro-3-methyl-phenyl, 4-chloro-3-(difluoromethoxy)phenyl, 3-(difluoromethoxy)-4-fluoro-phenyl, 4-fluoro-3-(trifluoromethyl)phenyl, 3-(difluoromethyl)-4-fluoro-phenyl, 4-chloro-3-(difluoromethyl)phenyl, and 3-(1,1-difluoroethyl)-4-fluoro-phenyl;

n is 1 or 2; and

each R^4 is independently selected from the group consisting of: halo, C_{1-3}alkyl, $C(CH_3)_2OH$, C_{1-3}perhaloalkyl, OCH_3, and cyclopropyl.

2017217542 30 Apr 2021

17. A compound selected from the group consisting of:

2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;

2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;

3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine;

2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine;

2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine;

4-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;

4-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;

3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridazine;

2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]pyrimidine;

2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;

2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;

2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4,6-dimethyl-pyrimidine;

2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;

2-[[1-(4-Fluoro-3-methoxy-phenyl)triazol-4-yl]methoxy]pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrazine;

2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;

5-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;

2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrazine;

2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;

5-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;

2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;

2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;

2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;

30 Apr 2021
2017217542

2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-chloro-pyrimidine;
2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;
2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
5-Chloro-2-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;
5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
(R*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
(S*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;
(R*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;
(S*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;
(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-4-methyl-pyrimidine;
(R/S)-5-Chloro-2-[1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;

2017217542 30 Apr 2021

2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
5-Ethyl-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
5-Fuoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-(5-Bromo-6-methyl-2-pyridyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine;
3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-2-methoxy-pyridine;
5-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-2-methyl-pyridine;

2017217542 30 Apr 2021

3-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine;
5-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-methoxy-pyridine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-fluoro-pyridine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-methoxy-pyridine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;
5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine;
5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine;
5-Methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
5-Methyl-2-((1-(4-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
2-((1-(3-(Difluoromethyl)-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
2-((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
2-((1-(4-Chloro-3-(oxetan-3-yl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-fluoro-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylthiazole;
1-(4-Chloro-3-(difluoromethyl)phenyl)-4-(((5-methyl-1H-imidazol-2-yl)oxy)methyl)-1H-1,2,3-triazole;
2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyridine;

2017217542 30 Apr 2021

2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methylpyridine;
6-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,3-dimethylpyridine;
2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methylpyrazine;
5-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,3-dimethylpyrazine;
5-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyrimidine;
6-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,4-dimethylpyridazine;
3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(trifluoromethyl)pyridazine;
3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methoxypyridazine;
4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyrimidine;
4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-(trifluoromethyl)pyrimidine;
4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methoxypyrimidine;
2-((1-(5-Chloro-6-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
2-((1-(2-(Difluoromethyl)pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxypyridine;
4-Chloro-3-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
4-((1-(3-(Difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine;
2-((1-(3-(Difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
5-Methyl-2-((1-(5-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;

30 Apr 2021
2017217542

2-((1-(5-Bromo-6-fluoropyridin-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
5-Methyl-2-((1-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
1-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
(R/S)-1-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine;
[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-4-carboxamide;
(R/S) 1-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]ethanamine;
5-Chloro-2-[[1-(4-fluorophenyl)triazol-4-yl]methoxy]pyrimidine;
5-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine;
4-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]morpholine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
2-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methyl-pyrimidine;
5-Methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;
5-Methyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]pyrimidine;

30 Apr 2021
2017217542

5-Methyl-2-[[1-(5-methyl-3-pyridyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[2-[[1-(3-Cyclobutyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-[2-[[1-(4-Fluoro-3-isopropyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-[2-[[1-(3-Cyclopropyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-[2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-[2-[[1-(3-Ethyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
5-Bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1-methylpyrazol-3-yl)pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1H-pyrazol-4-yl)pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1H-pyrazol-4-yl)pyrimidine;
4-(2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine;
2-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrazine;
4-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-fluoro-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine;
2-[[1-[4-Chloro-3-(2-fluoroethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-[4-Fluoro-3-(3-fluoropropyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-[3-(3-Chloropropyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine;
5-Chloro-2-[[1-(4-chlorophenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
2-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;
2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]pyrimidine;
5-Fluoro-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
5-Chloro-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine;

2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
5-Ethyl-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[[1-(o-Tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Fluoro-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Methoxy-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Chloro-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Methyl-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Ethyl-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
4-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Ethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Chloro-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Fluoro-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Methoxy-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
2-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
4-(Methoxymethyl)-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
4,5-Dimethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Fluoro-4-methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Chloro-4-methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidin-4-amine;
1-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
2-[[1-(p-Tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Fluoro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Methoxy-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Chloro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Methyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;
5-Ethyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]pyrimidine;
5-Fluoro-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
5-Chloro-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
5-Ethyl-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine;

2017217542 30 Apr 2021

2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
2-[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
5-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
4-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
5-(Difluoromethoxy)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-Chloro-4-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine;
5-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
4-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine;
5-Methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Ethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Isopropyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-(Difluoromethyl)-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
4,5-Dimethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Chloro-4-methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Bromo-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;
[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
2-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine;

2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine;
(R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;
1-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
(R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;
(R/S)-2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(1-methoxyethyl)pyrimidine;
5-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;
2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
5-Chloro-2-[[1-[3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
5-Chloro-2-[[1-[4-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;

2017217542 30 Apr 2021

2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
2-[[1-[4-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Fluoro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Methoxy-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Chloro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Methyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Ethyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
1-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
2-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
4-(Methoxymethyl)-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
4-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Fluoro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Methoxy-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Chloro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Ethyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine;
N-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]pyrimidine;
5-Chloro-2-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
5-Chloro-2-[[1-(3,5-dimethylphenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
2-[(1-Indan-5-yltriazol-4-yl)methoxy]-5-methyl-pyrimidine;
5-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]pyrimidine;
2-[(1-Indan-5-yltriazol-4-yl)methoxy]-4-(methoxymethyl)pyrimidine;

30 Apr 2021 2017217542

2-[2-[(1-Indan-5-yltriazol-4-yl)methoxy]pyrimidin-5-yl]propan-2-ol;
4-(Difluoromethyl)-2-[(1-indan-5-yltriazol-4-yl)methoxy]pyrimidine;
5-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]-4-methyl-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;
2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
5-Chloro-2-[(1R)-1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;
2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methoxy-pyrimidine;
2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
5-Chloro-2-[(1S)-1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine;
2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine;
2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methoxy-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
2-[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-isopropoxypyrimidine;
Methyl 2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine-4-carboxylate;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-N-(2,2-difluoroethyl)-5-fluoro-pyrimidin-4-amine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;

30 Apr 2021 2017217542

2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine;

5-(Azetidin-1-yl)-2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;

2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine;

2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3,3-difluoroazetidin-1-yl)pyrimidine;

2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-6-fluoro-pyridine;

2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-(trifluoromethyl)pyridine;

2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrazine;

2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(2-thienyl)pyrazine;

5-Bromo-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;

2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;

[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;

2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;

4-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;

2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine;

(R/S)-2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol;

5-(Difluoromethoxy)-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;

5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;

2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;

2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;

2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-5-carboxamide;

2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidine-4-carboxamide;

30 Apr 2021
2017217542

2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methoxy-5-methyl-pyrimidine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine;
5-(Azetidin-1-yl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1-yl)pyrimidine;
5-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoro-3-methylazetidin-1-yl)pyrimidine;
2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-(difluoromethyl)azetidin-1-yl)pyrimidine;
2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3,3-difluoropyrrolidin-1-yl)pyrimidine;
5-Cyclopropyl-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(2-furyl)pyrimidine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]-5-iodo-triazol-4-yl]methoxy]-5-methyl-pyrimidine;
[3H]-2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl-5-t)methoxy)-5-methylpyrimidine;
3-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine;
5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine;

30 Apr 2021
2017217542

2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine;
2-[6-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-3-pyridyl]propan-2-ol;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrazine;
2-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(methoxymethyl)pyrimidine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
5-(Difluoromethyl)-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
4-(Difluoromethyl)-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
(R/S)-1,1,1-Trifluoro-2-[2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;
5-Ethoxy-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
5-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
1-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
(R/S)-1-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
5-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;

2017217542 30 Apr 2021

2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-5-carboxamide;
5-Cyclopropyl-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
5-Bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
2-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine;
4-(2-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine;
5-(Azetidin-1-yl)-2-((1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methylpyrimidine;
2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethyl-4-methylpyrimidin-5-amine;
2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethylpyrimidin-5-amine;
2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1-yl)pyrimidine;
5-Chloro-2-[[1-[2-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine;
4-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-6-methyl-pyrimidine;
5-Chloro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
5-Fluoro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[2-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
5-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
5-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
5-(Difluoromethoxy)-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-4-amine;
2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
5-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
5-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
5-Ethyl-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;

30 Apr 2021
2017217542

2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
5-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
5-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
5-(2-Fluoroethoxy)-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(2-Fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
5-Chloro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
5-Fluoro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
5-Fluoro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
5-Chloro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
5-Ethyl-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
5-Bromo-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-ethyl-pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;
[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
2-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-amine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethylpyrimidin-4-amine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-phenyl-pyrimidine;

30 Apr 2021 2017217542

2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine;
5-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
4-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3-fluoroazetidin-1-yl)pyrimidine;
4-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;
(R)-2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-[(3R)-3-fluoropyrrolidin-1-yl]pyrimidine;
5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine;
N-(2,2-Difluoroethyl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidin-4-amine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;
N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine;
1-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)-N-methylmethanamine;
2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
1-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
5-Bromo-2-[[1-[3-(difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidine;

30 Apr 2021
2017217542

2-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
2-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine;
(R/S)-2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol;
[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;
5-Chloro-2-[[1-[4-chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;

30 Apr 2021
2017217542

2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4,6-dimethyl-pyrimidine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;
1-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;
(R/S)-1-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-cyclopropyl-pyrimidine;
2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-3-fluoro-pyridine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine;
6-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-2,3-dimethyl-pyridine;
3-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-2-methoxy-pyridine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine;
(R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol;
2-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;

30 Apr 2021 2017217542

2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine;
[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(methoxymethyl)pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
[2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine-5-carbonitrile;
2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methylsulfonyl-pyrimidine;

2017217542 30 Apr 2021

1-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone;

(R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol;

5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;

5-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine;

2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine;

2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N,N-dimethylpyrimidin-5-amine;

2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;

2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine;

2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-ethyl-pyrimidine;

5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine;

2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;

5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-4-methyl-pyrimidine;

2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]pyrimidine;

2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;

2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine;

5-Chloro-2-[[1-(3,4-difluorophenyl)triazol-4-yl]methoxy]pyrimidine;

2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;

2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;

2-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;

2-[2-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;

5-Chloro-2-[[1-(2,3-difluorophenyl)triazol-4-yl]methoxy]pyrimidine;

2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;

2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]pyrimidine;

2-[2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;

30 Apr 2021
2017217542

2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine;
5-Chloro-2-[[1-(3-chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine;
2-[2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
[2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;
[2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine;
2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine;
[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol;
[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
2-[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-cyclopropyl-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-cyclopropyl-pyrimidine;
2-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine;

30 Apr 2021 2017217542

2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine;
2-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine;
2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-isopropyl-pyrimidine;
2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-isopropyl-pyrimidine;
5-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
4-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
2-[2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
5-(Difluoromethoxy)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
5-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
4-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine;
5-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine;
2-[[1-[3-(Difluoromethyl)-2,4-difluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine;
5-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
5-(Difluoromethyl)-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
5-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine;
5-Cyclopropyl-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine;
5-Chloro-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;
5-Ethyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;
5-Chloro-4-methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;

30 Apr 2021 2017217542

5-Methyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;
5-Ethyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine;
5-Ethyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]pyrimidine;
2-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine;
5-Methyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-yl]methoxy]pyrimidine;
5-Ethyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-yl]methoxy]pyrimidine;
5-Fluoro-4-methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
5-Methoxy-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
5-(Trifluoromethyl)-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-(oxetan-3-yl)pyrimidin-4-amine;
5-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyridine;
5-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
2-(Azetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(3-fluoroazetidin-1-yl)pyridine;
2-(3,3-Difluoroazetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
4-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(3-fluoroazetidin-1-yl)pyridine;
4-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrrol-2-yl)pyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine;

30 Apr 2021
2017217542

2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrrol-2-yl)pyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethyl-5-fluoropyrimidin-4-amine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoro-N-(oxetan-3-yl)pyrimidin-4-amine;
N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine;
N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine;
N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine;
N-Cyclopropyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine;
N-Ethyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine;
2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(2-methyl-1H-imidazol-1-yl)pyrimidine;
2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(2-methyl-1H-imidazol-1-yl)pyrimidine;
2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine;
2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine;
4-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
4-((Difluoromethoxy)methyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-1-yl)pyrimidine;
2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-1-yl)pyrimidine;
(E)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one oxime;

5-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
(Z)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-one oxime;
(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-yl)methanol;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)-5-fluoropyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)pyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoro-4-((trifluoromethoxy)methyl)pyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((trifluoromethoxy)methyl)pyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(methoxymethyl-d2)pyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((methoxy-d3)methyl-d2)pyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((methoxy-d3)methyl)pyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(ethoxymethyl)pyrimidine;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1-methoxyethyl)pyrimidine;
1-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-ol;
2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(2-methoxypropan-2-yl)pyrimidine;
2-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)propan-2-ol; and
4-((2,2-Difluoroethoxy)methyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
and pharmaceutically acceptable salts thereof.

18. A compound selected from the group consisting of:
N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]pyridin-2-amine;

30 Apr 2021 2017217542

N-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
N-((1-(3-(Difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)pyrimidin-2-amine;
N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-imidazol-2-amine;
N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]oxazol-2-amine;
N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-4-amine;
N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-3-amine;
N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-3-amine;
N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-4-amine;
N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-4-amine;
N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidin-2-amine;
N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine;
5-Chloro-N-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine;
N-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methyl]-5-fluoro-pyrimidin-2-amine;
N-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine;
5-Chloro-N-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-4-methyl-pyrimidin-2-amine;
5-Chloro-N-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-4-methyl-pyrimidin-2-amine;
N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-ethyl-pyrimidin-2-amine;

30 Apr 2021
2017217542

N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-methoxy-pyrimidin-2-amine;
N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-(difluoromethyl)pyrimidin-2-amine;
N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine;
N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine;
N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-ethyl-pyrimidin-2-amine;
N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-isopropyl-pyrimidin-2-amine;
5-Cyclopropyl-N-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-4,5-dimethyl-pyrimidin-2-amine;
N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine;
5-Chloro-N-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine;
N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine;
2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methylamino]pyrimidin-5-yl]propan-2-ol;
N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine;
N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-ethylpyrimidin-2-amine;
N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine;
5-Chloro-N-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methylpyrimidin-2-amine;
N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine;
N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-imidazol-2-amine;

N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine;
N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidin-2-amine;
N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine; and
N-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethyl]-5-methyl-pyrimidin-2-amine;
and pharmaceutically acceptable salts thereof.

19. A compound selected from the group consisting of:
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine;
2-[[1-[4-Chloro-3-(2-fluoroethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-[3-(3-Chloropropyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine;
[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine;
[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;
2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;
2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;
5-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; and

2017217542 30 Apr 2021

5-Fluoro-4-methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;
and pharmaceutically acceptable salts thereof.

20. The compound of claim 19, wherein the compound is 2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a compound of any one of claims 1 to 20 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

22. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by NR2B receptor activity, comprising administering to a subject in need of such treatment an effective amount of the compound of any one of claims 1 to 20 or a pharmaceutically acceptable salt thereof.

23. The method of claim 22, wherein the disease, disorder, or medical condition mediated by NR2B receptor activity is

a) selected from the group consisting of: bipolar disorder, major depressive disorder, treatment-resistant depression, post-partum depression, seasonal affective disorder, Alzheimer's disease, Parkinson's disease, Huntington's chorea, multiple sclerosis, cognitive impairment, head injury, spinal cord injury, stroke, epilepsy, dyskinesias, amyotrophic lateral sclerosis, neurodegeneration associated with bacterial or chronic infections, pain, diabetic neuropathy, migraine, cerebral ischemia, schizophrenia, encephalitis, autism and autism spectrum disorders, memory and learning disorders, obsessive compulsive disorder, attention deficit hyperactivity disorder (ADHD), and an addictive illness; or

b) selected from the group consisting of treatment resistant depression and major depressive disorder; or

d) a central nervous system disorder; or

e) a neurologic or psychiatric disorder; or

f) (1) a mood disorder; (2) a neurotic, stress-related, or somatoform disorder; (3) a disorder of psychological development; (4) a behavioral syndrome associated with physiological disturbances and physical factors; (5) an extrapyramidal and movement disorder; (6) an episodic or paroxysmal disorder; (7) pain; (8) a form of neurodegeneration; or (9) a cerebrovascular disease.

24. The method of claim 23, wherein the neurologic disorder is epilepsy and the psychiatric disorder is a mood disorder, treatment-resistant depression, or major depressive disorder.

25. The method of claim 23, wherein the disease, disorder, or medical condition mediated by NR2B receptor activity is: (1) a mood disorder; (2) a neurotic, stress-related, or somatoform disorder; (3) a disorder of psychological development; (4) a behavioral syndrome associated with physiological disturbances and physical factors; (5) an extrapyramidal and movement disorder; (6) an episodic or paroxysmal disorder; (7) pain; (8) a form of neurodegeneration; or (9) a cerebrovascular disease, wherein the neurotic, stress-related, or somatoform disorder is an anxiety disorder; the episodic or paroxysmal disorder is epilepsy; and the cerebrovascular disease is an acute cerebrovascular disease or a chronic cerebrovascular disease.

26. Use of a compound according to any one of claims 1 to 20 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease, disorder, or medical condition mediated by NR2B receptor activity.